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Abstract 
Epigenetic  control  of  gene  expression  is  vital  for  normal  development  and 
differentiation of cells, and is also important in the development of disease. In 
particular, there is a strong association between hallmark epigenetic changes and 
cancer – namely, genome wide hypomethylation, gene specific hypermethylation 
and characteristic histone modification. Almost all studies of cancer epigenetics 
to date have been conducted in malignant tissues or already transformed cell 
lines, and therefore do not take into account epigenetic changes occurring during 
the  process  of  transformation.  Our  lab  has  developed  a  line  of  primary 
mesenchymal  stem  cells  (MSC;  thought  to  be  the  origin  of  various  types  of 
sarcoma) in which five oncogenic steps towards a fully transformed state are 
sequentially introduced including: human telomerase, necessary to extend the life 
span of MSC in culture, genes to inactivate the p53 and pRb tumour suppressor 
genes and genes to activate the oncogenes c-Myc and Ras. I hypothesized that 
hallmark epigenetic changes take place in this step-wise model of transformation, 
and aimed to investigate genome wide hypomethylation and the activity of the 
polycomb repressive 2 (PRC2) complex in this system. Utilizing the PCR based 
technique  MethyLight,  I  show  that  transformed  MSC  are  hypomethylated 
compared to parental MSC, with this decrease in methylation occurring on the 
introduction  of  oncogenic  H-Ras  in  the  final  step.  I  also  show  that  this 
hypomethylation  is  a  gradual  event  following  H-Ras  expression,  and 
transformation can take place in the absence of hypomethylation. I demonstrate 
that the three core components of the PRC2 complex are up-regulated during 
step-wise transformation and that PRC2 target genes are down-regulated. Finally, 
I show that MSC are able to be transformed when the PRC2 components EZH2 
and SUZ12 are knocked down before the final oncogenic hit. These studies show 
that  hallmark  epigenetic  changes  occur  during  step-wise  transformation  and 
suggest  that  tumour-associated  epigenetic  changes  occur  following  genetic 
aberrations.  This  model  is  valuable  and  relevant  to  further  explore  the 
mechanisms behind epigenetic alterations in cancer.  
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Chapter 1:  Introduction 
 
1.1     Epigenetic Regulation of Gene Expression    
 
‘Epigenetics’ describes the study of stable, reversible alterations affecting gene 
expression  that  are  not  stored  within  the  primary  DNA  sequence.  Since  the 
identification  of  epigenetic  regulation,  there  has  been  rapid  progress  in 
elucidating the nature and role of the mechanisms involved in this type of gene 
expression control (Qiu, 2006). Such research has shown that epigenetic factors 
play  a  vital  role  not  only  in  development  and  differentiation,  but  also  in 
pathogenesis. In particular, a strong link between epigenetic changes and the 
development of cancer has begun to emerge. In order to further explore this role 
of  epigenetics  in  cancer  development,  we  must  first  consider  the  nature  of 
epigenetic control acting across the genome.  
 
 
1.1.1    DNA Methylation 
 
Nucleic  acids  can  be  modified  by  the  covalent  addition  of  a  methyl  group, 
through interaction with an alkylating agent or by an enzymatic reaction. DNA 
methylation in mammalian genomes occurs predominantly on cytosine residues 
5’ of guanine in CpG dinucleotides (Jaenisch and Bird, 2003). Approximately 
70%  of  CpG  dinucleotides  in  the  human  genome  are  methylated,  though  the 
distribution of CpG dinucleotides and frequency of methylation are not random 
(Cooper and Krawczak, 1989). Although the CpG sequence is underrepresented   23 
in the genome as a result of spontaneous deamination of methylated cytosine to 
thymine, CpG dinucleotides are highly abundant in stretches approximately 1kb 
in length known as CpG islands – regions often associated with the promoters 
and first exons of genes (Bird et al., 1985). Despite constituting only 1% of the 
genome and containing 15% of CpG dinucleotides, 50% of unmethylated CpG 
sites can be found in CpG islands. These regions tend to have open chromatin 
structures lacking the linker histone H1 and are enriched for acetylated histone 
H3 and H4 (Tazi and Bird, 1990).  
DNA  methylation  is  established  and  maintained  by  three  DNA 
methyltransferases (DNMTs) – DNMT1, DNMT3a and DNMT3b. DNMT1, the 
first of these enzymes to be identified, is ubiquitously expressed, localises to 
replication  foci  and  exhibits  a  strong  preference  for  hemi-methylated  DNA 
(Leonhardt  et  al.,  1992;  Pradhan  et  al.,  1999;  Robertson  et  al.,  1999).  These 
observations  indicate  that  the  enzyme  is  involved  in  the  copying  of  DNA 
methylation to the daughter strand following DNA replication, leading to the 
common  classification  of  DNMT1  as  a  ‘maintenance’  methyltransferase. 
DNMT1  is  vital  for  normal  embryonic  development,  imprinting  and  X-
inactivation, with knockout mice showing global demethylation and embryonic 
lethality (Lei et al., 1996; Li et al., 1992). 
  In contrast, the DNMT3a and DNMT3b enzymes are highly conserved 
from  zebrafish  to  humans  and  show  an  affinity  for  both  hemi-  and  fully 
unmethylated DNA, suggesting a potential role in the de novo establishment of 
DNA  methylation  (Okano  et  al.,  1998).  In  line  with  this,  these  enzymes  are 
required for de novo genomic DNA methylation following embryo implantation 
and for the silencing of newly integrated retroviral sequences in mouse ES cells   24 
(Okano  et  al.,  1999).  Dnmt3a  knockout  mice  are  born  live  but  die  within  4 
weeks, whereas dnmt3b knockout is embryonic lethal around the same point as 
dnmt1 knockout, embryonic day (E) 9.5 (Li et al., 1992; Okano et al., 1999).  
  However, the classification of these enzymes as ‘maintenance’ or ‘de-
novo’ methyltransferases may not be so clear cut. Overexpression of DNMT1 in 
cancer cells has been shown to induce de-novo methylation of certain genes, 
although this effect may be the result of DNMT1 replicating methylation marks 
established by other methyltransferases (Vertino et al., 1996). A further study has 
demonstrated that cancer cells lacking DNMT1 maintain 80% of their normal 
methylation patterning, suggesting that DNMT3A and DNMT3B may also act as 
maintenance methyltransferases (Rhee et al., 2000).  
 
 
1.1.2    Histone Modifications and Chromatin Structure 
 
Chromatin structure also plays an important role in the regulation of transcription 
by  controlling  access  of  transcriptional  machinery  to  promoter  regions. 
Chromatin  is  comprised  of  DNA  wrapped  around  a  series  of  nucleosomes  - 
octomers made up of pairs of the histones H2A, H2B, H3, and H4 (Luger et al., 
1997;  Luger  and  Richmond,  1998).  Histones  themselves  are  made  up  of  a 
globular  protein  domain  and  an  N-terminal  tail,  which  can  be  the  target  of 
various  modifications  including  methylation,  acetylation,  phosphorylation, 
ubiquitination  and  sumoylation.  Such  modifications  alter  histone  structure, 
causing  changes  to  chromatin  conformation  and  affecting  accessibility  of  the 
region to transcriptional machinery (Jenuwein and Allis, 2001; Turner, 2002).   25 
Of the numerous modifications that can occur to histone tails, acetylation 
and  methylation  are  the  most  common.  Histone  acetylation  is  mediated  by 
histone  deacetylases  (HDACs)  and  histone  acetyltransferases  (HATs).  HATs 
acetylate the  -NH2 group on lysine residues within histone tails, causing an 
open  chromatin  conformation  and  transcriptional  activation (Marmorstein  and 
Roth, 2001; Sterner and Berger, 2000). Conversely, HDACs can cause chromatin 
condensation  and  transcriptional  repression  by  removing  acetyl  groups  on 
histone tails (Thiagalingam et al., 2003).  
  Methylation of histone tails by histone methyltransferases (HMTs) also 
plays  an  important  role  in  regulating  chromatin  structure.  These  methylation 
events can take place at a number of different residues (including lysine and 
arginine), with each change having a different effect. For example, methylation 
of  lysine  9  and  lysine  27  in  the  H3  tail  is  associated  with  transcriptionally 
repressed  chromatin,  whereas  H3  lysine  4  methylation  is  a  characteristic  of 
transcriptionally active chromatin (Zhang and Reinberg, 2001). 
Finally,  chromatin  structure  can  also  be  altered  through  the  action  of 
ATP-dependant  chromatin  remodelling  complexes  such  as  SWI/SNF2/Brm, 
ISWI, and the Mi-2/NuRD complex (Havas et al., 2000). Polycomb-group and 
trithorax  group  genes  also  play  roles  in  chromatin  remodelling,  acting  as 
epigenetic silencers and activators for gene transcription and will be discussed in 
greater depth later.  
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1.1.3    MicroRNAs 
 
MicroRNAs (miRNAs) are small non-coding RNAs that function as negative 
gene regulators through one of two mechanisms. First, miRNAs may function 
through the RNA-mediated interference (RNAi) pathway, leading to cleavage of 
complementary  mRNA  molecules.  Alternatively,  interactions  with  the  3’ 
untranslated  region  (UTR)  of  target  mRNA  can  lead  to  post  transcriptional 
repression,  decreasing  protein  levels  without  affecting  the  amount  of  mRNA 
(Esquela-Kerscher and Slack, 2006). 
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1.2    The Role of DNA Methylation 
 
1.2.1    Repression of Repetitive Element Transcription 
 
In considering the evolutionary role of DNA methylation, it is worth noting the 
genomic positioning of methylated CpG dinucleotides. Although much attention 
has focused on DNA methylation in CpG islands, the majority of methylated 
CpG  dinucleotides  are  in  fact  found  within  repetitive  elements,  in  particular 
parasitic  DNA  elements  such  as  transposons,  which  in  total  comprise 
approximately 45% of the human genome (Lander et al., 2001). Transposable 
elements pose a significant threat to the integrity of the genome in a number of 
ways.  Insertion  of  such  elements  during  transposition  can  disrupt  coding 
sequences of genes or result in aberrant initiation sites (Kazazian and Moran, 
1998; Montagna et al., 1999). It is believed that DNA methylation is an essential 
mechanism  in  silencing  the  transcription  of  these  elements  to  prevent  their 
movement and expansion throughout the genome (Yoder et al., 1997). In line 
with this, it has been shown that methylation of retrotransposon promoters results 
in repression of their transcription (Kochanek et al., 1995).   
In line with this, a number of studies have noted increased transcription 
of  repetitive  elements  following  genomic  hypomethylation.  Dnmt1  knockout 
mice, which retain only 30% of normal genomic methylation, show significantly 
increased  expression  of  the  intracisternal  A  particle  (IAP)  repetitive  element 
(Walsh et al., 1998). It is believed that increased transposition of this element 
may underlie the genomic instability and frequent gene rearrangements observed 
in  these  mice  (Chen  et  al.,  1998).  Kangaroo  hybrid  models,  which  display   28 
genome wide hypomethylation, also show expansion of retroviral like elements 
(O'Neill et al., 1998). Similarly, global loss of DNA methylation is a common 
event  in  a  number  of  cancers,  and  can  result  in  aberrant  transcription  of 
endogenous transposable elements, such as elevated LINE1 transcription in CML 
(Roman-Gomez et al., 2008). 
 
 
1.2.2    Transcriptional Repression 
 
DNA  methylation  is  also  traditionally  recognized  as  a  repressor  of  gene 
expression, and can function in this regard through two main mechanisms – by 
interfering  with  the  assembly  of  the  transcription  machinery  or  by  causing 
alterations  to  chromatin  structure.  The  transcriptional  repressor  methyl-CpG 
binding  protein  2  (MECP2),  which  can  bind  to  methylated  DNA  through  its 
methyl-CpG binding domain (MBD) whilst recruiting co-repressors through the 
transcriptional repressor domain (TRD), plays an important role in both of these 
mechanisms.  In  vitro  experiments  have  shown  that  MECP2  represses 
transcription from methylated templates through interactions between the TRD 
and  TFIIB,  a  key  component  of  the  transcriptional  machinery  (Kaludov  and 
Wolffe, 2000). It is believed that MECP2 functions in a similar manner in vivo, 
as it has been shown to cluster at sites of DNA methylation (Nan et al., 1996).   
  Methylated  DNA  binding  proteins,  including  MECP2,  MBD1,  MBD2 
and MBD3, also play a role in linking DNA methylation to the formation of a 
repressive chromatin structures. For example, MECP2 associates with repressor 
complexes  including  histone  deacetylases  -  enzymes  able  to  induce  a  stable   29 
repressive chromatin state - with this gene repression partially sensitive to the 
histone deacetylase inhibitor trichostatin A (TSA) (Jones et al., 1998; Nan et al., 
1998). Furthermore, MBD3 has been shown to associate with the Mi-2 chromatin 
remodelling  complex  in  Xenopus  eggs,  and  MBD2  can  be  co-purified  with 
histone deacetylases (HDAC) 1 and 2 in HeLa cell nuclear extracts (Ng et al., 
1999; Wade et al., 1999).  
As well as these interactions mediated by methyl-CpG binding proteins, 
direct associations have been observed between enzymes involved in establishing 
DNA methylation and those involved with chromatin modification. For example, 
the  minimal  interaction  domain  of  DNMT1  has  been  shown  to  mediate 
associations  between  this  enzyme  and  histone  deacetylases,  leading  to  gene 
repression  that  can  be  partly  relieved  by  TSA  treatment  (Fuks  et  al.,  2000; 
Robertson et al., 2000; Rountree et al., 2000).  
 
 
1.2.3    Maintenance of Genomic Integrity 
 
As well as its role in the regulation of gene and repetitive element expression, 
DNA  methylation  plays  a  vital  role  in  the  maintenance  of  genomic  integrity 
through  repression  of  recombination  events  between  homologous  repetitive 
sequences across the genome. Studies in the fungus Ascobolus immersus have 
demonstrated a reduction in recombination events when known recombination 
hotspots  are  methylated  (Maloisel  and  Rossignol,  1998).  Similar  results  have 
been obtained in studies of V(D)J recombination in mammalian systems (Hsieh 
and Lieber, 1992). Other lines of evidence in support of this hypothesis come   30 
from studies of genome wide loss of methylation in disease and following drug 
treatment or in vitro genetic manipulation of cells. Mouse embryonic stem cells 
deficient in dnmt1 show a significant increase in abnormal gene rearrangements 
(Chen et al., 1998). Similarly, ICF (immunodeficiency, centromeric instability, 
facial  anomalies)  syndrome  patients  display  characteristic  hypomethylation  of 
satellite  repeats  alongside  chromosomal  recombination  events  that  can  be 
recapitulated in cell lines following treatment with the demethylating agent 5-
aza-2’-deoxycytidine (Jeanpierre et al., 1993; Ji et al., 1997; Tuck-Muller et al., 
2000). Finally, genome-wide hypomethylation is a common event in cancer and 
could lead to an increase in abnormal karyotypic changes in transformed cells 
(Ehrlich, 2002). 
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1.3    Epigenetic Deregulation In Cancer 
 
The  six  hallmarks  of  cancer  necessary  for  continued  cell  growth  are:  self 
sufficiency  in  growth  signals,  insensitivity  to  antigrowth  signals,  evasion  of 
apoptosis, limitless replicative potential, sustained angiogenesis and metastasis 
(Hanahan and Weinberg, 2000). Dominant gain of function mutations, or other 
increases in the transcription of genes involved in these pathways, can contribute 
towards cellular transformation. Furthermore, cells must avoid inbuilt anticancer 
defence  mechanisms  through  loss  of  tumour  suppressor  function  in  order  for 
transformation to take place. Although many of these changes occur at the DNA 
level through mutation, there is mounting evidence that epigenetic changes in 
transcription  are  also  strongly  associated  with  transformation  of  cells.  Such 
changes could affect DNA methylation, chromatin structure, or both, leading to 
increased expression of oncogenes, or reduced expression of tumour suppressors.  
  Numerous studies have documented epigenetic changes in cancer cells 
including  genome-wide  hypomethylation,  gene  specific  hypermethylation  and 
characteristic histone modifications (Esteller, 2005; Feinberg and Tycko, 2004; 
Fraga et al., 2005). Genome-wide hypomethylation has been widely documented 
in  cancer  and  is  associated  with  loss  of  DNA  methylation  at  repetitive  and 
structural elements across the genome, potentially leading to genomic instability 
(Ehrlich, 2002). Hypermethylation, however, takes place in promoter regions of 
tumour-suppressor genes such as p16
INK4a, BRCA1 and the mismatch repair gene 
hMLH, resulting in gene silencing (Esteller, 2005; Jones and Baylin, 2002). As 
well as tumour suppressors, promoter regions for a broad range of other genes 
have  been  found  to  be  hypermethylated  in  cancer  cells.  These  include  genes   32 
involved  in  signal  transduction  (RASSF1  and  APC),  carcinogen  metabolism 
(GSTP1),  apoptosis  (DAPK  and  CASP8),  hormone  response  (EG,  PGR,  AR), 
angiogenesis (THBS1) and metastasis (TIMP3, CDH1) (Kopelovich et al., 2003). 
Genes involved in the establishment and maintenance of epigenetic changes are 
also deregulated in cancer. Such genes include DNA methyltransferases, histone 
acetyltransferases, histone deacetylases, methyl-CpG binding proteins, chromatin 
remodelling factors and SWI/SNF family proteins (reviewed in Esteller, 2006). 
In addition to methylation changes, histone modifications also play a key 
role in the regulation of gene expression. Certain histone modifications, such as 
histone 3 lysine 9 (H3K9) and 27 (H3K27) methylation have been shown to be 
involved  in  aberrant  gene  silencing  in  cancer  (Feinberg  et  al.,  2006). 
Additionally,  it  has  been  observed  that  tumours  display  ‘hallmark’  histone 
modifications, including loss of acetylation at K16 and trimethylation at K20 of 
histone H4 (Esteller, 2006; Feinberg and Tycko, 2004; Fraga et al., 2005). 
Finally, ATP dependant chromatin remodelling complexes such as the 
SWI/SNF complex and the antagonistic polycomb family of proteins can also 
affect  nucleosome  structure.  The  interplay  between  these  proteins,  DNA 
methylation changes and histone modifications all act to affect gene expression 
thorough changes in higher order chromatin structure. Alterations to the activity 
of such proteins could, therefore also play a large role in the epigenetic changes 
associated with cancer (Esteller, 2006). 
MicroRNAs have been shown to be involved in the regulation of cell 
growth,  differentiation  and  apoptosis  –  pathways  commonly  deregulated  in 
transformed  cells.  In  line  with  this,  miRNA  misexpression  and  mutation  are 
associated with various cancers. Furthermore, genes involved in the biogenesis   33 
and  processing  of  miRNAs  can  themselves  be  considered  as  epigenetic 
regulators  of  gene  transcription,  and  as  such  may  play  a  role  in  the 
transformation process (Esquela-Kerscher and Slack, 2006).  
Despite significant progress in the field of cancer epigenetics, the timing 
and causes of these changes remain subjects of investigation. Several studies 
have suggested that epigenetic changes occur early in the transformation process 
(Fearon  and  Vogelstein,  1990;  Feinberg  et  al.,  2006;  Suter  et  al.,  2004).  
However, most epigenetic studies of cancer are performed on malignant tissues, 
meaning that any observed epigenetic changes could be a consequence of the 
disease rather than a cause, or represent non-specific changes unassociated with 
the malignancy.  
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1.4    Genome Wide DNA Hypomethylation in Cancer 
 
Many  cancers  display  hallmark  epigenetic  changes  including  characteristic 
histone  modifications,  gene  specific  hypermethylation  and  global 
hypomethylation (Feinberg and Tycko, 2004; Fraga et al., 2005). Of these, the 
first to be described was genome wide hypomethylation, a decrease in the overall 
genomic methylcytosine content from approximately 4% in normal tissues to 2-
3% in cancers. This change was first observed in a 1983 study comparing lung 
and  colon  carcinomas  to  adjacent  normal  tissue,  demonstrating  that  overall 
genomic  methylcytosine  levels  were  lower  in  cancer  tissues  (Feinberg  and 
Vogelstein,  1983).  Since  this  pioneering  study,  the  observation  has  been 
reproducibly repeated in comparisons of a wide range of cancers and normal 
tissues using a variety of different techniques (Table A1; Ehrlich et al., 2002; 
Feinberg et al., 1988; Gama-Sosa et al., 1983b; Narayan et al., 1998; Qu et al., 
1999a; Weisenberger et al., 2005).  
 
 
1.4.1    Genomic Locations of Hypomethylation 
 
The precise genomic locations at which methylation is lost also remains a subject 
of investigation. An early study of methylation in randomly fragmented DNA 
from  human  gastric  adenocarcinoma  demonstrated  that  hypomethylation  was 
present  in  highly  repetitive,  moderately  repetitive  and  single  copy  DNA 
sequences  across  the  genome  (Gama-Sosa  et  al.,  1983b).  However,  the 
magnitude of the decrease in methyation observed in cancers is most commonly   35 
accounted for by loss of methylation at repetitive sequences, which constitute 
~45% of the genome as a whole  – comprising interspersed repeats derived from 
non-autonomous  or  autonomous  transposable  elements  and  tandem  repeats 
(Ehrlich, 2002; Lander et al., 2001; Prak and Kazazian, 2000).  
One  of  the  most  widely  studied  repetitive  elements  is  the  Long 
Interspersed Nuclear Element 1 (LINE-1), a 6kb interspersed DNA repeat which 
makes  up  around  15%  of  the  human  genome.  Instances  of  LINE-1 
hypomethylation  have  been  reported  in  chronic  lymphocytic  leukaemia, 
hepatocellular  carcinoma,  prostate  carcinoma  and  urinary  bladder  carcinoma 
amongst others (Dante et al., 1992; Jurgens et al., 1996; Santourlidis et al., 1999; 
Takai et al., 2000).  
Another highly repetitive interspersed DNA sequence is the ~300bp Alu 
repeat, with an average copy number of over 10
6, constituting approximately 
10% of the human genome.  However, changes in methylation of Alu repeats 
have not been widely investigated, with the exception of one study in germline 
tumours  (Rubin  et  al.,  1994).  Moderately  repeated  DNA  sequences  such  as 
human  endogenous  retrovirus-K  (HERV-K;  30-50  full  length  sequences  and 
10000  LTRs  in  the  human  genome)  have  also  been  observed  to  be 
hypomethylated in urinary bladder cancer (Florl et al., 1999).   
Satellite DNAs, highly repetitive tandem sequences commonly found in 
the heterochromatic regions around the centromere, also constitute a common 
site of hypomethylation in cancer. Satellite alpha (Sat  ) and Satellite 2 (Sat 2), 
located primarily on chromosomes 1, 10 and 16, have been extensively studied 
and shown to be hypomethylated in breast adenocarcinoma, ovarian epithelial   36 
carcinoma and Wilms tumours, among others (Narayan et al., 1998; Qu et al., 
1999b).  
Although global hypomethylation is often accounted for by the loss of 
methylation  across  these  repetitive  elements,  single  copy  sequences  in  the 
genome  including  imprinted  genes  also  exhibit  hypomethylation  in  cancer. 
Examples include the gamma-globin gene in breast and colon adenocarcinomas, 
MN/CA9  in  renal  cell  carcinomas  and  c-MYC  in  colorectal  cancers  and 
hepatocellular carcinomas (Cho et al., 2001; Ribieras et al., 1994; Sharrard et al., 
1992; Shen et al., 1998).  
 
 
1.4.2    Appropriate Normal Controls for Studies of Hypomethylation 
 
The variation in global methylation levels between different cells and tissues 
must be taken into account when choosing appropriate cases and controls for 
studies of global hypomethylation in cancer (Gama-Sosa et al., 1983a; Gama-
Sosa et al., 1983b). The variable nature of DNA methylation between tissues 
means  that  appropriate  controls  must  always  be  used.  At  the  extremes,  a 
comparison  of  global  methylcytosine  content  in  normal  somatic  tissues 
demonstrated  a  difference  of  17%  between  cerebellum  (4.03  +/-  0.14%)  and 
heart (3.43 +/- 0.12%) (Ehrlich et al., 1982). Furthermore, these tissues represent 
a mixed population of cells that may not be the same as the tumour population. 
In  order  to  account  for  this  variation,  many  studies  assess  tumour  tissue 
methylation  in  comparison  to  matched  adjacent  normal  tissue  or  a  panel  of 
unmatched normal tissues.   37 
1.4.3    Timing of Genome-wide Hypomethylation 
 
The timing of global DNA hypomethylation in cancer has also been a subject of 
investigation. Since global DNA hypomethylation has been observed in most 
cancers assayed, as well as in benign tumours, it is believed to constitute an early 
event in transformation (Fearon and Vogelstein, 1990; Feinberg et al., 2006). 
This  hypothesis  is  supported  by  a  study  of  LINE1  promoter  methylation  (a 
marker  of  global  methylation  levels)  in  colorectal  cancer  patients,  which 
observed  global  hypomethylation  in  tumours  and  apparently  normal  adjacent 
tissue when compared to control tissue from healthy individuals (Suter et al., 
2004). This hypomethylation was not present in peripheral blood from the same 
patients, suggesting that the loss of methylation was an early event that occurred 
in normal tissues before the acquisition of further oncogenic changes.  
The  relative  timings  of  global  hypomethylation  and  gene  specific 
hypermethylation  in  cancer  have  also  been  utilized  to  address  whether 
hypomethylation occurs at earlier stages of the transformation process. Although 
many  studies  have  failed  to  elucidate  a  link  between  the  two  events,  an 
investigation of LINE1 methylation levels in prostate carcinomas of different 
stages found that samples exhibiting hypomethylation formed a subclass of those 
with  gene  specific  hypermethylation.  The  lack  of  tumours  exhibiting 
hypomethylation in the absence of gene specific hypermethylation suggests that 
global loss of methylation is a secondary event in the progression of this cancer 
(Florl et al., 2004). Similarly, studies of genome-wide hypomethylation and gene 
specific  hypermethylation  in  prostate  cancer  progression  have  suggested  that 
hypomethylation only occurs in late stage metastatic cancer (Yegnasubramanian   38 
et al., 2008; Yegnasubramanian et al., 2004). Further investigations are required 
to  establish  the  relative  timings  of  these  epigenetic  changes  during 
transformation (reviewed in Ehrlich, 2002; Wilson et al., 2007).  
 
 
1.4.4    Consequences of Genome Wide Hypomethylation 
 
As discussed previously, a large proportion of DNA methylation in the genome 
is  associated  with  repetitive  elements,  including  many  types  of  transposable 
elements  as  well  as  tandem  repeats  such  as  satellite  sequences.  The  strong 
sequence similarity between repetitive elements can increase the probability of 
recombination events taking place between these loci, with this recombination 
normally suppressed in eukaryotes through DNA methylation and subsequent 
formation  of  heterochromatin,  restricting  access  of  these  sequences  to 
recombination  machinery  (Garrick  et  al.,  1998;  Nguyen  et  al.,  2001).  It  is 
believed  that  loss  of  methylation  at  such  sequences,  as  is  often  observed  in 
cancer, could reverse this restriction and contribute to karyotypic instability and 
tumour progression. In order to investigate this possibility, parallels have been 
drawn between DNA hypomethylation in cancer and ICF (immunodeficiency, 
centromeric  instability,  facial  anomalies)  syndrome.  Hypomethylation  of 
pericentromeric Sat2 repeats on chromosomes 1 and 16 is commonly observed in 
cancer  and  is  also  a  characteristic  of  ICF.  In  karyotypic  studies  of  ICF 
lymphocytes and lymphoblastoid cell lines, these regions of chromosomes 1 and 
16 are specifically targeted for chromosomal rearrangements (Jeanpierre et al., 
1993; Tuck-Muller et al., 2000). Additionally, Sat2 rich regions are often the site   39 
of chromatin decondensation and the break point in chromosomal deletions or in 
the formation of multi-radial chromosomes in these cells (Ehrlich et al., 2001; 
Tuck-Muller et al., 2000). Finally, global DNA hypomethylation induced by 5-
azacytidine treatment of normal lymphoid cultures results in karyotypic changes 
identical to those observed in ICF (Hernandez et al., 1997; Ji et al., 1997).  
  Similar pericentromeric rearrangements involving chromosomes 1 and 16 
have been described in both hepatocellular carcinoma, breast cancer and Wilms 
tumour,  and  have  been  shown  to  correlate  with  hypomethylation  of  Sat2 
sequences on these chromosomes (reviewed in Ehrlich, 2002; Tsuda et al., 2002). 
As  well  as  karyotypic  instability  resulting  from  hypomethylation  of 
pericentromeric sequences, global DNA hypomethylation alongside an increase 
in abnormal chromosomal rearrangements has been observed in dnmt1 knockout 
mouse embryos as well as in a mammalian hybrid model (Biniszkiewicz et al., 
2002; Chen et al., 1998; O'Neill et al., 1998). Similar observations have also 
been  made  in  human  cancers,  including  increased  chromosomal  instability  in 
conjunction with genome wide hypomethylation in hepatocellular and prostate 
carcinomas  as  well  as  colorectal  cancer  cell  lines  and  tumours  (Karpf  and 
Matsui, 2005; Lengauer et al., 1997; Rodriguez et al., 2006; Schulz et al., 2002; 
Wong  et  al.,  2001).  Together,  these  results  strongly  suggest  that  global 
hypomethylation,  particularly  of  Sat2  elements,  can  lead  to  karyotypic 
abnormalities in cancer through increased frequency of recombination events.  
As well as promoting karyotypic instability, the strong link between DNA 
methylation  and  transcriptional  silencing  suggests  that  hypomethylation  in 
cancer may lead to elevated transcription of genes which favour oncogenesis. 
Cancer associated increases in gene expression due to promoter hypomethylation   40 
have been reported for genes including PS2, HOX11 and MN/CA9 (Cho et al., 
2001; Martin et al., 1997; Watt et al., 2000) and other proto-oncogenes (Tao et 
al., 2000). Similarly, global hypomethylation may contribute to loss of silencing 
at imprinted loci, leading to aberrant expression of paternal transcripts (Sullivan 
et al., 1999; Takai et al., 2001). Finally, studies of global hypomethylation in 
mammalian  model  systems  have  also  demonstrated  increased  expression  of 
transposons  as  a  result  of  demethylation  of  these  elements.    For  example, 
elevated expression of the instracisternal-A particle (IAP) retrotransposon has 
been reported in dnmt1 deficient mouse embryos (Walsh et al., 1998). Similarly, 
demethylation  of  the  LINE1  promoter  in  CML  has  been  shown  to  increase 
transcription of this element (Roman-Gomez et al., 2008). 
  Hypomethylation  across  the  genome  may  also  alter  gene  expression 
patterns  through  trans  effects.  In  particular,  demethylation  may  disrupt  the 
normal  heterochromatin-euchromatin  balance  in  cells,  as  suggested  in  ICF 
lymphoid  cells  (Ehrlich  2001).  Alternatively,  aberrant  recruitment  of  proteins 
involved in transcriptional control to demethylated regions of the genome may 
disrupt the action of these proteins in normal transcription (reviewed in Ehrlich, 
2002). 
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1.4.5    Potential Causes of Genome Wide Hypomethylation 
 
1.4.5.1   Passive DNA Demethylation 
 
The  importance  of  DNA  methyltransferases  (DNMTs)  in  establishing  and 
maintaining DNA methylation patterns suggests that disruption of the activity of 
these  genes  could  result  in  passive  global  hypomethylation  through  loss  of 
methylation  on  consecutive  rounds  of  DNA  replication.  For  example,  dnmt1 
knockout  mice  display  global  hypomethylation  and  increased  frequency  of 
certain  cancers  including  T-cell  lymphomas,  hepatocellular  adenomas  and 
carcinomas (Gaudet et al., 2003; Yamada et al., 2005). However, it is unclear 
whether reduced DNMT1 expression leads to genome-wide hypomethylation in 
cancer.  Studies  of  DNMT1  levels  in  a  variety  of  tumour  types  show  that 
expression  correlates  with  cell  proliferation,  but  there  is  no  significant 
relationship between DNMT1 expression and incidence of hypomethylation in 
cancer (reviewed in Eads et al., 1999; Wilson et al., 2007). 
  Mutations in DNMT3B have been linked to hypomethylation of the Sat2 
tandem  repeat  in  ICF  patients  (Hansen  et  al.,  1999;  Xu  et  al.,  1999).  While 
similar patterns of hypomethylation at this element are observed in cancer, no 
study has yet linked this to reduced DNMT3B expression or function. In fact, 
increased DNMT3B levels in relation to other DNMTs have been reported in 
several cancers (Girault et al., 2003; Kanai et al., 2001).  
  The interplay between histone modifications and DNA methylation also 
suggests that changes to these marks in transformed cells may affect the global 
DNA methylation profile and could potentially play a role in the induction of   42 
hypomethylation. In line with this, an investigation of histone modifications in a 
variety of cancer cell lines and tumours revealed loss of acetylation of H4K16 
and increased trimethylation of H4K20 in cancers compared to normal controls. 
Furthermore, these changes were found to occur at repetitive elements – such as 
the Sat2 pericentromeric repeat as well as subtelomeric D4Z4 and NBL2 repeats 
–  and  correlated  with  hypomethylation  of  these  regions.  However,  the  study 
could not establish whether changes in these histone modifications were a cause 
or consequence of the DNA hypomethylation at these sites (Fraga et al., 2005).  
 
 
1.4.5.2     Active DNA Demethylation   
 
Although the mechanisms described above could result in a ‘passive’ loss of 
DNA methylation through disruption of maintenance or de-novo methylation, 
DNA  hypomethylation  could  alternatively  be  induced  in  an  ‘active’  manner 
through direct removal of the methyl groups. Whilst the enzymes involved in 
establishing DNA methylation have been well characterised, the mechanisms by 
which methyl groups are removed from cytosine residues are less well explored. 
  In particular, genome wide changes in methylation during gametogenesis 
and early embryogenesis provide the strongest evidence in favour of an active 
demethylation mechanism. In mammals, there are at least two periods during 
which global DNA methylation patterns are drastically altered – during zygote 
development and in the preimplantation embryo - in order to impart somatic cells 
with  the  epigenetic  reprogramming  required  for  the  broad  developmental   43 
potential and appropriate imprinting of gametes and the early embryo (reviewed 
in Morgan et al., 2005; Reik et al., 2001; Santos et al., 2002). 
  In  mice,  the  genomes  of  both  male  and  female  primordial  germ  cells 
undergo global DNA demethylation around embryonic day 13 or 14. Following 
this  period,  the  cells  enter  mitotic  or  meiotic  arrest,  after  which  methylation 
patterns  are  re-established  (reviewed  in  Reik  et  al.,  2001).  It  is  not  clear, 
however, whether this process is an active or passive demethylation.  
  Clearer  evidence  for  active  demethylation  occurs  in  the  early  embryo 
following fertilization. During this period, the male pronucleus undergoes drastic 
modification,  including  replacement  of  protamines  with  histones  and  global 
DNA  demethylation.  Crucially,  this  demethylation  occurs  before  DNA 
replication  is  complete,  indicating  that  the  loss  of  methylation  is  an  active 
process. Although this loss of methylation may be a result of changes in the 
chromatin structure, this is unlikely as the same chromatin changes occur in non-
mammalian genomes in the absence of global demethylation (reviewed in Reik et 
al., 2001). 
  Several  studies  have  attempted  to  identify  the  enzymes  involved  in 
demethylation in mammals. Two studies of oestrogen receptor-alpha responsive 
genes in cultured breast cancer cells noted cyclical patterns of demethylation and 
remethylation of CpG sites in target genes over a two hour period following 
treatment  with  oestrogen.  Chromatin  immunoprecipitation  demonstrated 
coincident recruitment of DNMT3A and DNMT3B to the promoter regions of 
these genes, suggesting that these enzymes may be involved in the demethylation 
process. The authors suggest that the deaminase activity of these enzymes allows 
them to mediate oxidative deamination of methylcytosine in the absence of the   44 
methyl  donor  AdoMet  (S-adenosine  L-methionine).  This  converts  the 
methylcytosine  to  a  thymine  residue,  leading  to  a  guanine:thymine  (G:T) 
mismatch, and subsequent removal of the thymine by thymine DNA glycosylase 
(TDG) and methyl-binding protein 4 (MBD4). Finally, this site is repaired by the 
base excision repair mechanisms, ultimately replacing the methylated cytosine 
residue with an unmethylated counterpart (Kangaspeska et al., 2008; Métivier et 
al., 2008; Ooi and Bestor, 2008). However, the short time frame of this reported 
demethylation  would  require  DNMT3A  and  3B  to  be  extremely  efficient 
deaminases. Furthermore, concentrations of AdoMet would have to be limiting 
in vivo in order for the conversion of methylcytosine to thymine to take place.  
Demethylase activity has reportedly been observed in several studies of 
nuclear and whole cell extracts, including a protease-sensitive activity in murine 
erythroleukemia nuclear extracts and RNAse sensitive activity in whole cell rat 
myoblast extracts (Gjerset and Martin, 1982; Weiss et al., 1996). However, these 
reports have faced widespread criticism and subsequent characterisation of this 
demethylase activity has not been forthcoming. Thymine DNA glycosylase has 
also been identified as having methylcytosine glycosylase activity, however the 
efficiency  of  this  reaction  of  too  low  for  the  enzyme  to  be  a  viable  DNA 
demethylase (Cortázar et al., 2007; Jost, 1993).  
It has also been proposed that methyl-binding protein 2 (MBD2) is able 
to catalyse direct removal of the methyl group from methylcytosine, however 
several other groups have subsequently been unable to repeat these experiments 
(Bhattacharya  et  al.,  1999;  Boeke  et  al.,  2000;  Ng  et  al.,  1999;  Wade  et  al., 
1999). Additionally, mbd2 knockout mice display similar levels and distribution 
of methylcytosine to wild type mice, alongside normal imprinting, suggesting   45 
that this protein does not play an essential role in normal methylation patterning 
(Hendrich et al., 2001).  
 Finally, studies in both Xenopus and zebrafish have suggested that the 
nuclear  protein  Gadd45a  may  be  involved  in  DNA  demethylation  via  a  base 
excision repair mechanism. In vitro experiments in HEK293T cells indicated that 
GADD45A  overexpression  lead  to  demethylation  of  a  methylation-silenced 
reporter  plasmid  as  well  as  global  loss  of  DNA  methylation.  Additionally, 
Gadd45a is specifically recruited to the Oct4 gene during active demethylation of 
this region in Xenopus oocytes (Barreto et al., 2007). Similar experiments in 
zebrafish  revealed  a  demethylase  activity  on  the  introduction  of  in  vitro 
methylated DNA into zebrafish embryos (Rai et al., 2008). This activity was 
shown  to  be  dependent  on  the  5-methylcytosine  deaminase  AID,  the  G:T 
mismatch  repair  enzyme  Mbd4  and  Gadd45a.  The  authors  suggest  a 
demethylation  mechanism  similar  to  that  described  above,  whereby 
methylcytosine is first deaminated to thymine by AID, followed by base excision 
repair to cytosine by Mbd4 and Gadd45a (Rai et al., 2008). However, another 
study of GADD45A activity using in vitro demethylation assays in human and 
mouse cell lines failed to reproduce these findings. Additionally, the authors note 
that  Gadd45a  is  not  expressed  during  early  mouse  development  when  active 
demethylation of the genome is observed, suggesting that this enzyme may not 
act as a DNA demethylase (Jin et al., 2008). 
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1.4.5.3   SAM availability and Hypomethylation 
 
In  addition  to  active  demethylation  or  passive  loss  of  methylation  through 
decreased DNMT expression or activity, global hypomethylation may also result 
from changes in the availability of the substrates required by DNMTs. DNA 
methylation is achieved through an enzymatic reaction whereby a methyl group 
from the donor S-adenosylmethionine (SAM) is transferred to the C-5 in the 
pyrimidine  ring  of  cytosine.  In  this  process,  SAM  is  converted  to  S-
adenosylhomocysteine  (SAH),  which  is  in  turn  broken  down  to  yield 
homocysteine and adenosine.  Methionine is generated from homocysteine in a 
folate dependent reaction catalysed by MTR and MTRR and is finally converted 
to SAM to complete the cycle (reviewed in Laird and Jaenisch, 1996). 
  Disruption  of  SAM  production,  through  altered  metabolic  activity  or 
reduced  substrate  availability,  could  therefore  lead  to  genome  wide 
hypomethylation  in  cells.  Since  the  conversion  of  homocysteine  to  SAM  via 
methionine requires donation of a methyl group from substrates including dietary 
components such as folate, deficiency of these methyl donors could disrupt this 
process.  A  number  of  studies  in  rats  support  a  causal  relationship  between 
methyl-deficient diets and decreased levels of SAM to global hypomethylation 
and cancer (reviewed in Szyf et al., 2004). Similarly, dietary methyl or folate 
deficiency together with high alcohol intake in humans have been suggested to 
increase risk of colorectal cancer, suggesting that altered SAM metabolism and 
subsequent disruption to DNA methylation may play an important role in the 
development of other cancers (Kim, 2005).  
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1.5    Polycomb Group Proteins and Target Gene Silencing 
 
Polycomb group (PcG) proteins are epigenetic gene silencers first identified in 
Drosophila as developmental repressors of homeotic Hox genes (Ringrose and 
Paro,  2004).    The  vertebrate  homologues  of  these  genes  play  a  similar  role, 
acting  to  epigenetically  silence  gene  expression  through  histone  modification 
(Levine  et  al.,  2002).  Functionally,  PcG  proteins  form  conserved  polycomb 
repressive complexes (PRCs), of which PRC2 plays a key role in normal and 
neoplastic development. PRC2 is composed of three core proteins – enhancer of 
Zeste homologue 2 (EZH2), suppressor of Zeste 12 (SUZ12) and enhancer of 
ectodermal development (EED) (Müller et al., 2002; Tie et al., 2001). 
EZH2 catalyses the trimethylation of histone H3 lysine 27 (H3K27me3) 
and to a lesser extent trimethylation of histone H3 lysine 9 (H3K9me3) (Cao et 
al., 2002; Kuzmichev et al., 2002). This action of the PRC2 complex leads to 
gene repression by a number of downstream mechanisms.  First, H3K27me3 is 
believed to provide a binding site for polycomb repressive complex 1 (PRC1), 
which in turn blocks the recruitment of transcriptional activation factors such as 
the ATP-dependent nucleosome remodelling complex SWI/SNF and prevents the 
initiation of transcription by RNA polymerase II (Dellino et al., 2004; Shao et al., 
1999).  Secondly,  EZH2  is  able  to  recruit  DNA  methyltransferases  to  certain 
target  genes,  resulting  in  gene  silencing  through  promoter  hypermethylation 
(Vire et al., 2006). Finally, there have been reported cases of PRC2 methylation 
of  histone  H1  lysine  26  (H1K26me),  which  may  influence  higher  order 
chromatin structure by affecting the binding of heterochromatin binding protein 
1 (HP1) (Daujat et al., 2005; Kuzmichev et al., 2004).    48 
The closely related polycomb repressive complex 1 (PRC1) also plays a 
key  role  in  the  transcriptional  silencing  of  polycomb  target  genes.  The  core 
components of PRC1 were originally identified in Drosophila as Polycomb (PC), 
Polyhomeotic  (PH),  Posterior  Sex  Combs  (PSC)  and  Sex  Combs  Extra 
(SCE/RING), with the mammalian homologues of these proteins (CBX4, PH1, 
BMI1  and  RING1B,  respectively,  in  humans)  also  forming  stable  complexes 
(Shao  et  al.,  1999;  Simon  and  Kingston,  2009).  PRC1  is  able  to  bind  the 
H3K27me3  chromatin  modification  through  the  chromodomain  of  PC,  with 
localisation  of  the  complex  to  target  genes  potentially  mediated  through  this 
interaction  (Min  et  al.,  2003).  Although  the  exact  mechanisms  of  PRC1 
dependent gene silencing have yet to be established, this action is believed to 
result  from  chromatin  compaction  and  ubiquitylation  of  histone  H2A  by  the 
complex (Wang et al., 2004). 
 
 
1.5.1    Targeting of Polycomb Group Complexes 
 
The mechanisms by which PRC1 and PRC2 are targeted to genes have been well 
studied in Drosophila, where PcG complexes are recruited to DNA sequences 
termed  polycomb  responsive  elements  (PREs)  (Müller  and  Kassis,  2006). 
Although  several  PREs  have  been  characterised  through  investigation  of 
polycomb targets including the Hox genes and Engrailed, no consensus sequence 
between  PREs  has  yet  been  identified.  However,  binding  sites  for  the  DNA 
binding protein Pleiohomeotic (PHO) and PHO-like are shared between PREs, 
with both proteins playing an essential role in PcG recruitment (Fritsch et al.,   49 
1999; Simon and Kingston, 2009). Although mammalian PREs have yet to be 
defined, OCT4 and YY1 have been suggested to be involved in the recruitment 
of PcG complexes to target genes (Mihaly et al., 1998).  
  A number of investigations have also suggested a role for non-coding 
RNAs (ncRNAs) in PcG complex targeting. For example, the ncRNA HOTAIR, 
transcribed  from  the  HOXC  locus,  has  been  shown  to  interact  with  PRC2 
subunits.  Furthermore,  depletion  of  this  RNA  causes  loss  of  H3K27me3  and 
desilencing of the HOXD locus in trans (Rinn et al., 2007). Similarly, the ncRNA 
XIST has been implicated in PRC2 targeting, with in vitro studies indicating that 
PRC2 interacts with a 28bp repeat element within the XIST transcript known as 
repA (Zhao et al., 2008). Further investigations will be required to establish the 
full  role  of  ncRNAs  and  other  mechanisms  in  PcG  complex  targeting  in 
mammalian systems (Simon and Kingston, 2009).  
 
 
1.5.2    The Role of PRC2 
 
Gene  repression  by  PRC2  is  essential  in  normal  development  and  cell  fate 
decisions,  specifically  the  maintenance  of  embryonic  stem  (ES)  cell 
pluripotency. This role was first suggested by experiments which demonstrated 
that  ES  cell  lines  could  not  be  established  from  ezh2  deficient  blastocysts 
(Erhardt  et  al.,  2003).  Further  characterisation  of  PRC2  target  genes  by 
chromatin  immunoprecipitation  (ChIP)  indicated  that  PcG  proteins  target  a 
number of genes associated with differentiation and lineage specification (Boyer 
et al., 2006; Lee et al., 2006). Repression of these genes by PcG proteins is   50 
therefore essential in maintaining an undifferentiated state in stem cells, as has 
been shown during neuronal differentiation (Bracken et al., 2006). Intriguingly, 
in  ES  cells  many  PcG  target  genes  are  co-occupied  by  OCT4,  SOX2  and 
NANOG  –  transcription  factors  required  for  the  maintenance  of  stem  cell 
pluripotency  (Sparmann  and  van  Lohuizen,  2006).    Although  no  direct 
interaction  between  these  transcription  factors  and  PcG  proteins  has  been 
reported, it is possible that PcGs are recruited to these genes in order to maintain 
gene silencing and repress differentiation (Boyer et al., 2006; Lee et al., 2006). In 
support of this view, it has been observed that SUZ12 is displaced from certain 
target genes following OCT4 knockdown (Squazzo et al., 2006). 
 
 
1.5.3    The Role of Bilvalent Chromatin in ES Cell Pluripotency 
 
The repressive histone modification established by PRC2, H3K27me3, is one 
half  of  an  unique  chromatin  state  found  at  the  promoter  regions  of  key 
developmental genes along with methylated H3 lysine 4 (H3K4me) - a chromatin 
modification normally associated with active promoters. It is believed that this 
‘bivalent’ chromatin domain maintains repression of developmental genes whilst 
keeping  them  poised  for  quick  activation  when  growth  signals  are  received 
(Bernstein et al., 2006). Genes associated with bivalent chromatin domains are 
transcribed at low levels in ES cells as a result of RNA polymerse binding, and 
become  activated  or  repressed  on  the  induction  of  differentiation  through  an 
increase in H3K4me or H3K27me3, respectively (Bernstein et al., 2006). The 
importance  of  these  chromatin  modifications  in  differentiation  has  been   51 
confirmed by a genome wide study of chromatin modifications in mouse ES 
cells,  neural  protenitor  cells  and  embryonic  fibroblasts.  This  investigation 
confirmed  that  relative  levels  of  H3K4  and  H3K27  trimethylation  effectively 
discriminates genes that are expressed, poised for expression, or stably repressed, 
therefore  reflecting  the  current  state  and  lineage  potential  of  these  cells 
(Mikkelsen et al., 2007). Furthermore, another study has shown that premature 
expression of genes associated with bivalent chromatin domains occurs in Eed 
deficient mouse ES cells (Azuara et al., 2006). Polycomb repressive complexes 
therefore play an important role in maintaining ES cell pluripotency through the 
creation and preservation of bivalent domains at key developmental genes.  
 
 
1.5.4    PRC2 and Cancer 
 
PRC2  also  plays  an  important  role  in  the  development  of  cancer.  EZH2  up-
regulation was initially identified in prostate cancer and has subsequently been 
shown in a variety of neoplasms including several types of lymphoma, breast 
cancer  and  melanoma  (Varambally  et  al.,  2002).  Additionally,  SUZ12  shows 
similar overexpression in colon and breast cancer (Sparmann and van Lohuizen, 
2006). Further characterisation has demonstrated that EZH2 has many properties 
consistent with an oncogene. In particular, EZH2 overexpression increases cell 
proliferation,  invasion  of  benign  cells,  colony  formation  and  in  vivo  tumour 
growth in nude mice (Bracken et al., 2003; Kleer et al., 2003; Varambally et al., 
2002). Conversely, EZH2 knockdown results in growth arrest of cancer cells, as 
well as decreasing tumour growth and metastasis in vivo (Croonquist and Van,   52 
2005;  Varambally  et  al.,  2002).  Finally,  high  levels  of  EZH2  expression  are 
associated with metastatic states in both prostate and breast cancer (Croonquist 
and Van, 2005; Kleer et al., 2003; Varambally et al., 2002).  
The repressive action of PRC2 suggests a role for this complex in gene 
silencing  during  tumourigenesis  (Schlesinger  et  al.,  2007).  In  support  of  this 
view, a study of DNA methylation in colorectal cancers and matched normal 
mucosa  indicated  that  PcG  targets  are  up  to  12  fold  more  likely  to  be 
hypermethylated than non-targets in the cancer (Widschwendter et al., 2007).  
Additionally, there is a strong inverse correlation between PRC2 occupancy and 
RNA polymerase II occupancy at target gene promoters, suggesting that these 
genes are not transcribed (Lee et al., 2006; Squazzo et al., 2006). However, other 
studies have also suggested a role for PRC2 in gene activation. In particular, 
PRC2 knockdown in colon cancer cells resulted in down-regulation of a small 
subset of genes and EZH2 has also been linked to activation of cell cycle control 
genes in breast cancer cells (Simon and Lange, 2008). 
There  are  two  possible  ways  in  which  this  gene  repression  could 
contribute towards transformation. Firstly, PcG complexes may silence tumour 
suppressor genes, which normally act to limit uncontrolled cellular proliferation. 
Secondly,  the  involvement  of  PcG  proteins  in  maintaining  pluripotency  may 
contribute  to  the  multipotency  of  cancer  cells  (Sparmann  and  van  Lohuizen, 
2006). Shared properties between cancer cells and stem cells, namely the ability 
to  divide  indefinitely  and  generate  a  diverse  set  of  progeny,  suggest  that 
tumourigenesis  may  take  place  in,  or  involve  a  transition  towards 
undifferentiated  or  de-differentiated  cells.  The  role  of  EZH2  in  maintaining 
pluripotency by repressing differentiation suggests that the PRC2 complex may   53 
play a similar role during transformation (Ohm et al., 2007; Schlesinger et al., 
2007; Widschwendter et al., 2007). Furthermore, similarities in gene expression 
signatures  between  poorly  differentiated  tumours  and  ES  cells  comprise  a 
number of PRC2 target genes alongside OCT4, SOX2, NANOG and c-MYC 
target genes, supporting the view that aberrant PRC2 activity plays an important 
role in maintaining transformed cells in a more stem cell-like state (Ben-Porath 
et al., 2008).  
As well as increased expression of PcG proteins in cancer, there are 
indications  that  PRC2  target  gene  preference  may  also  be  altered  in  cancer. 
Although PcG proteins normally target developmental transcription factors in 
embryonic cell lines, SUZ12 has been shown to also target glycoprotein genes in 
adult tumour cells (Squazzo et al., 2006). Alterations to the composition and 
substrate specificity of PcG complexes may account for these changes in target 
preference. EZH2 is able to associate with different EED isoforms, of which 
there are four. Classical PRC2 contains the longest form of EED, EED1, whereas 
shorter isoforms associate with EZH2 to form alternative ‘PRC2-like’ complexes 
PRC3 and PRC4. PRC4 is selectively enriched in cancer cells and formation of 
this complex is favoured when EZH2 is overexpressed (Kuzmichev et al., 2005). 
PRC4 displays a different substrate affinity to PRC2 – preferring to methylate 
histone H1K26 rather than H3K27. Furthermore, the histone deacetylase SIRT1 
also  forms  part  of  the  complex  and  targets  H1K26,  potentially  allowing  the 
complex to deacetylate this histone before a methylation event (Kuzmichev et al., 
2004). However, a study of H1 methylation by recombinant EZH2 complexes in 
the presence of different EED isoforms failed to detect any significant variation 
in substrate preference (Martin et al., 2006).   54 
 
1.5.5    Mechanisms of PRC2 Up-regulation 
 
Several studies have investigated the mechanisms by which expression of PRC2 
components are regulated (Figure 1.1). A study of EZH2 regulation identified 
microRNA-101  as  a  negative  regulator  of  its  expression  and  function. 
Furthermore,  the  genomic  region  containing  this  micro-RNA  was  deleted  in 
some  prostate  tumours,  leading  to  EZH2  overexpression  (Varambally  et  al., 
2008).  
A link between the control of EZH2 expression and the oncogene MYC 
has  also  been  identified.  Utilizing  a  murine  model  of  lymphoma  and  human 
Burkitt’s lymphoma samples, MYC was shown to be a negative regulator of 
miR-26a, which is in turn an inhibitor of EZH2 expression.  Increased MYC 
expression  or  activity  in  cancer  can  therefore  lead  to  concurrent  increase  in 
EZH2 expression via this microRNA mediated mechanism (Sander et al., 2008).  
EZH2, SUZ12 and EED have been shown to be downstream of the pRb-
E2F pathway, with the E2F transcription factor binding to and activating all three 
promoters in normal and transformed cells (Bracken et al., 2003; Müller et al., 
2001; Weinmann et al., 2001).  
Finally, viral oncogenes have also been shown to regulate expression of 
PRC2  components.  For  example,  human  papillomavirus  16  (HPV16)  E7  has 
been  shown  to  increase  EZH2  expression  by  releasing  E2F.  Additionally,  a 
separate  study  has  demonstrated  that  EZH2  expression  is  required  for 
proliferation  of  HPV  positive  tumour  cells  and  contributes  to  the  apoptotic 
resistance of cervical cancer cells (Holland et al., 2008).    55 
 
 
 
 
Figure 1.1: Summary of PRC2 regulation. Expression of the PRC2 components EZH2, EED 
and  SUZ12  has  been  shown  to  be  governed  by  a  number  of  mechanisms,  including  direct 
transcriptional  regulation  of  all  components  by  the  transcription  factor  E2F  and  negative 
regulation of EZH2 expression and function by microRNAs. 
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1.6    The Cancer Stem Cell Theory 
 
Identifying the ‘normal’ tumour originating cells which are subject to oncogenic 
changes  has  been  a  subject  of  much  debate  in  recent  years.  A  number  of 
observations  have  questioned  the  traditional  view  of  terminally  differentiated 
cells  acquiring  oncogenic  hits.  In  particular,  the  heterogeneous  nature  of 
tumours, comprising a wide variety of cells in different states of maturity and 
transformation,  has  been  difficult  to  account  for.  Furthermore,  only  a  small 
proportion of cancer cell lines are able to form tumours in experimental models, 
often only with the introduction of a large quantity of cells. Finally, cancer cell 
lines and tumour xenografts can only be obtained from patient tumours with a 
very low efficiency (Bjerkvig et al., 2005; Polyak and Hahn, 2006; Reya et al., 
2001).  
Evidence for the existence of cancer stem cells first arose during an in 
vivo study of acute myeloid leukaemia (AML) whereby it was demonstrated that 
only a small subset (1 in 250,000) of cancer cells were able to recapitulate a full 
cancer  when  transplanted  into  immunodeficient  mice,  with  the  CD34
+/CD38
- 
fraction  of  cells  enriched  for  tumour  forming  ability  (Lapidot  et  al.,  1994). 
Cancer  stem  cells  have  subsequently  been  identified  in  a  variety  of  different 
cancers (Visvader and Lindeman, 2008). The first report of cancer stem cells in a 
solid tumour came from a study of breast cancer in which cells from 9 patients 
were isolated and sorted on the basis of surface marker expression. As few as 
200 cells from the fraction of cells expressing CD44 and low levels of CD24 
(CD44
+/CD24
-/low)  were  required  to  form  tumours  when  injected  into  mice,   57 
whereas injection of 100-fold more cells from the CD44
+/CD24
+ fraction failed 
to form tumours (Al-Hajj et al., 2003). Cancer stem cells have also been isolated 
using CD133 in a variety of cancers including several types of brain tumour, as 
well as colorectal and pancreatic carcinoma (Beier et al., 2007; Hermann et al., 
2007; O'Brien et al., 2007; Ricci-Vitiani et al., 2007; Singh et al., 2004; Taylor et 
al., 2005). 
 
 
1.6.1    Similarities Between Normal and Cancer Stem Cells 
 
1.6.1.1   Signaling Pathways 
 
Many of the signalling pathways involved in the self-renewal capacity of normal 
stem cells are also implicated in development of cancer. In particular, the Wnt, 
Notch,  Hedgehog,  PTEN  and  BMI1  pathways  all  play  an  important  role  in 
maintaining self-renewal in normal stem cells and have been shown to promote 
neoplastic proliferation when deregulated (Pardal et al., 2003). For example, Wnt 
signalling plays in important role in regulating intestinal stem cell self renewal, 
in part by controlling cell migration and proliferation through downstream ephrin 
family proteins and c-MYC respectively (Dodge et al., 2005; van de Wetering et 
al., 2002). Mutations that activate Wnt signalling in intestinal progenitors lead to 
hyperproliferation of these cells and subsequent development of benign polyps in 
which multi-lineage differentiation can be observed (Moser et al., 1992; Powell 
et  al.,  1992;  van  de  Wetering  et  al.,  2002).  Wnt  signalling  has  also  been 
implicated in the maintenance of haematopoietic stem cell self renewal  as well   58 
as the renewal of CML stem cells in vivo (Austin et al., 1997; Reya and Clevers, 
2005; Van Den Berg et al., 1998; Zhao et al., 2007). 
  Notch  signalling  has  also  been  shown  to  play  an  important  role  in 
haematopoietic stem cell maintenance, with stimulation by the Jagged-1 ligand 
increasing progenitor activity of these cell in vitro and in vivo (Karanu et al., 
2000;  Varnum-Finney  et  al.,  2000).  Increased  self-renewal  of  haematopoietic 
stem  cells  has  also  been  observed  in  vitro  in  response  to  sonic  hedgehog 
signalling in combination with other growth factors (Bhardwaj et al., 2001).  
 
 
1.6.1.2    Polycomb Group Activity 
 
Polycomb group proteins also play an important role in the maintenance of stem 
cells  through  their  repressive  action.  A  particularly  important  protein  in  this 
group  is  BMI1,  which  promotes  cell  proliferation  through  inhibition  of 
CDKN2A, encoding for the cyclin dependent kinase inhibitors INK4A (p16) and 
ARF (p14) (Jacobs et al., 1999a; Jacobs et al., 1999b). Haematopoietic stem cells 
lacking  BMI1  show  limited  self  renewal  capacity  (Park  et  al.,  2003). 
Additionally,  proliferation  of  leukaemic  stem  cell  has  been  shown  to  be 
dependent on BMI1, with deficient stem cells lacking the ability to recapitulate 
the  cancer  when  transplanted  into  immunodeficient  mice  (Lessard  and 
Sauvageau,  2003).  The  dependence  of  both  normal  and  cancer  stem  cells  on 
similar signalling pathways is a further indication that cancer stem cells may 
arise as a result of dysregulation of self-renewal pathways in normal stem cells.  
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1.6.2    Normal Cells Subject To Transformation 
 
The  identity  of  the  cells  from  which  cancer  stem  cells  originate  has  been  a 
subject of widespread debate. The self-renewal properties of cancer stem cells 
suggest  that  they  develop  either  from  normal  adult  stem  cells,  through  the 
acquisition  of  oncogenic  mutations,  or  from  differentiated  cells  that  ‘de-
differentiate’ into a more stem-cell like state (Zilberman, 2007). The fact that 
several mutations or epigenetic changes are required for transformation to take 
place suggests that cells with a longer lifespan, such as stem cells, are more 
likely to accumulate such oncogenic changes (Knudson et al., 1973). Since the 
turnover of differentiated cells in many organs is high, it has been suggested that 
the adult stem cells in these organs are subject to transformation as these are the 
only cells with a long enough life span. Studies of leukaemic stem cells have 
demonstrated that they display similar surface markers to haematopoietic stem 
cells, suggesting that they may arise from transformation of these progenitors 
(Bonnet and Dick, 1997). In support of this hypothesis, leukaemogenic mutations 
increase the proliferation rate and block differentiation of haematopoietic stem 
cells  (Kelly  and  Gilliland,  2002;  Pereira  et  al.,  1998).  In  addition,  there  are 
numerous  phenotypic  similarities  between  soft  tissue  sarcoma  cells  and 
mesenchymal  progenitor  cells,  and  these  progenitors  can  be  converted  into 
Ewing’s sarcoma through expression of the fusion protein ETS-FL1 (Riggi et al., 
2005). Additionally, a mouse model in which the SYT-SSX fusion protein is 
conditionally expressed has been used to show that synovial sarcomas derive 
from myogenic precursor cells (Haldar et al., 2007). Although in both these cases 
the progenitor cells are derived from the same tissue of origin as the cancer,   60 
gastric  cancers  can  originate  from  transformation  of  bone  marrow  derived 
progenitor cells (Houghton et al., 2004). These studies suggest that cancers arise 
following oncogenic changes in adult stem cells or progenitor cells.  
The alternate hypothesis is that cancer stem cells could originate from 
committed  progenitors  or  fully  differentiated  cells  that  acquire  self-renewal 
capacities and de-differentiate towards a more stem cell like state. In line with 
this, a number of fusion proteins including MOZ-TIF2 and MLL-AF9 have been 
shown to activate self-renewal systems and confer stem cell like properties on 
committed haematopoietic progenitor cells, leading to the generation of cancer 
stem cells (Huntly et al., 2004; Krivtsov et al., 2006). Similarly, a  -catenin 
mutation  promotes  self-renewal  in  granulocyte-macrophage  progenitors  in 
patients  with  chronic  myeloid  leukaemia  (Jamieson  et  al.,  2004).  A  number 
studies  have  demonstrated  that  pluripotent  cells  can  be  created  from  fully 
differentiated cells through the expression of a small number of transcription 
factors – namely Oct4, Sox2, Klf4 and c-Myc, although some of these factors 
have been shown to be dispensable or can be replaced with others (Feng et al., 
2009; Nakagawa et al., 2007; Takahashi et al., 2007). These induced pluripotent 
cells (iPS) are virtually indistinguishable from normal embryonic stem cells and 
are able to differentiate into cell types from the three germ layers (Takahashi et 
al.,  2007).  It  remains  a  strong  possibility,  therefore,  that  similar  ‘de-
differentiation’ events occur in differentiated cells during the development of 
cancer, allowing the cells to acquire more stem-cell like characteristics.   
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1.6.3    Limitations Of The Cancer Stem Cell Theory 
 
1.6.3.1   Differences In Surface Markers 
 
A number of cell surface markers and dye efflux assays have been described for 
the  selective  isolation  of  cancer  stem  cells  from  a  variety  of  cancers.  These 
include  CD133,  CD24,  CD44,  EpCAM,  THY1  as  well  as  exclusion  of 
Hoechst33342  dye  from  a  side  population  (Visvader  and  Lindeman,  2008).  In 
many cases, cancer stem cells share many of the surface markers of normal stem 
cells  from  the  same  organ.  Although  markers  such  as  CD133  and  CD44  are 
present on cancer stem cells from a variety of origins, a single definitive marker 
for cancer stem cells has not yet been identified. In fact, there is a great degree of 
heterogeneity in the cancer stem cell markers reported by different groups for the 
same tumour type. For example, in breast cancer, high aldehyde dehydrogenase 1 
(ALDH1)  activity  has  been  reported  in  the  tumourigenic  fraction  of  cells. 
However,  very  little  overlap  was  observed  between  these  cells  and  the 
CD44
+/CD24
- phenotype previously described for breast cancer stem cells (Al-
Hajj et al., 2003; Ginestier et al., 2007). There also appears to be a degree of 
heterogeneity  within  individual  cancer  stem  cell  populations.  A  study  of 
glioblastoma  cancer  stem  cells  indicated  that  both  CD133
+  and  CD133
-  cells 
could form tumours when injected into nude mice (Beier et al., 2007). Another 
investigation of cell lines derived from brca1 deficient mouse mammary tumours 
showed  that  either  CD44
+/CD42
-  or  CD133
+  cells  could  form  tumours  when 
injected into immunodeficient mice in small numbers, with no overlap between 
the two populations (Wright et al., 2008).    62 
  As  well  as  differences  between  the  reported  markers  for  cancer  stem 
cells, there is also a great degree of variation in reports of the proportion of 
tumour cells with tumour initiating potential. The proportion of ABCB5
+ cells 
reported  in  melanomas  varies  from  1.6-20%  of  total  tumour  cells  and  the 
proportion  of  CD133
+  cells  in  colorectal  carcinomas  ranges  from  1.8-24.5% 
(O'Brien et al., 2007; Schatton et al., 2008). These findings indicate that although 
considerable progress has been made in the identification and characterization of 
cancer stem cells, there is significant variation in the phenotype and percentage 
of putative cancer stem cells in different tumours. Further studies are required to 
determine the source and significance of this variation.  
 
 
1.6.3.2   Differences In Transplantation Efficiency 
 
Although serially injecting cells into immunodeficient mice is currently the gold 
standard test for cancer stem cells, this method has a number of drawbacks. First, 
differences  between  both  species  and  tissue  specific  microenvironments  may 
introduce  a  selection  bias  for  cells  with  enhanced  immune  evasion  and 
propagation potential rather than genuine cancer stem cells (Kelly et al., 2007). A 
number of modifications to the standard protocols have been trialled in order to 
minimise such differences and recapitulate a more permissive environment for 
the transplanted cells. For example, human breast fibroblasts can be injected into 
a mouse mammary pad in order to create a more ‘humanized’ environment for 
xenotransplantation. Although transplanted normal breast stem cells are able to 
grow  at  these  sites,  repopulation  frequency  remains  low  (Kuperwasser  et  al.,   63 
2004).  Alternative  strategies  include  mixing  the  stem  cells  with  other  cancer 
associated  cells  such  as  fibroblasts  or  mesenchymal  stem  cells  may  help  to 
recreate a more appropriate niche (Karnoub et al., 2007).  
As well as the immediate cellular environment, other systemic factors 
may also play a role in the efficiency of tumour formation in mice. For example, 
oestrogen levels were shown to be important in the growth of oestrogen-receptor 
negative breast cancers in mice, leading to recruitment of stromal cells important 
for the development of these tumours (Gupta et al., 2007).  
  The  efficiency  of  tumour  formation  in  mice  can  also  be  affected  by 
residual immune function in the host. Although the most commonly used non-
obese  diabetic/severe  combined  immunodeficiency  (NOD/SCID)  mice  are 
severely immunocompromised, these mice do retain a small degree of natural 
killer  cell  activity.  This  could  potentially  result  in  an  underestimation  of  the 
efficiency at which transplanted cells are able to recapitulate tumours. In fact, a 
study utilizing the more severely immunocompromised NOD/SCID interleukin-2 
receptor gamma chain null (il2rg
-/-) mice demonstrated that the proportion of 
detectable tumourigenic melanoma cells can be drastically increased (Quintana et 
al., 2008). Injection of unselected melanoma cells from 12 different patients into 
these  mice  showed  that  approximately  25%  of  these  cells  were  able  to  form 
tumours. Furthermore, in single cell transplants, 27% of unselected melanoma 
cells were able to form tumours. Finally, a screen of surface marker expression in 
these tumour forming cells failed to detect any suitable markers to distinguish 
these cells from the population unable to form tumours. These results show that 
the proportion of cancer initiating cells in melanoma is much higher than was 
previously  reported  and  that  the  tumour  forming  cells  are  apparently   64 
phenotypically  heterogeneous  and  lack  the  classic  cancer  stem  cell  markers 
previously reported (Quintana et al., 2008).  
  Finally,  the  site  of  transplantation  may  also  have  an  effect  on  the 
frequency of tumour initiation. A number of studies have reported significant 
differences in tumour initiating potential when cells are injected into different 
sites in mice. A study of glioblastoma derived cell transplantation revealed an 
increase in tumour initiation frequency from 50% when injected subcutaneously 
to 100% when cells were injected into the cranium (Galli et al., 2004). However, 
strict orthotopic transplantation of the cells does not always seem necessary – 
injection  of  colorectal  cancer  stem  cells  under  the  kidney  capsule  can  also 
increase tumour formation to 100% compared to 30% subcutaneously (Visvader 
and  Lindeman,  2008).  This  suggests  that  a  number  of  factors  –  such  as 
differences in vascularisation, growth factors and extracellular matrix at the site 
of  injection  -  play  a  role  in  generating  the  observed  differences  in  tumour 
formation efficiency.  
 
 
 
 
 
 
 
 
 
   65 
1.7    The Epigenetic Progenitor Origin of Cancer 
 
A landmark paper by Feinberg et al. has attempted to unify the notions of genetic 
and epigenetic changes alongside the cancer stem cell theory by exploring the 
role  of  progenitor  cells  in  cancer  formation  and  proposing  a  step-wise 
mechanistic basis for epigenetic disruption and transformation (Feinberg et al., 
2006).  
  In this report, the authors note that many lines of evidence indicate that 
stem cells or progenitor cells may be the targets of transformation. Furthermore, 
epigenetic mechanisms are key in maintaining this stem cell identity, and are also 
commonly dysregulated during the development of cancer. Taken together, they 
postulate that early epigenetic disruption of stem cells is a key determinant of 
cancer  risk,  tumour  progression  and  heterogeneity.  Five  key  observations  are 
provided to support the notion that cancers arise from epigenetically disrupted 
progenitor cells: firstly, in vitro studies have demonstrated that tumour related 
growth properties of both leukaemia and solid tumours are reversible, indicating 
an  epigenetic  basis  to  this  phenotype  (Lotem  and  Sachs,  2002;  Sachs,  1986; 
Yuspa,  1983).  Secondly,  the  ubiquity  of  global  epigenetic  changes  such  as 
genome  wide  hypomethylation  and  promoter  hypermethylation  in  cancers, 
including  benign  neoplasms,  indicates  that  these  changes  are  likely  to  occur 
before any genetic changes that lead to transformation (Feinberg and Vogelstein, 
1983;  Goelz  et  al.,  1985).  Thirdly,  a  study  has  demonstrated  that  mouse 
melanoma nuclei can be used to clone a normal mouse, indicating that many of 
the tumourigenic properties of these cells are epigenetically controlled and can 
be  reversed  (Hochedlinger  et  al.,  2004).  Fourthly,  serial  transplantation  of   66 
selected cell populations derived from tumours has demonstrated that a small 
subset of tumour cells retain self-renewal capabilities and are able to recapitulate 
a full tumour with a range of cell types (Kim et al., 2005; Pardal et al., 2003; 
Singh et al., 2004). Finally, a study of colorectal cancer cases associated with 
loss of imprinting (LOI) of the IGF2 gene demonstrated that this LOI is observed 
in the apparently normal colonic epithelium of these patients, and is therefore 
likely to have occurred before further tumourigenic hits. Additionally, LOI of 
IGF2 in both humans and mice is associated with a shift in the proportion of 
progenitor and differentiated cells in the colonic epithelium (Cui et al., 2003; 
Sakatani et al., 2005; Woodson et al., 2004).  
  In this model, tumourigenesis occurs in three distinct stages. The first of 
these involves epigenetic disruption of tumour progenitor genes – genes that can 
increase cancer likelihood by increasing cell ‘stemness’, or properties of self-
renewal and pluripotency over a tendency towards limited replicative potential 
and differentiation. Candidate tumour progenitor genes include OCT4, IGF2, E-
cadherin, FOXD3 and EZH2, all genes involved in the maintenance of stem cell 
pluripotency. Following this epigenetic disruption in a progenitor cell population, 
the second step towards transformation can take place – an initiating mutation 
that is specific to the cancer type. For example, specific mutations of APC occur 
in colorectal cancer, and specific recombination events lead to the formation of 
fusion  proteins  such  as  BCR-ABL  in  CML.  Finally,  genetic  and  epigenetic 
plasticity is required for further tumourigenic changes to take place. This can 
take the form of genomic instability or changes to DNA methylation and histone 
modifications, or to the mechanisms governing these epigenetic marks.   
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1.8    The Stem Cell Model 
 
In order to investigate the potential link between adult stem cells and cancer, 
Funes et al. have established a line of primary mesenchymal stem cells - thought 
to be the origin of various types of sarcoma - in which five oncogenic steps 
towards a fully transformed state are sequentially introduced (Figure 1.2a; Funes 
et al., 2007).  
Primary human MSC were isolated from the bone marrow of a healthy 34 
year  old  male  donor  by  density  gradient  centrifugation,  with  MSC  colonies 
formed  after  plating  designated  passage  0  and  subsequently  passaged 
approximately 7 days after isolation. Isolated MSC were shown by FACS to 
express the MSC markers including SH2, SH4 and Stro-1 and did not express 
negative markers of MSC including CD34 (haematopoietic stem cell maker) and 
CD45 (pan-leukocycte marker). Isolated MSC were also shown to be able to 
differentiate into into adipocytes, chrondrocytes and osteocytes, confirming the 
multipotency of these cells (Funes et al., 2007).  
The primary MSC were transformed in a step-wise manner through the 
sequential expression of the following genes:  
 
•  hTERT (the catalytic subunit of human telomerase) - necessary to extend 
the life span of MSC in culture 
•  HPV-16 E6 and E7 to abrogate the functions of p53 and pRb tumour 
suppressor family members respectively 
•  SV40 small T antigen (ST) to inactivate protein phosphatase 2A (PP2A), 
resulting in stabilization of the c-Myc oncogene   68 
•  Constitutively active Ras (H-Ras
V12) 
 
These  genetic  elements  were  sequentially  introduced  into  the  cells  by 
retroviral infection, with successful mRNA and protein expression confirmed by 
qRT-PCR and western blot respectively (Figure 1.2b). Previous models of step-
wise transformation have suggested that although the total number of oncogenic 
changes required for transformation of a given cell type remains fixed, the order 
in which these events take place can be flexible (Fearon and Vogelstein, 1990; 
Hahn et al., 1999; Rangarajan et al., 2004). The particular sequence utilized in 
the MSC model was chosen for a number of reasons. Firstly, initial expression of 
hTERT  was  necessary  to  extend  the  lifespan  of  primary  MSC  in  culture  by 
overcoming  replicative  senescence  (Counter  et  al.,  1992;  Hayflick,  1965; 
Hayflick  and  Moorhead,  1961).  Secondly,  inactivation  of  tumour  suppressor 
genes  was  necessary  before  the  expression  of  oncogenes  in  order  to  avoid 
oncogene  induced  senescence.  Although  the  relative  order  of  c-Myc  and  H-
Ras
V12 over-expression (at MSC 4 and MSC 5 in the model) were shown to be 
interchangeable, it remains possible that variability also exists in the order in 
which the earlier ‘hits’ are introduced - for example, SV40 small-T antigen could 
have been a suitable first ‘hit’ in place of hTERT (Funes et al., 2007). However, 
the order of genetic aberrations utilized in this model allows specific changes 
linked to immortalization (through hTERT expression) to be distinguished from 
the  other  transforming  effects  of  viral  oncoproteins  such  as  SV40  small-T 
antigen. 
The validity of this model was demonstrated in a number of ways. In a 
soft agarose test of anchorage independent growth, cells transduced with hTERT,   69 
E6, E7 and ST formed small colonies in soft agarose after 12 days, with the final 
addition  of  H-Ras  resulting  in  rapidly  growing  large  colonies  (Figure  1.2c). 
Furthermore, cells with all 5 transforming steps were able to induce tumours 
when  injected  into  immunodeficient  mice  (Figure  1.2d).  Gene  expression 
microarray  analysis  of  these  cells  also  showed  typical  hallmark  changes  to 
transformed  cells:  up-regulation  of  anti-apoptotic  pathways,  up-regulation  of 
angiogenic genes and down-regulation of MHC class I and II molecules. Finally, 
gene expression microarrays also show that the expression of genes downstream 
of pRB, p53, PP2A and H-Ras are affected with each transformation step. 
This system provides a well defined model of transformation in which 
known genetic hits can be linked to downstream genetic or epigenetic changes. 
Furthermore,  this  model  provides  a  unique  insight  into  processes  occurring 
during transformation in pre-malignant cells.  
This  stepwise  model  of  transformation  has  been  used  to  investigate 
cancer associated changes in bioenergetics and to identify novel putative anti-
cancer drug targets (Flanagan et al., 2009; Funes et al., 2007). I hypothesise that 
epigenetic changes traditionally associated with cancer cells will also occur in 
this stem cell model. By providing a well defined background in which known 
genetic hits may be linked to observed epigenetic changes, the model could be 
useful to investigate the epigenetic hallmarks of cancer.  
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Figure  1.2:  Step-wise  transformation  of  human  MSC.  (a)  Schematic  diagram  of  stepwise 
MSC transformation. (b) Cell lines were probed by antibodies against the expressed oncoproteins 
or their downstream cellular targets. Proliferating cell nuclear antigen (PCNA) reflects cell entry 
in S phase after pRB inactivation by E7. (c) Anchorage independent growth of MSC infected 
with empty retroviruses or combinations of different oncogenes. (d) Tumours formed in mice 
inoculated with 5 hit MSC (arrows) but not in those inoculated with 4 hit MSC (left). Adapted 
from Funes et al., 2007. 
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1.9    Aims of this thesis 
 
The  aim  of  this  work  is  to  investigate  epigenetic  changes  that  occur  during 
stepwise transformation in this MSC model. This research centres on two major 
themes – investigation of global hypomethylation and of histone modifications 
mediated  by  the  PRC2  complex.    Firstly,  I  aim  to  determine  whether  global 
hypomethylation occurs in this stepwise model of transformation, and establish 
at which point this takes place. Furthermore, if genome-wide hypomethylation is 
observed,  I  will  explore  the  causes  of  this  loss  of  methylation.  Secondly,  an 
investigation  of  the  role  of  PRC2  in  this  step-wise  transformation  will  be 
conducted. In particular, I aim to establish whether the three core components of 
PRC2 (EZH2, EED and SUZ12) are up-regulated during stepwise transformation 
and whether PRC2 target genes are down-regulated through the repressive action 
of this complex. If this is the case, I aim to explore whether PRC2 activity is 
required for transformation to take place in this model.  
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Chapter 2:  Materials and Methods  
2.1    Cell Culture Techniques 
2.1.1    Cell Lines and Maintenance 
 
Mesenchymal  stem  cells  (MSC)  and  human  fibroblast  cells  (HF)  were 
transformed  in  a  step-wise  manner  through  the  sequential  addition  of  the 
following genetic elements (cell line abbreviations are denoted in bold) (Funes et 
al., 2007): 
 
1.  hTERT (the catalytic subunit of human telomerase) - necessary to extend 
the life span of MSC and HF in culture (MSC 0 / HF 0) 
2.        a.   HPV-16 E6 to abrogate the function of p53 (MSC 2E6) 
b.  HPV-16 E7 to inhibit the function of pRb (MSC 2E7) 
3.  A combination of HPV-16 E6 and E7 to inhibit both p53 and pRb tumour 
suppressor pathways (MSC 3 / HF 3) 
4.  SV40 small T antigen (ST) to inactivate protein phosphatase 2a (PP2a), 
resulting in stabilization of the c-Myc oncogene (MSC 4 / HF 4) 
5.  Constitutively active H-Ras
V12 (MSC 5 / HF 5) 
 
Mesenchymal  stem  cells  (MSC)  were  cultured  in  Mesencult  medium 
supplemented  with  10%  human  serum  (StemCell  Technologies,  Vancouver, 
Canada) and 1 ng/ml basic fibroblast growth factor (R&D Systems, Minneapolis, 
MN).    73 
Human fibroblasts (HF) and Human Embryonic Kidney 293T cells were 
maintained  in  Dulbecco’s  Modified  Eagles  medium  (DMEM)  (Gibco, 
Invitrogen, Carlsbad, USA) supplemented with 10% heat inactivated foetal calf 
serum  (FCS;  Gibco),  100  units/ml  penicillin  G,  and  100  µg/ml  streptomycin 
(Gibco). 
All cells were grown at 37°C, 5% CO2 and 100% humidity. Cells were 
kept at subconfluent levels and were typically passaged when 70-80% confluent. 
The cells were washed with 4ml Dulbecco’s phosphate buffered saline (DPBS) 
(Sigma Aldrich, St. Louis, US) and incubated with 1ml 0.05% trypsin EDTA 
(Gibco) for 3-5 minutes at 37°C. An equal volume of full media was added to 
quench the reaction and the cells were centrifuged at 1200rpm for 5 minutes. The 
cell pellet was resuspended in an appropriate volume of fresh media and seeded 
at the following dilutions (Table 2.1). 
 
Table 2.1: Typical seeding dilutions for cell culture  
Cell Line  Dilution 
MSC 0 / HF 0  1:3 
MSC 1 / HF 1  1:3 
MSC 2E6  1:5 
MSC 2E7  1:7 
MSC 3 / HF 3  1:10 
MSC 4 / HF 4  1:12 
MSC 5 / HF 5  1:12 
293T  1:6 
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2.1.2    Cryogenic Storage and Recovery of Cells  
Cells  were  cryogenically  stored  by  resuspending  the  live  cell  pellet  in  foetal 
bovine serum (FBS) supplemented with 10% dimethyl sulphoxide (DMSO) to a 
concentration of 10
5 cells per millilitre. The cell suspension was aliquotted into 
polypropylene  cryotubes  (Corning,  New  York,  US)  and  placed  at  -80°C 
overnight in a cryogenic storage vessel containing 250ml isopropanol to slow the 
freezing process. Once frozen, tubes were stored in liquid nitrogen until used. 
Frozen cells were thawed at 37°C before the cell suspension was added to 
5ml full media. Cells were centrifuged at 1200rpm for 5 minutes and the cell 
pellet was resuspended in full media and seeded into a 10cm dish.  
 
2.1.3    Cell Harvesting for DNA and RNA Extraction 
Cells  were  washed  with  4ml  Dulbecco’s  phosphate  buffered  saline  (DPBS) 
(Sigma) and incubated with 1ml trypsin (Gibco) for 3-5 minutes at 37°C. Once 
detached, the trypsin was inactivated by the addition of 4ml fresh media, and the 
cells were pelleted in a 15ml Falcon tube by centrifugation at 1200rpm for 5 
minutes.  The  cells  were  washed  with  1ml  DPBS  and  pelleted  in  a  1.5ml 
Eppendorf tube by centrifugation at 2000rpm for 5 minutes at 4°C. Cell pellets 
were stored at -80°C before use.  
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2.1.4    Clonal Cell Population Isolation 
Clone isolation was performed by seeding cells at a density of 100 cells per 
10cm dish and incubating at 37°C until colonies were visible. Individual clones 
were  removed  by  placing  a  cloning  cylinder  (Sigma  Aldrich,  St.  Louis,  US) 
around  the  cells  and  adding  100µl  trypsin  0.05%  EDTA.  The  trypsin  was 
neutralized by addition of an equal volume of full media, and the cells were 
transferred to a 96 well plate with the media replaced once the cells had attached. 
Cells  were  grown  as  normal  and  expanded  until  the  required  number  were 
available.  
 
2.1.5    5-Azacytidine treatment 
Cell culture media was supplemented with 5-aza-2’-deoxycytidine (Sigma) to a 
final concentration of 5µM and added to cells 24 hours after seeding. Fresh drug-
containing media was added to the cells every 24 hours, with drug treatment 
continuing for a total of four days, after which time cells were harvested for 
DNA or RNA extraction.  
 
2.1.6    Cell Viability and Growth Assay 
Cell viability and growth were assessed using the CellTiter 96 AQueous One 
Solution Cell Proliferation Assay (Promega, Madison, US). This assay utilizes 
the  compound  3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-
sulfophenyl)-2H-tetrazolium,  inner  salt  (MTS)  that  is  reduced  to  a  coloured   76 
formazan product in a reaction dependent on NADPH or NADH, levels of which 
are  in  turn  directly  proportional  to  the  number  of  metabolically  active  cells 
present in a culture.  
Cells were seeded at a density of 1000 cells per well containing 100µl 
media in a 96 well plate. Viable cell numbers were determined at the initial time 
point and every 24 hours by adding 20µl of the detection reagent to each well 
and incubating at 37°C for 2 hours. Absorbance at 490nm was recorded using a 
Fluoroskan  spectrophotometer  (Thermo  Fisher,  Waltham,  USA).  This 
measurement is directly proportional to the number of live cells in each well. 
Cell lines were assayed in triplicate for each time point, with blank readings 
obtained from wells containing media plus reagent only.  
 
2.1.7    Soft Agarose Transformation Assay 
Transformation was assessed by anchorage independent growth of cells in soft 
agarose. 6 well plates were prepared with a 2ml layer of 0.6% low melting point 
agarose  (Sigma)  in  DMEM  (Gibco).  10
4  cells  were  suspended  in  0.35%  low 
melting point agarose in DMEM and seeded in triplicate on the 0.6% agarose 
layer.  Cells  were  grown  at  37°C  for  12  days,  with  colony  number  and  size 
quantified visually at 40x magnification on the Axiovert 100 microscope (Carl 
Zeiss,  Oberkochen,  Germany)  and  with  the  SynGene  G:Box  and  GeneTools 
software (Syngene, Frederick, USA).  
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2.2    Transfection and Virus Production 
2.2.1    Cell Transfection 
Cells  were  transfected  using  the  Fugene  transfection  reagent  (Roche,  Basel, 
Switzerland) according to the manufacturer’s instructions. To transfect one well 
of a 6 well plate, 1µg of DNA and 3µl of Fugene (3x the amount of DNA) were 
added  to  two  separate  1.5ml  Eppendorf  tubes  containing  50µl  of  serum  free 
Optimem (Gibco) and incubated at room temperature (22°C) for 5 minutes. The 
contents  of  the  two  tubes  were  combined  to  a  total  volume  of  100µl  and 
incubated at room temperature (22°C) for a further 15 minutes. During this time, 
the  target  cells  were  washed  with  PBS  and  media  replaced  with  serum  free 
Optimem. The Fugene mixture was added to the cells in a dropwise manner and 
incubated at 37°C for 5 hours, after which the media was replaced with DMEM 
containing 10% FCS.  
 
2.2.2    shRNA Lentivirus Production and Infection of Target Cells 
Stable gene knockdown was achieved by infecting target cells with lentivirus 
containing  shRNA  constructs  expressed  from  the  pGIPZ  plasmid  (Open 
Biosystems, Huntsville, USA). Lentivirus was produced in 293T cells seeded at 
25% confluence, with one 10cm plate per plasmid. The cells were transfected 
with  1µg  each  of  p8.91  (group  specific  antigen  and  polymerase;  gag-pol), 
pMDG.2  (Vesicular  stomatitis  virus-G  envelope;  VSV-G)  and  pGIPZ 
(containing  the  shRNA  sequences  detailed  in  Table  2.2)  using  the  Fugene 
protocol described above. Transfection efficiency was assessed by monitoring   78 
GFP levels 24 hours following transfection. Lentivirus was harvested 48 hours 
post transfection by collecting the media and passing it through a 0.45 µm filter. 
Aliquots of lentivirus were stored at -80°C.  
Lentiviral infections were performed by adding an appropriate volume of 
lentivirus containing supernatant to target cells (seeded at 1x10
5 cells per well in 
a 6 well plate), incubating at 37°C for 5 hours before replacing with fresh full 
media.  Infection efficiency was assessed by monitoring the percentage of GFP 
positive  cells  48  hours  post  infection  with  the  Axiovert  100  fluorescent 
microscope (Carl Zeiss, Oberkochen, Germany). GFP positive cells were isolated 
by cell sorting with a modular flow system (Dako, Glostrup, Denmark).  
 
Table 2.2: shRNA sequences 
Target Gene  shRNA sequence (Sense, loop, antisense) 
EZH2  5’-CGGAAAGAACGGAAATCTTAAATAGTGAAGCCAC 
AGATGTATTTAAGATTTCCGTTCTTTCCA-3’ 
SUZ12  5’-CGCAGTTATGCTCTTAATGCTTTAGTGAAGCCACA 
GATGTAAAGCATTAAGAGCATAACTGCT-3’ 
Non-silencing 
Control 
5’-CTCTCGCTTGGGCGAGAGTAAGTACATCTGTGGCTTC 
ACTACTTACTCTCGCCCAAGCGAGAT-3’ 
 
 
   79 
2.2.3    Retrovirus Production and Infection of Target Cells 
Retroviruses  containing  H-Ras
V12  in  the  pWZL  plasmid  were  produced  by 
transfection  of  293T  cells  using  polyethylenimine  (PEI;  Sigma).  293T  were 
seeded at 25% confluence, with one 10cm dish per plasmid. 4.8µg of pMLV 
(gag-pol), 1.6µg of pHIT (VSV-G), 8µg of pWZL (hygromycin resistance and 
cassette of interest) and 64µl of PEI (1mg/ml; Sigma) were added to 800µl serum 
free Optimem in a 1.5ml Eppendorf tube. The mixture was incubated at room 
temperature (22°C) for 30 minutes. During this time, the 293T cells were washed 
with  PBS  and  media  replaced  with  serum  free  Optimem.  The  transfection 
mixture was added to one 10cm dish of 293T cells in a dropwise manner. After 5 
hours,  the  media  was  replaced  with  DMEM  supplemented  with  10%  FCS. 
Transfection  efficiency  was  monitored  by  parallel  transfection  with  pMSCV 
(YFP) vector. Virus was harvested 48 hours post transfection by collecting the 
supernatant and passing it through a 0.45µm filter.  
Target cells were seeded at 6x10
5 cells per 10cm dish the day before 
infection. 0.5ml of retroviral supernatant was added to each 10cm dish, incubated 
at 37°C for 5 hours and replaced with fresh full media. Infection efficiency was 
assessed  by  monitoring  the  percentage  of  YFP  positive  cells  24  hours  after 
infection  with  pMSCV  (YFP)  retrovirus.    Selection  of  infected  cells  with 
hygromycin  (100µg/ml)  was  commenced  48  hours  following  infection  and 
continued until no viable cells were remaining in a control population lacking the 
resistance cassette. 
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2.3    Molecular Biology Techniques 
2.3.1    Isolation and Preparation of Nucleic Acids 
2.3.1.1   Genomic DNA Extraction 
Genomic DNA was extracted with phenol-chloroform as described previously 
(Miller  et  al.,  1988).  Typical  cell  pellets  (~1x10
6  cells)  were  resuspended  in 
300µl nuclei lysis solution (0.1M Tris pH 8, 2mM EDTA pH 8, 0.1M NaCl), 
0.33mg/ml  proteinase  K  (Qiagen,  Venlo,  Netherlands)  and  0.66%  SDS  and 
incubated at 60°C for 90 minutes, or until homogenous.  
Protein was precipitated by adding 100µl of saturated (5M) salt solution 
to  each  sample  before  shaking  vigorously  for  2  minutes  and  centrifuging  at 
13000rpm for 15 minutes at 4°C. The supernatant was aspirated into a fresh tube 
and  an  equal  volume  of  phenol/chloroform/isoamyl  alcohol  pH  8.0  25:24:1 
(Sigma) was added before shaking gently for 10 minutes and centrifuging for 10 
minutes at 13000rpm. The upper phase was removed to a fresh tube and an equal 
volume chloroform/isoamyl alcohol 24:1 (Fluka) was added. The samples were 
again shaken for 10 minutes and centrifuged for 10 minutes at 13000rpm before 
the upper phase was transferred to a fresh tube and 0.1 volumes 2M sodium 
acetate pH 5.6 and 1ml of ice-cold 100% ethanol was added. The solution was 
inverted  several  times  to  precipitate  the  DNA  and  placed  at  -20°C  for  30 
minutes.  Samples  were centrifuged  at  13000rpm  for  15  minutes  to  pellet  the 
DNA before the supernatant was removed and the pellet washed in 1ml 70% 
ethanol.  The samples were again centrifuged for 5 minutes at 13000 rpm, any   81 
remaining alcohol was removed and the DNA pellet allowed to air dry until clear 
before being resuspended in 50µl 10mM Tris buffer. 
The  quantity  and  purity  of  the  DNA  was  determined  by  measuring 
absorbance  at  260nm  (A260)  and  280nm  (A280)  with  a  NanoDrop 
spectrophotometer (NanoDrop, Wilmington, US). An A260/A280 ratio of 1.8-
2.0, indicating DNA free of contaminating protein or phenol, was obtained for all 
samples. Genomic DNA was stored at 4°C. 
 
2.3.1.2   RNA Extraction 
Total  RNA  was  extracted  using  the  RNeasy  kit  (Qiagen)  according  to  the 
manufacturer’s  instructions.  Cell  pellets  (typically  ~1x10
6  cells)  were 
resuspended in 350µl lysis buffer RLT and disrupted by vortexing vigorously for 
15 seconds. 350µl of 70% ethanol was added before each sample was transferred 
to an RNeasy spin column. Following wash steps, the RNA was eluted in 30µl 
DEPC treated H2O (Ambion, Austin, US). The amount and purity of the RNA 
was determined by measuring absorbance at 260nm (A260) and 280nm (A280) 
with  a  spectrophotometer  (NanoDrop).  An  A260/A280  ratio  of  1.8-2.0, 
indicating RNA free of contaminating protein or phenol, was obtained for all 
samples. RNA was stored at -80°C. 
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2.3.1.3   cDNA Synthesis 
RNA  samples  were  first  treated  with  DNaseI ( Invitrogen)  to  remove  any 
contaminating genomic DNA. 1U of DNaseI (Invitrogen) was added to 300ng of 
RNA, 1µl of 10X DNaseI reaction buffer (Invitrogen) and made up to 10µl with 
DEPC-treated H2O (Ambion). The samples were incubated for 15 minutes at 
room temperature (22°C) before inactivating the DNaseI by the addition of 1µl 
25mM EDTA (Invitrogen) followed by a 10 minute incubation at 65°C. 
1µl (200ng) of random hexamer (ABGene, Portsmouth, USA) was added 
before  the  samples  were  incubated  at  70°C  for  10  minutes  and  placed 
immediately on ice. 4µl of 5X first strand buffer (Invitrogen), 2µl of 0.1M DTT 
(Invitrogen), 1µl 10µM of dNTP mix (Yorkshire Biosciences, York, UK) and 1µl 
of SuperScript II reverse transcriptase (Invitrogen) were added to each sample. 
Reverse transcriptase negative controls were also made up without the addition 
of SuperScript II. The reaction mixtures were incubated at 25°C for 10 minutes, 
42°C for 50 minutes and 70°C for 15 minutes. The final cDNA was diluted 1:5 
with H2O to a final volume of 100µl and stored at  -20°C. 
 
2.3.1.4   Bisulphite Conversion of DNA 
1µg of genomic DNA was resuspended in H2O to a final volume of 10µl before 
1µl of 3M NaOH was added to a final concentration of 0.3M. The samples were 
incubated at 42°C for 20 minutes and cooled on ice. Sodium bisulphite solution 
was prepared by adding 4.56g sodium bisulphite (Sigma) to 8ml 0.3M NaOH 
and  heating  at  55°C  in  the  dark  until  dissolved.  Hydroquinone  solution  was   83 
prepared by adding 55mg hydroquinone (Sigma) to 50ml H2O and heating at 
55°C in the dark until dissolved. 104µl of sodium bisulphite solution and 6µl of 
10mM hydroquinone solution were added to each sample, followed by a 5hr 
incubation at 55°C in the dark. 
Following  bisulphite  conversion,  DNA  was  recovered  using  Microcon 
centrifugal filters (Millipore, Billerica, USA). The samples were washed three 
times with H2O and desulphonated with 0.1M NaOH for 5 minutes. Following a 
further wash, DNA was eluted in 50µl EB (Qiagen) and stored at -20°C. 
 
2.3.1.5    In Vitro DNA Methylation 
100µg peripheral blood leukocyte DNA (Promega) was incubated with 1U/µg 
M.SssI    DNA  methylase  (New  England  Biosciences,  Ipswich,  USA)  and 
0.16mM  S-adeno-methionine  (SAM;  NewEngland  Biosciences)  overnight  at 
37°C.  The following day the reaction mixture was supplemented with 0.2mM 
SAM and 0.065 U/µl M.SssI followed by another overnight incubation at 37°C. 
The fully methylated DNA was stored at 4°C.  
 
2.3.1.6   Whole Genome Amplification  
Fully unmethylated DNA was obtained by whole genome amplification of MSC 
5 DNA using the Illustra GenomiPhi V2 kit (GE Healthcare, Chalfont St. Giles, 
UK)  according  to  the  manufacturer’s  instructions.  9µl  of  sample  buffer  was 
added to 1µl (10ng) template, heated to 95°C for 3 minutes and cooled on ice.   84 
9µl reaction buffer and 1µl enzyme was added, and the reaction mix incubated at 
30°C for 1.5 hours before inactivating the enzyme at 65°C for 10 minutes. The 
amplified samples, containing ~4µg DNA, were stored at 4°C.  
 
2.3.2    Polymerase chain reaction (PCR) Based Techniques 
2.3.2.1   MethyLight Quantitative Polymerase Chain Reaction (qPCR) 
MethyLight reactions were performed as previously described (Weisenberger et 
al., 2005). qPCR reactions were conducted in a 30µl reaction volume containing 
60ng  of  template,  0.3µM  forward  and  reverse  primers,  0.1µM  probe  and  the 
remaining volume made up with TaqMan master mix No AmpErase (Applied 
Biosystems,  Carlsbad,  USA).  Reactions  were  performed  on  an  Eppendorf 
Realplex 4 (Eppendorf, Hamburg, Germany) with the cycling conditions detailed 
below.  Primers  (Operon)  and  probes  (Applied  Biosystems  for  MGB  labelled 
probes and Operon for BHQ-1 labelled probes) are detailed in Table 2.3. 
   
MethyLight PCR Cycling Conditions 
95°C for 15 minutes  
50 cycles of: 
95°C for 15s  
60°C for 1min   85 
Table 2.3: Primer and probe sequences for MethyLight reactions 
Element  Forward Primer  Reverse Primer  Probe 
Alu-C4   5’-GGTTAGGTATAGTGGTTTA 
TATTTGTAATTTTAGTA-3’ 
5’-ATTAACTAAACTAATCTTAAAC 
TCCTAACCTCA-3’ 
5’-6FAM-CCTACCTTAACC 
TCCC-3’ MGB 
Alu-M2  5’-GCGCGGTGGTTTACGTTT-3’  5’-AACCGAACTAATCTCGAA 
CTCCTAAC-3’ 
5’-6FAM-AAATAATCCGCC 
CGCCTCGACCT-3’ BHQ-1 
Sat2-M1  5’-TCGAATGGAATTAATATTT 
AACGGAAAA-3’ 
5’-CCATTCGAATCCATTCGA 
TAATTCT-3’ 
5’-6FAM-CGATTCCATTCGATAAT 
TCCGTTT-3’ MGB 
LINE1-M1  5’-GGACGTATTTGGAAAA 
TCGGG-3’ 
5’-AATCTCGCGATACGCCGTT-3’  5’-6FAM-TCGAATATTGCGTTTT 
CGGATCGGTTT-3’ BHQ-1   86 
All  samples  were  run  in  triplicate  for  each  element  assayed.  Fold  change  in 
methylation  relative  to  the  fully  methylated  reference  was  quantified  by  the 
comparative Ct (fluorescence threshold value) method using the Alu-C4 reaction 
as a loading control, according to the following formulae: 
 Ct (Sample) = Ct (Sample) – Ct (AluC4) 
  Ct = 2 ^ (  Ct (Meth. Reference) -  Ct (Sample) ) 
Negative control reactions containing ddH2O and unmethylated reference DNA 
were performed with every reaction.  
 
2.3.2.2   PCR for Bisulphite Sequencing 
Primers  were  designed  using  the  Primer3  software  (http://frodo.wi.mit.edu/) 
against the same genomic regions assayed by MethyLight.  
PCR of the Alu, Sat2 and LINE1 repetitive elements was performed in a 
30µl reaction volume containing 0.3µM forward and reverse primers (Operon, 
Huntsville, USA), 3.5mM MgCl2, 200µM dNTPs (Yorkshire Bioscience), 1U 
HotStartTaq (Qiagen) and 60ng of template DNA. PCR cycling conditions and 
primers (Operon) were are detailed below (Table 2.4). 
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LINE1 PCR Cycling Conditions 
95°C for 15 minutes 
35 cycles of: 
95°C for 30s 
60°C for 20s       
72°C for 30s 
72°C for 5 min 
 
Sat2 PCR Cycling Conditions 
95°C for 15 minutes 
35 cycles of:  
95°C for 30s 
55°C for 30s  
72°C for 30s 
72°C for 5 minutes 
 
Table 2.4: Primer sequences for amplification of Alu, Sat2 and LINE1 repetitive 
elements from bisulphite converted DNA 
Element  Forward Primer  Reverse Primer 
Alu  5’-GGTTAGGTATAGTGGT 
TTATATTTGTAATTTTAGTA-3’ 
5’-ATTAACTAAACTAATCT 
TAAACTCCTAACCTCA-3’ 
Sat2  5’-TTTAATGGTYGYGAATGG-3’  5’-CRAATCCATAAATTATTCCA-3’ 
LINE1  5’-YGAGTTAAAGAAAGGGGTGA-3’  5’-CCCTCCTAACCAAATACAAA-3’ 
   88 
Amplification of the correct PCR products was verified by gel electrophoresis, 
followed by cloning and sequencing of 12-20 individual products per sample as 
described below.  
 
2.3.2.3  Quantitative  reverse  transcriptase  polymerase  chain  reaction 
(qRT-PCR) 
Total RNA was extracted and used for cDNA synthesis as above, with real-time 
PCR  performed  on  an  Eppendorf  Realplex  4  (Eppendorf).  Reactions  were 
performed in a 25µl volume containing 0.3µM forward and reverse primers, and 
the  remaining  volume  made  up  with  1x  SYBR  Green  PCR  mix  (Applied 
Biosystems).  PCR  conditions  and  primers  (Operon)  were  are  detailed  below 
(Table 2.5). 
 
qRT-PCR Cycling Conditions 
50°C for 2 minutes 
95°C for 2 minutes  
45 cycles of: 
95°C for 15s  
60°C for 1 min   89 
Table 2.5: Primer sequences for qRT-PCR reactions 
Gene  Forward primer  Reverse primer 
DNMT1  5’-CTGTACCGAGTTGGTGATGGTGTG-3’  5’-CTCTGGGTACAGGTCCTCATCCAC-3’ 
EZH2  5’-TTTTTGCCAAGAGAGCCATC-3’  5’-AAGGCAGCTGTTTCAGAGGA-3’ 
SUZ12  5’-CCGTCCACAAGAAATGGAAG-3’  5’-TCATGACATGGAGATTCCAGA-3’ 
EED  5’-CCAGACGGACACTCTGGTG-3’  5’-GAATGATCCATACCACAGGACA-3’ 
GAPDH  5’-GGAGTCAACGGATTTGGTCGTA-3’  5’-GGCAACAATATCCACTTTACCAGAGT-3’ 
DKK2  5’-ATGTGCTGCCCCAGTACC-3’  5’-GTGCCGAGTACCATCCAGAG-3’ 
EN1  5’-CTGGGTGTACTGCACACGTT-3’  5’-GCTTGTCCTCCTTCTCGTTC-3’ 
HOXB3  5’-CTGGGGCTCGATGTGAATA-3’  5’-CTCCTCCGGGGTCTGTTC-3’ 
TBX2  5’-GCTGAAGCTGACCAACAACA-3’  5’-GCTGGTACTTGTGCATGGAG-3’ 
RBP4  5’-ACCCTGCCAAGTTCAAGATG-3’  5’-TCTGTGTCGACGATCCAGTG-3’ 
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Relative expression levels were quantified by the comparative Ct (fluorescence 
threshold value) method using GAPDH as a loading control, according to the 
following formulae: 
 Ct (Sample) = Ct (Sample) – Ct (GAPDH) 
  Ct = 2 ^ (  Ct (Reference) -  Ct (Sample) ) 
All  samples  were  run  in  triplicate  for  each  gene  assayed  alongside  negative 
control reactions using ddH2O and reverse transcriptase negative cDNA samples. 
 
2.3.3    PCR Product Purification and Cloning 
2.3.3.1   Agarose Gel Electrophoresis 
PCR  products  and  restriction  enzyme  digests  were  visualized  by  agarose  gel 
electrophoresis.  Typically,  1.5%  weight  /  volume  (w/v)  agarose  (Sigma)  gels 
were  made  up  in  0.4M  tris-acetate,  0.01M  ethylene  diamino  tetraacetic  acid 
(TAE;  National  Diagnostics,  Atlanta,  USA)  containing  0.04  mg/ml  ethidium 
bromide  (Sigma).  DNA  samples  were  loaded  using  6x  DNA  loading  buffer 
(Fermentas, Burlington, Canada) and run in TAE at 100V. Bands were visualized 
using Sygene G:Box UV transilluminator (Syngene, Frederick, USA) and run 
alongside  a  1kb  DNA  ladder  (Fermentas)  to  estimate  the  size  of  the  DNA 
molecules.  
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2.3.3.2   Agarose Gel Extraction of DNA 
Appropriate bands were excised from the gel with a clean scalpel and placed in a 
1.5ml Eppendorf tube. DNA was extracted using the QIAquick Gel Extraction 
Kit (Qiagen) as described by the manufacturer. After weighing the gel fragment, 
an appropriate volume of buffer QG was added (3µl for ever µg of gel) and the 
solution was incubated at 50°C for 10 minutes to dissolve the gel. Isopropanol 
was added to the solution (1µl for every µg of gel) and the samples were loaded 
onto the QIAquick spin column and washed as described by the manufacturer. 
The DNA was eluted in 20µl ddH2O and used immediate in a ligation reaction or 
stored at -20°C 
 
2.3.3.3   Ligation of PCR Products into pGEM-T 
3µl of gel extracted PCR product was added to 1µl (50ng) of pGEM-T Easy 
vector (Promega), 1µl of (3 Weiss units) T4 DNA ligase (Promega), and 5µl of 
2X reaction buffer (Promega). The ligation reaction was allowed to proceed at 
room  temperature  (22°C)  for  1  hour,  and  used  immediately  for  bacterial 
transformation or stored at -20°C. A negative control (containing H2O instead of 
insert) was always conducted in parallel to monitor self-ligation of the vector.  
 
2.3.3.4   Other Ligations 
Ligations were performed in a 20µl volume containing 1µl (20 units) of T4 DNA 
ligase (New England Biosciences), 2µl of 10x DNA ligase buffer (New England   92 
Biosciences)  and  50  to  200ng  of  vector.  The  amount  of  insert  added  to  the 
ligation mixture (AInsert) was calculated using the following formula, with a ratio 
of 8:1 (insert:vector) optimal.  
AInsert = [ (AVector * LInsert ) / LVector ] * Ratio 
Where LInsert and LVector denote the length of insert and vector respectively 
(measured in kilobases), AInsert and AVector are the amount of insert and vector 
respectively (measured in nanograms) and ‘Ratio’ is an integer value of the 
insert:vector ratio (for example, 8). 
Ligation reactions were conducted at room temperature (22°C) for 1 hour 
or at 4°C overnight for optimal efficiency. Vector controls containing no insert 
were run in parallel to monitor the incidence of vector self ligation.  
 
2.3.4    Plasmid Preparation and Purification 
2.3.4.1   Bacterial Transformation 
5µl of ligated plasmid was added to One Shot TOP10 chemically competent E. 
coli cells (Invitrogen), mixed gently and incubated on ice for 30 minutes. The 
cells were heat shocked at 42°C for 30 seconds and rapidly cooled on ice. 250µl 
of pre-warmed SOC medium (Invitrogen) was added to the cells and the vials 
were shaken at 37°C for 1hr at 225rpm. 80µl of the culture was spread onto LB 
agar  plates  (Invitrogen)  supplemented  with  100µg/ml  ampicillin  (Sigma)  to 
select for successfully transformed bacteria.    93 
 2.3.4.2  Minipreps 
A single bacterial colony was picked and grown overnight at 37°C in 5ml of 
Luria-Bertani  broth  (Invitrogen)  supplemented  with  100µg/ml  ampicillin 
(LB
amp). Plasmids were extracted with a MiniPrep kit (Qiagen) according to the 
manufacturer’s instructions. Bacteria were pelleted by centrifugation at 3500rpm 
for  15  minutes.  The  pellet  was  resuspended  in  250µl  buffer  P1,  lysed  and 
neutralised  through  an  alkaline  lysis  method  according  to  the  protocol.  The 
resultant  solution  was  centrifuged  at  13000rpm  for  10  minutes  and  the 
supernatant was transferred to a Qiagen column. Wash steps were performed 
according to the manufacturer’s protocol and the plasmid DNA was eluted in 
50µl of ddH2O. Typical minipreps yielded approximately 10µg DNA.  
 
2.3.4.3   Maxipreps 
When larger amount of plasmid were required for cell transfections and virus 
production, purification was conducted using a maxiprep kit (Qiagen). 100ml of 
bacterial culture was grown overnight by inoculating LB
amp with a single colony 
picked  from  an  agar  plate.  The  following  day,  the  bacterial  suspension  was 
pelleted by centrifugation at 3500rpm for 15 minutes at 4°C. The pellet was 
resuspended in 10ml buffer P1, lysed by the addition of 10ml buffer P2 at room 
temperature (22°C) for 5 minutes and neutralised with 10ml chilled buffer P3. 
The mixture was incubated on ice for 20 minutes and centrifuged at 3500rpm for 
30 minutes at 4°C. The supernatant was added to a Qiagen maxiprep column that 
had been previously equilibrated with 10ml buffer QBT. Following wash steps as   94 
directed  by  the  manufacturer,  the  DNA  was  eluted  and  precipitated  with 
isopropanol. The DNA was pelleted and washed as described in the protocol 
before being resuspended in 300µl H2O overnight at 4°C.  
 
2.3.4.4   Restriction Enzyme Digestion 
Diagnostic  restriction  enzyme  digestions  were  performed  using  10  units  of 
enzyme  in  a  reaction  volume  of  25µl  containing  the  appropriate  1x  reaction 
buffer  (New  England  Biosciences)  and  1µg  or  less  of  DNA.  Reactions  were 
typically performed for 1-2 hours at 37°C. Successful digestion was confirmed 
by gel electrophoresis of the products, with appropriate bands excised and gel 
extracted when required.  
 
2.3.5    DNA Sequencing 
2.3.5.1   Sanger Sequencing 
Sanger  sequencing  of  PCR  products  cloned  in  the  pGEM-T  easy  vector  was 
performed  by  the  Scientific  Support  Service  (WIBR,  UCL,  London).  Chain 
termination reactions were conducted using T4 sequencing primer and BigDye 
terminator (Applied Biosystems), with reaction products sequenced on an ABI 
PRISM 3700 sequencer (Applied Biosystems).  
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2.3.5.2   Pyrosequencing 
Methylation analysis of selected promoters was performed by pyrosequencing. 
PCR  reactions  were  conducted  in  a  30µl  reaction  volume  containing  1.5mM 
MgCl2 (Qiagen), 0.2mM dNTPs (Yorkshire Biosciences), 5 pmoles forward and 
reverse PCR primers (Operon), 0.2 units of HotStarTaq (Qiagen) and 1x PCR 
buffer (Qiagen). PCR cycling conditions and primers sequences (Operon) are 
detailed below (Table 2.6). 
 
PCR Cycling Conditions 
95°C for 15 minutes 
45 cycles of: 
    95°C for 20 sec 
    50°C for 20 seconds 
    72°C for 20 seconds 
72°C for 5 minutes   96 
 
Table 2.6: Primer sequences for pyrosequencing PCR product amplification from bisulphite converted DNA 
  Gene  Forward Primer  Reverse Primer 
DKK2  5’-GTAAAGAGGATTGGGGAGAGAGTA-3’  5’-BIO-CCCCTAACTCACAAAAAACAAC-3’ 
EN1  5’-TGTGGGTTTGGGTGTGTGTA-3’  5’-BIO-CTCCCACTACCAAAAAAAATCCA-3’ 
RBP4  5’-TAGGTAGGGTTTTTGGGGAATT-3’  5’-BIO-CAAACCCCTACTATCATCCTT-3’ 
TBX2  5’-GATTATAGAAGAGGGGGTTTTAATTATAGG-3’  5’-BIO-ACCCCCCCCTAAACTTTCCA-3’   97 
10µl of the biotin labelled PCR product was made up to 40µl with ddH2O before 
2µl of straptavidin-coated sepharose beads (GE Healthcare) and 38µl of binding 
buffer (Qiagen) was added to each sample.  The PCR product was immobilized 
to the beads by shaking for 5 minutes at room temperature (22°C). 
  The beads were captured on a Vacuum Prep Tool (Qiagen) and subjected 
to strand separation by treatment with 70% ethanol, denaturation solution (0.2M 
NaOH) and wash buffer (Qiagen). The beads were released into a PSQ HS 96 
plate containing 12µl of 0.3uM sequencing primer per well. Primer annealing 
was achieved by heating the plates to 80°C for 2 minutes before cooling the 
samples to room temperature (22°C).  
  The  pyrosequencing  reaction  was  conducted  on  a  PyroMark  MD 
sequencer (Qiagen). A bisulphite conversion control was included in each assay. 
The methylation status of each CpG site was analyzed using the Pyro Q-CpG 
software  (Qiagen),  with  average  methylation  values  calculated  for  each  PCR 
product.  Sequencing  primers  and  dispensation  orders  for  the  reactions  are 
detailed below (Table 2.7). 
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Table 2.7: Sequencing primers and nucleotide dispensation orders for pyrosequencing 
Gene  Sequencing Primer  Dispensation Order 
DKK2  5’-GAGAGAGTAGAGAGAGAGAA-3’  GATGTCGATGTCAGTCTGTCGATGTCGTCATGTCGTATGTC
GTTAGTGATCGTAGTCG 
EN1  5’-AAATAGTAAAATTTGAAAGG-3’  GTCGTAGTCGTAGTATGTCAGTCGTGATCGTGATCGTGTGA
TCGTTAGTCTGTC 
RBP4  5’-TTTTTGGGGAATTTTGGA-3’  AGTCGTATGTCGTCAGTAGTTCTGTCGTATGATTAAGTATC
GTATCGTT 
TBX2  5’-GAGAAGAAATTAAAAAAGTGG-3’  ATGCTATGTCGAGAGAGATGTCGTGATTCGAGAGAGTATTC
AGTTCGTGATCGATATGTCGAA   99 
2.3.6    Western Blot 
Cells were lysed in RIPA buffer containing protease and phosphatase inhibitor 
cocktails (Sigma), as described below. 
 
Cell Lysis (RIPA) Buffer 
150 mM NaCl 
50mM Tris-HCl pH 7.5 
1% (v/v) NP40 
0.5% (w/v) Deoxycholic acid 
0.1% (w/v) Sodium dodecyl sulfate (SDS) 
1:100 Protease inhibitor cocktail 
1:100 Phosphatase inhibitor cocktail I 
1:100 Phosphatase inhibitor cocktail II 
 
50-100µl of lysis buffer was added directly to cells in a 10cm dish that had been 
washed  with  5ml  cold  PBS.  The  cells  were  scraped,  aspirated  into  a  1.5ml 
Eppendorf tube and incubated for 30 minutes on ice. Samples were centrifuged at 
13000rpm for 30 minutes at 4°C and the supernatant transferred to a fresh tube. 
Protein was quantified by the Bradford assay. 1µl of cell lysate was added 
to 1ml Bradford solution (BioRad Laboratories, Hercules, USA) and 100µl H2O. 
Absorbance  at  595nm  was  measured  on  a  Fluoroskan  spectrophotometer 
(Thermo Fisher) and protein concentration calculated on the basis of a regression   100 
line  obtained  from  known  protein  standards  comprising  dilutions  of  bovine 
serum albumin (BSA) solution (Promega).  
Typically, 20µg of protein was mixed with 4x sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) sample loading buffer, heated 
at  100°C  for  3  minutes  and  allowed  to  cool.  SDS-PAGE  loading  buffer 
composition is described below. 
 
SDS-PAGE loading buffer 
250mM Tris-HCl pH 6.8 
8% (w/v) SDS 
10% (v/v) Glycerol 
5% (v/v) Beta-mercaptoethanol 
0.05% (w/v) Bromophenol blue 
 
Proteins were resolved on a 12% SDS-PAGE gel (comprising a stacking gel and 
resolving gel described below) run at 100V for two hours in SDS-PAGE running 
buffer  (National  Diagnostics)  and  transferred  to  an  immobilon  membrane 
(Millipore) using a Transblot SD semi-dry transfer unit (BioRad) and transfer 
buffer (National Diagnostics) at 20V 500mA for 1hr. Membranes were blocked 
in 5% (w/v) milk in PBS containing 0.05% (v/v) Tween 20 (Sigma) for 1hr and 
incubated with primary antibody overnight at 4°C. Three 10 minute washes in 
PBS 0.05% Tween were performed before probing the membrane with secondary 
horseradish peroxidase (HRP) conjugated antibody at room temperature (22°C)   101 
for 1 hour. Following three 10 minute washes in PBS 0.05% Tween, excess wash 
buffer  was  removed  from  the  membrane  before  it  was  covered  with  ECL 
detection reagent (GE Healthcare) and incubated at room temperature (22°C) for 
1  minute.  Excess  ECL  was  drained  and  bands  were  visualized  with  high 
performance autoradiography film (GE Healthcare). Densitometric quantification 
of  bands  was  performed  on  scanned  images  using  the  Scion  Image  software 
(Scion  Corporation,  Frederick,  USA).  Antibodies  and  concentrations  used  for 
western blots are described below (Table 2.8). 
 
Stacking Gel 
1.4 ml ddH2O 
0.33 ml 30% (w/v) acrylamide 
0.25 ml 1M Tris pH 6.8 
0.02 ml 10% (w/v) SDS 
0.02 ml 10% (w/v) ammonium persulfate 
0.002 ml TEMED 
 
12% Resolving Gel 
3.3 ml ddH2O 
4 ml 30% (w/v) acrylamide 
2.5 ml 1.5M Tris pH 8.8 
0.1 ml 10% (w/v) SDS 
0.1 ml 10% (w/v) ammonium persulfate 
0.004 ml TEMED   102 
Table 2.8: Antibodies used in this study for western blots 
Antigen  Antibody  Species   Monoclonal/ Polyclonal  Dilution  Source 
H-Ras  259  Rat  Monoclonal  WB 1:100  Santa Cruz 
Phospho-p44/42 MAP Kinase   9101  Rabbit  Monoclonal  WB 1:1000  Cell Signaling 
Total ERK1/2  06-182  Rabbit  Monoclonal  WB 1:5000  Upstate 
GAPDH  RGM2  Mouse  Monoclonal  WB 1:10000  Advanced Immunochemicals 
Anti-Rat HRP  P0450  Rabbit  Polyclonal  WB 1:5000  Dako 
Anti-Mouse HRP  P0447  Goat  Polyclonal  WB 1:5000  Dako 
Anti-Rabbit HRP  P0448  Goat  Polyclonal  WB 1:5000  Dako 
EZH2  3147  Mouse  Monoclonal  WB 1:1000  Cell Signaling 
EED  SC-28701  Rabbit  Polyclonal  WB 1:1000  Santa Cruz 
SUZ12  3737  Rabbit  Monoclonal  WB 1:1000  Cell Signaling 
H3K27me3  07-449  Rabbit  Polyclonal  WB 1:2000  Upstate 
Histone H3  9715  Rabbit  Polyclonal  WB 1:1000  Cell Signaling   103 
2.3.7    Chromatin Immunoprecipitation (ChIP) 
ChIP was performed using the Histone ChIP Kit (Diagenode, Liege, Belgium) 
according  to  the  manufacturer’s  instructions.  Each  10cm  dish  of  cells  was 
washed  in  PBS  and  crosslinked  by  the  addition  of  8ml  serum  free  DMEM 
containing  1%  formaldehyde  (Sigma)  for  10  minutes  at  room  temperature 
(22°C).  The  crosslinking  reaction  was  neutralized  by  the  addition  of  800µl 
1.25M glycine and the plates were washed twice with ice cold PBS before cells 
were scraped, aspirated to a 1.5ml Eppendorf tube and centrifuged at 2000rpm 
for 5 minutes. The supernatant was removed and the cell pellet resuspended in an 
appropriate volume of buffer A, to a final concentration of 1.25x10
5 cells per 
10µl volume. 
  Chromatin was sheared in a Bioruptor sonicator waterbath (Diagenode) 
for 30 minutes at high power, with a cycle interval of 30 seconds on and 30 
seconds  off.  Samples  were  centrifuged  at  13000rpm  for  5  minutes  to  pellet 
debris,  with  the  supernatant  containing  the  sheared  chromatin  retained. 
Successful  shearing  of  this  chromatin  to  an  average  size  of  200-600bp  was 
confirmed by running 5µl of the sample on a 1% agarose gel. Unused chromatin 
was snap frozen in liquid nitrogen and stored at -80°C. 
  Each IP was performed using 10µl of sheared chromatin, corresponding 
to 1.25x10
5 cells, with 10µl of each sample stored at -20°C to use as an input 
control. The samples were diluted in IP incubation mix and pre-cleared with 20µl 
of  the  pre-blocked  beads  for  1  hr  at  4°C.  The  beads  were  pelleted  by 
centrifugation at 3000rpm for 2 minutes and the supernatant retained. 1.5µg of   104 
antibody was added for each IP and incubated overnight at 4°C on a rotating 
wheel.  IP  was  conducted  using  antibodies  against  H3K27me3  (Upstate, 
Millipore),  total  H3  (Abcam,  Cambridge,  UK)  and  an  IgG  isotype  control 
(Becton Dickinson, Oxford, UK). 
  The following day, 20µl of pre-blocked beads were added to each sample 
before incubating at 4°C for 1 hour on a rotating wheel. The beads were pelleted 
by  centrifugation  and  washed  as  directed  in  the  protocol.  The  precipitated 
chromatin was eluted in 400µl buffer C, with input samples processed alongside 
precipitated  samples  from  this  point  onwards.  Crosslinking  was  reversed  by 
adding 16µl 5M NaCl to each sample and incubating at 65°C for 4 hours with 
rotation. Finally, DNA was phenol/chloroform purified, precipitated in ethanol 
overnight, washed and resuspended in 50µl H2O as described in the protocol.  
 
2.3.7.1   ChIP-PCR 
5µl of IP DNA and 100ng of input DNA was used as template for each qPCR 
reaction conducted in a volume of 25µl containing 0.3µM forward and reverse 
primers,  and  1x  SYBR  Green  PCR  mix  (Applied  Biosystems).  PCR  Cycling 
conditions and primer sequences (Operon) are described below (Table 2.9). 
 
PCR Cycling Conditions 
50°C for 2 minutes 
95°C for 2 minutes    105 
45 cycles of: 
 95°C for 15s  
60°C for 1 min 
 
Table 2.9: Primer sequences for ChIP-PCR reactions 
Gene  Forward primer  Reverse primer 
DKK2  5’-AGCTAGATCCCCCTTTTCCA-3’  5’-GTGCTGCTTCTGCTTCTGC-3’ 
EN1  5’-CCCTCCCTCCACTACACACA-3’  5’-TTGAAGGATGGGTGGTTGTT-3’ 
HOXB3  5’-GCCTCAGGGTCTCTGGTCTA-3’  5’-CCGAGCTTTTTGGAGATGTG-3’ 
DCN  5’-CTGGTGGACAGGGAGAAAGA-3’  5’-TGTCCTGAAAGAAAGTCATGGTT-3’ 
 
All samples were run in triplicate alongside negative control reactions containing 
ddH2O. Percentage input for the H3K27me3 and total H3 IPs were calculated as: 
% input = 2 ^ (Ct (Input) – Ct (ChIP)) * 100 
Where Ct ( Input) and Ct ( ChIP) are threshold values for the input and IP reactions 
respectively.  
 
2.3.8    Flow Cytometry  
2.3.8.1   Fluorescence Assisted Cell Sorting (FACS) for Methylated DNA 
Cells were harvested and fixed in 70% ethanol at -20°C for 30 minutes, pelleted 
by centrifugation at 2500rpm for 5 minutes and washed in 1ml PBS (Sigma). 
Samples  were  permeabilised  with  500µl  0.2%  Triton-X-100  (Sigma)  for  15   106 
minutes at room temperature (22°C).  Histones were removed by treating the 
cells with 500µl 2M HCl at 37°C for 25 minutes, before neutralising the acid 
with  1ml  0.1M  Tris-HCl  pH  8.5  for  5  minutes  at  room  temperature  (22°C). 
Although this treatment is likely to hydrolyse RNA, the cells were further treated 
with 200µl 0.1mg/ml RNase A (Sigma) for 30 min at 37°C. Following a wash 
with 1ml PBS supplemented with 1% BSA (Sigma) and 0.1% Tween 20 (Sigma) 
(PBST-BSA), cells were blocked in 1ml PBST-BSA for 20 minutes at 37°C. 
Samples  were  incubated  with  mouse  anti-5-methylcytosine  antibody 
(Eurogentec, Serainge, Belgium) for 1 hour at 37°C in a volume of 100µl. The 
cells were washed three times in PBS before incubation for 45 minutes at 37°C 
with anti-mouse secondary antibodies conjugated to fluorescein isothiocyanate 
(Vector Labs, Burlingame, USA) at a concentration of 7.5µg/ml in a volume of 
50µl.  Samples  were  washed  three  times  in  PBS  and  resuspended  in  500µl 
50µg/ml  propidium  iodide  (Sigma)  for  45  minutes  at  37°C.  Cell  suspensions 
were analysed on a FACScalibur cell sorter (Becton Dickinson, Oxford, UK) 
using CellQuest analysis software. Full details of antibodies used for FACS are 
described below (Table 2.10). 
 
Table  2.10:  Antibodies  used  for  FACS  analysis  of  nuclear  methylcytosine 
content 
Antigen  Antibody  Species   Monoclonal/ 
Polyclonal 
Dilution  Source 
IgG1 control  555746  Mouse  Polyclonal  FACS 1:1000  BD 
5’-Methyl cytidine  33D3  Mouse  Monoclonal  FACS 1:1000  Eurogentec 
Anti-Mouse FITC    Goat  Polyclonal  FACS 1:200  Vector Labs   107 
2.3.8.2   FACS for Cell Cycle Analysis 
Cells were harvested and fixed in 70% ethanol at -20°C for 30 minutes, pelleted 
by centrifugation at 2500rpm for 5min and washed in 1ml PBS (Sigma). Samples 
were permeabilised with 500µl 0.2% Triton-X-100 (Sigma) for 15 minutes at 
room temperature (22°C) before being washed in PBS and resuspended in 500µl 
50µg/ml  propidium  iodide  (Sigma)  and  0.1mg/ml  RNase  A  (Sigma)  for  30 
minutes  at  37°C.  Cell  suspensions  were  analysed  on  a  FACScalibur  (Becton 
Dickinson,  Oxford,  UK)  using  CellQuest  analysis  software.  Percentage  of 
tetraploid  cells  in  each  population  was  calculated  using  the  ModFit  software 
(Verity Software House, Topsham, USA).  
 
2.3.9    Karyotypic Analysis 
Fully karyotyping of the MSC 5 cell line was conducted by Helena Kempski and 
Steve Chatters (Institute of Child Health, Great Ormond Street Hospital, London) 
as described previously (Kempski et al., 2006). 
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2.4    Bioinformatics  
2.4.1    Gene Expression Microarray (GEM) Data Analysis 
Gene  expression  microarray  data  for  the  5  hit  stem  cell  model  was obtained 
previously (Funes et al., 2007). cDNA from each cell line (with the exception of 
MSC 2E6) was hybridized to Affymetrix hg-u133+2 GeneChips (Affymetrix, 
Santa Clara, USA) in triplicate and processed to obtain log expression values 
(Funes et al., 2007). Significant changes in gene expression between MSC 0 and 
MSC  5  were  determined  by  FDR  corrected  T-Test  of  log  expression  values 
between conditions, with q   0.01 considered significant. In order to adjust gene 
expression data for cell proliferation rate, the statistical analysis described above 
was  also  repeated  on  log  expression  values  for  all  genes  normalized  against 
expression of the proliferation-linked marker PCNA. 
  In order to focus the analysis on relevant genes involved in epigenetic 
regulation,  a  list  of  epigenetic  regulators  was  compiled  from  an  extensive 
literature review, comprising 967 probe sets for 341 genes. The list included 
DNA  methyltransferases,  histone  deacetylases,  histone  acetyltransferases, 
histone  methyltransferases,  histone  demethylases,  methyl-cytosine  binding 
proteins,  ATP  dependent  chromatin  remodelling  proteins,  imprinted  genes, 
micro-RNA processing genes, nucleosome assembly proteins, polycomb proteins 
and cytosine deaminases (Table A2).  GEM data for this list was extracted from 
the total array data for further analysis. 
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2.4.2    Gene Expression Heat Maps 
Heat  maps  were  created  with  the  dChip  microarray  analysis  package 
(http://www.biostat.harvard.edu),  using  the  relevant  probe  sets  and  log 
expression values. These were used to visually represent differential changes in 
gene expression, and display expression of each probe set in units of standard 
deviation across all replicates. The colour corresponds to the direction of change 
(down  regulation:  blue,  up-regulation:  red),  with  intensity  correlating  with 
magnitude of the change (scale in units of standard deviation is displayed under 
each figure).  
 
2.4.3    Gene Set Enrichment Analysis (GSEA) 
GSEA  is  an  unbiased  computational  method  used  to  determine  whether  a 
particular set of genes are significantly up- or down-regulated in comparison to a 
ranked list of all genes in a GEM experiment (Subramanian et al., 2005). The 
enrichment score measures the skew of the gene set within the order of genes 
sorted by expression difference between two samples. Significance is determined 
by the false discovery rate (q value), a measure of enrichment scores greater than 
1000 enrichment scores generated from a random gene sets of equal size to the 
gene set of interest.  
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2.4.4    Statistical Analyses 
Student’s T-tests were conducted using Microsoft Excel as two tailed, unequal 
sample  variance,  with  p     0.05  considered  statistically  significant.  FDR 
correction for multiple testing and Mann-Whitney U tests were conducted using 
the  statistical  package  R.  Error  bars  are  standard  error  of  the  mean  (SE), 
calculated as standard deviation divided by the square root of the number of 
samples.  
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Chapter  3:  Transformation  of  mesenchymal  stem  cells  can 
induce repetitive element hypomethylation 
 
3.1    Background 
 
Many cancer types show hallmark epigenetic changes including characteristic 
histone  modifications,  gene  specific  hypermethylation  and  global 
hypomethylation (Feinberg and Tycko, 2004). Of these, the first to be described 
was  genome  wide  hypomethylation,  a  decrease  in  the  overall  genomic 
methylcytosine  content  from  approximately  4%  in  normal  tissues  to  2-3%  in 
cancers. This change was first observed in a 1983 study comparing lung and 
colon carcinomas to adjacent normal tissue, demonstrating that overall genomic 
methylcytosine levels were lower in cancer tissues (Feinberg and Vogelstein, 
1983).  Since  this  pioneering  study,  the  observation  has  been  reproducibly 
repeated in comparisons of a wide range of cancers and normal tissues using a 
variety of different techniques (Ehrlich et al., 2002; Feinberg et al., 1988; Gama-
Sosa et al., 1983a; Narayan et al., 1998; Qu et al., 1999; Weisenberger et al., 
2005).  
The range of methods available for the study of global methylation has also 
expanded  considerably  since  initial  studies  in  the  field.  Traditionally,  global 
methylcytosine  content  was  measured  using  high  performance  liquid 
chromatography  (HPLC)  of  DNA  digested  to  individual  deoxynucleosides 
(Gama-Sosa et al., 1983a; Gama-Sosa et al., 1983b; Kuo et al., 1980). Although   112 
this method gives an absolute quantitative measure of methylcytosine content, it 
is  time  consuming  and  requires  a  large  amount  of  DNA.  Several  alternative 
methods, based on measuring DNA methylation in repetitive elements as a proxy 
for global methylation, have since been developed. These include: 
1.  Digestion  of  genomic  DNA  with  methylation  sensitive  restriction 
enzymes followed by Southern blot analysis against repetitive elements, 
with  differences  in  digestion  pattern  indicative  of  changes  to  DNA 
methylation  (Jurgens  et  al.,  1996;  Narayan  et  al.,  1998).  Although 
reproducible  and  easier  than  HPLC,  this  method  does  not  give  a 
quantitative  measure  of  genomic  methylcytosine  content  and  also 
requires a large amount of DNA.   
2.  Bisulphite sequencing, based on bisulphite conversion of unmethylated 
cytosine residues to uracil, which also gives an absolute readout of DNA 
methylation  at  individual  CpG  dinucleotides  (Frommer  et  al.,  1992; 
Shapiro  et  al.,  1973).  However,  this  technique  is  only  practical  in 
assessing methylation at unique loci, not on a genome wide scale unless a 
repetitive element is assayed. Additionally, the technique is very time 
consuming and expensive due to the number of PCR products that have 
to be individually cloned and sequenced.  
3.  A methylation sensitive PCR (MSP) and the quantitative PCR (qPCR) 
based method MethyLight (Trinh et al., 2001; Weisenberger et al., 2005). 
This  method  utilizes  primers  which  selectively  amplify  methylated  or 
unmethylated sequences in bisulphite converted DNA. For MethyLight, 
methylation levels are expressed in relation to a fully methylated or fully   113 
unmethylated  control.  These  methods  require  a  very  small  amount  of 
starting DNA and provide high throughput, quantitative results.  
4.  Monoclonal  antibodies  against  5-methylcytosine  have  been  developed 
and  used  to  reliably  stain  methylated  DNA  in  vitro  (Bensaada  et  al., 
1998;  Habib  et  al.,  1999).    As  well  as  being  applied  to 
immunohistochemistry,  such  antibodies  may  be  used  for  more 
quantitative  measurement  of  methylated  DNA  content  in  a  cell  by 
fluorescence assisted flow cytometry (FACS) where individual cells can 
be stained and assayed. However, this is a relatively new method, the 
accuracy of which has not yet been fully established.  
5.  Methylated DNA immunoprecipitation (MeDIP). Methylated regions of 
the  genome  can  be  precipitated  from  whole  genomic  DNA  using 
antibodies against methyl-cytosine, with the identity of the precipitated 
DNA confirmed by microarray analysis or high throughput sequencing 
(Weber  et  al.,  2005).  As  well  as  providing  a  measure  of  global 
methylation levels, these methods allow regions from which methylation 
is lost to be identified. However, due to the current high cost of these 
techniques,  they  have  not  been  routinely  used  to  address  global 
hypomethylation in cancer.  
 
Despite  these  numerous  observations  of  genome-wide  hypomethylation  in 
cancer, relatively little is known about the causes of this loss of methylation. 
Most studies to date have been conducted in primary cancer tissues compared 
only  to  corresponding  matched  or  unmatched  normal  tissues.  In  doing  so,  a 
specific link between a particular genetic or epigenetic change and the induction   114 
of  global  hypomethylation  in  these  cancers  can  not  be  established  due  to 
variation in the cellular composition or the genetic and epigenetic background of 
tumours  compared  to  corresponding  normal  tissues.  Furthermore,  although 
matched cases and control samples remove the effect of some of this genetic 
variation, no convincing studies have been conducted in which hypomethylation 
has been induced in a specific cellular population through transformation with 
defined genetic or epigenetic changes.  
The step-wise model of MSC transformation developed in our laboratory 
provides an excellent model in which to study epigenetic changes such as the 
induction of global hypomethylation. This model allows a direct comparison of 
normal cells (parental MSC) to equivalent transformed cells derived from the 
same lineage. Furthermore, by inducing transformation in a step-wise manner, a 
link between these oncogenic ‘hits’ and subsequent epigenetic changes can be 
established. I hypothesize that global DNA hypomethylation occurs during step-
wise transformation in MSC, and aim to utilize a number of different methods to 
assess  genome-wide  methylation  levels  at  each  step  in  the  model.  An 
investigation of genome-wide methylation levels in these cells could therefore 
suggest  a  causal  relationship  between  the  genetic  change  and  induction  of 
hypomethylation.  Furthermore,  this  study  will  also  determine  whether  this 
change is an early or late event during the transformation process.  
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3.2    Aims 
1)  To test and optimise a number of methods for assaying genome-wide 
DNA methylation levels, namely: 
a.  Antibody  staining  of  5-methylcytosine  followed  by  FACS 
analysis of fluorescence. 
b.  MethyLight,  a  qRT-PCR  based  assay  of  repetitive  element 
methylation.  
2)  Utilize these methods to establish whether genome wide hypomethylation 
is observed in the MSC model and identify the step at which it occurs.  
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3.3    Results 
3.3.1    FACS Analysis of Global Methylation 
In order to obtain a direct measure of total DNA methylation in the MSC cell 
lines,  the  feasibility  of  a  novel  flow  cytometry  based  method  for  measuring 
global methylation was explored. In this method, cells are permeabilised and 
incubated with a primary antibody against methylated cytosine. A fluorescein 
isothiocyanate  (FITC)  conjugated  secondary  antibody  is  used  to  label  the 
primary antibody, such that green fluorescence directly correlates to the amount 
of methylated DNA within the nucleus. To control for total amount of DNA, co-
staining of total genomic DNA with propidium iodide (PI) is also carried out in 
parallel. Both fluorescence readings are obtained at the single cell level with a 
flow cytometer.  
Extensive optimisation of this method was carried out using MSC 5 cells 
(Figure 3.1). Briefly, 150,000 cells per condition were fixed, permeabilized and 
stained for methylcytosine (green) and total DNA (red), with both fluorescence 
measurements recorded by FACS on FL1 (methylcytosine) and FL2 (total DNA) 
channels.  Initially,  methylcytosine  staining  was  not  distinguishable  from 
background fluorescence (Figure 3.1a). In order to overcome this problem, the 
protocol was modified to include a treatment with hydrochloric acid to remove 
histones,  which  resulted  in  a  significant  increase  in  specific  staining  (Figure 
3.1b) (Habib et al., 1999).  
Primary and secondary antibody concentrations were also optimised by 
titration. MSC 5 cells were incubated with increasing concentrations of primary   117 
antibody,  ranging  from  0.05  - 4 µg,  followed  by  incubation  with  7.5µg/ml 
secondary antibody. Efficiency of staining was determined by monitoring the 
geometric  mean  (GeoMean)  green  fluorescence  (FL1)  of  the  total  cell 
population.  These  data  indicated  that  the  primary  antibody  saturates  when 
present  at  amounts  greater  than  1µg  (Figure  3.1c).  Since  optimal  results  are 
obtained when the primary antibody is not in excess, 0.1µg of antibody was used 
in further experiments. Titration of the secondary antibody was conducted in a 
similar manner. In this instance, fluorescence continued to increase with higher 
concentrations  of  antibody,  indicating  that  the  saturation  point  had  not  been 
reached  at  the  highest  concentration  (15µg/ml)  (Figure  3.1d).  A  secondary 
antibody concentration of 7.5µg/ml was chosen for further experiments.   
Following  optimisation  of  this  method,  analysis  of  genome-wide 
methylation  levels  in  the  MSC  cell  lines  was  conducted,  comparing 
untransformed MSC 4 with transformed MSC 5. As a positive control, MSC 4 
cells  were  treated  with  5µM  5-aza-deoxycytidine  for  four  days  to  induce 
hypomethylation and assayed alongside the experimental samples. FL1 signals 
above the levels from a matched isotype control antibody were obtained for all 
samples,  indicating  specific  staining  of  methylcytosine  in  these  cells  (Figure 
3.2c). GeoMean FL1 measurements were analysed for the total cell populations 
as well as for cells in G1, M and G2 phases of the cell cycle (Figure 3.2d). These 
data  indicated  that  the  method  was  able  to  detect  a  significant  decrease  in 
methylcytosine levels when MSC 4 cells were treated with the hypomethylating 
agent  5-aza-deoxycytidine.  However,  no  significant  difference  in  methylation 
was evident between MSC 4 and transformed MSC 5 cells. To control for the 
amount of total DNA in these cells, the FL1:FL2 ratio (methyl-cytosine : total   118 
DNA) was calculated for these cell populations (Figure 3.2e). These results also 
indicated  a  significant  decrease  in  genome-wide  methylation  in  the  5-aza-
deoxycytidine treated cells, but detected no significant difference between MSC 
4 and MSC 5 cells at any stage of the cell cycle.  
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Figure 3.1: Optimisation of a FACS based method of measuring genomic 5-methylcytosine 
content. MSC 4 were grown as normal, fixed in ethanol and permeabilized with Triton-X. (a) 
MSC 4 stained with mouse anti-methylcytosine primary antibody followed by anti-mouse FITC 
secondary antibody. (b) MSC 4 incubated with 2M HCl for 25 minutes before the addition of 
primary and secondary antibody. Flow cytometry analysis shows FL1 signal (methyl-cytosine) 
for unstained (black), secondary antibody only (blue), isotype control (green), and double stained 
(red) cells. (c) MSC 4 stained with increasing amounts of mouse anti-methylcytosine primary 
antibody followed by anti-mouse FITC secondary (8 µg/ml). (d) MSC 4 stained with 1µg mouse 
anti-methylcytosine primary antibody followed by increasing concentrations of anti-mouse FITC 
secondary  antibody.  GeoMean  FL1  was  recorded  by  flow  cytometry  and  corrected  for 
background fluorescence as measured by staining with an equivalent amount of IgG1 isotype 
control. Optimal concentrations used for further experiments are indicated with red circles.    120 
 
Figure  3.2:  Analysis  of  global  methylation  by  flow  cytometry  is  unable  to  detect  any 
significant difference in methylation between MSC 4 and MSC 5. Cells were stained with 
0.05µg  mouse  anti-methylcytosine  primary  antibody  and  8µg/ml  anti-mouse  FITC  labelled 
secondary  antibody  and  analysed  by  flow  cytometry.  (a)  Dot  plot  displaying  forward  scatter 
(FSC) versus side scatter (SSC) for MSC 5 cells. (b) Dot plot displaying FL2 area (FL2-A) 
versus FL2 width (FL2-W) for MSC 5 cells, used for doublet discrimination and separation of   121 
G1,  M  and  G2  phase  cells.  (c)  Histogram  displaying  FL1  signal  of  unstained  (black),  IgG1 
isotype control stained (red) and anti-methylcytosine stained (green) MSC 5. (d) GeoMean FL1 
measurements for total, G1 phase, S phase and G2/M phase populations of MSC 4, MSC 4 
treated  with  5µM  5-aza-deoxycytidine  for  four  days  (MSC  4  +  aza)  and  MSC  5  cells.  (e) 
FL1:FL2 ratio for total, G1 phase, S phase and G2/M phase populations of MSC 4, MSC 4 
treated with 5µM 5-aza-deoxycytidine for four days (MSC 4 + aza) and MSC 5 cells. . Student’s 
T-test was performed for all statistical analyses. * p < 0.05 wrt. MSC 4. Columns display average 
of three replicates; Error bars display SEM.  
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3.3.2    Global Methylation Analysis by MethyLight- Optimisation 
In order to investigate repetitive element methylation in the MSC cell lines, the 
qRT-PCR based method MethyLight was utilized to assess methylation of Alu, 
pericentromeric  satellite-2  (Sat2)  and  long  interspersed  nuclear  element  1 
(LINE1) repetitive elements. Methylation of these elements has previously been 
shown  to  correlate  strongly  with  global  methylation  as  measured  by  high 
performance  liquid  chromatography  (Weisenberger  et  al.,  2005).  MethyLight 
reactions which showed the strongest correlation (Alu-M2, Sat2-M1 and LINE1-
M1)  were  chosen  for  use  in  this  study.  The  primer  and  probe  sets  for  each 
reaction  were  designed  to  amplify  methylated  sequences  from  bisulphite 
converted DNA, with the efficiency of amplification depending on the degree of 
methylation  present  at  the  loci.  An  unbiased  primer  and  probe  set  designed 
against a region of the consensus Alu sequence absent of CpG dinucleotides 
(Alu-C4)  was  utilized  as  a  loading  control  and  to  control  for  efficiency  of 
bisulphite  conversion.  All  samples  were  run  alongside  fully  methylated  and 
unmethylated  control  DNA,  with  methylation  levels  of  experimental  samples 
expressed as a fold change relative to the fully methylated reference.  
Optimisation of primer and probe concentrations were conducted for all 
MethyLight  reactions  to  ensure  maximal  reaction  efficiency  (Figure  3.3). 
Starting concentrations for these optimisations were obtained from Weisenberger 
et  al.  and  varied  around  these  points.  Primer  optimisation  was  conducted  by 
maintaining  probe  concentration  at  0.1µM  and  varying  primer  concentration 
from  50-900nM,  with  several  combinations  of  forward  and  reverse  primer 
concentrations. The same template (fully methylated DNA) was used for each   123 
reaction in equal amount (50ng). Interpretation of average threshold (Ct) values 
and  standard  error  for  these  reactions  indicated  highest  reaction  efficiency  at 
900nM forward and reverse primers for all reactions (Figure 3.3 a-c).  
Next,  primer  concentrations  were  maintained  constant  at  900nM  and 
probe concentration was varied. As before, analysis of average Ct values and 
standard error indicated highest reaction efficiency at 0.2µM for Alu-M2 and 
LINE1-M1 reactions, and 0.1µM for the Sat2-M1 reaction (Figure 3.3 d-f).  
To control for the efficiency of bisulphite conversion, all samples were 
treated  in  the  same  bisulphite  reaction  along  with  fully  methylated  (M.SssI 
treated)  and  unmethylated  (GenomiPhi  whole  genome  amplification  product) 
controls. Every cell line was assayed in triplicate, with each PCR reaction also 
conducted  in  triplicate.  The  fully  methylated  and  unmethylated  reference 
samples were used as controls for the PCR reaction and as standards against 
which to express methylation levels. Final methylation values were expressed as 
a fold change relative to the fully methylated reference.  
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Figure 3.3: Optimisation of MethyLight Reactions. Quantitative PCR reactions using 50ng of 
fully methylated DNA as template were performed with varying concentrations of forward and 
reverse primers for the (a) Alu-M2, (b) LINE1-M1 and (c) Sat2-M1 MethyLight reactions, with 
average threshold (Ct) values recorded. Optimal primer concentrations were subsequently used 
for probe concentration optimisation for the same three reactions (d-f). MethyLight reactions 
were performed as before but with probe concentration was varied. Columns display average of 
three replicates; Error bars display SEM. * optimal concentration used in further experiments.  
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3.3.3    5-aza-deoxycytidine Treatment of MSC and HF 
To  test  the  sensitivity  of  the  MethyLight  reactions,  MSC  and  HF  cells  were 
treated  with  5-aza-deoxycytidine  for  four  days  in  order  to  induce  global 
hypomethylation  (Figure  3.4).  MethyLight  analysis  of  Alu,  Sat2  and  LINE1 
elements  in  MSC  0  demonstrated  a  decrease  in  methylation  with  increasing 
concentrations of 5-aza-deoxycytidine. Transformed MSC 5 cells, however, did 
not  respond  well  to  the  treatment,  displaying  increased  cell  death  alongside 
unchanged or increased methylation values as determined by MethyLight (Figure 
3.4  a-c).  Hypomethylation  of  all  elements  was  observed  in  parental  and 
transformed HF treated with 1µM 5-aza-deoxycytidine for four days (Figure 3.4 
d-f).  These  results  indicated  that  MethyLight  was  able  to  detect  global 
hypomethylation at these repetitive elements, and that hypomethylation could be 
successfully induced in parental mesenchymal stem cells and human fibroblasts. 
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Figure 3.4: 5-aza-deoxycytidine treatment induces repetitive element hypomethylation in 
MSC and HF that is detectable by MethyLight. Parental MSC (MSC 0), transformed MSC 
(MSC  5),  parental  HF  (HF  0)  and  transformed  HF  (HF  5)  were  treated  with  increasing 
concentrations of 5-aza-deoxycytidine for 4 days. Fold change in methylation of (a) Alu, (b) Sat2 
and (c) LINE1 elements in MSC and (d) Alu, (e) Sat2 and (f) LINE1 in HF with respect to fully 
methylated reference DNA was assayed by MethyLight as described previously.    127 
3.3.4  Analysis  of  Global  Methylation  levels  in  the  MSC  Model  by 
MethyLight 
To determine whether genome-wide hypomethylation takes place during step-
wise  transformation  of  MSC,  methylation  of  Alu,  Sat2  and  LINE1  repetitive 
elements was compared between MSC 0 and MSC 5 by MethyLight. These data 
showed no change in Alu methylation but a significant decrease in Sat2 and 
LINE1 methylation between these two cell lines (Figure 3.5 a-c). 
To identify the step at which this decrease in methylation occurs during 
transformation, Sat2 methylation was assessed in more detail at each step during 
transformation  of  MSC  (Figure  3.5d).  This  element  was  chosen  for  further 
investigation because it provided a strong indicator of global methylation levels 
and also displayed the most significant decrease in methylation in this model. 
These data indicated a decrease in Sat2 methylation between MSC 0 and MSC 1 
(on  expression  of  hTERT),  followed  by  a  return  to  similar  levels  with  p53 
inhibition in MSC 2E6. With further genetic hits, Sat2 methylation remained 
similar to parental MSC levels until the introduction of H-Ras
V12 between MSC 4 
and  MSC  5,  at  which  point  a  significant  decrease  was  observed.  Sat2 
hypomethylation was also maintained in MSC 5 tumours grown in mice (Figure 
3.5d).  
To  test  whether  these  observed  changes  were  specific  to  the 
mesenchymal  stem  cell  model,  MethyLight  analysis  was  also  conducted  in 
human fibroblasts (HF) transformed using the same 5 oncogenic steps and in 
tumour derived by injection of transformed HF into nude mice. No decrease in 
methylation was observed for any of the repetitive elements assayed (Figure 3.6)   128 
 
Figure 3.5: MethyLight analysis of repetitive element methylation shows decrease in Sat2 
and  LINE1  methylation  between  parental  and  transformed  MSC.  Quantitative  PCR  was 
conducted using primers against methylated (a) Alu, (b & d) Sat2 and (c) LINE1 sequences in 
parental MSC (MSC 0), transformed MSC (MSC 5), tumours derived by injecting transformed 
MSC into nude mice (Tumour) and fully unmethylated GenomiPhi amplified DNA (Unmeth). (d) 
Quantitative PCR for the Sat2 element was also conducted in all MSC cell lines (MSC 0 – 5) and 
tumours.  Fold-change  in  methylation  was  calculated  in  three  replicates  by    Ct  using  an 
unbiased Alu reaction as a loading control and normalised to fully methylated (M.SssI treated) 
reference DNA. Student’s T-test was performed for all statistical analyses. * p < 0.05, ** p < 
0.01. Columns display average of three replicates; Error bars display SEM. 
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Figure  3.6:  MethyLight  analysis  of  repetitive  element  methylation  shows  no  change  in 
methylation between parental and transformed HF. Quantitative PCR was conducted using 
primers against methylated (a) Alu, (b) Sat2 and (c) LINE1 sequences in parental HF (HF 0), 
transformed HF (HF 5), tumours derived by injecting transformed HF into nude mice (Tumour) 
and fully unmethylated GenomiPhi amplified DNA (Unmeth). Fold-change in methylation was 
calculated in three replicates by   Ct using an unbiased Alu reaction as a loading control and 
normalised to fully methylated (M.SssI treated) reference DNA. Student’s T-test was performed 
for all statistical analyses. * p < 0.05, ** p < 0.01. Columns display average of three replicates; 
Error bars display SEM. 
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3.3.5    Bisulphite Sequencing Confirmation of MethyLight Data 
To confirm the results observed by MethyLight, bisulphite sequencing of the 
Alu,  Sat2  and  LINE1  elements  was  conducted  (Figure  3.7).  Control  primers 
without a bias for methylated or unmethylated sequences were designed against 
the regions assayed previously by MethyLight. These regions were amplified by 
PCR  and  cloned  into  the  pGEM-T  vector,  with  10-25  individual  clones 
sequenced  in  order  to  assess  CpG  methylation  across  the  element.  The  PCR 
products covered 3 CpG dinucleotides in the Alu element, 11 in LINE1 and 10 in 
Sat2.  Analysis  of  parental  and  transformed  MSC  and  HF  confirmed  the 
MethyLight data, demonstrating a significant decrease in both Sat2 and LINE1 
element methylation between MSC 0 and 5, but no change in Alu methylation 
(Figure 3.7 a-d). Further analysis was conducted to confirm that this decrease in 
Sat2  and  LINE1  methylation  occurred  on  the  introduction  of  H-Ras
V12. 
Bisulphite sequencing of Sat2 and LINE1 elements was conducted in MSC 4 and 
5, indicating that hypomethylation of these elements was induced on H-Ras
V12 
overexpression. No changes in Alu, Sat2 or LINE1 methylation were observed 
between HF 0 and 5, confirming the data obtained by MethyLight  (Figure 3.7 a-
d). 
To establish whether hypomethylation of these elements occurred in a 
site  specific  manner,  average  methylation  values  for  each  CpG  site  were 
compared between parental and transformed MSC and HF (Figure 3.8). This 
indicated  a  drastic  decline  in  methylation  across  CpG  sites  5-7  in  the  Sat2 
element between parental and transformed MSC and HF. Analysis of this region 
for  transcription  factor  binding  sites  using  TF  Search   131 
(http://www.cbrc.jp/research/db/TFSEARCH.html)  revealed  potential  binding 
sites for v-Myb and c-Ets in this region (Figure 3.8b). 
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Figure 3.7: Bisulphite sequencing of repetitive elements confirms MethyLight data. Sat2 and 
LINE1 elements were amplified by PCR from bisulphite modified genomic DNA with individual 
PCR products cloned into pGEM-T and sequenced. (a) Representative sequencing data for Sat2 
and LINE1 elements, with each line displaying one cloned PCR product. Open circles represent 
unmethylated CpG sites, closed circles methylated CpGs and absent circles polymorphic sites 
where the expected CpG is not present. Average methylation is also expressed as a percentage of 
all CpG sites assayed for (b) Sat2, (c) LINE1 (d) and Alu elements.  
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Figure 3.8: Sat2 hypomethylation occurs in a site specific manner. (a) Average methylation 
values displayed for each CpG site across the Alu, Sat2 and LINE1 repetitive elements. Blue 
lines indicate the region of Sat2 at which the greatest loss of methylation is observed between 
MSC 0 and MSC 5. (b) Transcription factor binding site analysis of Sat2 element CpG sites 5-7. 
* p <0.05 Paired Wilcoxon Signed Rank Test. Columns display average methylation percentages. 
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3.3.6    Isolation and Characterisation of Clonal MSC5 Populations 
The MSC 5 cell line was initially generated as a mixed population following 
hygromycin selection of MSC 4 cells infected with H-Ras
V12 retrovirus. In order 
to  further  characterize  this  mixed  population,  and  investigate  whether  global 
hypomethylation occurs within a specific sub-population of cells, clonal MSC 5 
populations were isolated (Figure 3.9). MSC 5 were plated at a density of 100 
cells  per  10cm  dish  and  grown  until  individual  colonies  were  visible.  These 
colonies  were  individually  trypsinised,  replated  and  expanded.  Following 
isolation, individual clones were shown to express different levels of H-Ras
V12, 
with concurrent variation in downsteam MAPK signalling as measured by levels 
of phospho-ERK1/2 (pERK) relative to total ERK1/2  (Figure 3.9a). In order to 
confirm that the clonal cell lines were transformed, in vitro growth of the cells in 
soft  agarose  was  assessed.  All  cell  lines  were  able  to  form  colonies  in  soft 
agarose, although a significant variation in the average colony size after 12 days 
growth was observed (Figure 3.9b). Comparison of average colony diameter to 
H-Ras protein levels indicated a strong correlation between the two (r
2 = 0.72; 
Figure  3.9c).  To  determine  whether  increased  H-Ras
V12  expression  correlated 
with greater hypomethylation in the MSC 5 clones, bisulphite sequencing of the 
Sat2 element was conducted in low H-Ras (MSC 5, clone 2) and high H-Ras 
(MSC 5, clone 5) expressing populations. This indicated that Sat2 elements in 
both high and low H-Ras expressing lines were hypomethylated compared to 
MSC 4. Sat2 methylation in clone 5 (high H-Ras) was lower than in clone 2 (low 
H-Ras), although this difference was not statistically significant (Figure 3.9d). 
These data show that both high and low H-Ras expressing clones within the 
mixed MSC 5 population display hypomethylation of the Sat2 pericentromeric   136 
repeat, although the degree of hypomethylation did not significantly correlate 
with H-Ras expression.  
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Figure  3.9:  H-Ras  expression  and  repetitive  element  methylation  in  MSC  5  clones.  (a) 
Western  blot  showing  Ras,  GAPDH,  phosphorylated  MAPK1/2  (pERK)  and  total  MAPK1/2 
(total ERK) levels in the original MSC 5 population (MSC 5) and six clonal MSC 5 populations. 
(b) Quantification of H-Ras levels relative to the original MSC 5 population by densitometry. (c) 
Correlation between H-Ras levels and colony diameter in soft agarose transformation assay. (d) 
Percentage  methylation  of  Sat2  repetitive  element  as  determined  by  bisulphite  sequencing  in 
MSC 4, MSC 5, a low H-Ras expressing clone (MSC 5 Clone 2) and a high H-Ras expressing 
clone  (MSC  5  Clone  5).  *  p  <0.05  Paired  Wilcoxon  Signed  Rank  Test.  Columns  display 
averages. 
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3.3.7    MSC 5 Karyotype 
Loss  of  methylation  at  repetitive  elements  can  lead  to  increased  genomic 
instability and abnormal karyotypic changes. To establish whether such changes 
occur during step-wise transformation of MSC, a full karyotypic analysis of the 
mixed MSC 5 population including multicolour fluorescence in situ hybridisation 
(MFISH) was conducted (Figure 3.10). This revealed that the MSC 5 population 
consisted  of  several  sub-populations  with  unique  translocations,  including  a 
tetraploid sub-population making up approximately 17% of the total number of 
cells (Figure 3.10c). The fully karyotype of this cell line is as follows: 
 
46,XY,der(9)t(9;?12)(q34;?),der(10)t(10;12)(p1?1;?),der(21) t(?12;21)(?;p10)  
[cp16]/47,idem,+der(?20)t(20;21)(p1?1.2;?) [2]/92,XXYY,idemx2,inc[2] 
 
Further analysis of cell ploidy by FACS revealed that this tetraploid population 
was  also  present  in  the  MSC  4  population  at  a  level  of  approximately  10% 
(Figure 3.10d).  
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Figure 3.10: MSC 5 karyotype. (a) Karyogram showing, arrowed, der(9), der(10) and der(21). 
(b) Partial side line MFISH karyogram showing, arrowed, der(9), der(10), der(20) and der(21). 
(c) Cell cycle analysis of MSC 5. Cells were grown as normal, fixed and permeabilised, stained 
with propidium iodide and analysed by flow cytometry. Tetraploid G2 population is arrowed. (d) 
Percentage  of  tetraploid  cells  in  the  MSC  3,  4  and  5  populations  were  calculated  using  the 
ModFit  software  package.  Student’s  T-test  was  used  for  all  statistical  analyses.  *  p  <  0.05. 
Columns display average of three replicates; Error bars display standard deviation.    140 
3.4    Discussion 
Global hypomethylation has been observed in a wide range of cancers as assayed 
by a number of different techniques, many of which utilize repetitive elements as 
markers for genome wide methylation status. Despite the wealth of studies on 
global DNA hypomethylation, very little progress has been made to elucidate the 
mechanism of this loss of methylation.  
  Our  laboratory  developed  a  stem  cell  model  of  cancer  in  which 
mesenchymal  stem  cells  (MSC)  have  been  transformed  through  5  oncogenic 
steps (hits) – the introduction of hTERT, HPV E6 and E7, SV40 small T and 
oncogenic  H-Ras  (Funes  et  al.,  2007).  This  stepwise  model  provides  a  well 
defined genetic background in which to investigate epigenetic changes that occur 
during the process of transformation. Studies of the methylation status in this 
model  could  therefore  provide  indications  of  the  causes  of  global 
hypomethylation in cancer.  
My studies on this model have revealed a number of interesting findings. 
Firstly, hypomethylation of the Sat2 and LINE1 repetitive elements is observed 
during  transformation,  with  the  decrease  in  methylation  occurring  on  the 
introduction of oncogenic H-Ras
V12 in the final step. Hypomethylation of these 
elements  has  been  widely  observed  and  shown  to  correlate  strongly  with 
genome-wide methylation levels, suggesting that genome-wide hypomethylation 
occurs in this system as a result of H-Ras
V12 expression in MSC 5 (Ehrlich, 2002; 
Weisenberger  et  al.,  2005).  Although  these  repetitive  elements  constitute  a 
sizable percentage of the genome, hypomethylation was not observed in the most 
common repeat, the Alu element, which alone makes up approximately 10% of   141 
the human genome (Lander et al., 2001). Few studies have assessed changes in 
Alu methylation in cancer, with those that have producing contradictory results. 
One  study  of  neuroendocrine  tumours  noted  reduced  Alu  methylation  in  this 
cancer compared to adjacent normal tissue (Choi et al., 2007). Similarly, Alu 
hypomethylation  has  been  detected  in  the  chronic  phase  of  chronic  myeloid 
leukaemia (CML) and blast crisis CML compared to normal bone marrow cells 
(Roman-Gomez et al., 2008). However, a study of seminoma and dysgerminoma 
observed an increase in Alu methylation when compared to normal sperm and 
spleen, although this may be complicated by the hypomethylated state of Alu 
repeats in normal sperm (Rubin et al., 1994). Finally, a genome-wide study of 
repetitive  element  methylation  by  MeDIP  and  high  throughput  sequencing  in 
malignant peripheral nerve sheath tumours (MPNST) noted similar patterns of 
hypomethylation to those observed in my investigation (Figure 3.11). Results 
from  this  report  indicate  that  satellite  repeats,  and  to  a  lesser  extent  LINE 
elements, are hypomethylated in the cancer compared to normal control tissue, 
whereas SINE elements (including Alu repeats) show no change in methylation 
(Feber et al., in press). It is possible, therefore, that certain repetitive elements, 
such  as  satellite  and  LINE  sequences,  may  be  more  likely  to  display  DNA 
hypomethylation in cancer.  
Although I was able to detect loss of methylation in the Sat2 and LINE1 
elements  by  bisulphite  sequencing  and  MethyLight,  this  difference  was  not 
apparent when global methylcytosine levels were assayed by FACS. Antibody 
optimization curves and matched IgG1 controls indicated that staining is specific 
for  methylcytosine.  Furthermore,  a  significant  decrease  in  the  methylcytosine 
signal is observed in MSC 4 cells treated with 5-aza-deoxycytidine to induce   142 
hypomethylation, suggesting that changes in genome-wide methylation levels are 
detectable by this method. Although there is a small decline in the amount of 
methylcytosine relative to total DNA (FL1:FL2 ratio) in MSC 5 compared to 
MSC  4,  this  change  does  not  achieve  statistical  significance.  Therefore,  the 
hypomethylation of Sat2 and LINE1 elements in MSC 5 may not constitute a 
large enough demethylation event to be detectable using this method.  
  The widespread incidence of genome wide hypomethylation in a range of 
cancers, including benign neoplasms, has suggested that this epigenetic change 
occurs early during the process of transformation (Feinberg et al., 2006; Goelz et 
al., 1985; Suter et al., 2004). The results obtained from this step-wise model of 
transformation  are  contrary  to  these  studies,  indicating  that  hypomethylation 
occurs  in  fully  transformed  cells  following  the  final  oncogenic  ‘hit’.  This 
suggests that hypomethylation is a late event during step-wise transformation, 
supporting previous reports that hypomethylation arises in the latter stages of 
cancer progression (Gama-Sosa et al., 1983a; Yegnasubramanian et al., 2008). 
However, transformation in the MSC model is induced by a series of genetic hits 
and may not fully recapitulate the true early epigenetic changes that occur during 
in vivo transformation as suggested by the epigenetic progenitor model of cancer 
(Feinberg  et  al.,  2006).  It  is  possible,  therefore,  that  although  global 
hypomethylation is a late event in this model, it may occur earlier during in vivo 
cancer progression as a prelude for further genetic and epigenetic changes.  
  Previous  reports  have  suggested  links  between  Ras  signalling  and 
changes  in  DNA  methylation,  including  incidences  of  Ras  induced 
hypermethylation  and  hypomethylation.  These  include  hypermethylation  of  a   143 
CpG island upsteam of the clusterin promoter and a CpG island of the MMP2 
promoter in H-Ras transformed rat fibroblasts (Lund et al., 2006). Additionally, 
genome-wide methylation levels in the adrenocortical tumour cell line Y1 have 
been  shown  to  be  regulated  by  Ras  mediated  modulation  of  DNA 
methyltransferase activity, with reduced Ras signalling resulting in genome-wide 
hypomethylation (MacLeod et al., 1995; Rouleau et al., 1995). One of the most 
well characterised examples of Ras dependent hypermethylation is the down-
regulation of the pro-apoptotic Fas gene in NIH 3T3 cells. Investigation of this 
system revealed a range of factors required for Ras-mediated epigenetic silencing 
of Fas including DNMT1, EZH2, EED and HDAC9 (Gazin et al., 2007). As well 
as this role in DNA hypermethylation, studies have suggested that Ras may also 
be involved in the induction of DNA hypomethylation. For example, my findings 
are consistent with a study of v-H-Ras induced general DNA demethylation in 
mouse embryonal P19 cells (Szyf et al., 1995). Although these previous studies 
demonstrate that there is an interaction between Ras signaling and the control of 
DNA methylation in cells, my investigation is the first to link Ras signaling and 
global hypomethylation during step-wise transformation in human cells.  
  In this study, I observed hypomethylation in MSC transformed using 5 
oncogenic hits. As a control for cell type, I conducted parallel analyses in a 
model  of  step-wise  transformation  whereby  differentiated  human  fibroblasts 
were transformed using the same oncogenic hits. These cells, however, did not 
exhibit  hypomethylation  of  any  repetitive  elements  tested.  It  is  possible  that 
differences  in  the  epigenetic  state  of  pluripotent  MSC  and  differentiated  HF 
account for these differences. Chromatin modifications and DNA methylation 
have been profiled on a genome wide scale in pluripotent and differentiated cells   144 
(Azuara et al., 2006; Meissner et al., 2008; Mikkelsen et al., 2007). Interestingly, 
pluripotent cells display a characteristic epigenetic signature, with the promoters 
of  key  developmental  regulators  in  a  ‘bilvalent’  state  –  repressed  with  the 
potential  to  be  activated  during  lineage  commitment.  Furthermore,  DNA 
methylation  patterns  strongly  correlate  with  histone  methylation  patterns  and 
undergo  changes  during  differentiation.  Stem  cells  therefore  maintain 
pluripotency and initiate different patterns of differentiation through a greater 
epigenetic  ‘plasticity’  than  differentiated  cells  committed  to  a  particular 
epigenetic state. It is likely, therefore, that the initial epigenetic background of 
the  MSC  and  HF  and  the  ability  to  change  this  epigenetic  patterning  were 
radically different at the start of the transformation process. Human fibroblasts, 
therefore, may lack the epigenetic plasticity required for this loss of methylation 
to take place.   
Both low and high H-Ras expressing clones were isolated and shown to 
exhibit hypomethylation of Sat2 elements compared to MSC 4, although there 
was  no  statistically  significant  correlation  between  the  degree  of  Sat2 
hypomethylation and H-Ras expression. This suggests that Sat2 hypomethylation 
in  these  cells  was  dependent  on  transformation  rather  than  H-Ras  expression 
levels. Additionally, hypomethylation of Sat2 elements can be observed in at 
least two of the clonal cell populations, suggesting that a single sub-population of 
cells is not responsible for the hypomethylation observed in the original MSC 5 
population.  
  Our studies of the MSC 5 karyotype also confirmed that a number of 
distinct cell populations displaying abnormal recombination events were present 
in  the  mixed  MSC  population.  This  is  consistent  with  the  hypothesis  that   145 
hypomethylation of repetitive elements can lead to increased genomic instability 
and abnormal karyotypic changes. For example, ICF syndrome is characterized 
by hypomethylation of Sat2 elements, resulting in specific recombination events 
at genomic regions where these elements are located on chromosomes 1 and 16 
(Tuck-Muller et al., 2000). Similarly, a correlation between LINE1 and Sat-  
hypomethylation and karyotypic changes has been observed in multiple myeloma 
(Bollati et al., 2009). Although the MSC 5 cell line does display a number of 
recombination  events,  none  appear  to  involve  recombination  events  between 
chromosomes  1  and  16  as  observed  in  ICF.    Our  karyotype  analysis  also 
indicated the presence of a tetraploid sub-population making up approximately 
17% of the total MSC 5 population. Further characterization of the percentage of 
tetraploid cells by FACS indicated that this population was also present in MSC 
4,  albeit  to  a  smaller  degree  (~10%  of  cells).  Although  the  link  between 
abnormal  cell  ploidy  and  genome-wide  hypomethylation  has  not  been 
extensively investigated, one study has shown that LINE1 and Sat-  elements 
are  less  methylated  in  non-hyperdiploid  compared  to  hyperdiploid  multiple 
myelomas (Bollati et al., 2009). Additional karyotypic studies of the other MSC 
cell lines are required to determine whether these abnormalities are a direct result 
of repetitive element hypomethylation in MSC 5.  
  An important consideration for the interpretation of these findings is the 
cell cycle length at each stage of this model. The typical seeding dilutions for 
each  MSC  cell  line  indicate  a  significant  shortening  of  the  cell  cycle  with 
increasing  genetic  ‘hits’.  This  has  important  implications  for  studies  of 
methylation in these cell populations, since the proportion of cells in S-phase 
(containing hemi-methylated DNA) will differ between cell lines. The effect of   146 
cell cycle length on repetitive element DNA methylation status can be observed 
in my studies of 5-azacytidine treatment of MSC 5. The increase in Alu, Sat2 and 
LINE1  methylation  levels  on  1uM  5-azacytidine  treatment  could  result  from 
slower cell growth, decreasing the proportion of cells in S-phase compared to the 
untreated  population.  This  would  in  turn  reduce  the  proportion  of  cells 
containing  hemi-methylated  DNA,  leading  to  the  observed  increase  in 
methylation levels that are overcome by the greater demethylating effect of drug 
treatment at higher concentration. Differences in cell cycle length between these 
cell  lines  must  therefore  be  taken  into  consideration  when  interpreting 
observations in this model.  
  In  conclusion,  this  study  has  demonstrated  a  link  between  H-Ras
V12 
expression and hypomethylation of repetitive elements during a step-wise model 
of transformation in human MSC. This model provides a controlled background 
in which known genetic hits can be linked to observed epigenetic changes. By 
transforming cells in this manner, I am able to compare transformed cells to the 
most appropriate normal cell controls, therefore overcoming problems arising 
from variation in methylation between cell types. Our results provide the first 
step towards elucidating a mechanistic basis for genome wide hypomethylation 
in cancer and a valuable model for further establishing the consequences of this 
change. 
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Figure  3.11:  Analysis  of  repetitive  element  methylation  in  MPNST  by  ChIP-seq.  Global 
analysis  of  repeat  family  methylation  suggests  that  there  is  no  overall  change  in  SINE 
methylation  in  MPNST  (cancer)  compared  to  NF  (benign)  or  normal  Schwann  cell  tissue. 
However, microsatellites display significant hypomethylation in the cancer compared to benign 
and normal tissues. A small increase in LINE hypomethylation is also evident. Adapted from 
Feber et al. (in press). 
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Chapter 4: Genome-wide hypomethylation occurs gradually and 
is not essential for transformation of mesenchymal stem cells 
 
4.1    Background 
Although the incidence and consequences of genome-wide hypomethylation in 
cancer have been extensively studied, relatively little remains known about the 
causes  of  this  loss  of  methylation.  DNA  methylation  patterns  result  from 
competing processes that establish, maintain and remove this epigenetic mark. 
Any shift in the balance of these processes could therefore result in genome wide 
alterations  to  DNA  methylation  such  as  genome-wide  hypomethylation. 
Specifically,  genome-wide  hypomethylation  may  occur  in  a  ‘passive’  manner 
through inefficient DNA methylation maintenance, or in an ‘active’ manner by 
direct enzymatic removal of methyl groups from DNA.  
The  importance  of  DNA  methyltransferases  (DNMTs)  in  the 
establishment and maintenance of DNA methylation suggests that disruption of 
normal  DNMT  activity  or  expression  could  lead  to  the  genome-wide  DNA 
hypomethylation  observed  in  cancer.  For  example,  loss  of  the  maintenance 
methylation  activity  of  DNMT1  could  result  in  passive  DNA  demethylation 
through  consecutive  rounds  of  DNA  replication.  In  line  with  this,  dnmt1 
knockout  mice  display  a  loss  of  ~90%  of  genome-wide  methylation  levels, 
resulting in embryonic lethality (Li et al., 1992). Conditional dnmt1 knockout in 
mouse fibroblasts also causes genome-wide demethylation and p53 mediated cell 
death  (Jackson-Grusby  et  al.,  2001).  Similar  effects  have  been  observed  in   149 
human  colon  cancer  cell  lines  in  which  DNMT1  can  be  knocked  out  in  an 
inducible  manner,  leading  to  cell  cycle  arrest,  global  genetic  instability  and 
apoptosis as a result of genome-wide loss of DNA methylation (Chen et al., 
2007). Additionally, disruption of de-novo methyltransferase expression could 
also  induce  global  hypomethylation,  as  observed  in  dnmt3b  knockout  mouse 
embryonic  fibroblasts  (Dodge  et  al.,  2005)  and  DNMT3B  mutations  in  ICF 
patients (Hansen et al., 1999; Xu et al., 1999). 
  As  well  as  passive  demethylation  processes,  global  hypomethylation 
could be induced in an active manner through increased expression or activity of 
DNA demethylases (Ooi and Bestor, 2008). Although active DNA demethylation 
has been observed during early mouse embryogenesis, a DNA demethylase in 
human cells has not been identified (Reik et al., 2001). Studies in zebrafish and 
Xenopus  models  have  produced  promising  indications  that  the  DNA  damage 
response gene Gadd45a may act as a DNA demethylase, although other reports 
dispute these findings (Barreto et al., 2007; Rai et al., 2008; Varambally et al., 
2008).  
In addition to altered gene expression or activity, global hypomethylation 
may also result from changes in the availability S-adenosylmethionine (SAM), a 
key  substrate  required  for  DNMT  activity  (Szyf  et  al.,  2004).  Methionine 
metabolism,  an  essential  part  of  SAM  biosynthesis,  is  often  disrupted  in 
transformed  cells  and  may  also  be  altered  in  this  step-wise  model  of 
transformation (reviewed in Kim, 2005; Laird and Jaenisch, 1996).   
An  important  factor  distinguishing  passive  and  active  demethylation 
processes is the time period over which this loss of methylation takes place.   150 
Active demethylation could take place in a short time frame in the absence of 
DNA  replication  as  observed  in  early  mouse  embryogenesis  (Oswald  et  al., 
2000). Conversely, passive demethylation requires DNA replication, and would 
be expected to occur as a more gradual decline over time with each round of 
DNA replication. The mechanistic basis of hypomethylation in the MSC model 
may  therefore  be  determined  by  investigating  the  time  course  over  which 
methylation is lost following H-Ras
V12 expression in MSC 4.  
The mechanistic basis of genome-wide hypomethylation in MSC 5 may 
also be elucidated through analysis of changes in gene expression during step-
wise  transformation.  Alterations  in  the  expression  of  DNMTs,  putative 
demethylases  such  as  GADD45A  or  enzymes  involved  in  SAM  biosynthesis 
could be responsible for the hypomethylation observed in this system through the 
mechanisms described above. Microarray data have previously been obtained in 
all MSC cell lines, allowing further analysis of these data to be conducted in 
order to investigate epigenetic deregulation during transformation (Funes et al., 
2007). 
Although genome-wide hypomethylation in cancer has traditionally been 
viewed as an early event during transformation, few studies have definitively 
addressed whether hypomethylation is causative of transformation (Fearon and 
Vogelstein,  1990;  Feinberg  et  al.,  2006).  Induction  of  genome-wide 
hypomethylation  by  dnmt1  knockdown  has  been  shown  to  increase  tumour 
formation  in  mice,  suggesting  a  causal  relationship  between  the  two  events 
(Gaudet et al., 2003). However, conflicting evidence has been obtained regarding 
the occurrence of genome-wide hypomethylation in benign neoplasms, indicating   151 
that this change is not always an early requirement of transformation (Gama-
Sosa et al., 1983). Experiments with the conditional H-Ras
V12 system will test 
whether transformation is dependent on genome-wide hypomethylation in the 
MSC model.  
I hypothesize that repetitive element hypomethylation in MSC 5 results 
from a disrupted equilibrium of DNA methylation processes in these cells. This 
disruption is likely to result in a gradual loss of methylation following H-Ras
V12 
expression in MSC 4 cells but is not likely to be a requirement of transformation. 
I  therefore  aim  to  investigate  the  time  course  of  hypomethylation  following 
conditional  and  constitutive  H-Ras
V12  expression  and  assess  whether 
hypomethylation is required for transformation to take place. Finally, I aim to 
investigate  potential  causes  of  genome-wide  hypomethylation  in  this  system 
through analysis of gene expression microarray data from all MSC cell lines.   
 
4.2    Aims 
1.  To  establish  the  time  course  over  which  hypomethylation  takes  place 
following H-Ras expression.  
2.  To determine whether cells can be transformed in the absence of genome-
wide hypomethylation. 
3.  To conduct an analysis of gene expression microarray data in order to 
identify alterations to the expression of epigenetic regulators during step-
wise transformation. 
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4.3    Results 
 
4.3.1    Conditional H-Ras System – Cloning and Characterisation 
 
A clear picture of the time course over which hypomethylation occurs in this 
model could provide an indication of the mechanistic basis behind this loss of 
methylation. If hypomethylation results from active mechanism (through direct 
removal of methyl groups from the DNA), loss of methylation could occur in a 
very  short  space  of  time.  If,  however,  hypomethylation occurs  in  a  ‘passive’ 
manner due to a loss of maintenance methylation, this loss would be expected to 
occur  over  a  longer  period  of  time  through  consecutive  rounds  of  DNA 
replication.  
The original MSC 5 population was created by infecting MSC 4 cells 
with  retrovirus  containing  the  oncogenic  H-Ras
V12  construct  and  selecting 
successfully infected cells. The time period over which infection and selection 
takes place makes it difficult to establish exactly when selected cells begin to 
express H -Ras
V12,  or  the  point  at  which  genome-wide  hypomethylation  takes 
place.  A  more  efficient  way  to  explore  the  time  course  of  demethylation 
following H-Ras expression would be to use a conditional system. To this end, a 
conditional H-Ras
V12 construct was obtained from Dr. Julian Downward (CR-UK 
London Research Institute). This construct consisted of the full coding sequence 
for oncogenic H-Ras
V12 and a mutated form of the oestrogen receptor (ER
TM) 
expressed together as a fusion protein. ER
TM is sensitive to 4-hydroxytamoxifen 
(4-OHT) but not to the natural ligand for the wild type receptor (17 -estradiol) 
(Danielian  et  al.,  1993).  In  the  absence  of  4-OHT,  the  fusion  protein  is   153 
complexed  with  hsp90  in  the  cytoplasm,  preventing  downstream  H-Ras 
signaling.  This  interaction  is  abolished  when  treated  with  hydroxytamoxifen, 
allowing active H-Ras signaling to take place (Mattioni et al., 1994).  
  In  order  to  use  this  construct  in  the  MSC  model,  the  ER
TM-H-Ras
V12 
fragment  (ER-Ras) had to be subcloned from the original vector (pLZRS) into 
the  pWZL  retroviral  vector  (containing  a  hygromycin  resistance  cassette) 
previously used for H-Ras overexpression in MSC 4. Sequencing data previously 
obtained from the pLZRS vector indicated that the ER
TM-H-Ras fragment was 
flanked by BamHI and SalI restriction enzyme sites (David Hancock, personal 
communication), which were also present in the multiple cloning site of pWZL. 
Double digestion of pLZRS-ER-Ras released a fragment of the expected size 
(1.6kb), which was gel extracted and ligated into pWZL previously linearised 
with BamHI and SalI (Figure 4.1a). Following transformation of bacteria with 
the  ligation  product,  individual  colonies  were  picked  and  maxipreps  of  the 
plasmid were prepared. Diagnostic digestion of the final plasmids indicated that 
a fragment of the correct size had been cloned into pWZL, with the identity of 
this fragment confirmed by sequencing (Figure 4.2b). The sequencing data also 
showed that no mutations were introduced to the sequence during cloning, and 
the entire sequence was in frame (data not shown).  
  Retroviruses containing the pWZL-ER
TM-H-Ras
V12 construct and empty 
vector control (pWZL) were produced and used to infect MSC 4 cells. Following 
selection of infected cells with hygromycin, extensive characterisation of ER
TM-
H-Ras
V12 activity was conducted. To test that expression of the fusion protein 
could be induced by 4-OHT treatment, MSC 4 containing ER
TM-H-Ras
V12 (MSC 
4
ER-Ras) or empty vector (MSC 4
pWZL) were treated with 100nM 4-OHT for 24   154 
hours  before  total  protein  was  harvested  and  used  for  western  blot  analysis. 
When the membrane was probed with an anti-H-Ras antibody, a band of the 
expected size (50kDa) was present in MSC 4
ER-Ras cells treated with 4-OHT but 
not in empty vector control cells. A small basal level of ER
TM-H-Ras expression 
was evident in untreated MSC 4
ER-Ras cells (Figure 4.1c). To test whether the 
expression  of  this  fusion  protein  resulted  in  functional  downstream  MAPK 
signaling, levels of phospho-ERK1/2 (pERK) were assessed by western blot and 
compared to total ERK1/2 levels. This indicated that MSC 4
ER-Ras cells treated 
with  4-OHT  contained  higher  levels  of  pERK  compared  to  total  ERK, 
demonstrating elevated MAPK signaling relative to untreated cells and empty 
vector control cells (Figure 4.1c). 
  In order to establish the optimal concentration of 4-OHT to use with these 
cell lines, ER
TM-H-Ras, pERK and total ERK levels were assessed 24 hours after 
incubation  with  increasing  concentrations  of  4-OHT  (Figure  4.2a).  Elevated 
expression of the fusion protein was observed in MSC 4
ER-Ras cells treated with 
increasing concentrations of 4-OHT, with levels of pERK relative to total ERK 
increasing in parallel. No expression of the fusion protein or increase in pERK 
levels was observed in MSC 4
pWZL cells treated with the same concentrations of 
4-OHT (Figure 4.2b).  
  Similarly,  ER
TM-H-Ras  and  pERK  levels  were  assessed  over  time 
following the addition of 4-OHT. Analysis of protein levels in MSC 4
ER-Ras and 
MSC 4
pWZL cells treated with 100nM 4-OHT for 72 hours revealed increasing 
levels of ER
TM-H-Ras over time, with this increase first occurring 12 hours after 
4-OHT addition and reaching maximal levels after 48 hours (Figure 4.2c). No   155 
fusion protein was detectable in MSC 4
pWZL cells treated with 4-OHT for the 
same time (Figure 4.2d).  
  The effect of ER
TM-H-Ras expression on cell viability was assessed by 
conducting  a  MTS  assay  on  MSC  4
ER-Ras  and  MSC  4
pWZL  cells  treated  with 
100nM and 500nM 4-OHT or equivalent amounts of ethanol over the course of 
72  hours  (Figure  4.3  a  &  b).  In  all  cases,  these  results  show  no  significant 
difference in cell growth between conditions, indicating that 4-OHT treatment 
and ER
TM-H-Ras expression do not adversely affect cell viability. 
  Finally, an in vitro assay of transformation was conducted by assessing 
the  growth  of  cells  in  soft  agarose.  MSC  4
ER-Ras  and  MSC  4
pWZL c ells  were 
seeded in soft agarose in the presence or absence of 100nM 4-OHT, with the 
number of colonies quantified after 12 days. This experiment demonstrated that 
MSC 4
ER-Ras cells grown in the presence of 100nM 4-OHT were able to form 
colonies in soft agarose, whereas untreated and vector control cells were not 
(Figure 4.3 c & d). Colony formation by MSC 4
ER-Ras cells was also assessed at 
different  concentrations  of  4-OHT,  indicating  a  modest  increase  in  colony 
number on increasing concentrations of 4-OHT (Figure 4.3e). This demonstrates 
that MSC 4
ER-Ras cells are transformed when H-Ras signaling is induced by 4-
OHT treatment. 
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Figure 4.1: Cloning of ER
TM-H-Ras fragment from pLZRS to pWZL and characterisation 
of  ER
TM-H-Ras  activity.  (a)  Agarose  gel  electrophoresis  of  restriction  enzyme  digestion 
products. The ER
TM-H-Ras fragment (1.6kb in length) was removed from pLZRS by restriction 
enzyme digestion with BamHI and SalI. The target vector (pWZL) was linearised by BamHI and 
SalI  digestion  before  the  ER
TM-H-Ras  fragment  was  ligaed  into  the  vector  backbone.  (b) 
Successful  ligation  products  were  confirmed  by  diagnostic  digest  with  BamHI  and  SalI.  (c) 
Western blot analysis of MSC 4 cells infected with retrovirus containing ER
TM-H-Ras (MSC 4
ER-
Ras) or empty vector (MSC 4
pWZL), treated with 4-OHT (+) or ethanol (-) for 24 hours. Levels of 
H-Ras, pERK, total ERK and GAPDH (loading control) were assessed using antibodies against 
each of these proteins.  
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Figure  4.2:  Characterisation  of  conditional  ER
TM-H-Ras  dose  and  time  response.  (a-b) 
Western blot analysis of MSC 4
ER-Ras and MSC 4
pWZL cells treated with increasing concentrations 
of 4-OHT for 24 hours. Levels of H-Ras, pERK, total ERK and GAPDH (loading control) were 
assessed using antibodies against each of these proteins. (c-d) Western blot analysis of MSC 4
ER-
Ras and MSC 4
pWZL cells were treated with 100nM 4-OHT over the course of 72 hours. Levels of 
H-Ras, pERK, total ERK and GAPDH (loading control) were assessed using antibodies against 
each of these proteins. 
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Figure 4.3: Cell viability and growth of MSC 4
ER-Ras and MSC 4
pWZL is not affected by 4-
OHT and MSC 4
ER-Ras treated with 4-OHT are transformed. Cell viability (MTS) assay for 
(a) MSC 4
ER-Ras and (b) MSC 4
pWZL seeded at a density of 1000 cells per well and grown over the 
course of 72 hours in the presence of 100 and 500nM 4-OHT or equivalent volumes of ethanol. 
Each  point  represents  the  average  absorbance  (490nm)  from  5  replicates  when  background 
absorbance is subtracted. (c) Soft agarose transformation assay of MSC 4
ER-Ras and (d) MSC 
4
pWZL cells seeded at a density of 10,000 cells per well and grown for 12 days in the presence of 
100nM 4-OHT (+) or an equivalent volume of ethanol (-). Positive control (MSC 5) and negative 
control (MSC 4) cells were grown in parallel (data not shown). Whole well photographs are 
depicted alongside 40x magnification. (e) Soft agarose transformation assay of MSC 4
ER-Ras and 
MSC 4
pWZL repeated as above, but with increasing concentrations of 4-OHT. The number of 
colonies  after  12  days  growth  at  37°C  was  quantified  using  the  SynGene  GeneTools  image 
analysis software. Columns depict average of three replicates; Error bars depict SEM.  
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4.3.2    Global Methylation Levels Following ER
TM-H-Ras Induction 
 
To investigate whether repetitive element hypomethylation occurred following 
ER
TM-H-Ras induction and to establish the time course of this change, MSC 4
ER-
Ras and MSC 4
pWZL cells were grown in the presence and absence of 500nM 4-
OHT for one month, with methylation of Alu, LINE1 and Sat2 elements assayed 
by MethyLight 72 hours after the addition of 4-OHT and every week for four 
weeks thereafter (Figure 4.4a-c). These results indicated that Alu, LINE1 and 
Sat2  methylation  did  not  differ  significantly  between  MSC  4
ER-Ras  and  MSC 
4
pWZL  cells  treated  with  4-OHT  at  any  of  the  time  points.  This  result  was 
confirmed by bisulphite sequencing of the Sat2 element (Figure 4.4d). Continued 
expression of the fusion protein and elevated pERK levels in MSC 4
ER-Ras cells 
were confirmed at the final time point by western blot (Figure 4.4e).  
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Figure  4.4:  Sat2,  LINE1  and  Alu  methylation  does  not  change  following  induced 
transformation  of  MSC  4
ER-Ras  cells.  MSC  4
ER-Ras  and  MSC  4
pWZL  cells  were  grown  in  the 
presence  of  500nM  4-OHT  for  one  month,  with  DNA  harvested  for  methylation  analysis  at 
various  time  points  during  this  period.  MethyLight  was  conducted  using  primers  against 
methylated (a) Alu (b) LINE1 and (c) Sat2 elements in bisulphite converted DNA from MSC 
4
ER-Ras  and  MSC  4
pWZL  at  each  time  point,  alongside  fully  unmethylated  DNA  as  a  negative 
control (not shown). Fold-change in methylation was calculated in triplicate by   Ct using an 
unbiased Alu reaction as a loading control and normalised to fully methylated (M.SssI treated) 
reference  DNA.  Student’s  T-test  was  performed  for  all  statistical  analyses.  Columns  display 
average of three replicates; Error bars display SEM. (d) Bisulphite sequencing confirmation of 
the MethyLight data. Sat2 elements were amplified by PCR from bisulphite modified genomic 
DNA with individual PCR products cloned into pGEM-T and sequenced. Average methylation is 
expressed as a percentage of all CG sites assayed by sequencing 12 PCR products. Columns 
display  average  percentage  methylation;  Statistical  analysis  was  conducted  using  the  Paired 
Wilcoxon  Signed  Rank  Test.  (e)  Western  blot  analysis  of  ER-H-Ras,  pERK,  total  ERK  and 
GAPDH  (loading  control)  protein  levels  in  all  cell  lines  at  the  final  time  point  (four  weeks 
following 4-OHT induction).  
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4.3.3  H-Ras
V12  Overexpression  in  MSC  4  and  Sat2  Methylation 
Analysis 
 
To determine whether the repetitive element hypomethylation observed in the 
original  MSC  5  cells  could  be  recapitulated,  oncogenic  H-Ras
V12  was 
overexpressed in MSC 4 cells. Retrovirus containing H-Ras
V12 within the pWZL 
vector was generated alongside empty vector control virus. Infection of MSC 4 
cells was performed in triplicate for each virus, with hygromycin resistant cells 
selected over the course of one week following infection. After selection, H-
Ras
V12 overexpression was confirmed by western blot and transformation of the 
cells  was  assessed  by  anchorage  independent  growth  in  soft  agarose  (Figure 
4.5a-c). This indicated that MSC 4 cells expressing H-Ras
V12 were transformed 
whereas cells containing the empty vector control were not.  
  Sat2  methylation  levels  in  these  cells  were  assayed  by  MethyLight, 
indicating  no  significant  difference  between  H-Ras
V12  and  empty  vector 
containing  cells  one  week  following  infection  (Figure  4.6a).  To  determine 
whether Sat2 hypomethylation would take place over a longer period of time, all 
cells  were  cultured  as  normal  for  four  weeks,  with  Sat2  methylation  levels 
assessed at this time point by MethyLight (Figure 4.6b). These data demonstrated 
a significant reduction in Sat2 methylation between MSC 4 cells expressing H-
Ras
V12 and empty vector control cells. 
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Figure 4.5: Overexpression of H-Ras
V12 in MSC 4 cells induces transformation. Retrovirus 
containing H-Ras
V12 within the pWZL vector was generated and used to infect MSC 4 cells in 
triplicate alongside empty vector control virus. (a) Western blot analysis of H-Ras and GAPDH   165 
(loading control) protein levels following infection and selection of MSC 4 cells. (b) Soft agarose 
transformation assay of MSC 4 cells expressing H-Ras
V12 (MSC 4 + H-Ras) or empty vector 
control (MSC 4 + pWZL) seeded at a density of 10,000 cells per well and grown for 12 days at 
37°C. Images at 40x magnification. (c) Quantification of colony number from soft agarose assay 
using SynGene GeneTools image analysis software.  
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Figure 4.6: Sat2 hypomethylation is induced following H-Ras
V12 expression in MSC 4 cells 
and  continued  culturing  for  four  weeks.  MethyLight  was  conducted  using  primers  against 
methylated Sat2 elements in bisulphite converted DNA from MSC 4 cells expressing H-Ras
V12 
(MSC 4 + H-Ras) or empty vector control (MSC 4 + pWZL) (a) one week and (b) four weeks 
following  retroviral  infection,  alongside  fully  unmethylated  DNA  as  a  negative  control  (not 
shown). Fold-change in methylation was calculated in triplicate by   Ct using an unbiased Alu 
reaction as a loading control and normalised to fully methylated (M.SssI treated) reference DNA. 
Student’s  T-test  was  performed  for  all  statistical  analyses. Columns  display  average  of  three 
replicates; Error bars display SEM. 
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4.3.4    Analysis of gene expression microarray data 
In order to establish whether changes in the expression of epigenetic regulators 
during  step-wise  transformation  were  responsible  for  repetitive  element 
methylation in MSC 5, analysis of gene expression microarray data for all MSC 
cell lines was conducted.  
Gene expression microarray data were previously obtained for all MSC 
lines in triplicate on Affymetrix U133+2 arrays (Funes et al., 2007). Significant 
changes in gene expression between MSC 0 and MSC 5 were determined by 
FDR corrected T-Test of log expression values between conditions, with q < 0.01 
considered significant. In order to focus the analysis on relevant genes involved 
in epigenetic regulation, a list of epigenetic regulators was compiled from an 
extensive literature review, comprising 967 probe sets for 341 genes (Table A2). 
Expression data for these probe sets were extracted from the genome-wide list of 
differentially expressed genes. 
I  identified  106  probe  sets,  representing  69  genes,  which  were 
significantly up- or down- regulated between MSC 0 and MSC 5 (Figure 4.7 & 
Table  A3).  Of  the  DNA  methyltransferase  genes,  only  DNMT1  showed  a 
significant change in expression between MSC 0 and MSC 5, with a significant 
increase  in  expression  (1.7  fold  increase,  q  =  1x10
-6).  qRT-PCR  analysis 
confirmed  this  result,  demonstrating  that DNMT1  mRNA  expression  was  up-
regulated in MSC 5 compared to MSC 0, increasing significantly at MSC 2E7 on 
pRb inhibition, with this increase maintained through subsequent oncogenic hits 
(Figure 4.8a). In comparison, the de novo methyltransferases DNMT3a, 3b and 
3l did not display any significant changes in expression between MSC 0 and   168 
MSC 5. Reduced DNMT1 expression is therefore unlikely to account for the 
hypomethylation observed in this model.  
Analysis of gene expression microarray data also indicated a significant 
up-regulation of GADD45A, a putative DNA demethylase, between MSC 0 and 
MSC 5 (2.6 fold increase, q = 0; Figure 4.7a). This increase occurred between 
MSC 4 and MSC 5, the same point at which repetitive element hypomethylation 
was observed. Analysis of GADD45A mRNA levels by qRT-PCR confirmed this 
result, demonstrating a significant up-regulation following H-Ras
V12 expression 
(Figure 4.8b). Furthermore, qRT-PCR data obtained from the conditional H-Ras 
model  also demonstrated  a  significant  up-regulation  of GADD45A  expression 
one week following 4-OHT induction (Figure 4.8c).  
  Analysis of gene expression microarray data for enzymes involved in the 
metabolic pathways linked to methionine production also indicated significant 
changes to the expression of these genes (Figure 4.9). A number of genes coding 
for enzymes involved in the conversion of metabolites away from production of 
methionine and towards de novo purine biosynthesis are up-regulated in MSC 5 
compared to MSC 0. Additionally, MTHFR, a gene involved in the conversion of 
5,10-methylenetetrahydrofolate to the methyl donor 5-methyltetrahydrofolate is 
significantly down-regulated in MSC 5 relative to MSC 0.  
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Figure  4.7:  Expression  of  epigenetic  regulator  genes  changes  during  step-wise 
transformation.  Gene  expression  microarray  data  for  epigenetic  regulators  was  analysed  for 
significant changes in expression between MSC 0 and MSC 5. Heatmaps showing triplicate gene 
expression microarray data for significantly (a) up-regulated and (b) down-regulated genes in 
each of the five transforming steps (MSC 0 - 5). 
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Figure  4.8:  DNMT1  and  GADD45a  expression  increase  significantly  during  step-wise 
transformation of MSC. (a) Quantitative RT-PCR confirmation of DNMT1 expression. Fold-
change in DNMT1 expression with respect to MSC 0 was calculated in triplicate by   Ct using 
GAPDH as a loading control and normalised to parental MSC. (b) Fold-change in GADD45A   173 
expression  with  respect  to  MSC  0  was  calculated  in  triplicate  by    Ct  using  GAPDH  as  a 
loading control and normalised to parental MSC. (c) MSC 4
ER-Ras and MSC 4
pWZL cells grown in 
the presence of 500nM 4-OHT or an equivalent volume of ethanol for one week. GADD45A 
expression was assessed by qRT-PCR as described above, with fold change calculated relative to 
MSC 4
pWZL cells. Student’s T-test was performed for all statistical analyses. * p < 0.05 with 
respect to MSC 0. Columns display average of three replicates; Error bars display SEM.  
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Figure  4.9:  Enzymes  involved  in  the  methotrexate  pathway  show  a  distinct  pattern  of 
regulation towards de novo purine synthesis and away from S-adenosylmethionine (SAM) 
synthesis.  (a)  Schematic  showing  the  substrates  and  enzymes  of  biochemical  reactions   175 
surrounding the methotrexate pathway and SAM biosynthesis. Genes which show a significant 
increase in expression between parental and transformed MSC are highlighted in red, with genes 
displaying  reduced  expression  highlighted  in  blue.  Figure  adapted  from  PharmGKB  website 
(www.pharmgkb.org) and Flanagan et al. 2009. (b) Heatmaps showing triplicate gene expression 
microarray  data  for  significantly  down-regulated  and  up-regulated  genes  in  each  of  the  five 
transforming steps (MSC 0 - 5). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   176 
 
4.3.5  Correction of GEM Data for Cell Proliferation Rate 
 
In order to account for differences in proliferation rate between MSC cell lines 
and changes in gene expression resulting from this difference, correction of the 
GEM data was conducted. Log expression values for all probe sets were adjusted 
based on expression values of the proliferation-linked marker PCNA in each cell 
line. The adjusted array data were subjected to statistical analysis as described 
above to extract significant changes in epigenetic regulators between MSC 0 and 
MSC 5 (Figure 4.10).  
  This analysis indicated significant changes in the expression of 383 probe 
sets, representing 203 genes, with the majority of genes down-regulated over the 
course of step-wise transformation (Figure 4.10a & Table A4) and 15 genes up-
regulated (Figure 4.10b). Furthermore, there is a significant difference between 
the  genes  identified  in  this  analysis  compared  to  analysis  of  the  unadjusted 
expression  data.  For  example,  expression  of  DNMT1  does  not  significantly 
change  when  corrected  for  proliferation  (q  =  0.17),  whereas  expression  of 
DNMT3a  decreases  between  MSC  0  and  MSC  5  (q  =  0.002).  Some  of  the 
changes  identified  in  the  previous  analysis,  such  as  increasing  expression  of 
GADD45a  between  MSC  4  and  MSC  5  (q  =  0),  still  achieve  statistical 
significance when expression values are corrected for proliferation. 
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Figure  4.10:  Expression  of  epigenetic  regulator  genes  changes  during  step-wise 
transformation when corrected for cell proliferation. Gene expression microarray data for 
epigenetic regulators was normalized to expression of the proliferation-linked gene PCNA and 
analysed for significant changes in expression between MSC 0 and MSC 5. Heatmaps showing 
triplicate  gene  expression  microarray  data  for  significantly  (a)  down-regulated  and  (b)  up-
regulated genes in each of the five transforming steps (MSC 0 - 5). 
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4.4    Discussion 
 
Results from the previous chapter indicated that Sat2 and LINE1 elements were 
hypomethylated in the MSC 5 cell line compared to previous stages in step-wise 
transformation.  Experiments  conducted  as  part  of  this  chapter  aimed  to 
investigate the time course of hypomethylation following H-Ras expression to 
determine  whether  this  loss  of  methylation  was  due  to  an  active  or  passive 
mechanism. These experiments also aimed to determine whether transformation 
could take place in the absence of genome-wide hypomethylation. Additionally, I 
aimed  to  investigate  changes  to  the  expression  of  epigenetic  regulators  and 
metabolic  enzymes  during  step-wise  transformation  in  order  to  identify 
alterations that could lead to the observed hypomethylation.   
My investigation of cellular transformation by the conditional ER
TM-H-
Ras  aimed  to  address  the  time  course  of  demethylation  following  H-Ras
V12 
expression. However, these experiments did not demonstrate hypomethylation of 
Sat2  or  LINE1  elements  in  transformed  cells  grown  over  the  course  of  one 
month.  Conversely,  MSC  4  cells  expressing  H-Ras
V12  without  a  conditional 
domain exhibited Sat2 hypomethylation when grown for the same length of time. 
Differences in the rate of methylation loss between the two systems may account 
for this observation. Alternatively, although the activity of the conditional ER
TM-
H-Ras
V12 was extensively characterised, differences between this fusion protein 
and the constitutively expressed H-Ras
V12 could also affect the incidence of Sat2 
hypomethylation.  For  example,  although  the  fusion  protein  exhibited  similar 
signaling properties through the MAPK cascade, downstream PI3K or Ral-GEF 
signaling may have been disrupted (Rangarajan et al., 2004).    180 
Data obtained from both the conditional and the constitutively expressed 
H-Ras
V12 cell lines point to a number of interesting conclusions. First, loss of 
Sat2  methylation  following  H-Ras
V12  expression  is  a  gradual  event,  reaching 
statistical  significance  only  after  four  weeks.  This  suggests  that  repetitive 
element  hypomethylation  in  this  system  does  not  result  from  an  active 
demethylation process, which would be expected to induce hypomethylation in a 
shorter  period  of  time.  Although  both  active  and  passive  demethylation  have 
been shown to induce genome-wide hypomethylation in mouse cells, this is the 
first  study  to  address  the  time  course  and  potential  mechanism  of 
hypomethylation following transformation of human cells (Gaudet et al., 2003; 
Reik et al., 2001). Secondly, both the conditional and constitutively expressed H-
Ras
V12 cell lines exhibited transformation in the absence of repetitive element 
hypomethylation,  suggesting  that  genome-wide  hypomethylation  is  not  a 
requirement of transformation.  
Many other studies have attempted to address the question of whether 
genomic  hypomethylation  is  causative  of  transformation  or  vice  versa.  For 
example, mice containing a hypomorphic allele of dnmt1, which reduces protein 
expression to 10% of wild type levels, exhibited global hypomethylation along 
with an increased incidence of T-cell lymphoma. The authors concluded that 
genome-wide loss of methylation resulted in transformation through increased 
incidence of karyotypic changes and chromosomal abnormalities (Gaudet et al., 
2003).  Although  the  causative  role  of  hypomethylation  during  transformation 
could be tissue specific, studies in mice have suggested that soft tissue sarcoma 
incidence  increases  following  global  loss  of  methylation  induced  by  Dnmt1 
hypomorphic alleles in Nf1
+/- p53
+/- mice (Eden et al., 2003). This finding is of   181 
direct relevance to my study, since MSC are believed to be the cell of origin for 
various  types  of  sarcoma  (Helman  and  Meltzer,  2003).  Whilst  both  of  these 
reports suggest that genome-wide hypomethylation can promote transformation, 
they do not address whether transformation can take place in the absence of this 
loss of methylation.  
However,  another  mouse  model  of  genome-wide  hypomethylation 
induced by dnmt1 knockdown notes opposing effects on the growth of different 
tumour  types  (Yamada  et  al.,  2005).  Incidence  of  liver  and  intestinal 
carcinogenesis was monitored in APC
Min/+ mice in which Dnmt1 function was 
reduced  using  hypomorphic  alleles,  leading  to  increased  development  of 
multifocal  liver  tumours  but  decreased  incidence  of  macroscopic  intestinal 
tumours.  The  authors  speculate  that  transformation  events  requiring  loss  of 
imprinting benefited from genome-wide hypomethylation, whereas this loss of 
methylation was detrimental to transformation processes dependent on epigenetic 
gene silencing by promoter methylation (Yamada et al., 2005). Together, these 
reports show that genome-wide hypomethylation can promote some instances of 
carcinogenesis but there is no definitive demonstration that hypomethylation is a 
strict requirement of transformation.  
Similarly,  the  timing  of  genome  wide  hypomethylation  during  the 
development of cancer could provide an indication of whether this change is 
required  for  transformation  to  take  place.  Many  studies  have  suggested  that 
genome-wide DNA hypomethylation is an early event in transformation, and can 
be  observed  in  benign  tumours  or  adjacent  normal  cells.  Genome-wide 
hypomethylation is also included as an early event in a classic model of step-
wise  transformation  in  colorectal  cancer  (Fearon  and  Vogelstein,  1990).  This   182 
model  cites  two  early  investigations  of  genome-wide  methylation  levels  in 
benign and malignant colonic neoplasms as evidence to this effect (Feinberg et 
al.,  1988;  Goelz  et  al.,  1985).  A  more  recent  study  of  LINE1  promoter 
methylation (a marker of genome-wide methylation levels) in colorectal cancer 
patients observed genome-wide hypomethylation in tumours compared to tissue 
from  healthy  individuals.  Furthermore,  hypomethylation  was  also  evident  in 
adjacent normal tissues in 6 out of 19 cancer patients, but was not present in 
peripheral blood from the same individuals. The authors concluded that global 
hypomethylation in the adjacent normal tissue indicates that this change is an 
early  event  in  the  transformation  process,  potentially  leading  to  karyotypic 
instability and further oncogenic changes (Suter et al., 2004).  
  However,  several  other  investigations  have  failed  to  detect  reduced 
genome-wide methylcytosine levels in benign cancers. One of the earliest studies 
of genome-wide methylation levels in cancer surveyed a range of benign and 
neoplastic tissues by HPLC (Gama-Sosa et al., 1983b). These data indicated that 
global methylation levels in benign tumours were very similar to those observed 
in  normal  tissues.  Furthermore,  a  large p roportion  of  malignant  samples 
displayed  genome-wide  hypomethylation,  with  secondary  malignancies 
exhibiting the greatest degree of hypomethylation (Gama-Sosa et al., 1983b). 
Several studies have also addressed global methylation levels in different stages 
of ovarian carcinogenesis. In one such investigation, satellite repeat methylation 
levels  were  assessed  by  genomic  DNA  digestion  with  methylation  specific 
restriction enzymes followed by southern blot hybridization. This indicated that 
while  ovarian  carcinomas  and  low  malignant  potential  tumours  were 
significantly hypomethlyated compared to normal tissues, benign cystadenomas   183 
displayed weak or no hypomethylation (Ehrlich et al., 2006). Together, these 
studies  show  that  genome-wide  hypomethylation  is  not  always  detectable  in 
early stage or premalignant lesions, suggesting that this epigenetic change is not 
required for transformation to take place.  
  The  relative  timings  of  global  hypomethylation  and  gene  specific 
hypermethylation  in  cancer  have  also  been  utilized  to  address  whether 
hypomethylation occurs in the early stages of transformation. Although many 
studies have failed to elucidate a link between the two events, an investigation of 
LINE1 methylation levels in prostate carcinomas of different stages found that 
samples  exhibiting  hypomethylation  formed  a  subclass  of  those  with  gene 
specific hypermethylation. The lack of tumours exhibiting hypomethylation in 
the  absence  of  gene  specific  hypermethylation  suggests  that  global  loss  of 
methylation is a secondary event to hypermethylation in the progression of this 
cancer. This finding was supported by another study of DNA hypomethylation in 
prostate  cancer  progression,  which  noted  significant  hypomethylation  only  in 
metastatic cancers, later than CpG island hypermethylation (Yegnasubramanian 
et al., 2008; Yegnasubramanian et al., 2004).  
  Together,  these  studies  suggest  that  although  genome  wide 
hypomethylation  has  traditionally  been  viewed  as  an  early  event  in 
carcinogenesis,  there  is  ample  evidence  supporting  both  this  view  and  the 
alternative, that hypomethylation can occur later in transformation or not at all. 
Results obtained from my investigation suggest that hypomethylation can occur 
during  step-wise  transformation,  although  it  is  not  a  necessary  event  for 
transformation  to  take  place.  Furthermore,  in  the  instance  where   184 
hypomethylation was observed, this was a late event in this step-wise genetic 
model, occurring on the introduction of the last oncogenic hit.  
In order to explore the possibility that altered expression of epigenetic 
regulators caused repetitive element hypomethylation in MSC 5, an analysis of 
gene expression microarray data was conducted for each of the steps in the MSC 
model, with significant changes in the expression of key epigenetic regulators 
extracted from the data set. Furthermore, order to correct these observations for 
changes in gene expression resulting from differences in proliferation between 
cell lines, the analysis was repeated using expression values normalized against 
expression of the proliferation marker PCNA. The different results obtained from 
these two analyses suggest that many of the gene expression changes observed in 
the unadjusted array data may be caused by transcriptional changes linked to 
differences  in  the  rate  of  proliferation  between  MSC  cell  lines,  further 
highlighting  the  importance  of  this  consideration  when  interpreting  results 
obtained from the model. Therefore, the results obtained from the adjusted array 
data may give a stronger indication of true changes in expression caused by the 
genetic hits introduced in this model.  
These data indicated that of the genes involved in the establishment and 
maintenance of DNA methylation, only DNMT1 showed a significant change in 
expression, increasing between MSC 0 and 5 in the uncorrected array analysis. 
However,  when  adjusted  for  proliferation,  expression  of  DNMT1  does  not 
change  significantly  during  step-wise  transformation.  It  remains  possible, 
therefore,  that  the  genome-wide  hypomethylation  observed  during  step-wise 
transformation of MSC could result from insufficient DNMT activity to cope 
with  the  faster  cell  cycle  in  the  later  stages  of  step-wise  transformation.   185 
However, future work on DNMT1 enzymatic activity should be conducted in 
order  to  establish  whether  any  changes  in  enzymatic  function  contribute  to 
hypomethylation in MSC 5. 
Although many studies have assessed DNMT expression levels in cancer, 
no clear link between altered DNMT expression and the incidence of genome-
wide hypomethylation has emerged. One study of genome-wide hypomethylation 
in  uterine  leiomyoma  noted  unchanged  or  elevated  DNMT1  expression  and 
decreased  DNMT3A  and  DNMT3B  expression  compared  to  adjacent  normal 
tissue. Additionally, genome-wide hypomethylation in ovarian epithelial tumours 
of different malignant potential has been shown to be independent of RNA levels 
for all DNMTs, although no comparison of DNMT expression in normal tissues 
was conducted (Ehrlich et al., 2006). A similar investigation of Wilm’s tumour 
showed global hypomethylation in 60% of samples when compared to a panel of 
normal  postnatal  tissues,  but  failed  to  find  any  correlation  between  global 
methylation levels and relative RNA levels of DNMT1, DNMT3A and DNMT3B 
(Ehrlich et al., 2002). 
As  well  as  passive  demethylation  processes,  global  hypomethylation 
could be induced in an active manner through increased expression or activity of 
DNA  demethylases.  Although  active  DNA  demethylation  has  been  observed 
during early mouse embryogenesis, a DNA demethylase in human cells has not 
yet been identified (Morgan et al., 2004; Ooi and Bestor, 2008). Analysis of gene 
expression  microarray  data  for  putative  demethylases  including  MBD2  and 
GADD45A revealed a significant increase in GADD45A expression in MSC 5 
compared  to  MSC  0,  with  this  increase  occurring  on  the  introduction  of  H-
Ras
V12. Furthermore, this significant change in gene expression is also evident   186 
when the gene expression microarray data is normalised for proliferation rate of 
the cells. It remains a possibility, therefore, that increased demethylase activity 
of  this  enzyme  in  transformed  MSC  could  result  in  global  hypomethylation, 
although future characterisation and studies of this enzyme in the MSC model 
are required to test this hypothesis. 
  Normal DNA methylation patterns may also be disrupted by changes in 
the availability of SAM, a key substrate required for the activity of DNMTs. 
Disrupted  SAM  biosynthesis  through  dietary  alterations  or  disrupted 
methoionine metabolism has previously been linked to global hypomethylation 
and cancer (reviewed in Kim, 2005; Laird and Jaenisch, 1996; Szyf et al., 2004). 
Gene expression microarray data from the MSC model suggest that metabolic 
pathways directed away from SAM production are up-regulated in transformed 
MSC, raising the possibility that SAM levels are limiting in these cells. These 
observations  are  concurrent  with  other  studies  in  which  polymorphisms  that 
reduce the activity of MTHFR, a key player in methyl-donor biosynthesis, are 
associated with increased cancer risk (reviewed in Szyf et al., 2004). Reduced 
SAM availability may therefore contribute to the hypomethylation observed in 
MSC 5.  
Together,  these  data  indicated  that  there  is  no  single  change  in  gene 
expression  that  could  lead  to  repetitive  element  hypomethylation  in  MSC  5. 
However, concurrent changes to the expression of a number of different enzymes 
involved in DNA methylation suggested that the combinatorial effects of these 
alterations could result in a gradual loss of normal DNA methylation patterning 
over time.      187 
  In conclusion, experiments conducted as part of this chapter have aimed 
to  address  the  time  course  and  potential  mechanism  of  repetitive  element 
hypomethylation during step-wise transformation of MSC. Analysis of repetitive 
element methylation over time following conditional H-Ras
V12 expression failed 
to detect hypomethylation of these sequences despite the evident transformation 
of these cells. Conversely, expression of H-Ras
V12 lacking a conditional domain 
was able to recapitulate the Sat2 hypomethylation previously observed in the 
original MSC 5 population. This hypomethylation reached significance following 
growth of these cells for one month, suggesting that methylation is lost in a 
gradual manner, potentially through a passive mechanism. Finally, analysis of 
gene expression microarray data for epigenetic regulators and enzymes relating 
to  methionine  metabolism  indicated  deregulation  of  these  pathways  during 
transformation.  Together,  these  results  provide  insight  into  the  causes  of 
genome-wide  hypomethylation  in  cancer  and  suggest  that  this  loss  of 
methylation is not a requirement for transformation.   
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Chapter 5: PRC2 up-regulation and mechanisms of target gene 
silencing during step-wise transformation 
 
5.1    Background 
Although  genome-wide  hypomethylation  is  one  of  the  most  widely  reported 
epigenetic changes in cancer, other hallmark epigenetic changes occur during 
transformation,  including  gene  specific  hypermethylation  and  characteristic 
histone modifications (Esteller, 2006; Fraga et al., 2005; Herman and Baylin, 
2003;  Jones  and  Baylin,  2002).  An  important  class  of  epigenetic  regulators 
involved in the latter two of these changes is the polycomb repressive complex 2 
(PRC2) - an epigenetic silencing complex essential for normal developmental 
processes and commonly deregulated in cancer (Sparmann and van Lohuizen, 
2006). The main action of PRC2 is to maintain embryonic stem cell pluripotency 
by  repression  of  genes  involved  in  differentiation  (Lee  et  al.,  2006).    Gene 
silencing  is  achieved  by  creation  of  the  repressive  H3K27me3  histone 
modification, one half of the ‘bivalent’ chromatin state found at the promoter 
regions of key developmental genes in embryonic stem cells (Cao et al., 2002; 
Kuzmichev et al., 2002). This unique chromatin state maintains these genes in an 
unexpressed state, but allows them to be quickly activated upon differentiation 
(Bernstein et al., 2006).  
  Up-regulated expression of the PRC2 components EZH2 and SUZ12 has 
been  well  documented  in  a  variety  of  cancers  (Sparmann  and  van  Lohuizen, 
2006). In many cases EZH2 has been shown to act as an oncogene, with over-
expression  leading  to  increased  cell  proliferation,  invasion  of  benign  cells,   189 
colony formation and in vivo tumour growth in nude mice (Bracken et al., 2003; 
Kleer  et  al.,  2003;  Varambally  et  al.,  2002).  Furthermore,  EZH2  knockdown 
results in growth arrest of cancer cells as well as decreasing tumour growth and 
metastasis in vivo (Croonquist and Van Ness, 2005; Varambally et al., 2002). A 
number  of  mechanisms  for  elevated  EZH2  expression  in  cancer  have  been 
identified,  including  disrupted  microRNA  expression  and  the  action  of  viral 
oncoproteins  
The repressive action of PRC2 suggests a role for this complex in gene 
silencing during tumourigenesis (Schlesinger et al., 2007). The identification of a 
‘stem cell like’ signature of gene silencing in cancer has given weight to this 
hypothesis,  with  a  number  of  studies  demonstrating  preferential 
hypermethylation and silencing of PRC2 targets in transformed cells (Ohm et al., 
2007; Schlesinger et al., 2007; Widschwendter et al., 2007). This suggests that 
aberrant  PRC2  activity  in  cancer  may  be  a  key  process  in  maintaining 
transformed cells in a ‘stem cell-like’ state by suppressing differentiation. 
Although many studies have focused on changes in PRC2 expression and 
activity  in  cancer,  none  have  investigated  how  or  when  these  changes  occur 
during  transformation.  Furthermore,  although  EZH2  has  been  shown  to  have 
oncogenic properties in cancer cells, the role of PRC2 during early stages of 
transformation  is  unknown.  Step-wise  transformation  of  MSC  provides  an 
excellent  model  in  which  to  investigate  changes  in  PRC2  expression  and 
subsequent downstream gene silencing, allowing insight into the mechanism and 
time scale of these changes to be gained. I hypothesized that alterations in the 
expression  and  activity  of  the  PRC2  complex  take  place  during  step-wise 
transformation, and that these changes result in hypermethylation and silencing   190 
of PRC2 target genes in transformed MSC. I therefore aimed to investigate the 
role of PRC2 during step-wise transformation of MSC. 
 
 
5.2    Aims 
To investigate the role of the PRC2 complex during step-wise transformation of 
MSC. Particular questions to address include: 
1.  Are PRC2 components up-regulated during step-wise transformation? 
2.  Are PRC2 target genes down-regulated during transformation? 
3.  Is  this  down-regulation  a  result  of  increased  H3K27me3  or  DNA 
methylation at target gene promoters? 
4.  Can cells be transformed in the absence of functional PRC2? 
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5.3    Results 
5.3.1  Analysis  of  Gene  Expression  Microarray  Data  and  qRT-PCR 
Confirmation 
In order to establish whether the three core components of PRC2 (EZH2, EED 
and SUZ12) are up-regulated during step-wise transformation, gene expression 
microarray  data  from  the  MSC  cell  lines  were  analysed.  Changes  in  gene 
expression between primary and transformed MSC of greater than 1.5 fold with a 
p-value of less than 0.05 as determined by the Student’s T-test were considered 
significant. This analysis revealed that EZH2, EED and SUZ12 mRNA levels 
were significantly higher in MSC 5 compared to MSC 0 (Figure 5.1a; q = 1x10
-6, 
q = 0 and q = 0, respectively). To show that this up-regulation was specific to the 
PRC2 complex, gene expression data for PRC1 components were extracted and 
analysed  (Figure  5.1b).  These  data  confirmed  that  there  was  no  significant 
change in expression for any of the genes involved with this alternate epigenetic 
regulator complex, suggesting that PRC2 is specifically up-regulated during step-
wise transformation.  
  These findings were confirmed by qRT-PCR analysis of EZH2, EED and 
SUZ12 mRNA levels in each of the MSC cell lines (Figure 5.1c-e). In all cases, 
significant up-regulation of gene expression was observed, with mRNA levels of 
EZH2 increasing 20-fold, SUZ12 4-fold and EED 2.2-fold in MSC 5 compared to 
MSC 0. This increase relative to MSC 0 was first observed at MSC 1 for EZH2, 
MSC 3 for SUZ12 and MSC 5 for EED. Together, these data confirmed that 
PRC2 components are specifically up-regulated during step-wise transformation. 
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Figure  5.1:  mRNA  levels  of  the  PRC2  components  EZH2,  EED  and  SUZ12  are  up-
regulated  during  step-wise  transformation.  Heatmap  showing  triplicate  gene  expression 
microarray  data  for  (a)  PRC2  and  (b)  PRC1  component  expression  in  each  of  the  five 
transforming steps (MSC 0 - 5). Expression profiles of (c) EZH2, (d) EED and (e) SUZ12 were 
confirmed by quantitative RT-PCR. Fold-change in mRNA levels with respect to MSC 0 were   194 
calculated in triplicate by   Ct using GAPDH as a loading control and normalised to parental 
MSC. Student’s T-test was performed for all statistical analyses. * p < 0.05, ** p < 0.01 with 
respect to MSC 0. Columns display average of three replicates; Error bars display SEM.  
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5.3.2    Western Blot Analysis 
Western blot analysis was conducted to confirm that increased EZH2, EED and 
SUZ12  mRNA  levels  translated  to  increased  protein  levels  during  step-wise 
transformation (Figure 5.2a). All MSC cell lines were grown in full media or 
serum  starved  for  24  hours  to  synchronize  cells  before  total  protein  was 
harvested. Analysis of cell lysates revealed an increase in EZH2 and SUZ12 
protein levels in both untreated and serum starved cells. No significant change in 
EED protein levels were observed in untreated cells although a modest increase 
was observed in serum starved cells from MSC 2E6 onwards.  
   To  determine  whether  PRC2  up-regulation  affected  the  amount  of 
H3K27me3 in these cells, levels of the modified histone and total histone H3 
were  measured  by  western  blot  (Figure  5.2a).  Although  H3K27me3  levels 
fluctuated during step-wise transformation, changes to the amount of total H3 
were also evident. To elucidate the underlying trend, densitometry of bands from 
triplicate  western  blot  was  conducted  for  each  cell  line,  with  the  ratio  of 
H3K27me3 : total H3 calculated (Figure 5.2b). For cells grown in full media, this 
analysis indicated that with the exception of MSC 1, there was no significant 
change in the ratio of H3K27me3 : total H3 in any of the MSC cell lines. In 
serum starved cells, however, this ratio was significantly lower in MSC 1 and at 
the later stages of transformation compared to MSC 0 (Figure 5.2b). These data 
suggested  that genome-wide  levels  of  H3K27me3 decreased  during  step-wise 
transformation of MSC, despite increased PRC2 expression.  
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Figure 5.2: Genome-wide H3K27me3 levels are reduced during step-wise transformation 
despite up-regulation of PRC2. (a) Western blot analysis of EZH2, EED, SUZ12, H3K27me3, 
Total H3 and GAPDH (loading control) protein levels in MSC cell lines grown in full media (+ 
Serum) or serum starved for 24 hours (- Serum). (b) Quantification of the H3K27me3 : Total H3 
ratio for all MSC cell lines grown in full media (+ Serum) or serum starved for 24 hours (- 
Serum). Student’s T-test was performed for all statistical analyses. * p < 0.05, ** p < 0.01 with 
respect to MSC 0. Columns display average of three replicates; Error bars display SEM.  
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5.3.3  Gene  Set  Enrichment  Analysis  (GSEA)  of  PRC2  Target  Gene 
Expression 
Since  PRC2  acts  as  repressor  complex,  down-regulation  of  target  gene 
expression would be expected following up-regulation of the complex in this 
model. Therefore, as another measure of PRC2 function, gene set enrichment 
analysis  (GSEA)  was  conducted  for  PRC2  target  genes.  This  unbiased 
computational approach compares two sets of gene expression microarray data, 
and determines whether a particular set of genes are significantly up- or down-
regulated compared to the genome as a whole. 
The  set  of  PRC2  target  genes  utilized  in  my  analysis  were  originally 
identified  by  chromatin  immunoprecipitation  followed  by  microarray 
hybridization (ChIP-chip) for SUZ12, EED and H3K27me3 in human embryonic 
stem cells (Lee et al., 2006). A set of 653 genes showing occupancy for all three 
of these marks were used for GSEA (Table A5). Comparison of MSC 0 to all 
other  MSC  cell  lines  indicated  that  PRC2  target  genes  were  significantly 
enriched in MSC 0 compared to MSC 4 (q = 0.001), or in other words that these 
genes were significantly down-regulated at MSC 4 (Figure 5.3a). A significant 
enrichment score for this gene set was also obtained when MSC 3 was compared 
to MSC 4 (q = 0), confirming that significant changes to the expression of PRC2 
target genes occurred at this stage of step-wise transformation.  No significant 
enrichment was observed when MSC 0 was compared to any of the other cell 
lines,  although  the  comparison  of  MSC  0  to  MSC  5  approached  statistical 
significance (q = 0.069). These results indicated that PRC2 target genes were 
significantly down-regulated during step-wise transformation, with this change in 
expression occurring at MSC 4.    198 
GSEA also provides a list of ‘core genes’ that show the most significant 
changes in expression, and primarily account for the observed enrichment in the 
gene set. Core gene lists from GSEA of MSC 0 vs. MSC 4 and MSC 3 vs. MSC 
4  were  obtained,  and  expression  data  for  genes  contained  in  both  lists  were 
extracted  (Tables  5.1  &  5.2).    Analysis  of  these  data  confirmed  the  down-
regulation of core gene expression between MSC 0 and MSC 4 (Figure 5.3b). A 
selection of candidate genes (DKK2, EN1, HOXB3, RBP4 and TBX2) with high 
GSEA core ranking and significant down-regulation in expression were selected 
for further investigation. Analysis of mRNA levels was conducted to confirm 
reduced expression of these genes between MSC 0 and MSC 4 (Figure 5.3c). 
These  data  displayed  the  expected  pattern  of  down-regulation  for  all  genes 
except  HOXB3,  which  showed  no  significant  change  in  expression  between 
MSC 0 and MSC 4.  
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Figure 5.3: Gene set enrichment analysis (GSEA) indicates significant down-regulation of 
PRC2 target gene expression in MSC 4 versus MSC 0. (a) Enrichment plot from GSEA of 
PRC2 target gene expression profiles in MSC 0 vs. MSC 4, revealing significant down-regulation 
of target genes in MSC 4 compared to MSC 0. (b) Heatmap showing triplicate gene expression 
microarray data for GSEA core gene expression in each of the five transforming steps (MSC 0 - 
5). Genes chosen for subsequent analysis are indicated by asterisks (*). (c) Quantitative RT-PCR 
confirmation  of  selected  GSEA  core  gene  down-regulation.  Fold-change  in  mRNA  levels  of 
DKK2, EN1, RBP4, HOXB3 and TBX2 with respect to MSC 0 were calculated in triplicate by 
  Ct using GAPDH as a loading control and normalised to parental MSC. Student’s T-test was 
performed for all statistical analyses. * p < 0.05, ** p < 0.01 with respect to MSC 0. Columns 
display average of three replicates; Error bars display SEM.  
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Table 5.1: Core gene list from GSEA of PRC2 target gene expression between 
MSC 0 and MSC 4  
 
Gene 
Symbol 
Rank In 
Gene List 
Rank Metric 
Score 
Running ES 
Core 
Enrichment 
OSR1  4  1.510  0.025  Yes 
DKK2  22  1.092  0.042  Yes 
FEZ1  28  1.075  0.059  Yes 
RNF128  41  0.918  0.074  Yes 
OLFML2B  56  0.841  0.087  Yes 
PENK  65  0.795  0.100  Yes 
CAMK2N1  72  0.777  0.112  Yes 
SLC26A4  99  0.691  0.122  Yes 
CH25H  124  0.643  0.132  Yes 
PTGFR  126  0.642  0.142  Yes 
TCEA3  137  0.623  0.152  Yes 
NPR3  154  0.592  0.161  Yes 
TMOD2  155  0.591  0.171  Yes 
RBP4  163  0.575  0.180  Yes 
FLRT2  171  0.564  0.189  Yes 
BHLHB3  180  0.556  0.198  Yes 
EN1  192  0.540  0.206  Yes 
PTGER2  222  0.506  0.213  Yes 
LTBP2  229  0.501  0.221  Yes 
THBD  250  0.479  0.228  Yes 
DGKI  327  0.417  0.231  Yes 
IRX5  359  0.397  0.236  Yes 
ADRA2A  363  0.396  0.242  Yes 
PITX2  369  0.393  0.248  Yes 
PAPPA  445  0.354  0.250  Yes 
MAFB  481  0.340  0.254  Yes 
TBX2  501  0.335  0.259  Yes 
BTG2  513  0.330  0.264  Yes   202 
Gene 
Symbol 
Rank In 
Gene List 
Rank Metric 
Score 
Running ES 
Core 
Enrichment 
VDR  553  0.317  0.267  Yes 
CLSTN2  585  0.309  0.271  Yes 
KIAA1199  588  0.307  0.276  Yes 
PTPRU  763  0.263  0.271  Yes 
KCNK2  775  0.261  0.275  Yes 
ZFYVE28  788  0.259  0.279  Yes 
KLF4  853  0.246  0.279  Yes 
PMP22  939  0.232  0.279  Yes 
PDGFRA  947  0.229  0.283  Yes 
PIR  956  0.229  0.286  Yes 
TMEM27  958  0.228  0.290  Yes 
KCNMA1  972  0.226  0.293  Yes 
KAZALD1  1031  0.219  0.293  Yes 
HTR7  1079  0.213  0.295  Yes 
HOXC12  1116  0.208  0.296  Yes 
FOXG1B  1149  0.203  0.298  Yes 
NRG1  1201  0.198  0.299  Yes 
PITX1  1209  0.197  0.302  Yes 
HOXC4  1211  0.197  0.305  Yes 
TBX3  1301  0.188  0.303  Yes 
ZIC1  1356  0.183  0.304  Yes 
HOXB2  1368  0.182  0.306  Yes 
RIPK3  1378  0.181  0.309  Yes 
NEF3  1400  0.178  0.311  Yes 
ZNF503  1453  0.175  0.311  Yes 
HLX1  1515  0.170  0.311  Yes 
NKX2-2  1551  0.167  0.312  Yes 
ZFHX1B  1563  0.166  0.314  Yes 
MLLT3  1568  0.166  0.316  Yes 
CRLF1  1570  0.166  0.319  Yes 
TSLP  1591  0.165  0.321  Yes   203 
Gene 
Symbol 
Rank In 
Gene List 
Rank Metric 
Score 
Running ES 
Core 
Enrichment 
GHR  1611  0.163  0.322  Yes 
PAX6  1643  0.161  0.324  Yes 
NRG2  1651  0.160  0.326  Yes 
PTHLH  1668  0.159  0.328  Yes 
IRX3  1672  0.159  0.330  Yes 
HBA2  1710  0.156  0.331  Yes 
null  1779  0.151  0.330  Yes 
ZNF436  1812  0.149  0.331  Yes 
LOC153684  1843  0.147  0.332  Yes 
FLJ37440  1859  0.147  0.333  Yes 
HTR2C  1888  0.145  0.334  Yes 
WNT16  1963  0.140  0.333  Yes 
COL24A1  2021  0.136  0.333  Yes 
LHX2  2045  0.135  0.334  Yes 
NTN1  2082  0.133  0.334  Yes 
CORO6  2094  0.133  0.336  Yes 
DUSP4  2152  0.130  0.335  Yes 
HOXB3  2212  0.128  0.334  Yes 
MSC  2221  0.128  0.336  Yes 
FBXL8  2264  0.126  0.336  Yes 
GABRA2  2445  0.119  0.329  Yes 
HES7  2485  0.118  0.329  Yes 
ALOX15  2487  0.118  0.331  Yes 
FRMD3  2513  0.117  0.331  Yes 
HPSE2  2526  0.117  0.333  Yes 
CA10  2533  0.116  0.334  Yes 
UCP1  2542  0.116  0.336  Yes 
RRP22  2691  0.112  0.330  Yes 
RASSF5  2700  0.112  0.332  Yes 
PODN  2744  0.110  0.331  Yes 
CD8A  2780  0.109  0.331  Yes   204 
Gene 
Symbol 
Rank In 
Gene List 
Rank Metric 
Score 
Running ES 
Core 
Enrichment 
SIX1  2794  0.108  0.333  Yes 
CDH7  2798  0.108  0.334  Yes 
ASTN2  2810  0.108  0.335  Yes 
GALNTL4  2811  0.108  0.337  Yes 
HHIP  2852  0.106  0.337  Yes 
FIGLA  2878  0.106  0.337  Yes 
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Table 5.2: Core gene list from GSEA of PRC2 target gene expression between 
MSC 3 and MSC 4  
 
Gene 
Symbol 
Rank In 
Gene List 
Rank Metric 
Score 
Running ES  Core Enrichment 
OSR1  2  1.438  0.025  Yes 
RBP4  20  1.069  0.042  Yes 
RNF128  33  0.950  0.058  Yes 
PTHLH  37  0.924  0.073  Yes 
PENK  43  0.895  0.089  Yes 
CAMK2N1  46  0.865  0.103  Yes 
DKK2  48  0.854  0.118  Yes 
THBD  53  0.827  0.132  Yes 
BHLHB3  57  0.805  0.146  Yes 
CRLF1  59  0.795  0.159  Yes 
NEF3  66  0.734  0.171  Yes 
CH25H  70  0.722  0.184  Yes 
FEZ1  71  0.721  0.196  Yes 
FLRT2  88  0.664  0.207  Yes 
TBX2  91  0.658  0.218  Yes 
KLF4  103  0.619  0.228  Yes 
TCEA3  125  0.563  0.237  Yes 
PTGER2  130  0.559  0.246  Yes 
DUSP4  150  0.525  0.254  Yes 
CYP24A1  162  0.497  0.262  Yes 
EN1  242  0.399  0.265  Yes 
NPR3  247  0.393  0.271  Yes 
NPTX1  258  0.384  0.278  Yes 
HHIP  265  0.379  0.284  Yes 
PTGFR  266  0.377  0.290  Yes 
KAZALD1  280  0.366  0.296  Yes 
INA  284  0.362  0.302  Yes 
FRMD3  300  0.353  0.307  Yes   206 
Gene 
Symbol 
Rank In 
Gene List 
Rank Metric 
Score 
Running ES  Core Enrichment 
TSLP  312  0.348  0.313  Yes 
PITX2  340  0.326  0.317  Yes 
OLFML2B  344  0.324  0.322  Yes 
SLC26A4  387  0.312  0.326  Yes 
TMOD2  441  0.280  0.328  Yes 
FLJ33790  467  0.268  0.331  Yes 
WNT16  534  0.249  0.332  Yes 
PITX1  543  0.247  0.336  Yes 
PMP22  590  0.235  0.338  Yes 
LTBP2  594  0.235  0.341  Yes 
PAX6  647  0.222  0.343  Yes 
HTR7  693  0.213  0.344  Yes 
TRH  764  0.199  0.344  Yes 
TLX2  864  0.182  0.342  Yes 
PAPPA  924  0.174  0.342  Yes 
DGKI  946  0.170  0.344  Yes 
KCNMA1  947  0.170  0.347  Yes 
NAGS  958  0.169  0.349  Yes 
DLX2  986  0.165  0.351  Yes 
HOXB3  1019  0.161  0.352  Yes 
LHX2  1049  0.159  0.353  Yes 
STMN2  1063  0.158  0.355  Yes 
RGS20  1159  0.150  0.353  Yes 
NPAS1  1211  0.146  0.353  Yes 
TBX3  1218  0.145  0.355  Yes 
CLSTN2  1234  0.143  0.357  Yes 
ZIC1  1264  0.141  0.358  Yes 
KCNC4  1271  0.140  0.360  Yes 
EGR3  1296  0.139  0.361  Yes 
HOXC4  1300  0.139  0.364  Yes 
ZFHX1B  1301  0.139  0.366  Yes   207 
Gene 
Symbol 
Rank In 
Gene List 
Rank Metric 
Score 
Running ES  Core Enrichment 
CXCL16  1383  0.133  0.364  Yes 
COMP  1399  0.132  0.366  Yes 
PKP1  1416  0.131  0.367  Yes 
F2R  1435  0.129  0.368  Yes 
ALOX15  1460  0.128  0.369  Yes 
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5.3.4    H3K27me3 Chromatin Immunoprecipitation (ChIP) 
Chromatin  immunoprecipitation  was  conducted  to  determine  whether  the 
promoter regions of DKK2, EN1 and HOXB3 contained the H3K27me3 histone 
modification  and  whether  levels  of  this  modified  histone  change  during 
transformation. Chromatin from MSC 0 and MSC 5 was harvested and subjected 
to  immunoprecipitation  with  anti-H3K27me3  and  anti-H3  antibodies. 
H3K27me3 levels at genomic regions immediately upstream of the transcription 
start sites for DKK2, EN1 and HOXB3 were assessed by qPCR. A genomic 
region  upstream  of  DCN,  a  non-PRC2  target  gene,  was  used  as  a  negative 
control.  These  data  showed  that  DNA  from  the  anti-H3K27me3 
immunoprecipitation amplified significantly more efficiently than DNA from the 
rabbit IgG control immunoprecipitation, indicating that the IP was successful 
(Figure 5.4 a & b). Furthermore, H3K27me3 levels were significantly higher at 
PRC2 target genes than at the negative control gene, DCN. Between cell lines, 
H3K27me3 levels at PRC2 target genes were significantly higher in parental 
MSC 0 than in transformed MSC 5 (Figure 5.4 a & b). These data indicated that 
PRC2 target genes were marked with the H3K27me3 histone modification in 
MSC 0, and that levels of this mark declined during step-wise transformation in a 
similar manner to genome-wide H3K27me3 levels (Figure 5.2b). 
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Figure 5.4: PRC2 target gene promoters are enriched for H3K27me3 in MSC 0, with levels 
of  this  modified  histone  decreasing  during  step-wise  transformation.  (a)  Analysis  of 
H3K27me3 and total histone H3 levels by ChIP at selected PRC2 target gene promoters and the 
non-PRC2 target gene DCN was conducted in MSC 0 and MSC 5. IP of MSC 5 chromatin with 
an equivalent amount of rabbit IgG was conducted as a negative control. H3K27me3 percentage 
of input for each cell line was calculated in triplicate relative to input reactions containing 100ng 
of template. (b) The ratio of percentage input for H3K27me3 and total H3 reactions were also 
calculated. Student’s T-test was performed for all statistical analyses. * p < 0.05, ** p < 0.01 with 
respect to MSC 0. Columns display average of three replicates; Error bars display SEM.   
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5.3.5    Analysis of Promoter DNA Methylation by Pyrosequencing 
H3K27me3 has been hypothesized to direct DNA methylation and subsequent 
silencing of gene expression in cancer. To investigate whether DNA methylation 
at PRC2 target genes changes during step-wise transformation, pyrosequencing 
assays were designed for the promoter regions of DKK2, EN1, RBP4 and TBX2. 
CpG rich regions upstream of the transcription start sites of these genes were 
amplified by PCR from bisulphite converted genomic DNA and subjected to 
pyrosequencing. Methylation levels for each region were calculated as average 
percentage methylation across all CpG sites within the amplicon. These results 
indicated that the promoter regions of DKK2 and TBX2 were unmethylated in all 
MSC cell lines (Figure 5.5 a & d). Conversely, EN1 was moderately methylated 
in MSC 0, with significant hypermethylation occurring on further oncogenic hits 
up to MSC 4, before decreasing again in MSC 5 (Figure 5.5b). Finally, RBP4 
showed low methylation in all MSC cell lines with the exception of MSC 4, 
where significant hypermethylation of the promoter was observed (Figure 5.5c).  
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Figure 5.5: PRC2 target gene promoters show variable methylation patterns during step-
wise transformation. Promoter regions from (a) DKK2, (b) EN1, (c) RBP4 and (d) TBX2 were 
amplified by PCR using bisulphite converted genomic DNA from all MSC cell lines (MSC 0 – 5) 
as  well  as  from  fully  methylated  and  unmethylated  control  DNA  (data  not  shown).  CpG 
methylation in these amplification products was assessed by PyroSequencing in triplicate and 
averaged across the region assayed. Student’s T-test was performed for all statistical analyses. * p 
< 0.05, ** p < 0.01 with respect to MSC 0. Columns display average of three replicates; Error 
bars display SEM.   
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5.3.6    Short Hairpin RNA (shRNA) Knockdown of PRC2 Components 
To investigate whether PRC2 target gene silencing in MSC 4 could be reversed, 
levels  of  EZH2  and  SUZ12  were  knocked-down  in  these  cells  using 
OpenBiosystems pGIPZ shRNA constructs (http://www.openbiosystems.com/). 
Stable gene knockdown was achieved by infecting target cells with lentivirus 
containing the shRNA expression construct. Since significant down-regulation of 
PRC2 target genes was observed in MSC 4, PRC2 knockdown was carried out in 
these cells, with the effect of this knockdown on PRC2 target gene expression 
assessed by qRT-PCR. 
  Lentiviruses  containing  shRNA  constructs  against  EZH2  and  SUZ12 
along with non-silencing shRNA and empty vector controls were generated by 
FuGene transfection of 293T cells with the relevant lentiviral vectors. After 48 
hours,  supernatant  containing  the  lentivirus  was  harvested  and  filtered.  To 
control  for  the  efficiency  of  viral  production  with  different  constructs,  the 
lentiviral  supernatants  were  titrated.  Increasing  volumes  of  supernatant  were 
added to MSC 4, with the percentage of GFP cells assessed by FACS after 48 
hours (Figure 5.6 a & b). In all cases, an increase in the percentage of GFP 
positive cells was observed on the addition of increasing volumes of lentivirus. 
MSC  4  cells  were  infected  with  lentivirus  containing  either  EZH2 
shRNA, SUZ12 shRNA, non-silencing shRNA or empty vector. On the basis of 
viral titration, an appropriate volume of lentiviral supernatant was added to the 
cells in order to achieve a level of infection resulting in 30% GFP positive cells 
(Figure 5.6c). 48 hours post infection, GFP positive cells were sorted by MoFlow 
and  cultured  as  normal  (Figure  5.6d).  Successful  knockdown  of  EZH2  and 
SUZ12 relative to the non-silencing control was confirmed at the mRNA and   213 
protein  levels  by  qRT-PCR  and  western  blot  respectively  (Figure  5.7a-c). 
Viability  and  growth  of  all  cell  lines  was  assessed  using  the  MTS  assay, 
indicating  no  significant  decrease  in  growth  potential  for  any  of  the  shRNA 
expressing  cells  compared  to  uninfected  MSC  4,  although  EZH2  knockdown 
cells  proliferated  significantly  faster  than  non-silencing  control  cells  (Figure 
5.7d; p < 0.05).  
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Figure  5.6:  shRNA  knockdown  of  PRC2  components  in  MSC  4.  Lentiviruses  containing 
shRNA constructs against EZH2 and SUZ12 along with non-silencing shRNA (NS) and empty 
vector (EV) controls were generated and used to infect MSC 4.  (a) FACS plot displaying the 
GFP  profile  of  MSC  4  cells  following  infection  with  increasing  volumes  of  EZH2  shRNA   216 
lentivirus. (b) Analysis of FACS data for all lentiviral infections, displaying percentage of GFP 
positive cells following infection with increasing volumes of viral supernatant. (c) GFP image of 
MSC 4 cells infected with an appropriate volume of virus to achieve 10-25% GFP positive cells. 
(d)  FACS  plots  from  cell  sorting  of  GFP  positive  cells  infected  with  empty  vector  (EV) 
lentivirus. 
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Figure 5.7: shRNAs induce knock-down of EZH2 and SUZ12 mRNA and protein in MSC 4. 
Quantitative  RT-PCR  confirmation  of  (a)  EZH2  and  (b)  SUZ12  mRNA  down-regulation  in 
shRNA expressing cell lines. Fold-change in mRNA levels with respect to non-silencing shRNA 
control  (NS)  were  calculated  in  triplicate  by    Ct  using  GAPDH  as  a  loading  control  and 
normalised to NS. (c) Western blot analysis of EZH2, SUZ12 and GAPDH (loading control) 
protein levels in EZH2 and SUZ12 shRNA expressing cells, non-silencing shRNA expressing 
cells  (NS),  empty  vector  control  cells  (EV)  and  uninfected  MSC  4  cells  (MSC  4).  (d)  Cell 
viability (MTS) assay for all shRNA and control cell lines seeded at a density of 1000 cells per 
well  and  grown  over  the  course  of  72  hours.  Each  point  represents  the  average  absorbance 
(490nm)  from  5  replicates  when  background  absorbance  is  subtracted.  Student’s  T-test  was 
performed for all statistical analyses. * p < 0.05, ** p < 0.01 with respect to MSC 0. Columns 
display average of three replicates; Error bars display SEM.  
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5.3.7  PRC2 Target Gene Expression and Methylation following EZH2 
and SUZ12 Knockdown 
To  investigate  whether  down-regulation  of  PRC2  target  gene  expression  was 
maintained  in  the  absence  of  EZH2  and  SUZ12,  qRT-PCR  for  DKK2,  EN1, 
HOXB3, RBP4 and TBX2 was conducted in the shRNA knockdown cell lines 
(Figure 5.8a). These data indicated no significant changes in expression for EN1, 
HOXB3 or RBP4 in the SUZ12 or EZH2 knockdown cell lines. Similarly, there 
was  no  change  in  DKK2  or  TBX2  expression  following  SUZ12  knockdown. 
However, a significant increase in expression of these genes was observed in 
EZH2  knockdown  cells  compared  to  cells  expressing  a  non-silencing  control 
shRNA (Figure 5.8a).  
  Analysis  of  methylation  at  selected  PRC2  target  gene  promoters  was 
carried out by pyrosequencing in order to establish whether methylation levels 
changed following EZH2 or SUZ12 knockdown. Analysis of genomic regions 
upstream of the DKK2, EN1, RBP4 and TBX2 transcription start sites indicated 
no significant change in methylation following PRC2 knockdown (Figure 5.8b-
e). Together, these data showed that expression of methylated genes (EN1 and 
RBP4)  was  not  affected  by  reduced  EZH2  expression,  whereas  unmethylated 
genes (DKK2 and TBX2) were up-regulated in response to EZH2 knockdown.  
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Figure  5.8:  PRC2  target  genes  show  differential  changes  in  gene  expression  but  no 
alteration in promoter DNA methylation following shRNA knockdown of EZH2 or SUZ12. 
(a) Quantitative RT-PCR analysis of PRC2 target gene expression in shRNA expressing and 
control cell lines. Fold-change in DKK2, EN1, RBP4, HOXB3 and TBX2 mRNA levels with 
respect  to  non-silencing  shRNA  control  (NS)  were  calculated  in  triplicate  by    Ct  using 
GAPDH as a loading control and normalised to NS. (b-e) Average CpG methylation for (b) 
DKK2, (c) EN1, (d) RBP4 and (e) TBX2 promoter regions were assessed by Pyrosequencing in 
triplicate. Student’s T-test was performed for all statistical analyses. * p < 0.05, ** p < 0.01 with 
respect to MSC 0. Columns display average of three replicates; Error bars display SEM.  
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5.3.8  H-Ras
V12 Infection of PRC2 Knockdown Cells and Transformation Assay 
In order to assess whether transformation could take place in the absence of 
PRC2  over-expression,  H-Ras
V12  was  expressed  in  the  EZH2  and  SUZ12 
knockdown cell lines. Retroviruses containing the H-Ras
V12 construct or empty 
vector  were  generated  and  used  to  infect  the  MSC  4  knockdown  cell  lines. 
Following  hygromycin  selection  of  infected  cells,  H-Ras
V12  expression  and 
continued  knockdown  of  EZH2  and  SUZ12  was  confirmed  by  western  blot 
(Figure  5.9a).  A  viability  assay  of  these  cell  lines  indicated  no  significant 
difference in cell growth or viability between PRC2 knockdown and untreated 
MSC 4 cells expressing H-Ras
V12 (Figure 5.9b). Finally, transformation of these 
cell lines was assessed by anchorage independent growth, with all cell lines able 
to  form  colonies  when  grown  for  12  days  in  soft  agarose  (Figure  5.9c). 
Furthermore,  colonies  formed  by  the  MSC  4  knockdown  cells  were  GFP 
positive, indicating continued expression of the shRNA constructs. These data 
suggested that step-wise transformation could still occur in the absence of PRC2 
over-expression. 
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Figure 5.9: EZH2 and SUZ12 knockdown in MSC 4 does not prevent transformation on 
expression of H-Ras
V12. shRNA and control MSC 4 cell lines were infected with retrovirus 
containing a H-Ras
V12 construct and subjected to selection with hygromycin. (a) Western blot 
analysis of H-Ras and GAPDH (loading control) protein levels following infection of MSC 4 cell 
lines with H-Ras
V12 retrovirus. (b) Cell viability (MTS) assay for all shRNA and control cell lines 
following H-Ras
V12 expression, seeded at a density of 1000 cells per well and grown over the 
course of 72 hours. Each point represents the average absorbance (490nm) from 5 replicates 
when background absorbance is subtracted. (c) Soft agarose transformation assay for all shRNA 
and  control  cell  lines  following  H-Ras
V12  expression  or  infection  with  empty  vector  control 
retrovirus (pWZL). Cells were seeded at a density of 10,000 cells per well and grown for 12 days. 
Positive control (MSC 5) and negative control (MSC 4) cells were grown in parallel (data not 
shown). Phase contrast and GFP images are depicted at 40x magnification. (d) Quantification of 
soft agarose colony numbers using SynGene GeneTools. Student’s T-test was performed for all 
statistical analyses. * p < 0.05, wrt. NS shRNA + H-Ras. Columns display average of three 
replicates; Error bars display SEM.  
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5.4    Discussion 
The  PRC2  complex  is  an  epigenetic  silencing  complex  essential  for  the 
maintenance of embryonic stem cell pluripotency through repression of genes 
involved in differentiation (Boyer et al., 2006). Furthermore, this complex has 
been shown to play an important role in the development of cancer (Sparmann 
and van Lohuizen, 2006). PRC2 components are up-regulated in a variety of 
cancers, along with a characteristic epigenetic ‘signature’ of target gene silencing 
(Widschwendter et al., 2007). Although the importance of PRC2 over-expression 
in cancer has been well established, no investigation has addressed the role of 
this complex during transformation. The aims of this chapter were to further 
characterize changes in the expression and activity of PRC2 components during 
step-wise transformation and to establish whether transformation of MSC could 
take place in the absence of PRC2 over-expression. 
  Initial investigation of EZH2, EED and SUZ12 mRNA and protein levels 
indicated up-regulation of all three components during step-wise transformation. 
This finding is consistent with previous studies of PRC2 expression, which have 
shown  increased  expression  of  EZH2  and  SUZ12  in  a  variety  of  cancers 
(Sparmann and van Lohuizen, 2006). Furthermore, my data are consistent with 
previous  models  of  EZH2  regulation.  For  example,  EZH2  and  SUZ12  have 
previously been shown to be targets of the E2F transcription factor (Bracken et 
al., 2003; Weinmann et al., 2001). In line with this, there are significant increases 
in both EZH2 and SUZ12 mRNA levels when pRB activity is inhibited at MSC 
2E7, leading to the release of E2F. However, although c-MYC has been shown 
to  increase  EZH2  expression  by  way  of  miR-26a  ,  no  significant  increase  in 
EZH2 mRNA is evident following the stabilization of c-MYC in MSC 4 .    224 
  A number of analyses were conducted in order to establish whether the 
increased  expression  of  PRC2  components  lead  to  functional  changes  in  this 
model. Since PRC2 primarily acts to create the H3K27me3 histone modification, 
levels of this mark would be expected to increase in line with elevated PRC2 
expression  during  transformation.  Western  blot  analysis  indicated  changes  in 
genome-wide levels of H3K27me3 during step-wise transformation. However, 
when these changes were corrected for alterations in the amount of total histone 
H3, a downward trend was evident, suggesting that H3K27me3 levels declined in 
the latter stages of step-wise transformation. This trend was also observed in the 
gene  specific  analysis  of  H3K27me3  levels  by  ChIP,  which  indicated  lower 
levels  of  the  modified  histone  at  PRC2  target  gene  promoters  in  MSC  5 
compared  to  MSC  0.  Although  no  other  studies  have  investigated  global 
H3K27me3  levels  during  carcinogenesis  in  this  way,  altered  EZH2  substrate 
specificity has been reported in cancer (Kuzmichev et al., 2004). EZH2 can form 
alternate PRC3 and PRC4 complexes with different EED isoforms, which act to 
methylate H1K26 rather than H3K27 (Kuzmichev et al., 2004). It is possible, 
therefore,  that  altered  EZH2  substrate  specificity  in  MSC  5  results  in  lower 
genome-wide levels of H3K27me3.  
Altered PRC2 target gene preference in different cell types has also been 
suggested  by  a  study  of  SUZ12  occupancy  in  a  variety  of  normal  and 
transformed human and mouse cell lines by ChIP-chip (Squazzo et al., 2006). 
Results from this investigation indicated that SUZ12 binding preference differed 
between tissues derived from embryonic or adult cells. However, a comparison 
of normal and transformed human cells was not conducted in this study, making 
it difficult to determine whether a similar shift in target gene preference occurs   225 
during  transformation.  It  is  possible,  therefore,  that  altered  PRC2  target 
preference may contribute to the decline in H3K27me3 levels at PRC2 target 
genes between MSC 0 and MSC 5.  
As another measure of PRC2 function, target gene expression profiles 
were analysed to determine whether repression of these genes occurred during 
step-wise transformation of MSC. GSEA indicated significant down-regulation 
of PRC2 targets in MSC 4 compared to MSC 0. Reduced expression of PRC2 
target  genes  in  cancer  has  also  been  suggested  by  ChIP-chip  experiments  in 
mouse  F9  teratocarcinoma  cells,  indicating  an  inverse  correlation  between 
SUZ12 and RNA polymerase II occupancy at gene promoters (Squazzo et al., 
2006).  
To determine the mechanistic basis of this gene silencing, H3K27me3 
and DNA methylation levels at PRC2 target gene promoters were analysed by 
ChIP  and  pyrosequencing  respectively.  These  results  showed  that  two  PRC2 
target genes – DKK2 and EN1 – were enriched for H3K27me3 in MSC 0 and 
MSC 5 compared to the non-PRC2 target gene DCN. However, levels of this 
modified histone at the promoter regions of these genes decreased between MSC 
0  and  MSC  5.  Furthermore,  HOXB3  – a   well  described  target  of  the  PRC2 
complex  in  embryonic  stem  cells  -  did  not  show  significant  H3K27me3 
enrichment. Expression of this gene also showed no decline during step-wise 
transformation, suggesting that it may not be targeted by the PRC2 complex in 
this cell type.  
Methylation  patterns  at  PRC2  target  gene  promoters  also  varied 
significantly.  DKK2  and  TBX2  showed  minimal  promoter  methylation  at  all 
stages  of  step-wise  transformation,  whereas  EN1  and  RBP4  displayed   226 
hypermethylation in some MSC cell lines, most notably MSC 4. However, the 
four promoter regions assayed in this study did not display hypermethylation in 
MSC 5 compared to MSC 0, contrary to previous reports of PRC2 target gene 
hypermethylation  in  cancer  (Ohm  et  al.,  2007;  Schlesinger  et  al.,  2007; 
Widschwendter  et  al.,  2007).  These  data  indicated  that  hypermethylation  of 
PRC2 target gene promoters is not always necessary for down-regulation of gene 
expression  during  transformation  of  MSC.  However,  it  is  possible  that  these 
genes  remain  silenced  in  MSC  5  through  mechanisms  other  than  DNA 
hypermethylation, such as repressive chromatin states. Furthermore, the genetic 
hits utilized in this model may have introduced a degree of redundancy, leading 
to gene silencing through other mechanisms and replacing the requirement for 
continued repression by PRC2.  
Whether gene silencing and DNA hypermethylation could be maintained 
in the absence of PRC2 over-expression was also investigated as part of this 
chapter. These results indicated that EZH2 and SUZ12 knockdown in MSC 4 
could  relieve  repression  of  PRC2  target  genes  with  minimal  promoter 
methylation  -  including  DKK2  and  TBX2  -  although  hypermethylated  target 
genes ( EN1  and  RBP4)  remained  silenced.  Furthermore,  methylation  at  the 
promoter regions of all PRC2 target genes was unaffected by EZH2 or SUZ12 
knockdown. These results indicated that promoter hypermethylation and gene 
silencing could be maintained in the absence of PRC2 over-expression.  
The relationship between PRC2 activity and DNA hypermethylation in 
cancer has been widely debated and remains the subject of current investigation. 
Two major models of this relationship have arisen from the findings in this field. 
On  the  one  hand,  it  is  hypothesized  PRC2  activity  marks  target  genes  with   227 
H3K27me3, leading to subsequent DNA hypermethylation and gene silencing 
(Vire  et  al.,  2006).  According  to  this  model,  reduced  PRC2  activity  –  for 
example, by EZH2 knockdown – would lead to a concurrent reduction in the 
levels of H3K27me3 and DNA methylation at target gene promoters, resulting in 
re-activation  of  gene  expression.  The  alternative  model  stipulates  that 
H3K27me3 and DNA hypermethylation are independent mechanisms of gene 
silencing (Kondo et al., 2008). EZH2 knockdown would therefore only reverse 
silencing  of  genes  repressed  by  H3K27me3  and  not  affect  the  expression  of 
hypermethylated genes. The data presented in this chapter support the second 
model.  
Several  previous  reports  have  noted  a  ‘stem  cell  like’  signature  of 
hypermethylation  at  PRC2  target  genes,  suggesting  that  this  aberrant  DNA 
hypermethylation is directed by H3K27me3 early during transformation (Ohm et 
al., 2007; Schlesinger et al., 2007; Widschwendter et al., 2007). These findings 
are supported by a study of EZH2 depletion and PRC2 target gene expression in 
U20S osteosarcoma cells (Vire et al., 2006). Following EZH2 knockdown, ChIP 
analysis of the MYT1 and WNT1 promoter regions showed reduced levels of 
H3K27me3, DNMT1 and DNA methylation at these loci. Additionally, these 
changes lead to increased expression of the previously silenced genes (Vire et al., 
2006).  These  findings  strongly  support  the  notion  that  EZH2  activity  and 
H3K27me3 can direct DNA methylation and subsequent gene silencing, as well 
as suggesting a direct interaction between EZH2 and DNMT1. In addition, these 
results suggest that continued EZH2 expression is necessary to maintain gene 
silencing.    228 
The  requirement  of  PRC2  activity  for  the  maintenance  of  target  gene 
silencing in cancer has also been addressed through the use of dominant negative 
versions of histone H3 (Abbosh et al., 2006). Transgenic H3-K27R – containing 
a lysine to arginine mutation, preventing methylation at this residue – expression 
in CP70 ovarian cancer cells resulted in both genome-wide and gene specific 
hypomethylation  alongside  re-expression  of  genes  previously  silenced  by 
H3K27me3 (Abbosh et al., 2006). However, another study suggested that DNA 
hypermethylation can remain in the absence of EZH2 expression (McGarvey et 
al.,  2007).  Following  EZH2  knockdown  in  U20S  and  RKO  cancer  cells,  the 
authors  observed  a  genome-wide  reduction  in  H3K27me3  levels.  This 
knockdown  had  opposing  effects  on  the  expression  of  PRC2  target  genes 
previously shown to display EZH2 dependent silencing in cancer (hMLH, MYT, 
WNT1  and  p16
INK4A).  The  results  indicated  that  basally  expressed  genes 
containing  minimal  DNA  methylation  showed  elevated  expression  following 
EZH2 knockdown. Conversely, densely hypermethylated promoters retained this 
methylation  signature  and  remained  silenced  in  the  knockdown  cells.  These 
findings suggest that DNA methylation and resultant gene silencing can remain 
in the absence of EZH2 over-expression in cancer cells (McGarvey et al., 2007).  
The link between H3K27me3 and DNA hypermethylation in cancer has 
also been questioned by a study of chromatin modification and DNA methylation 
patterns in prostate cancer cells (Kondo et al., 2008). Analysis of genome wide 
H3K27me3  levels  in  PC3  cells  by  ChIP-chip  identified  5%  of  promoters 
enriched for this modified histone. These promoters were specifically silenced in 
cancer and generally showed low promoter methylation levels whereas classical 
targets of DNA hypermethylation in cancer - such as RASSF1 and CDKN2A  -   229 
showed no H3K27me3 enrichment.  Furthermore, silencing of H3K27me3 target 
genes  could  be  reversed  by  EZH2  knockdown  or  treatment  with  the  HDAC 
inhibitor TSA in the absence of DNA demethylation. Conversely, expression of 
genes displaying promoter hypermethyation could be activated by treatment with 
the  demethylating  agent  5-aza-deoxycytidine,  but  not  following  EZH2 
knockdown or TSA treatment. Finally, transfection of RAR 2, a gene normally 
silenced by H3K27me3, into PC3 and SW480 cells resulted in rapid and stable 
gene silencing associated with H3K27me3 but not DNA hypermethylation. The 
authors suggested that H3K27me3 mediated gene silencing is important for the 
repression of tumour suppressor genes in cancer, but that it is mechanistically 
distinct from gene silencing by DNA hypermethylation.  
My  analyses  of  H3K27me3  and  DNA  methylation  levels  in  the  MSC 
model are consistent with these findings, suggesting that the two mechanisms of 
gene silencing in cancer are independent. PRC2 target genes are enriched for 
H3K27me3  and  show  down-regulation  of  expression  during  step-wise 
transformation both in the presence and absence of promoter hypermethylation. 
Furthermore,  target  genes  displaying  hypermethylation  do  not  retain  this 
signature in MSC 5, despite continued silencing and H3K27me3 occupancy. In 
these cases, loss of promoter hypermethylation between MSC 4 and MSC 5 may 
be a result of the genome-wide hypomethylation observed in transformed MSC. 
Finally,  EZH2  knockdown  relieved  repression  of  unmethylated  PRC2  target 
genes but did not affect DNA methylation levels at any of the promoter regions 
assayed. These findings suggest that PRC2 plays an important role in directing 
gene  silencing  from  the  earliest  stages  of  step-wise  transformation,  but  this 
silencing can take place without promoter DNA hypermethylation.    230 
In the MSC model, PRC2 target genes show H3K27me3 enrichment from 
the earliest stage, in normal parental MSC. The observed decrease in H3K27me3 
levels  between  these  cells  and  transformed  MSC  5  is  contrary  to  previous 
comparisons of normal cells and their transformed equivalents. For example, a 
comparison  of  H3K27me3  levels  between  normal  peripheral  blood  cells  and 
cultured prostate epithelial cells to prostate cancer cells only noted H3K27me3 
enrichment  and  gene  silencing  in  the  cancer  cells  (Kondo  et  al.,  2008). 
Differences in the epigenetic profile of normal stem cells and differentiated cells 
may  therefore  affect  the  role  and  requirement  of  PRC2  up-regulation  during 
transformation. In other words, stem cells may not require PRC2 up-regulation 
for transformation to take place because they already possess a permissive ‘stem 
cell like’ epigenetic state.  
Several  previous  studies  have  shown  elevated  expression  of  PRC2 
components  in  a  variety  of  cancers  and  shown  that  EZH2,  the  key  catalytic 
component  of  the  complex,  has  properties  characteristic  of  an  oncogene 
(Sparmann  and  van  Lohuizen,  2006).  EZH2  depletion  by  siRNA  in  prostate 
cancer and multiple myeloma cells has been shown to inhibit cell proliferation in 
vitro (Croonquist and Van, 2005; Varambally et al., 2002). Furthermore, EZH2 
over-expression  induces  growth  factor  independence  in  multiple  myeloma  as 
well  as  anchorage  independent  growth  and  invasion  of  immortalized  human 
mammary  epithelial  cells  (Croonquist  and  Van,  2005;  Kleer  et  al.,  2003). 
Although  this  suggests  that  PRC2  components  play  an  important  role  in 
malignant  cells,  it  is  not  known  whether  over-expression  of  this  complex  is 
required during the transformation process. My results indicate that knockdown 
of EZH2 and SUZ12 in MSC 4 cells does not prevent subsequent transformation   231 
of these cells with the addition of H-Ras
V12, suggesting that transformation of 
MSC can take place in the absence of PRC2 over-expression and that EZH2 does 
not necessarily act as an oncogene in this model.  
  In  conclusion,  this  study  is  the  first  to  investigate  changes  in  PRC2 
expression and activity during step-wise transformation. My results showed a 
significant and specific increase in EZH2, SUZ12 and EED mRNA expression 
between parental and transformed MSC, with EZH2 and SUZ12 protein levels 
also increasing. GSEA indicated a functional output of this over-expression, with 
down-regulation of PRC2 target gene expression between MSC 0 and MSC 4. 
ChIP analysis of selected target genes indicated that H3K27me3 is present at 
these genes in MSC 0, but that levels decreased during step-wise transformation. 
Methylation  analysis  of  these  genes  demonstrated  that  although  some  show 
hypermethylation during transformation, none retain this methylation signature 
in MSC 5, contrary to previous reports of PRC2 target gene hypermethylation in 
cancer.  Finally, stable knockdown of EZH2 in MSC 4 reversed repression of 
unmethylated PRC2 target genes, though hypermethylated target genes remained 
unexpressed. Furthermore, the methylation status of target gene promoters did 
not  change  following  EZH2  knockdown  in  MSC  4,  suggesting  that  PRC2 
mediated gene repression is independent of promoter hypermethylation. Finally, 
both EZH2 and SUZ12 knockdown cells could be transformed following over-
expression of oncogenic H-Ras
V12, suggesting that PRC2 does not function as an 
oncogene in this model. These findings suggest that PRC2 plays an important 
early role in transformation and that target gene silencing by H3K27me3 and 
DNA hypermethylation may be independent events during transformation.  
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Chapter 6:  Conclusions  
 
Hallmark  epigenetic  changes,  including  genome-wide  hypomethylation,  gene 
specific hypermethylation and characteristic chromatin modifications, have been 
well documented in cancer (Esteller, 2006; Feinberg and Tycko, 2004; Fraga et 
al., 2005; Herman and Baylin, 2003; Jones and Baylin, 2002). Although these 
changes have been noted in many comparisons of normal and malignant cells, 
relatively little is known about the importance or timing of epigenetic changes 
during  the  transformation  process.  The  overall  aim  of  this  thesis  was  to 
investigate  these  epigenetic  changes  in  a  genetic  step-wise  model  of 
transformation  in  mesenchymal  stem  cells.  This  study  is  the  first  to  show 
changes in genome-wide methylation levels during step-wise transformation and 
to show that this hypomethylation is induced by the expression of oncogenic H-
Ras
V12. Although hypomethylation was observed in the MSC model, this change 
was  not  required  for  transformation  to  take  place.  As  well  as  genome-wide 
hypomethylation,  other  hallmark  epigenetic  changes  including  gene  specific 
hypermethylation and characteristic histone modifications have been shown to 
occur in transformed cells. In order to investigate the mechanisms governing 
these changes in the MSC model, the role of the epigenetic silencing complex 
PRC2 during step-wise transformation was investigated. My study has shown 
that  up-regulation  of  PRC2  expression  takes  place  during  step-wise 
transformation along with repression of PRC2 target genes. Down-regulation of 
target  gene  expression  can  take  place  both  with  or  without  DNA   233 
hypermethylation,  suggesting  that  these  silencing  mechanisms  may  act 
independently.  
 
6.1    Relevance of the MSC Model 
Many  studies  of  cancer  consider  differences  between  normal  and  fully 
transformed tissues and are therefore unable to distinguish between early and late 
changes  during  transformation  or  determine  the  relationships  between  these 
changes. The MSC model was originally developed to study the events occurring 
during transformation in a controlled manner. As well as including a series of 
genetic  hits  reflecting  typical genetic aberrations  that  occur  during  neoplastic 
development,  this  model  also  displays  several  characteristics  of  in  vivo 
transformation including up-regulation of anti-apoptotic pathways, up-regulation 
of  angiogenic  genes  and  down-regulation  of  MHC  class  I  and  II  molecules 
(Funes  et  al.,  2007).  Furthermore,  this  thesis  has  demonstrated  that  hallmark 
epigenetic changes commonly observed in cancer also take place in this model, 
suggesting  that  it  provides  a  relevant  and  accurate  representation  of 
transformation processes.  
Although  in  vitro  models  of  cancer  are  widely  used  in  research,  it  is 
important  to  recognize  the  differences  between  these  models  and  in  vivo 
transformation  processes.  First,  in  vitro  cancer  cell  line  cultures  have  proved 
valuable tools for the study of neoplastic development since these cells can be 
easily grown and manipulated, allowing numerous experiments to be conducted 
that would not otherwise be possible with primary tissue samples. However, in 
vitro  cell  culture  conditions  do  not  accurately  mimic  the  in  vivo  micro-  234 
environment,  and  may  therefore  affect  the  growth  and  behaviour  of  cultured 
cancer cells (van Staveren et al., 2009). Furthermore, it is possible that continued 
in vitro culture of cells may introduce epigenetic changes that would not arise 
during  in  vivo  growth.  For  example,  an  analysis  of  genome-wide  DNA 
methylation patterns in mesenchymal stromal cells demonstrated that although 
overall  methylation  patterns  were  maintained  during  long  term  cell  culture,  
highly  significant  differences  were  observed  at  specific  CpG  sites,  similar  to 
those observed during in vivo aging (Bork et al., 2010). This is an important 
consideration  when  interpreting  results  obtained  from  the  step-wise  model  of 
transformation in MSC, since later stages in the model have been cultured for a 
much greater length of time relative to parental MSC.  However, the stability of 
cellular phenotypes in the MSC model and reproducibility of results obtained in 
this  thesis  suggest  that  these  observations  are  a  result  of  the  genetic  hits 
introduced in this model rather than epigenetic changes arising from continued 
cell culture.  
Furthermore, the link between many epigenetic regulatory mechanisms 
and  cell  proliferation  must  be  considered  when  interpreting  results  from  this 
thesis in light of the difference in proliferative rate between the MSC cell lines. 
In particular, cell cycle length will determine the proportion of cells in S-phase at 
any  given  time,  therefore  influencing  genome-wide  methylation  levels  in  an 
unsynchronized population of these cells. Additionally, changes in the expression 
of  E2F  responsive  may  account  for  some  of  the  observed  changes  in  gene 
expression during step-wise transformation, as demonstrated by differences in 
gene  expression  microarray  analysis  when  corrected  for  expression  of  the 
proliferation marker PCNA. The complex interaction between cell cycle length,   235 
gene  expression  and  DNA  methylation  levels  must  therefore  be  carefully 
considered when interpreting findings from this model and in the design of future 
experiments. 
  Although results from this thesis demonstrate that genetic aberrations can 
precede and induce epigenetic changes, this may not reflect the order in which 
these events occur during in vivo transformation. Several previous models have 
described the tumourigenic process through a series of genetic and epigenetic 
aberrations (Baylin and Ohm, 2006; Fearon and Vogelstein, 1990; Feinberg et 
al., 2006). Although the MSC model is similar to these in that it involves a 
sequential series of events necessary and sufficient to induce transformation, this 
model  differs  in  the  nature  and  order  of  these  changes.  Both  the  Baylin  and 
Vogelstein  models  include  epigenetic  changes  such  as  genome-wide 
hypomethylation  as  early  events  in  the  step-wise  transformation  process. 
Conversely, the MSC model is based on a series of genetic events that induce 
significant  epigenetic  changes  such  as  genome-wide  hypomethylation  and 
selected  PRC2  target  gene  silencing  in  the  later  stages  of  transformation.  It 
remains  possible  that  these  differences  are  reflective  of  the  varying 
transformation requirements in the development of carcinomas and sarcomas.  
Further differences between in vitro and in vivo transformation processes 
may arise from the choice of an adult stem cell as the starting point for this 
model.  The  cancer  stem  cell  hypothesis  stipulates  that  tumour-initiating  cells 
share many properties with normal stem cells (Reya et al., 2001; Visvader and 
Lindeman, 2008). It is believed that cancer stem cells arise from transformation 
events  affecting  normal  stem  cells,  or  that  fully  differentiated  cells  may  ‘de-
differentiate’ towards a more stem cell-like state through epigenetic alterations   236 
(Zilberman,  2007).  By  utilizing  MSC  as  the  starting  point  for  step-wise 
transformation, this model may not accurately reflect the importance of early 
epigenetic  ‘de-differentiation’  processes  in  neoplastic  development.  However, 
the cellular origin of cancer stem cells remains a subject of investigation and it is 
possible that transformation of both stem cells and differentiated cells takes place 
in vivo. 
  Despite  these  considerations,  this  step-wise  model  of  transformation 
remains a valuable and relevant tool for the investigation of changes occurring 
during the development of cancer. The validity of this model has been confirmed 
by  extensive  characterization  of  all  MSC  cell  lines,  demonstrating  expected 
downstream changes in gene expression on the introduction of each genetic hit. 
Furthermore, tumours formed by growth of MSC 5 cells in nude mice show gene 
expression patterns that cluster with the expression profiles of primary human 
spindle  cell  sarcoma,  indicating  that  the  in  vitro  transformed  MSC  are  very 
similar  to  in  vivo  transformed  from  the  same  lineage  (Funes  et  al.,  2007). 
Furthermore, this model is particularly powerful for studies of the transformation 
process since a completely matched normal cell control can be compared to the 
transformed equivalent. Results obtained from this model therefore have direct 
relevance to cancer and can offer novel insight into carcinogenesis. This thesis 
demonstrates that epigenetic changes occur during step-wise transformation, and 
that there is a complex interplay between genetic and epigenetic changes during 
transformation.  Furthermore,  it  suggests  that  hallmark  epigenetic  changes 
observed in vitro can arise from the step-wise genetic hits utilized in the MSC 
model.  
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6.2  Genome-wide Hypomethylation   
Although genome-wide hypomethylation is one of the most widely documented 
epigenetic  changes  in  cancer,  little  is  known  about  the  cause  of  this  loss  of 
methylation. In this study, I aimed to investigate whether this epigenetic change 
occurs during step-wise transformation of MSC, and to identify the step at which 
this loss of methylation takes place.  
The correlation between repetitive element methylation and genome-wide 
methylation  levels  has  been  well  documented,  with  these  sequences  often 
displaying  hypomethylation  in  cancer  (Ehrlich,  2002b;  Weisenberger  et  al., 
2005). Analysis of repetitive element methylation using the qPCR based method 
MethyLight  was  therefore  conducted  to  provide  a  measure  of  genome-wide 
methylation in the MSC model. This method was chosen as it is high throughput, 
well optimized and can be performed with small amounts of DNA. Comparison 
of Alu, Sat2 and LINE1 methylation levels as measured by MethyLight between 
parental and transformed MSC and HF revealed a significant decline in Sat2 and 
LINE1 methylation in MSC 5, occurring at the introduction of H-Ras in the final 
oncogenic  step.  Hypomethylation  of  these  elements  was  not  observed  in  a 
parallel step-wise model of transformation in HF. The MethyLight data were 
confirmed by bisulphite sequencing, indicating significant loss of methylation at 
specific  sites  within  the  Sat2  element.  This  study  is  the  first  to  definitively 
address the timing of genome-wide hypomethylation during transformation and 
to  demonstrate  repetitive  element  hypomethylation  following  H-Ras
V12 
expression.    238 
Although DNA hypomethylation in cancer has been shown to affect a 
wide variety of sequences throughout the genome, it is believed that much of the 
observed hypomethylation occurs at repetitive elements, which together account 
for ~45% of the genome (Ehrlich, 2002b; Gama-Sosa et al., 1983c; Weisenberger 
et al., 2005). Results obtained from the MSC model are consistent with these 
findings,  indicating  a  significant  loss  of  methylation  at  the  Sat2  and  LINE1 
repetitive elements in MSC 5, suggesting that transformed MSC display genome-
wide  hypomethylation.  Although  I  attempted  to  measure  genome-wide 
methylation levels in these cells with a novel FACS based approach, this method 
did not indicate a significant difference in methylation between MSC 4 and MSC 
5. Further investigation by nuclease digestion of total nuclear DNA followed by 
HPLC  analysis  is  required  to  quantitatively  determine  whether  genome-wide 
methylation levels are significantly lower in MSC 5 compared to the other MSC 
cell  lines.  Nonetheless,  the  FACS  method  remains  a  valuable  tool  for  future 
studies of genome-wide hypomethylation, and provides an attractive alternative 
to  HPLC  for  quantitative  analysis  of  genomic  methylcytosine  content.  This 
method has several advantages over the available alternatives in that it can be 
used on a very small number of cells and provides methylation data at a single 
cell resolution. Additionally, the method could be used in conjunction with co-
staining for other markers of interest to investigate correlations between marker 
expression and genome-wide methylation levels. 
A number of previous studies have linked Ras signaling to changes in 
DNA methylation. Ras mediated hypermethylation of FAS, MMP2, DNMT1 and 
clusterin has been observed in a variety of transformed cells (Gazin et al., 2007; 
Lund et al., 2006; MacLeod et al., 1995). Furthermore, v-Ha-Ras overexpression   239 
has been demonstrated to induce a demethylase activity in mouse embryonal P19 
cells,  leading  to  demethylation  of  endogenous  and  exogenous  methylated 
sequences  (Szyf  et  al.,  1995).  My  findings  are  consistent  with  these  studies, 
indicating that H-Ras signaling plays an important role in the regulation of DNA 
methylation  patterning,  and  can  induce  genome-wide  hypomethylation  in 
transformed human cells.  
This investigation of genome-wide methylation has also provided insight 
into the timing of this epigenetic change during transformation. Genome-wide 
hypomethylation  has  traditionally  been  viewed  as  an  early  event  in 
carcinogenesis, and has been included as such in many well established models 
of  transformation  (Fearon  and  Vogelstein,  1990;  Feinberg  et  al.,  2006).  This 
view is supported by the observation of genome-wide hypomethylation in benign 
neoplasms and normal tissues adjacent to tumours (Feinberg et al., 2006; Goelz 
et al., 1985; Suter et al., 2004). My results suggest the opposite, indicating that 
genome-wide  hypomethylation  can  occur  at  the  final  stages  during  step-wise 
transformation.  This  observation  concurs  with  several  other  studies  which 
demonstrate  genome-wide  hypomethylation  as  a  late  event  during  cancer 
progression (Ehrlich et al., 2006; Gama-Sosa et al., 1983a; Yegnasubramanian et 
al., 2008). However, by using a series of genetic hits to model events during 
transformation, this system may not accurately reflect the importance of early 
epigenetic changes such as hypomethylation during in vivo transformation. 
The  relationship  between  genetic  and  epigenetic  aberrations  during 
transformation  has  also  been  widely  studied.  Both  genetic  and  epigenetic 
changes  can  lead  to  the  activation  of  oncogenes  and  silencing  of  tumour 
suppressor  genes,  acting  concurrently  to  contribute  towards  transformation   240 
(Esteller,  2006;  Feinberg  and  Tycko,  2004;  Jones  and  Baylin,  2002).    For 
example,  simultaneous  genetic  and  epigenetic  disruptions  to  DNA  repair  and 
Wnt  signaling  pathways  contribute  towards  the  transformed  phenotype  of 
HCT116 colon cancer cells (Herman et al., 1998; Morin et al., 1997; Suzuki et 
al., 2004). However, the order in which these two types of disruption take place 
remains unclear. It has been suggested that early epigenetic changes may lead to 
subsequent genetic abnormalities in one of two ways – either through epigenetic 
disruption of pathways involved in DNA repair leading to an elevated mutation 
rate,  or  through  early  oncogene  addiction  that  is  subsequently  maintained 
through  genetic  changes  (Baylin  and  Ohm,  2006).  In  support  of  this  first 
hypothesis,  epigenetic  inactivation  of  MGMT  and  hMLH1  can  lead  to  the 
accumulation  of  specific  mutations  through  ineffective  DNA  repair,  and 
silencing of CDKN2A may allow breast epithelial cells to escape senescence and 
accumulate genetic abnormalities (Esteller et al., 1999; Kane et al., 1997; Kiyono 
et al., 1998; Romanov et al., 2001). 
The second hypothesis is based on oncogene addiction – the notion that 
transformed  cells  become  dependent  on  abnormal  oncogene  products  or 
activation of specific pathways (Weinstein, 2002). Although originally applied to 
aberrant genetic changes in cancer, it is becoming clear that early epigenetic 
disruptions  may  also  lead  pre-malignant  cells  to  become  dependent  on 
dysfunctional pathways. This could predispose these cells to additional genetic 
alterations in the same pathways, further increasing the dependence of such cells 
on these abnormalities. For example, aberrant activation of the Wnt signaling 
pathway through APC mutation is known to play an important role in the early 
progression of colorectal cancer, with restoration of APC function in cultured   241 
colon  cancer  cells  resulting  in  apoptosis  (Gregorieff  and  Clevers,  2005; 
Weinstein,  2002).  This  signaling  pathway  can  also  be  activated  during  early 
stages of the transformation process through epigenetic changes in the absence of 
genetic  mutations.  The  promoters  of  SFRP  gene  family  members,  which 
normally  act  to  antagonize Wnt  signaling,  have  been  shown  to  be  aberrantly 
methylated  and  silenced  in  pre-invasive  colon  lesions  (Suzuki  et  al.,  2004; 
Taketo, 2004). Epigenetic activation of the Wnt signaling pathway is essential 
for  continued  growth  of  HCT116  colon  cancer  cells,  with  DNMT  deletion 
causing  loss  of  methylation  and  re-activation  of  SFRP  expression,  leading  to 
reduced  Wnt  signaling  and  subsequent  cellular  apoptosis  (Baylin  and  Ohm, 
2006). Epigenetic mechanisms may therefore play an important role in the early 
expansion  of  pre-malignant  cells,  which  accumulate  further  genetic  and 
epigenetic changes leading to transformation. 
Although these examples demonstrate that early epigenetic disruptions 
can  lead  to  oncogene  addiction  and  subsequent  genetic  changes  in  similar 
pathways, my results suggest the opposite. In the MSC model, genetic hits lead 
to  subsequent  epigenetic  changes,  which  together  contribute  towards  the 
transformation  process.  This  suggests  that  genetic  changes  can  precede  and 
induce epigenetic changes, and that the order of these events may be flexible for 
transformation to occur. However, as noted earlier, the nature of our MSC model 
may  not  accurately  reflect  the  order  of  events  during  in  vivo  transformation, 
where epigenetic changes may play a more important role in the early expansion 
of cells.  
Further characterization of the MSC cell lines is necessary to determine 
the consequences of repetitive element hypomethylation in this model. Aberrant   242 
transcription  of  repetitive  elements,  one  potential  effect  of  hypomethylation, 
could be investigated by qRT-PCR (Kochanek et al., 1995; Yoder et al., 1997). 
Similarly,  active  transposition  of  LINE1  elements  may  occur  following 
hypomethylation, and could be monitored by analysis of repetitive element copy 
number by quantitative PCR (Coufal et al., 2009). Finally, repetitive element 
hypomethylation  may  lead  to  increased  recombination  events  between  these 
areas  of  high  sequence  similarity,  causing  karyotypic  instability  (Chen  et  al., 
1998; Chen et al., 2007; Hsieh and Lieber, 1992). For example, characteristic 
karyotypic changes following Sat2 hypomethylation have been observed in ICF 
syndrome (Ehrlich, 2002a; Tuck-Muller et al., 2000). Although my results show 
severe  karyotypic  abnormalities  in  the  MSC  5  population,  without  further 
karyotypic analysis of the other MSC cell lines, it is not possible to establish 
whether the chromosomal changes observed in MSC 5 are the result of DNA 
hypomethylation. Additional karyotypic analysis following the time course of H-
Ras induced hypomethylation will also be required to test whether these changes 
are  caused  by  loss  of  repetitive  element  methylation  during  step-wise 
transformation of MSC.  
This study is the first to investigate epigenetic changes during step-wise 
transformation of MSC with a defined series of genetic hits. My results indicate 
that repetitive element hypomethylation can be induced in this system, and that 
this  loss  of  methylation  occurs  after  the  expression  of  H-Ras
V12  in  the  final 
oncogenic  hit.  This  indicates  that  in  the  MSC  model,  genome-wide 
hypomethylation  is  a  late  event  during  transformation  and  demonstrates  that 
genetic changes can precede and induce epigenetic changes. 
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6.3    Conditional Expression of ER
TM-H-Ras
V12 
To gain further insight into the potential mechanism of hypomethylation, I aimed 
to investigate the time course of this loss of methylation following H-Ras
V12 
expression. A conditional H-Ras
V12 system, based on a fusion protein comprising 
H-Ras
V12 and a mutated estrogen receptor domain, ER
TM, was utilized for this 
investigation. The system was extensively characterized and shown to transform 
cells when H-Ras
V12 expression was induced with 4-OHT. However, analysis of 
repetitive element methylation following induced H-Ras
V12 expression failed to 
detect hypomethylation when cells were grown in the presence of 4-OHT for one 
month.  
Expression of constitutive H-Ras
V12 in MSC 4 was repeated in order to 
determine whether repetitive element hypomethylation could be recapitulated in 
this  model.  Sat2  methylation  was  assessed  by  MethyLight  in  these  cells  one 
week post infection and following growth of the cell lines for one month. These 
data showed no change in repetitive element methylation after one week, but 
demonstrated Sat2 hypomethylation in H-Ras
V12 expressing cells one month after 
retroviral infection.  This indicates that loss of repetitive element methylation 
following  H-Ras
V12  expression  takes  place  gradually,  suggesting  a  passive 
mechanism of hypomethylation.  
The widespread incidence of genome wide hypomethylation in a range of 
cancers,  as  well  as  in  benign  neoplasms,  has  suggested  that  this  epigenetic 
change occurs early during the process of transformation (Feinberg et al., 2006). 
The  results  obtained  from  this  step-wise  model  of  transformation,  however, 
indicate that hypomethylation occurred only in fully transformed cells following   244 
the final oncogenic ‘hit’. Furthermore, the loss of methylation was only observed 
after  4  weeks  in  culture  following  transformation.  This  suggests  that 
hypomethylation occurred as a late event in step-wise transformation via slow 
passive loss of methylation. However, transformation in this model is induced by 
a series of genetic hits and may not fully recapitulate the true early epigenetic 
changes that occur during in vivo transformation as suggested by the epigenetic 
progenitor origin of cancer model (Feinberg et al., 2006). It is possible, therefore, 
that although genome-wide hypomethylation is a late event in this model, it may 
occur earlier during in vivo cancer progression as a prelude for further genetic 
and epigenetic changes.  
Using conditional expression of the fusion protein ER
TM-H-Ras, I was 
unable  to  recapitulate  the  loss  of  methylation  observed  with  the  constitutive 
expression  of  H-Ras.  Despite  the  lack  of  hypomethylation,  these  cells  were 
transformed  as  shown  by  their  ability  to  form  colonies  in  soft  agarose.  This 
suggested  that  genomic  hypomethylation  was  not  essential  for  in  vitro 
transformation of these cells. The potential causal link between genome-wide 
hypomethylation  and  transformation  has  been  investigated  in  a  number  of 
previous studies, with conflicting findings. Genome-wide loss of methylation in 
mice containing a hypomorphic allele of dnmt1 can result in transformation and 
increased incidence of soft tissue sarcomas, possibly through increased incidence 
of  karyotypic  changes  and  chromosomal  abnormalities  (Eden  et  al.,  2003). 
However, another mouse model of genome wide hypomethylation induced by 
dnmt1  knockdown  notes  opposing  effects  on  the  growth  of  different  tumour 
types (Yamada et al., 2005). Together, these reports show that genome wide 
hypomethylation can promote some instances of transformation but there is no   245 
definitive  demonstration  that  hypomethylation  is  a  strict  requirement  for 
transformation.  
The timing of genome wide hypomethylation during the development of 
cancer could also provide an indication of whether this change is causative of 
transformation. Many studies have suggested that global DNA hypomethylation 
is an early event in transformation, and can be observed in benign tumours or 
adjacent  normal  cells  (Feinberg  et  al.,  1988;  Goelz  et  al.,  1985;  Suter  et  al., 
2004). Global hypomethylation is also included as an event in various models of 
step-wise  transformation  in  colorectal  cancer  (Fearon  and  Vogelstein,  1990; 
Feinberg  et  al.,  2006).  The  consensus  from  these  studies  is  that  global 
hypomethylation in the adjacent normal tissue indicates this change is an early 
event in the transformation process, potentially leading to karyotypic instability 
and further oncogenic changes. However, several other investigations have failed 
to detect reduced global methylcytosine levels in benign neoplasms (Ehrlich et 
al., 2006; Gama-Sosa et al., 1983b). Indeed, many studies have also failed to 
observe early hypomethylation during malignant tumor progression (Florl et al., 
2004;  Yegnasubramanian  et  al.,  2008).  My  study  agrees  with  the  latter 
observation, suggesting that genomic hypomethylation is not an early oncogenic 
change and thus is unlikely to be a cause of transformation. 
The  reason  as  to  why  the  conditional  ER
TM-H-Ras  did  not  promote 
hypomethylation, when the constitutive H-Ras did, is not clear. Differences in 
the rate of methylation loss between the two vector systems may account for this 
effect. Alternatively, although the activity of the conditional ER
TM-H-Ras
V12 was 
extensively characterized, differences between this fusion protein and H-Ras
V12 
could  also  have  affected  the  process  of  hypomethylation.  Additional   246 
characterization of these two systems by gene expression microarray analysis 
may provide further insight into functional differences between the two versions 
of  H-Ras  and  the  mechanism  of  genomic  hypomethylation  during 
transformation. 
  Analysis of gene expression microarray data for a number of epigenetic 
regulators  and  metabolic  enzymes  involved  in  DNA  methylation  indicated 
numerous alterations to the expression of these genes but failed to conclusively 
indicate the cause of hypomethylation in MSC 5. Furthermore, different patterns 
gene  expression  are  evident  when  the  GEM  data  are  corrected  for  cell 
proliferation  rate  in  each  MSC  cell  line.  The  effect  of  cell  proliferation  on 
expression of epigenetic regulators should therefore be taken into account when 
designing further experiments in this model, with appropriate correction factored 
into the analysis of future data.  
The microarray data and qRT-PCR analysis of mRNA levels in the MSC 
cell  lines  did  demonstrate  up-regulation  of  GADD45A,  a  putative  DNA 
demethylase, between MSC 4 and MSC 5. Finally, this analysis also suggested 
that  the  metabolic  pathways  surrounding  S-adenosylmethionine  (SAM) 
production were deregulated in MSC 5. Together, these data indicate that during 
step-wise  transformation,  there  are  changes  to  the  expression  of  enzymes 
involved in the regulation of DNA methylation, potentially leading to disruption 
of normal DNA methylation processes. However, no change in expression that 
would  individually  account  for  genome-wide  hypomethylation  in  MSC  5  is 
evident.    247 
Both elevated and reduced DNMT expression has been noted in previous 
studies of cancer and so far no clear link between altered expression of these 
enzymes and incidence of genome-wide hypomethylation has emerged (Ehrlich 
et  al.,  2006;  Li  et  al.,  2003).  Although  DNMT1  mRNA  expression  does  not 
increase during step-wise transformation when GEM data are corrected for cell 
proliferation, analysis of methyltransferase activity in the MSC cell lines will be 
necessary to determine whether the activity of this class of enzymes is altered 
during transformation. Similarly, the up-regulation of GADD45A expression at 
this stage suggests an attractive hypothesis of active demethylation taking place 
in MSC 5. However, the involvement of this enzyme in demethylation remains 
controversial, and a link between increased GADD45A expression and genome-
wide hypomethylation in cancer has not been previously shown (Barreto et al., 
2007; Jin et al., 2008; Rai et al., 2008). This could be tested through GADD45A 
knockdown  studies  in  MSC  4  or  MSC  5  followed  by  analysis  of  Sat2 
methylation levels. In vitro demethylation assays will also be necessary to show 
that this enzyme promotes active demethylation in human cells.  
Deregulated  methionine  metabolism  and  S-adenosylmethionine  (SAM) 
biosynthesis has also been suggested to play an important role in transformation 
(Laird and Jaenisch, 1996; Szyf et al., 2004). Analysis of SAM levels during 
step-wise transformation would provide an indication of whether levels of this 
key substrate are limiting in MSC 5 (Wagner et al., 1984). Manipulation of the 
biochemical  pathways  surrounding  SAM  biosynthesis,  by  siRNA  or  drug 
treatment, would also be valuable in determining whether disruptions to these 
pathways can cause repetitive element hypomethylation in MSC .    248 
The mechanism by which H-Ras
V12 signaling induces these changes will 
also be an interesting subject of investigation. Downstream Ras signaling can 
occur  via  the  Raf,  PI3K  and  Ral-GEF  pathways,  with  activation  of  different 
combinations  of  these  pathways  required  for  transformation  in  different  cell 
types  (Rangarajan  et  al.,  2004).  The  involvement  of  a  particular  pathway  in 
repetitive  element  hypomethylation  could  be  studied  by  introducing  mutant 
versions of Ras, capable of only signaling through one downstream pathway, in 
different combinations into MSC 4 (Rangarajan et al., 2004).  Alternatively, drug 
treatment could be used to block individual pathways in MSC 5. Identification of 
the downstream signaling pathways responsible for the induction of repetitive 
element hypomethylation will provide valuable insight into the mechanism of 
this  loss  of  methylation.  Additionally,  differences  in  downstream  signaling 
between  the  constitutive  H-Ras
V12  and  conditional  ER
TM-H-Ras
V12  may  be 
responsible for the lack of hypomethylation when MSC are transformed using 
the conditional system. 
In  summary,  although  genome  wide  hypomethylation  has  traditionally 
been viewed as an early event in oncogenesis, there is ample evidence supporting 
both  this  view  and  the  alternative,  that  hypomethylation  can  occur  later  in 
transformation or not at all. Here, I show that hypomethylation can occur late 
during  step-wise  transformation,  although  it  was  not  a  necessary  event  for 
transformation  to  take  place.  Furthermore,  in  the  instance  where 
hypomethylation was observed, this was a late event in this step-wise genetic 
model,  occurring  subsequent  to  a  common  genetic  aberration  in  cancer.  In 
conclusion,  this  study  has  demonstrated  a  link  between  H-Ras  and 
hypomethylation of repetitive elements in a stepwise model of transformation in   249 
human  MSC.  This  model  provides  a  controlled  background  in  which  known 
genetic hits can be linked to observed epigenetic changes. My results provide a 
further  step  towards  elucidating  a  mechanistic  basis  for  genome  wide 
hypomethylation  in  cancer  and  a  valuable  model  for  establishing  the 
consequences of this change. 
 
 
6.4    The Role of PRC2 During Step-wise Transformation of MSC 
The final results chapter of this thesis aimed to address other hallmark epigenetic 
changes  in  cancer,  namely  gene  specific  hypermethylation  and  chromatin 
modifications.  The  expression  of  PRC2,  an  important  epigenetic  regulator 
complex, is known to be deregulated in a variety of cancers, leading to aberrant 
gene silencing. Gene expression microarray analysis indicated that all three core 
components  of  the  PRC2  complex  were  significantly  up-regulated  in  MSC  5 
compared to MSC 0. This suggested that deregulated activity of this complex 
could be an important event during step-wise transformation. I aimed to confirm 
this up-regulation and address potential downstream effects on PRC2 target gene 
expression, methylation and chromatin modification. 
Expression of EZH2, SUZ12 and EED mRNA and protein were assessed 
by qRT-PCR and western blot respectively in all MSC cell lines, confirming the 
up-regulation observed in the microarray analysis. These findings are consistent 
with numerous other studies of cancer, which show elevated expression of PRC2 
components  in  transformed  cells  (Sparmann  and  van  Lohuizen,  2006).   250 
Furthermore, the MSC model provides a valuable tool for further investigation of 
the  mechanisms  by  which  PRC2  up-regulation  occurs  during  transformation. 
Although  several  pathways,  including  E2F  and  MYC,  have  been  shown  to 
regulate EZH2, SUZ12 and EED expression, many of the genetic aberrations 
employed in this step-wise model of transformation also appear to cause up-
regulation of these genes (Bracken et al., 2003; Weinmann et al., 2001). For 
example,  data  from  this  model  suggest  that  hTERT  and  HPV  E6  expression 
(abrogating  the  activity  of  p53)  could  cause  up-regulation  of  EZH2.  Further 
investigation of these observations could uncover novel regulatory mechanisms 
for PRC2 component expression.  
Global levels of H3K27me3 in all MSC cell lines were also analysed by 
western blot, indicating a reduction in the relative levels of this modified histone 
in MSC 1, MSC 3, MSC 4 and MSC 5 compared to parental MSC. One possible 
explanation of this observation could be altered substrate specificity of EZH2 
when associated with different EED isoforms in transformed cells (Kuzmichev et 
al.,  2005).  A  shift  in  the  relative  levels  of  EED  isoforms  during  step-wise 
transformation may affect PRC2 specificity or activity, leading to a reduction in 
genome-wide levels of H3K27me3 in favour of H1K26 methylation. However, it 
is not possible to verify this hypothesis without further characterization of EED 
isoform levels and the substrate specificity of EZH2 containing complexes in this 
system.  
  PRC2 target gene expression during step-wise transformation was also 
investigated by GSEA. Gene expression microarray data for a comprehensive list 
of PRC2 target genes identified in ES cells were analysed, revealing significant 
down-regulation of this gene set in MSC 4 compared to MSC 0 and between   251 
MSC 4 compared to MSC 3 (Boyer et al., 2006). Gene expression microarray 
data for GSEA core genes confirmed this trend, as did qRT-PCR analysis of 
PRC2 target gene mRNA levels. These data suggest that PRC2 up-regulation has 
a  functional  effect  in  the  MSC  model,  leading  to  repression  of  target  genes 
during step-wise transformation. This is in line with previous reports of PRC2 
target gene repression in cancer (Squazzo et al., 2006).  
  PRC2 mediated down-regulation of target gene expression results from 
creation of the repressive H3K27me3 histone modification at gene promoters, 
and  may  also  be  caused  by  direct  interactions  between  this  complex  and 
DNMT1,  leading  to  promoter  DNA  hypermethylation  (Kirmizis  et  al.,  2004; 
Sparmann and van Lohuizen, 2006). Selective hypermethylation of PRC2 target 
genes in cancer has been noted in a number of studies, suggesting that PRC2 up-
regulation during transformation may contribute to the transformed phenotype 
through aberrant silencing of these genes (Ohm et al., 2007; Schlesinger et al., 
2007;  Widschwendter  et  al.,  2007).  This  hypothesis  is  supported  by  the 
identification  of  direct  interactions  between  EZH2  and  DNMT1  in  an 
investigation of osteosarcoma cells (Viré et al., 2006). However, other studies of 
EZH2  knockdown  have  questioned  the  link  between  H3K27me3  and  PRC2 
target gene hypermethylation in cancer, showing that DNA methylation and gene 
expression  levels  do  not  always  change  when  levels  of  this  key  epigenetic 
regulator are reduced (Kondo et al., 2008; McGarvey et al., 2007). 
  In order to investigate the mechanism by which PRC2 target genes are 
down-regulated in the MSC model, levels of H3K27me3 and DNA methylation 
at selected PRC2 target genes were analysed by chromatin immunoprecipitation 
(ChIP). This demonstrated that PRC2 target gene promoters were enriched for   252 
H3K27me3 compared to a non-PRC2 target gene control. However, levels of this 
histone modification declined significantly between MSC 0 and MSC 5 at the 
regions assayed. Investigation of DNA methylation levels at four PRC2 target 
genes also produced a number of interesting results. Although all these genes 
showed significantly reduced expression between MSC 0 and MSC4, only two 
displayed  any  degree  of  hypermethylation  during  step-wise  transformation. 
Furthermore, none of the genes assayed were hypermethylated in MSC 5. This 
suggests that silencing of PRC2 target genes during step-wise transformation can 
take place both with and without DNA hypermethylation. 
To  establish  whether  this  gene  silencing  could  be  maintained  in  the 
absence  of  PRC2  over-expression,  EZH2  and  SUZ12  were  knocked-down  in 
MSC 4. This cell line was chosen for the experiment since the most significant 
down-regulation of PRC2 target genes was observed at this stage of step-wise 
transformation.  Analysis  of  target  gene  expression  in  these  knock-down  cells 
indicated  up-regulation  of  DKK2  and  TBX2  following  EZH2  knockdown. 
However, DNA methylation levels at the PRC2 target genes assayed did not 
change significantly following knockdown. Together, down-regulation of PRC2 
target gene expression during step-wise transformation both with and without 
DNA hypermethylation alongside reversal of this silencing in the absence of any 
changes in promoter methylation suggest that H3K27me3 and DNA methylation 
are  independent  gene  silencing  mechanisms,  contrary  to  the  hypothesis  that 
H3K27me3 directs DNA methylation (Viré et al., 2006). 
   Finally,  the  transformation  potential  of  MSC  4  following  EZH2  or 
SUZ12 knock-down was addressed by overexpression of H-Ras
V12 in these cell 
lines. Both EZH2 and SUZ12 knockdown cells were transformed and produced   253 
GFP positive colonies in soft agarose, indicating continued expression of the 
shRNA  constructs.  These  data  showed  that  transformation  of  MSC  can  take 
place in the absence of EZH2 or SUZ12 over-expression and that these genes do 
not necessarily act as typical oncogenes in this model.  These results are contrary 
to previous reports of EZH2 acting as an oncogene in prostate and breast cancer 
cells (Croonquist and Van, 2005; Kleer et al., 2003; Varambally et al., 2002).  
Maintenance of PRC2 target gene silencing by continued DNA hypermethylation 
following  EZH2  knockdown  in  MSC  4  may  account  for  the  difference  in 
oncogenic potential of EZH2 in this model. Additionally, the genetic hits utilized 
in this step-wise model of transformation may contribute towards silencing of 
PRC2 target genes through alternative mechanisms, removing the requirement of 
epigenetic gene repression by PRC2 for transformation to take place.  
  Future work will involve further characterization of histone modifications 
at PRC2 target gene promoters by ChIP. Analysis of gene specific H3K27me3 
signatures in all MSC, and PRC2 knockdown cell lines would be valuable in 
confirming  the  continued  presence  of  this  mark  throughout  step-wise 
transformation. Additionally, the relationship between this histone modification 
and DNA methylation in this model could be further explored by treating cells 
with  demethylating  agents  or  inhibitors  of  HDAC  activity  and  observing  the 
consequences of these interventions on expression of PRC2 target genes. Finally, 
although the candidate gene approach adopted in this study has produced several 
interesting  results,  a  comprehensive  picture  of  genome-wide  changes  to 
H3K27me3 patterning during step-wise transformation can only be obtained by 
ChIP  followed  by  microarray  hybridization  (ChIP-chip)  or  high  throughput 
sequencing (ChIP-seq).   254 
  Down-regulation of PRC2 target gene expression was observed during 
step-wise  transformation  despite  reduced  levels  of  H3K27me3  at  gene 
promoters.  Other  histone  modifications  may  therefore  play  a  role  in  the 
regulation  of  PRC2  target  gene  expression  and  incidence  of  DNA 
hypermethylation in this model. H3K27me3 is one part, along with H3K4me3, of 
the ‘bivalent’ chromatin state present at many key developmental genes in stem 
cells (Bernstein et al., 2006). PRC2 target gene down-regulation may therefore 
result  from  loss  of  the  activating  H3K4me3  mark  rather  than  an  increase  in 
H3K27me3  enrichment.  On  this  basis,  analysis  of  H3K4me3  levels  at  PRC2 
target genes may provide additional insight into the mechanisms by which PRC2 
target genes are silenced during step-wise transformation, and how silencing of 
some genes can remain following EZH2 or SUZ12 knockdown.  
Several studies have also noted the importance of H3K9 acetylation and 
methylation  for  gene  repression  in  cancer  and  the  association  between  this 
histone modification and DNA methylation (Bachman et al., 2003; Kondo et al., 
2004). It is possible that the patterns of DNA methylation observed at PRC2 
target  genes  may  also  be  directed  by  this  histone  modification.  Further 
investigation of H3K9 acetylation and other histone modifications in the MSC 
model is essential in gaining a more comprehensive understanding of epigenetic 
gene regulation during step-wise transformation. 
  Further analysis of DNA methylation at PRC2 target genes would also be 
useful in elucidating the interaction between chromatin modifications and DNA 
methylation. Although a candidate gene approach was adopted in this study, the 
most useful insight into PRC2 target gene methylation would be profiling of all 
MSC  cell  lines  in  a  genome-wide  manner  by  methylated  DNA   255 
immunoprecipitation  (MeDIP)  (Weber  et  al.,  2005).  This  would  provide  an 
unparalleled overview of gene specific changes to DNA methylation during step-
wise transformation, and would allow correlations between DNA methylation 
and alterations in gene expression to be studied in more detail.  
Overall, this thesis has demonstrated that hallmark epigenetic changes 
occur  during  step-wise  transformation  of  MSC,  suggesting  a  model  in  which 
both genetic and epigenetic changes contribute towards transformation (Figure 
6.1). Analysis of genome-wide methylation levels by MethyLight indicated that 
hypomethylation  of  repetitive  element  occurs  on  expression  of  oncogenic  H-
Ras
V12 in MSC 5. Up-regulation of PRC2 also takes place during transformation, 
leading  to  target  gene  silencing  both  with  and  without  gene  specific 
hypermethylation. These studies show that cancer specific epigenetic changes 
occur  during  step-wise  transformation  and  suggest  that  tumour-associated 
epigenetic changes can follow the genetic aberrations introduced in this model. 
This model is valuable and relevant to further explore the mechanisms behind 
epigenetic alterations in cancer. 
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Figure 6.1: Hallmark epigenetic changes occur during step-wise transformation of MSC. 
MSC were transformed through the sequential addition of five genetic ‘hits’ (hTERT, HPV E6 
and E7, SV40 Small-T and H-Ras
V12). Studies of this model conducted as part of this thesis have 
indicated  that  hallmark  epigenetic  changes  also  take  place  during  step-wise  transformation, 
including genome-wide hypomethylation, increased PRC2 expression and specific silencing of 
PRC2 target genes.  
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Appendix 
 
Table A1: Literature review detailing studies of genome-wide hypomethylation in cancer  
 
Reference  Global /       
Gene 
Specific 
Genes / Repeats  Method  Normal Tissue  n=  Cancer  n=  Matched  Methylation  Comments 
(Kondo et al.)  Gene  HRAS, KRAS  HpaII/MspI/Southern  Adjacent 
normal tissue 
8  Colonic 
adenocarcinoma (7) 
and small cell lung 
carcinoma 
8  Yes  Decrease   
(Weber et al.)  Gene  GH1, CRYGA, 
CGA and HBG1 
Southern  Adjacent 
normal tissue 
23  Colon 
Benign,Carcinoma 
10,13  Yes  Decrease   
(Feinberg and 
Vogelstein) 
Global    HPLC  Adjacent 
normal colon 
mucosa 
12  Colon 
Adenoma,Carcinoma 
8,11  Yes  Decrease   
(Goelz et al.)  Global    MAA  Adjacent 
parenchyma 
117  Primary invasive 
carcinomas 
117  Yes  Decrease   
(Feinberg et al.)  Global    MAA  Adjacent 
parenchyma 
5  Benign phyllodes 
tumours 
5  Yes  Decrease   
(Soares et al.)  Global    MAA  Adjacent 
parenchyma 
11  Fibroadenomas  11  Yes  Decrease   
(Soares et al.)  Global    MAA  Adjacent 
parenchyma 
3  Sclerosing adenosis  3  Yes  Decrease   
(Soares et al.)  Gene  HERV-K  MspI/HpaII/Southern  Adjacent 
bladder 
13  Bladder; urothelial 
carcinoma  
13  Yes  Decrease   
(Soares et al.)  Repeats  DMHA-1  RLGS & Southern  Adjacent 
normal liver 
21  HCC HBV-  21  Yes  Decrease     283 
(Santourlidis et 
al.) 
Gene  IGF2  MspI/HpaII/Southern  Adjacent 
normal kidney 
11  Wilms tumour  11  Yes  Decrease   
(Nagai et al.)  Global    Me-C antibody IF  Adjacent tissue  13  Colon adenocarcinoma  13  Yes  Decrease  Intensity of staining 
decreased by 17-29% 
(Sullivan et al.)  Global    MAA  Adjacent 
normal liver 
17  HCC  17  Yes  Decrease  Correlated with grade 
and size of tumour. 
No benign changes. 
(Hernandez-
Blazquez et al.) 
Repeats  Sat2 & 3  MspI/HpaII/Southern  Adjacent 
normal tissue 
67  HCC  67  Yes  Decrease  Hypometh in 67% of 
HCC / 18% normal 
(Lin et al.)  Repeat  Sat2; D16Z3 
locus 
MspI/HpaII/BstBI/Southern  Adjacent 
normal breast 
39  Breast  39  Yes  Decrease  Correlation with type 
and grade  
(Saito et al.)  Repeat  Sat2; D1Z1 
locus 
BstBI/Southern  Adjacent 
normal breast 
33  Breast  33  Yes  Decrease   
(Tsuda et al.)  Gene  BRCA2  COBRA, BS  Adjacent 
normal tissue 
30  Sporadic epithelial 
ovarian carcinoma 
30  Yes  Decrease  Correlated with 
elevated mRNA 
(Tsuda et al.)  Global    MAA  Adjacent 
myometria 
23  Leiomyoma  23  Yes  Decrease  ~2.2 fold increase in 
methyl acceptance in 
leiomyoma. 
(Chan et al.)  Global    IHC  Adjacent 
myometria 
23  Leiomyoma  23  Yes  Decrease   
(Li et al.)  Gene  SFN, CLDN4, 
CLN2, TFF2, 
S100A4, MSLN, 
PSCA 
MSP  Adjacent 
normal tissue, 
microdissected 
8  Primary pancreatic 
carcinoma, 
microdissected 
8  Yes  Decrease  Frequent hypometh in 
all 7 genes (75-100% 
of cancers). Cells 
microdissected. 
(Li et al.)  Gene  Synuclein 
gamma 
BS  Adjacent 
normal tissue 
5  Breast cancer  5  Yes  Decrease   
(Sato et al.)  Global    MAA  Adjacent 
normal mucosa  
3  Large adenoma  32  Some  Decrease  No change between 
benign or malignant 
(Gupta et al.)  Global    MAA  adjacent 
normal mucosa 
22  Colorectal cancer  24  Yes  Decrease     284 
(Bariol et al.)  Repeat  LINE1  COBRA   Adjacent 
normal tissue 
8  Bladder, head and 
neck, liver, lung, 
kidney, prostate, 
breast, eosophagus, 
thyroid, lymph node, 
stomach. 
8  Yes  Decrease   
(Bariol et al.)  Gene  Maspin  MSP  Adjacent 
normal thyroid 
17  Poorly differentiated 
thyroid cancer 
17  Yes  Decrease   
(Chalitchagorn 
et al.) 
Gene  Maspin  MSP  Adjacent 
normal thyroid 
13  Undifferentiated 
thyroid cancer 
13  Yes  Decrease   
(Ogasawara et 
al.) 
Gene  TRAG-3  BS, MSP  Adjacent 
normal tissue 
6  1 each of ovary, liver, 
lung, colon, breast, 
testis 
6  Yes  Decrease  Correlated with 
expression of 
TRAG3. 
(Ogasawara et 
al.) 
Repeats 
/ Global 
L1 promoter  MspI/HpaII/Southern; 
MAA 
adjacent 
normal colon 
mucosa 
8  Colorectal cancer  8  Yes  Decrease  CRC patient normal 
bowel displayed 
greater heterogeneity 
than from unaffected 
individuals.  
(Yao et al.)  Gene  Synuclein 
gamma 
MSP, BS  Matched 
nonneoplastic 
adjacent tissue 
160  Various, 20 each of 
liver, esophagus, 
prostate, gastric, colon, 
cervical, lung and 
breast 
160  Yes  Decrease  49/160 of the 
adjacent tissues 
showed 
demethylation of 
SNCG.  
(Suter et al.)  Global    Me-C antibody IHC  Benign sites 
within tumour 
30  Prostate tumour   30  Some  Decrease   
(Liu et al.)  Repeat  SatR-1  BS & LM-PCR , COBRA   Adjacent 
normal tissue 
11  Primary breast tumour  11  Yes  Decrease   
(Brothman et 
al.) 
Repeat  LINE1  COBRA  Adjacent 
normal ovary 
59  Epithelial ovarian 
cancer  
59  Yes  Decrease  Correlated with type, 
grade and poorer 
overall survival.   285 
(Costa et al.)  Gene  GLIPR1/RTVP-
1 
COBRA  Adjacent 
normal kidney 
17  Wilms tumour  24  Yes  Decrease   
(Pattamadilok 
et al.) 
Repeat  LINE1  MSP  Adjacent 
normal colon 
mucosa 
178  Colorectal cancer  205  Yes  Decrease  No association 
between LINE1 and 
CIMP phenotype  
(Chilukamarri 
et al.) 
Repeat  LINE1 & Alu  BS  Adjacent 
normal tissue 
35  Neuroendocrine 
tumour 
35  Yes  Decrease  Alu showed no 
change.LINE1  
correlated with ileal 
vs non-ileal carcinoid 
tumors, with lymph 
node metastasis, 
chromosome 18 loss 
and RASSF1A gene 
methylation.  
(Iacopetta et al.)  Repeat  LINE, SINE  MBD2 based microarray, 
BS 
Normal 
matched lung 
tissue 
4  Lung SCC (two stage 
I, one stage II, one 
stage III) 
4  Yes  Decrease  Non-conserved 
hypomethylation 
between tumours, 
suggesting the 
process is random.  
(Choi et al.)  Repeats  LINE1  BS  Adjacent 
normal tissue 
26  Head and Neck SCC  26  Yes  Decrease  Association with 
HPV status 
(Rauch et al.)  Gene  HGH, HBG1 and 
HBA1 
HpaII/HhaI/Southern  Adjacent 
normal tissue 
6  Lung & Colon   6  Yes  Decrease / 
No change 
1/4 colon showed no 
change 
(Richards et al.)  Repeats  LINE1  MspI/HpaII/Southern & 
LM-PCR 
Adjacent 
bladder  
73  Bladder   73  Yes  Decrease / 
No change 
4/73 showed no 
change 
(Feinberg and 
Vogelstein) 
Repeats  DMHA-1  RLGS & Southern  Adjacent 
normal liver 
8  HCC HBV+  8  Yes  Decrease / 
No change 
2/8 HCC (HBV+), 
17/21 (HBV-) 
showed no change 
(Florl et al.)  Repeats  LINE1  MspI/HpaII/Southern  Adjacent 
normal tissue 
9  HCC  9  Yes  Decrease / 
No change 
1/9 showed no 
change   286 
(Nagai et al.)  Gene  KvDMR1  BamHI/HpaII/Southern  Adjacent 
normal liver 
20  HCC  20  Yes  Decrease / 
No change 
Loss of methylation 
in 10/20 randomly 
selected HCCs. 
(Takai et al.)  Gene  WT1  BstuI/Bsh1236I/Southern, 
BS 
Adjacent 
normal kidney 
9  Wilms tumour  9  Yes  Decrease / 
No change 
2/9 showed no 
change 
(Schwienbacher 
et al.) 
Repeats  Sat2  BstBI/Southern  Adjacent 
normal tissue 
36  HCC  36  Yes  Decrease / 
No change 
11/36 showed no 
change 
(Malik et al.)  Gene  MAGE-A1 -A3 
and -B2 
MSP  Adjacent 
normal lung 
20  Non-small cell lung 
cancer 
20  Yes  Decrease / 
No change 
normal tissue: 
hypometh in 7/20; 
10/20 and 11/20; 
NSCLC hypometh in 
15/20, 16/20, 16/20 
(Wong et al.)  Gene  CTCF binding 
site in H19 
promoter 
BS  Adjacent 
normal bladder 
6  Bladder  6  Yes  Decrease / 
No change 
2/6 cases showed 
hypomethylation 
(Jang et al.)  Global    HPCE  Corresponding 
normal tissue 
57  Carcinoma; lung 
(n=27), colorectal 
(n=18), breast (n=12) 
57  Yes  Decrease / 
No change 
30% showed no 
change or higher 5-
methylcytosine. 
MTHFR SNP 
associated with lower 
levels of 5-meC in 
normal tissue. 
(Takai et al.)  Gene  LINE1; MAGE 
genes 
HpaII/MspI/Southern; BS  Adjacent 
normal tissue 
2  Gastric cancer  2  Yes  Decrease / 
No change 
1/2 showed no 
change 
(Paz et al.)  Gene  MAGE-A1, -A2, 
-A3, -B2, -C1, -
C2 
MSP  Adjacent 
normal tissue 
28  Gastric cancer  93  Some  Decrease / 
No change 
31/93 showed no 
change 
(Kaneda et al.)  Global    HPLC  Adjacent 
normal tissue 
9  Gastric cancer  9  Some  Decrease / 
No change 
5/9 less than lowest 
level of normal 
samples   287 
(Kaneda et al.)  Repeats  LINE1, Alu 
Yb8, Sat-a, 
NBL-2, D4Z4 
BS  Adjacent 
normal tissue 
38  bladder cancer  38  Yes  Decrease / 
No change 
 ~40% tumors show 
no change 
(Kaneda et al.)  Repeats  LINE1  MspI/HpaII/Southern & 
LM-PCR 
Adjacent 
kidney 
34  Kidney  34  Yes  No change   
(Choi et al.)  Repeat  Sat2; D16Z3 and 
D1Z1 loci 
MspI/HpaII/BstBI/Southern  Adjacent 
normal breast 
4  Benign breast tumours  4  Yes  No change   
(Florl et al.)  Gene  CAGE  MSP  Normal 
prostate 
14  Prostate  23  Yes  No change   
(Tsuda et al.)  Gene  CAGE  MSP  Normal colon  14  Colorectal  16  Yes  No change   
(Cho et al.)  Gene  Maspin  MSP  Adjacent 
normal thyroid 
6  Follicular thyroid 
adenoma 
6  Yes  No change  Inverse correlation 
between maspin 
promoter methylation 
and expression. 
(Cho et al.)  Gene  Maspin  MSP  Adjacent 
normal thyroid 
56  Well differentiated 
thyroid cancer 
56  Yes  No change   
(Ogasawara et 
al.) 
Repeats  LINE1  BS, LUMA  Adjacent 
normal tissue 
21  follicular thyroid 
cancer 
21  Yes  No change   
 
 
 
 
 
 
   288 
Table A2: Probe set IDs of epigenetic regulator genes utilized in GEM analysis  
  Probe Set ID  Gene Title  Gene Symbol 
   DNA methyltransferases    
DNMT  201697_s_at  DNA (cytosine-5-)-methyltransferase 1  DNMT1 
DNMT  206308_at  DNA (cytosine-5-)-methyltransferase 2  DNMT2 
DNMT  232121_at  DNA (cytosine-5-)-methyltransferase 2  DNMT2 
DNMT  243504_at  DNA (cytosine-5-)-methyltransferase 2  DNMT2 
DNMT  218457_s_at  DNA (cytosine-5-)-methyltransferase 3 alpha  DNMT3A 
DNMT  222640_at  DNA (cytosine-5-)-methyltransferase 3 alpha  DNMT3A 
DNMT  244428_at  DNA (cytosine-5-)-methyltransferase 3 alpha  DNMT3A 
DNMT  220668_s_at  DNA (cytosine-5-)-methyltransferase 3 beta  DNMT3B 
   Histone deacetylases    
HDAC  201209_at  histone deacetylase 1  HDAC1 
HDAC  201833_at  histone deacetylase 2  HDAC2 
HDAC  242141_at  Histone deacetylase 2  HDAC2 
HDAC  216326_s_at  histone deacetylase 3  HDAC3 
HDAC  240482_at  Histone deacetylase 3  HDAC3 
HDAC  1554322_a_at  histone deacetylase 4  HDAC4 
HDAC  204225_at  histone deacetylase 4  HDAC4 
HDAC  228813_at  histone deacetylase 4  HDAC4 
HDAC  240870_at  Histone deacetylase 4  HDAC4 
HDAC  202455_at  histone deacetylase 5  HDAC5 
HDAC  229408_at  histone deacetylase 5  HDAC5 
HDAC  206846_s_at  histone deacetylase 6  HDAC6 
HDAC  211722_s_at  histone deacetylase 6  HDAC6 
HDAC  216224_s_at  histone deacetylase 6  HDAC6 
HDAC  217937_s_at  histone deacetylase 7A  HDAC7A 
HDAC  236326_at  histone deacetylase 7A  HDAC7A 
HDAC  223345_at  histone deacetylase 8  HDAC8 
HDAC  223908_at  histone deacetylase 8  HDAC8 
HDAC  223909_s_at  histone deacetylase 8  HDAC8 
HDAC  1552758_at  histone deacetylase 9  HDAC9 
HDAC  1552760_at  histone deacetylase 9  HDAC9 
HDAC  205659_at  histone deacetylase 9  HDAC9 
HDAC  234393_at  histone deacetylase 9  HDAC9 
HDAC  242952_at  Histone deacetylase 9  HDAC9 
HDAC  226672_s_at  histone deacetylase 10  HDAC10 
HDAC  232870_at  histone deacetylase 10  HDAC10 
HDAC  219847_at  histone deacetylase 11  HDAC11 
HDAC  227679_at  Histone deacetylase 11  HDAC11 
HDAC  218878_s_at  sirtuin (silent mating type information regulation 2 homolog) 1 (S. 
cerevisiae) 
SIRT1 
HDAC  1558331_at  sirtuin (silent mating type information regulation 2 homolog) 2 (S. 
cerevisiae) 
SIRT2 
HDAC  220605_s_at  sirtuin (silent mating type information regulation 2 homolog) 2 (S. 
cerevisiae) 
SIRT2 
HDAC  221562_s_at  sirtuin (silent mating type information regulation 2 homolog) 3 (S. 
cerevisiae) 
SIRT3 
HDAC  221913_at  sirtuin (silent mating type information regulation 2 homolog) 3 (S. 
cerevisiae) 
SIRT3 
HDAC  49327_at  sirtuin (silent mating type information regulation 2 homolog) 3 (S. 
cerevisiae) 
SIRT3 
HDAC  220047_at  sirtuin (silent mating type information regulation 2 homolog) 4 (S. 
cerevisiae) 
SIRT4 
HDAC  222248_s_at  sirtuin (silent mating type information regulation 2 homolog) 4 (S. 
cerevisiae) 
SIRT4 
HDAC  1569938_at  sirtuin (silent mating type information regulation 2 homolog) 5 (S. 
cerevisiae) 
SIRT5 
HDAC  219185_at  sirtuin (silent mating type information regulation 2 homolog) 5 (S. 
cerevisiae) 
SIRT5 
HDAC  221010_s_at  sirtuin (silent mating type information regulation 2 homolog) 5 (S. 
cerevisiae) /// sirtuin (silent mating type information regulation 2 
homolog) 5 (S. cerevisiae) 
SIRT5   289 
  Probe Set ID  Gene Title  Gene Symbol 
HDAC  222080_s_at  Sirtuin (silent mating type information regulation 2 homolog) 5 (S. 
cerevisiae) 
SIRT5 
HDAC  222081_at  Sirtuin (silent mating type information regulation 2 homolog) 5 (S. 
cerevisiae) 
SIRT5 
HDAC  219613_s_at  sirtuin (silent mating type information regulation 2 homolog) 6 (S. 
cerevisiae) 
SIRT6 
HDAC  233179_x_at  sirtuin (silent mating type information regulation 2 homolog) 6 (S. 
cerevisiae) 
SIRT6 
HDAC  218797_s_at  sirtuin (silent mating type information regulation 2 homolog) 7 (S. 
cerevisiae) 
SIRT7 
HDAC  235046_at  Transcribed locus, moderately similar to XP_518244.1 
PREDICTED: similar to sirtuin 5 isoform 2; sir2-like 5; silent 
mating type information regulation 2, S.cerevisiae, homolog 5; 
sirtuin (silent mating type information regulation 2, S.cerevisiae, 
homolog) 5; sirtuin silent mating type information regulation 2 h... 
[Pan troglodytes] 
--- 
HDAC  239259_at  Transcribed locus, moderately similar to XP_518244.1 
PREDICTED: similar to sirtuin 5 isoform 2; sir2-like 5; silent 
mating type information regulation 2, S.cerevisiae, homolog 5; 
sirtuin (silent mating type information regulation 2, S.cerevisiae, 
homolog) 5; sirtuin silent mating type information regulation 2 h... 
[Pan troglodytes] 
--- 
HDAC  1570574_at  Similar to NAD-dependent deacetylase sirtuin 5 (SIR2-like protein 
5) 
LOC391047 
HDAC  1570575_at  Similar to NAD-dependent deacetylase sirtuin 5 (SIR2-like protein 
5) 
LOC391047 
HDAC  224974_at  SDS3 protein  SDS3 
HDAC  233841_s_at  SDS3 protein  SDS3 
HDAC  219433_at  BCL6 co-repressor  BCOR 
HDAC  223566_s_at  BCL6 co-repressor  BCOR 
HDAC  223915_at  BCL6 co-repressor  BCOR 
HDAC  223916_s_at  BCL6 co-repressor  BCOR 
   Histone acetyltransferases    
HAT  202652_at  amyloid beta (A4) precursor protein-binding, family B, member 1 
(Fe65) 
APBB1 
HAT  213419_at  amyloid beta (A4) precursor protein-binding, family B, member 2 
(Fe65-like) 
APBB2 
HAT  216747_at  amyloid beta (A4) precursor protein-binding, family B, member 2 
(Fe65-like) 
APBB2 
HAT  216750_at  amyloid beta (A4) precursor protein-binding, family B, member 2 
(Fe65-like) 
APBB2 
HAT  40148_at  amyloid beta (A4) precursor protein-binding, family B, member 2 
(Fe65-like) 
APBB2 
HAT  1559295_at  CREB binding protein (Rubinstein-Taybi syndrome)  CREBBP 
HAT  202160_at  CREB binding protein (Rubinstein-Taybi syndrome)  CREBBP 
HAT  211808_s_at  CREB binding protein (Rubinstein-Taybi syndrome)  CREBBP 
HAT  228177_at  CREB binding protein (Rubinstein-Taybi syndrome)  CREBBP 
HAT  235858_at  CREB binding protein (Rubinstein-Taybi syndrome)  CREBBP 
HAT  209058_at  endothelial differentiation-related factor 1  EDF1 
HAT  209059_s_at  endothelial differentiation-related factor 1  EDF1 
HAT  202221_s_at  E1A binding protein p300  EP300 
HAT  213579_s_at  E1A binding protein p300  EP300 
HAT  200878_at  endothelial PAS domain protein 1  EPAS1 
HAT  200879_s_at  endothelial PAS domain protein 1  EPAS1 
HAT  229904_at  Endothelial PAS domain protein 1  EPAS1 
HAT  235963_at  Endothelial PAS domain protein 1  EPAS1 
HAT  237843_at  Endothelial PAS domain protein 1  EPAS1 
HAT  241055_at  Endothelial PAS domain protein 1  EPAS1 
HAT  242868_at  Endothelial PAS domain protein 1  EPAS1 
HAT  202182_at  GCN5 general control of amino-acid synthesis 5-like 2 (yeast)  GCN5L2 
HAT  219198_at  general transcription factor IIIC, polypeptide 4, 90kDa  GTF3C4 
HAT  203138_at  histone acetyltransferase 1  HAT1 
HAT  200989_at  hypoxia-inducible factor 1, alpha subunit (basic helix-loop-helix 
transcription factor) 
HIF1A 
HAT  238869_at  Hypoxia-inducible factor 1, alpha subunit (basic helix-loop-helix  HIF1A   290 
  Probe Set ID  Gene Title  Gene Symbol 
transcription factor) 
HAT  206689_x_at  HIV-1 Tat interacting protein, 60kDa  HTATIP 
HAT  209192_x_at  HIV-1 Tat interacting protein, 60kDa  HTATIP 
HAT  214258_x_at  HIV-1 Tat interacting protein, 60kDa  HTATIP 
HAT  214885_at  MYST histone acetyltransferase 1  MYST1 
HAT  221820_s_at  MYST histone acetyltransferase 1  MYST1 
HAT  200049_at  MYST histone acetyltransferase 2 /// MYST histone 
acetyltransferase 2 
MYST2 
HAT  1562236_at  MYST histone acetyltransferase (monocytic leukemia) 4  MYST4 
HAT  211874_s_at  MYST histone acetyltransferase (monocytic leukemia) 4  MYST4 
HAT  212452_x_at  MYST histone acetyltransferase (monocytic leukemia) 4  MYST4 
HAT  214496_x_at  MYST histone acetyltransferase (monocytic leukemia) 4  MYST4 
HAT  243479_at  MYST histone acetyltransferase (monocytic leukemia) 4  MYST4 
HAT  1562314_at  Nuclear receptor coactivator 1  NCOA1 
HAT  209105_at  nuclear receptor coactivator 1  NCOA1 
HAT  209106_at  nuclear receptor coactivator 1  NCOA1 
HAT  209107_x_at  nuclear receptor coactivator 1  NCOA1 
HAT  210249_s_at  nuclear receptor coactivator 1  NCOA1 
HAT  243826_at  Nuclear receptor coactivator 1  NCOA1 
HAT  1562439_at  Nuclear receptor coactivator 3  NCOA3 
HAT  207700_s_at  nuclear receptor coactivator 3  NCOA3 
HAT  209060_x_at  nuclear receptor coactivator 3  NCOA3 
HAT  209061_at  nuclear receptor coactivator 3  NCOA3 
HAT  209062_x_at  nuclear receptor coactivator 3  NCOA3 
HAT  211352_s_at  nuclear receptor coactivator 3  NCOA3 
HAT  203845_at  p300/CBP-associated factor  PCAF 
HAT  239585_at  P300/CBP-associated factor  PCAF 
HAT  205085_at  origin recognition complex, subunit 1-like (yeast)  ORC1L 
HAT  1558331_at  sirtuin (silent mating type information regulation 2 homolog) 2 (S. 
cerevisiae) 
SIRT2 
HAT  220605_s_at  sirtuin (silent mating type information regulation 2 homolog) 2 (S. 
cerevisiae) 
SIRT2 
HAT  1552630_a_at  Snf2-related CBP activator protein  SRCAP 
HAT  1569138_a_at  Snf2-related CBP activator protein  SRCAP 
HAT  212275_s_at  Snf2-related CBP activator protein  SRCAP 
HAT  213667_at  Snf2-related CBP activator protein  SRCAP 
HAT  215053_at  Snf2-related CBP activator protein  SRCAP 
HAT  38766_at  Snf2-related CBP activator protein  SRCAP 
HAT  216711_s_at  TAF1 RNA polymerase II, TATA box binding protein (TBP)-
associated factor, 250kDa 
TAF1 
HAT  216955_at  TAF1 RNA polymerase II, TATA box binding protein (TBP)-
associated factor, 250kDa 
TAF1 
HAT  227205_at  TAF1 RNA polymerase II, TATA box binding protein (TBP)-
associated factor, 250kDa 
TAF1 
HAT  241982_at  TAF1 RNA polymerase II, TATA box binding protein (TBP)-
associated factor, 250kDa 
TAF1 
HAT  1553011_at  TAF1-like RNA polymerase II, TATA box binding protein (TBP)-
associated factor, 210kDa 
TAF1L 
HAT  213299_at  zinc finger and BTB domain containing 7A  ZBTB7A 
HAT  213303_x_at  zinc finger and BTB domain containing 7A  ZBTB7A 
HAT  219186_at  zinc finger and BTB domain containing 7A  ZBTB7A 
HAT  222082_at  zinc finger and BTB domain containing 7A  ZBTB7A 
HAT  226554_at  zinc finger and BTB domain containing 7A  ZBTB7A 
HAT  230709_x_at  Zinc finger and BTB domain containing 7A  ZBTB7A 
HAT  207225_at  arylalkylamine N-acetyltransferase  AANAT 
HAT  203025_at  ARD1 homolog A, N-acetyltransferase (S. cerevisiae)  ARD1A 
HAT  206964_at  putative N-acetyltransferase Camello 2  CML2 
HAT  225432_s_at  CSRP2 binding protein  CSRP2BP 
HAT  227316_at  CSRP2 binding protein  CSRP2BP 
HAT  228543_at  CSRP2 binding protein  CSRP2BP 
HAT  228544_s_at  CSRP2 binding protein  CSRP2BP 
HAT  233396_s_at  CSRP2 binding protein  CSRP2BP   291 
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HAT  218661_at  hypothetical protein FLJ14154  FLJ14154 
HAT  45526_g_at  hypothetical protein FLJ14154  FLJ14154 
HAT  228880_at  Hypothetical protein LOC339983  FLJ37478 
HAT  235316_at  hypothetical protein LOC339983  FLJ37478 
HAT  202182_at  GCN5 general control of amino-acid synthesis 5-like 2 (yeast)  GCN5L2 
HAT  1562089_at  glycine-N-acyltransferase-like 1  GLYATL1 
HAT  227695_at  glycine-N-acyltransferase-like 1  GLYATL1 
HAT  227794_at  glycine-N-acyltransferase-like 1  GLYATL1 
HAT  225853_at  glucosamine-phosphate N-acetyltransferase 1  GNPNAT1 
HAT  217745_s_at  Mak3 homolog (S. cerevisiae)  MAK3 
HAT  222393_s_at  Mak3 homolog (S. cerevisiae)  MAK3 
HAT  231199_at  Mak3 homolog (S. cerevisiae)  MAK3 
HAT  239138_at  Mak3 homolog (S. cerevisiae)  MAK3 
HAT  244341_at  Mak3 homolog (S. cerevisiae)  MAK3 
HAT  210603_at  hypothetical protein MGC10646  MGC10646 
HAT  223040_at  N-acetyltransferase 5 (ARD1 homolog, S. cerevisiae)  NAT5 
HAT  210289_at  N-acetyltransferase 8 (camello like)  NAT8 
HAT  206963_s_at  N-acetyltransferase 8 (camello like) /// putative N-acetyltransferase 
Camello 2 
NAT8 /// CML2 
HAT  204382_at  N-acetyltransferase 9  NAT9 
HAT  203845_at  p300/CBP-associated factor  PCAF 
HAT  239585_at  P300/CBP-associated factor  PCAF 
HAT  206518_s_at  regulator of G-protein signalling 9  RGS9 
HAT  203455_s_at  spermidine/spermine N1-acetyltransferase  SAT 
HAT  210592_s_at  spermidine/spermine N1-acetyltransferase  SAT 
HAT  210593_at  spermidine/spermine N1-acetyltransferase  SAT 
HAT  213988_s_at  spermidine/spermine N1-acetyltransferase  SAT 
HAT  230333_at  Spermidine/spermine N1-acetyltransferase  SAT 
HAT  225272_at  spermidine/spermine N1-acetyltransferase 2  SAT2 
   Histone methyltransferases    
HMT  212512_s_at  coactivator-associated arginine methyltransferase 1  CARM1 
HMT  214865_at  DOT1-like, histone H3 methyltransferase (S. cerevisiae)  DOT1L 
HMT  226201_at  DOT1-like, histone H3 methyltransferase (S. cerevisiae)  DOT1L 
HMT  231297_at  DOT1-like, histone H3 methyltransferase (S. cerevisiae)  DOT1L 
HMT  219339_s_at  euchromatic histone-lysine N-methyltransferase 1  EHMT1 
HMT  222873_s_at  euchromatic histone-lysine N-methyltransferase 1  EHMT1 
HMT  225461_at  euchromatic histone-lysine N-methyltransferase 1  EHMT1 
HMT  202326_at  euchromatic histone-lysine N-methyltransferase 2  EHMT2 
HMT  207484_s_at  euchromatic histone-lysine N-methyltransferase 2  EHMT2 
HMT  229079_at  Euchromatic histone-lysine N-methyltransferase 2  EHMT2 
HMT  243914_at  Euchromatic histone-lysine N-methyltransferase 2  EHMT2 
HMT  203358_s_at  enhancer of zeste homolog 2 (Drosophila)  EZH2 
HMT  207772_s_at  HMT1 hnRNP methyltransferase-like 4 (S. cerevisiae)  HRMT1L4 
HMT  230839_at  HMT1 hnRNP methyltransferase-like 4 (S. cerevisiae)  HRMT1L4 
HMT  213202_at  KIAA0339 gene product  KIAA0339 
HMT  1559856_s_at  myeloid/lymphoid or mixed-lineage leukemia (trithorax homolog, 
Drosophila) 
MLL 
HMT  1565034_s_at  AF4/FMR2 family, member 3 /// myeloid/lymphoid or mixed-
lineage leukemia (trithorax homolog, Drosophila) 
 MLL /// AFF3  
HMT  1565254_s_at  myeloid/lymphoid or mixed-lineage leukemia (trithorax homolog, 
Drosophila) /// elongation factor RNA polymerase II 
MLL /// ELL 
HMT  1565436_s_at  myeloid/lymphoid or mixed-lineage leukemia (trithorax homolog, 
Drosophila) 
MLL 
HMT  212076_at  myeloid/lymphoid or mixed-lineage leukemia (trithorax homolog, 
Drosophila) 
MLL 
HMT  212078_s_at  myeloid/lymphoid or mixed-lineage leukemia (trithorax homolog, 
Drosophila) 
MLL 
HMT  212079_s_at  myeloid/lymphoid or mixed-lineage leukemia (trithorax homolog, 
Drosophila) 
MLL 
HMT  216624_s_at  myeloid/lymphoid or mixed-lineage leukemia (trithorax homolog, 
Drosophila) 
MLL 
HMT  229935_s_at  Myeloid/lymphoid or mixed-lineage leukemia (trithorax homolog,  MLL   292 
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Drosophila) 
HMT  1557158_s_at  myeloid/lymphoid or mixed-lineage leukemia 3  MLL3 
HMT  222413_s_at  myeloid/lymphoid or mixed-lineage leukemia 3  MLL3 
HMT  222414_at  myeloid/lymphoid or mixed-lineage leukemia 3  MLL3 
HMT  222415_at  myeloid/lymphoid or mixed-lineage leukemia 3  MLL3 
HMT  232940_s_at  myeloid/lymphoid or mixed-lineage leukemia 3  MLL3 
HMT  234182_at  Myeloid/lymphoid or mixed-lineage leukemia 3  MLL3 
HMT  234651_at  Myeloid/lymphoid or mixed-lineage leukemia 3  MLL3 
HMT  235859_at  Myeloid/lymphoid or mixed-lineage leukemia 3  MLL3 
HMT  244010_at  Myeloid/lymphoid or mixed-lineage leukemia 3  MLL3 
HMT  1555409_a_at  myeloid/lymphoid or mixed-lineage leukemia 3 /// B melanoma 
antigen family, member 5 /// B melanoma antigen family, member 3 
/// B melanoma antigen family, member 2 
MLL3 /// BAGE5 
/// BAGE3 /// 
BAGE2 
HMT  219084_at  nuclear receptor binding SET domain protein 1  NSD1 
HMT  243612_at  Nuclear receptor binding SET domain protein 1  NSD1 
HMT  1556899_at  Protein arginine methyltransferase 5  PRMT5 
HMT  216069_at  Protein arginine methyltransferase 2  PRMT2 
HMT  216072_at  Protein arginine methyltransferase 2  PRMT2 
HMT  241019_at  Protein arginine methyltransferase 3  PRMT3 
HMT  219408_at  protein arginine N-methyltransferase 7  PRMT7 
HMT  224928_at  SET domain-containing protein 7  SET7 
HMT  220200_s_at  PR/SET domain containing protein 8  SET8 
HMT  225094_at  PR/SET domain containing protein 8  SET8 
HMT  225118_at  PR/SET domain containing protein 8  SET8 
HMT  228443_s_at  SET domain containing (lysine methyltransferase) 8  SETD8 
HMT  203155_at  SET domain, bifurcated 1  SETDB1 
HMT  214197_s_at  SET domain, bifurcated 1  SETDB1 
HMT  1564970_at  SET domain, bifurcated 2  SETDB2 
HMT  1564972_x_at  SET domain, bifurcated 2  SETDB2 
HMT  235338_s_at  SET domain, bifurcated 2  SETDB2 
HMT  235339_at  SET domain, bifurcated 2  SETDB2 
HMT  238731_at  SET domain, bifurcated 2  SETDB2 
HMT  1554059_at  SET domain and mariner transposase fusion gene  SETMAR 
HMT  1554060_s_at  SET domain and mariner transposase fusion gene  SETMAR 
HMT  206554_x_at  SET domain and mariner transposase fusion gene  SETMAR 
HMT  218788_s_at  SET and MYND domain containing 3  SMYD3 
HMT  218619_s_at  suppressor of variegation 3-9 homolog 1 (Drosophila)  SUV39H1 
HMT  1554572_a_at  suppressor of variegation 3-9 homolog 2 (Drosophila)  SUV39H2 
HMT  219262_at  suppressor of variegation 3-9 homolog 2 (Drosophila)  SUV39H2 
HMT  1565974_at  Suppressor of variegation 4-20 homolog 1 (Drosophila)  SUV420H1 
HMT  1565975_at  Suppressor of variegation 4-20 homolog 1 (Drosophila)  SUV420H1 
HMT  1570058_at  suppressor of variegation 4-20 homolog 2 (Drosophila)  SUV420H2 
HMT  218242_s_at  suppressor of variegation 4-20 homolog 1 (Drosophila)  SUV420H1 
HMT  222566_at  suppressor of variegation 4-20 homolog 1 (Drosophila)  SUV420H1 
HMT  222759_at  suppressor of variegation 4-20 homolog 1 (Drosophila)  SUV420H1 
HMT  224431_s_at  suppressor of variegation 4-20 homolog 2 (Drosophila) /// 
suppressor of variegation 4-20 homolog 2 (Drosophila) 
SUV420H2 
HMT  231457_at  Suppressor of variegation 4-20 homolog 2 (Drosophila)  SUV420H2 
HMT  242646_at  Suppressor of variegation 4-20 homolog 1 (Drosophila)  SUV420H1 
HMT  243105_at  Suppressor of variegation 4-20 homolog 1 (Drosophila)  SUV420H1 
   Histone demethylases    
HDMT  211412_at  peptidyl arginine deiminase, type IV  PADI4 
HDMT  211413_s_at  peptidyl arginine deiminase, type IV  PADI4 
HDMT  220001_at  peptidyl arginine deiminase, type IV  PADI4 
HDMT  1555897_at  amine oxidase (flavin containing) domain 2  AOF2 
HDMT  212348_s_at  amine oxidase (flavin containing) domain 2  AOF2 
HDMT  238652_at  Amine oxidase (flavin containing) domain 2  AOF2 
HDMT  212689_s_at  jumonji domain containing 1A  JMJD1A 
HDMT  242758_x_at  Jumonji domain containing 1A  JMJD1A 
HDMT  201643_x_at  jumonji domain containing 1B  JMJD1B 
HDMT  210878_s_at  jumonji domain containing 1B  JMJD1B   293 
  Probe Set ID  Gene Title  Gene Symbol 
HDMT  221763_at  jumonji domain containing 1C  JMJD1C 
HDMT  224933_s_at  jumonji domain containing 1C  JMJD1C 
HDMT  228793_at  jumonji domain containing 1C  JMJD1C 
HDMT  230007_at  jumonji domain containing 1C  JMJD1C 
HDMT  241659_at  Jumonji domain containing 1C  JMJD1C 
HDMT  241661_at  jumonji domain containing 1C  JMJD1C 
HDMT  203204_s_at  jumonji domain containing 2A  JMJD2A 
HDMT  203205_at  jumonji domain containing 2A  JMJD2A 
HDMT  1558447_at  Jumonji domain containing 2B  JMJD2B 
HDMT  1558448_a_at  Jumonji domain containing 2B  JMJD2B 
HDMT  1559073_at  Jumonji domain containing 2B  JMJD2B 
HDMT  212492_s_at  jumonji domain containing 2B  JMJD2B 
HDMT  212495_at  jumonji domain containing 2B  JMJD2B 
HDMT  212496_s_at  jumonji domain containing 2B  JMJD2B 
HDMT  215616_s_at  jumonji domain containing 2B  JMJD2B 
HDMT  216023_at  jumonji domain containing 2B  JMJD2B 
HDMT  217664_at  Jumonji domain containing 2B  JMJD2B 
HDMT  230126_s_at  Jumonji domain containing 2B  JMJD2B 
HDMT  235789_at  jumonji domain containing 2B  JMJD2B 
HDMT  240780_at  Jumonji domain containing 2B  JMJD2B 
HDMT  1556493_a_at  Jumonji domain containing 2C  JMJD2C 
HDMT  209984_at  jumonji domain containing 2C  JMJD2C 
HDMT  214861_at  jumonji domain containing 2C  JMJD2C 
HDMT  236732_at  Jumonji domain containing 2C  JMJD2C 
HDMT  239285_at  Jumonji domain containing 2C  JMJD2C 
HDMT  244385_at  Jumonji domain containing 2C  JMJD2C 
HDMT  220278_at  jumonji domain containing 2D  JMJD2D 
HDMT  242788_at  jumonji domain containing 2D  JMJD2D 
HDMT  1556066_at  jumonji domain containing 3  JMJD3 
HDMT  1556067_a_at  jumonji domain containing 3  JMJD3 
HDMT  218560_s_at  jumonji domain containing 4  JMJD4 
HDMT  222671_s_at  jumonji domain containing 4  JMJD4 
HDMT  237229_at  Jumonji domain containing 5  JMJD5 
   Methyl-C Binding Proteins    
MeCBP  1555611_s_at  methyl-CpG binding domain protein 1  MBD1 
MeCBP  203353_s_at  methyl-CpG binding domain protein 1  MBD1 
MeCBP  208595_s_at  methyl-CpG binding domain protein 1  MBD1 
MeCBP  226862_at  methyl-CpG binding domain protein 1  MBD1 
MeCBP  241813_at  methyl-CpG binding domain protein 1  MBD1 
MeCBP  202484_s_at  methyl-CpG binding domain protein 2  MBD2 
MeCBP  202485_s_at  methyl-CpG binding domain protein 2  MBD2 
MeCBP  214396_s_at  methyl-CpG binding domain protein 2  MBD2 
MeCBP  214397_at  methyl-CpG binding domain protein 2  MBD2 
MeCBP  236130_at  Methyl-CpG binding domain protein 2  MBD2 
MeCBP  202463_s_at  methyl-CpG binding domain protein 3  MBD3 
MeCBP  41160_at  methyl-CpG binding domain protein 3  MBD3 
MeCBP  209579_s_at  methyl-CpG binding domain protein 4  MBD4 
MeCBP  209580_s_at  methyl-CpG binding domain protein 4  MBD4 
MeCBP  214047_s_at  methyl-CpG binding domain protein 4  MBD4 
MeCBP  214048_at  methyl-CpG binding domain protein 4  MBD4 
MeCBP  202616_s_at  methyl CpG binding protein 2 (Rett syndrome)  MECP2 
MeCBP  202617_s_at  methyl CpG binding protein 2 (Rett syndrome)  MECP2 
MeCBP  202618_s_at  methyl CpG binding protein 2 (Rett syndrome)  MECP2 
MeCBP  241924_at  Methyl CpG binding protein 2 (Rett syndrome)  MECP2 
MeCBP  1564351_at  POU domain, class 2, transcription factor 1  POU2F1 
MeCBP  206789_s_at  POU domain, class 2, transcription factor 1  POU2F1 
MeCBP  229753_at  POU domain, class 2, transcription factor 1  POU2F1 
MeCBP  234649_at  POU domain, class 2, transcription factor 1  POU2F1 
MeCBP  214631_at  zinc finger and BTB domain containing 33  ZBTB33 
MeCBP  226255_at  zinc finger and BTB domain containing 33  ZBTB33   294 
  Probe Set ID  Gene Title  Gene Symbol 
   ATP-dependent chromatin remodelling    
ATP DR  207591_s_at  AT rich interactive domain 1A (SWI- like)  ARID1A 
ATP DR  210649_s_at  AT rich interactive domain 1A (SWI- like)  ARID1A 
ATP DR  212152_x_at  AT rich interactive domain 1A (SWI- like)  ARID1A 
ATP DR  218917_s_at  AT rich interactive domain 1A (SWI- like)  ARID1A 
ATP DR  234159_at  AT rich interactive domain 1A (SWI- like)  ARID1A 
ATP DR  217985_s_at  bromodomain adjacent to zinc finger domain, 1A  BAZ1A 
ATP DR  217986_s_at  bromodomain adjacent to zinc finger domain, 1A  BAZ1A 
ATP DR  208806_at  chromodomain helicase DNA binding protein 3  CHD3 
ATP DR  208807_s_at  chromodomain helicase DNA binding protein 3  CHD3 
ATP DR  201182_s_at  chromodomain helicase DNA binding protein 4  CHD4 
ATP DR  201183_s_at  chromodomain helicase DNA binding protein 4  CHD4 
ATP DR  201184_s_at  chromodomain helicase DNA binding protein 4  CHD4 
ATP DR  231764_at  chromatin accessibility complex 1  CHRAC1 
ATP DR  218166_s_at  hepatitis B virus x associated protein  HBXAP 
ATP DR  222540_s_at  hepatitis B virus x associated protein  HBXAP 
ATP DR  222541_at  hepatitis B virus x associated protein  HBXAP 
ATP DR  223818_s_at  hepatitis B virus x associated protein  HBXAP 
ATP DR  235381_at  Hepatitis B virus x associated protein /// Homo sapiens, clone 
IMAGE:3457110, mRNA 
HBXAP 
ATP DR  209113_s_at  high-mobility group 20B  HMG20B 
ATP DR  210719_s_at  high-mobility group 20B  HMG20B 
ATP DR  213966_at  High-mobility group 20B  HMG20B 
ATP DR  1558581_at  Metastasis associated 1  MTA1 
ATP DR  202247_s_at  metastasis associated 1  MTA1 
ATP DR  211783_s_at  metastasis associated 1 /// metastasis associated 1  MTA1 
ATP DR  203444_s_at  metastasis associated 1 family, member 2  MTA2 
ATP DR  208828_at  polymerase (DNA directed), epsilon 3 (p17 subunit)  POLE3 
ATP DR  210371_s_at  retinoblastoma binding protein 4  RBBP4 
ATP DR  217015_at  retinoblastoma binding protein 4  RBBP4 
ATP DR  217301_x_at  retinoblastoma binding protein 4  RBBP4 
ATP DR  239071_at  Retinoblastoma binding protein 4  RBBP4 
ATP DR  1557954_at  Retinoblastoma binding protein 7  RBBP7 
ATP DR  201092_at  retinoblastoma binding protein 7  RBBP7 
ATP DR  227520_at  Retinoblastoma binding protein 7  RBBP7 
ATP DR  206542_s_at  SWI/SNF related, matrix associated, actin dependent regulator of 
chromatin, subfamily a, member 2 
SMARCA2 
ATP DR  206543_at  SWI/SNF related, matrix associated, actin dependent regulator of 
chromatin, subfamily a, member 2 
SMARCA2 
ATP DR  206544_x_at  SWI/SNF related, matrix associated, actin dependent regulator of 
chromatin, subfamily a, member 2 
SMARCA2 
ATP DR  212257_s_at  SWI/SNF related, matrix associated, actin dependent regulator of 
chromatin, subfamily a, member 2 
SMARCA2 
ATP DR  212258_s_at  SWI/SNF related, matrix associated, actin dependent regulator of 
chromatin, subfamily a, member 2 
SMARCA2 
ATP DR  217707_x_at  SWI/SNF related, matrix associated, actin dependent regulator of 
chromatin, subfamily a, member 2 
SMARCA2 
ATP DR  228926_s_at  SWI/SNF related, matrix associated, actin dependent regulator of 
chromatin, subfamily a, member 2 
SMARCA2 
ATP DR  241756_at  SWI/SNF related, matrix associated, actin dependent regulator of 
chromatin, subfamily a, member 2 
SMARCA2 
ATP DR  202983_at  SWI/SNF related, matrix associated, actin dependent regulator of 
chromatin, subfamily a, member 3 
SMARCA3 
ATP DR  1569073_x_at  SWI/SNF related, matrix associated, actin dependent regulator of 
chromatin, subfamily a, member 4 
SMARCA4 
ATP DR  208793_x_at  SWI/SNF related, matrix associated, actin dependent regulator of 
chromatin, subfamily a, member 4 
SMARCA4 
ATP DR  208794_s_at  SWI/SNF related, matrix associated, actin dependent regulator of 
chromatin, subfamily a, member 4 
SMARCA4 
ATP DR  212520_s_at  SWI/SNF related, matrix associated, actin dependent regulator of 
chromatin, subfamily a, member 4 
SMARCA4 
ATP DR  213719_s_at  SWI/SNF related, matrix associated, actin dependent regulator of 
chromatin, subfamily a, member 4 
SMARCA4   295 
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ATP DR  213720_s_at  SWI/SNF related, matrix associated, actin dependent regulator of 
chromatin, subfamily a, member 4 
SMARCA4 
ATP DR  214360_at  SWI/SNF related, matrix associated, actin dependent regulator of 
chromatin, subfamily a, member 4 
SMARCA4 
ATP DR  214728_x_at  SWI/SNF related, matrix associated, actin dependent regulator of 
chromatin, subfamily a, member 4 
SMARCA4 
ATP DR  215714_s_at  SWI/SNF related, matrix associated, actin dependent regulator of 
chromatin, subfamily a, member 4 
SMARCA4 
ATP DR  217656_at  SWI/SNF related, matrix associated, actin dependent regulator of 
chromatin, subfamily a, member 4 
SMARCA4 
ATP DR  243655_x_at  SWI/SNF related, matrix associated, actin dependent regulator of 
chromatin, subfamily a, member 4 
SMARCA4 
ATP DR  202303_x_at  SWI/SNF related, matrix associated, actin dependent regulator of 
chromatin, subfamily a, member 5 
SMARCA5 
ATP DR  213251_at  SWI/SNF related, matrix associated, actin dependent regulator of 
chromatin, subfamily a, member 5 
SMARCA5 
ATP DR  213859_x_at  SWI/SNF related, matrix associated, actin dependent regulator of 
chromatin, subfamily a, member 5 
SMARCA5 
ATP DR  212167_s_at  SWI/SNF related, matrix associated, actin dependent regulator of 
chromatin, subfamily b, member 1 
SMARCB1 
ATP DR  228898_s_at  SWI/SNF related, matrix associated, actin dependent regulator of 
chromatin, subfamily b, member 1 
SMARCB1 
ATP DR  231324_at  SWI/SNF related, matrix associated, actin dependent regulator of 
chromatin, subfamily b, member 1 
SMARCB1 
ATP DR  201072_s_at  SWI/SNF related, matrix associated, actin dependent regulator of 
chromatin, subfamily c, member 1 
SMARCC1 
ATP DR  201073_s_at  SWI/SNF related, matrix associated, actin dependent regulator of 
chromatin, subfamily c, member 1 
SMARCC1 
ATP DR  201074_at  SWI/SNF related, matrix associated, actin dependent regulator of 
chromatin, subfamily c, member 1 
SMARCC1 
ATP DR  201075_s_at  SWI/SNF related, matrix associated, actin dependent regulator of 
chromatin, subfamily c, member 1 
SMARCC1 
ATP DR  239238_at  SWI/SNF related, matrix associated, actin dependent regulator of 
chromatin, subfamily c, member 1 
SMARCC1 
ATP DR  201320_at  SWI/SNF related, matrix associated, actin dependent regulator of 
chromatin, subfamily c, member 2 
SMARCC2 
ATP DR  201321_s_at  SWI/SNF related, matrix associated, actin dependent regulator of 
chromatin, subfamily c, member 2 
SMARCC2 
ATP DR  203183_s_at  SWI/SNF related, matrix associated, actin dependent regulator of 
chromatin, subfamily d, member 1 
SMARCD1 
ATP DR  209518_at  SWI/SNF related, matrix associated, actin dependent regulator of 
chromatin, subfamily d, member 1 
SMARCD1 
ATP DR  201827_at  SWI/SNF related, matrix associated, actin dependent regulator of 
chromatin, subfamily d, member 2 
SMARCD2 
ATP DR  204099_at  SWI/SNF related, matrix associated, actin dependent regulator of 
chromatin, subfamily d, member 3 
SMARCD3 
ATP DR  231144_at  SWI/SNF related, matrix associated, actin dependent regulator of 
chromatin, subfamily d, member 3 
SMARCD3 
ATP DR  211988_at  SWI/SNF related, matrix associated, actin dependent regulator of 
chromatin, subfamily e, member 1 
SMARCE1 
ATP DR  211989_at  SWI/SNF related, matrix associated, actin dependent regulator of 
chromatin, subfamily e, member 1 
SMARCE1 
ATP DR  214871_x_at  SWI/SNF related, matrix associated, actin dependent regulator of 
chromatin, subfamily e, member 1 
SMARCE1 
ATP DR  229511_at  SWI/SNF related, matrix associated, actin dependent regulator of 
chromatin, subfamily e, member 1 
SMARCE1 
   Imprinted genes       
Imprinted  208481_at  ankyrin repeat and SOCS box-containing 4  ASB4 
Imprinted  217228_s_at  ankyrin repeat and SOCS box-containing 4  ASB4 
Imprinted  217229_at  ankyrin repeat and SOCS box-containing 4  ASB4 
Imprinted  237720_at  ankyrin repeat and SOCS box-containing 4  ASB4 
Imprinted  237721_s_at  ankyrin repeat and SOCS box-containing 4  ASB4 
Imprinted  237800_at  Ankyrin repeat and SOCS box-containing 4  ASB4 
Imprinted  207607_at  achaete-scute complex-like 2 (Drosophila)  ASCL2 
Imprinted  229215_at  achaete-scute complex-like 2 (Drosophila)  ASCL2   296 
  Probe Set ID  Gene Title  Gene Symbol 
Imprinted  1568743_at  ATPase, Class V, type 10A  ATP10A 
Imprinted  214255_at  ATPase, Class V, type 10A  ATP10A 
Imprinted  214256_at  ATPase, Class V, type 10A  ATP10A 
Imprinted  207886_s_at  calcitonin receptor  CALCR 
Imprinted  207887_s_at  calcitonin receptor  CALCR 
Imprinted  1561726_s_at  CD81 antigen (target of antiproliferative antibody 1)  CD81 
Imprinted  200675_at  CD81 antigen (target of antiproliferative antibody 1)  CD81 
Imprinted  213182_x_at  cyclin-dependent kinase inhibitor 1C (p57, Kip2)  CDKN1C 
Imprinted  213183_s_at  Cyclin-dependent kinase inhibitor 1C (p57, Kip2)  CDKN1C 
Imprinted  213348_at  Cyclin-dependent kinase inhibitor 1C (p57, Kip2)  CDKN1C 
Imprinted  216894_x_at  cyclin-dependent kinase inhibitor 1C (p57, Kip2)  CDKN1C 
Imprinted  219533_at  cyclin-dependent kinase inhibitor 1C (p57, Kip2)  CDKN1C 
Imprinted  219534_x_at  cyclin-dependent kinase inhibitor 1C (p57, Kip2)  CDKN1C 
Imprinted  222298_at  Coatomer protein complex, subunit gamma 2  COPG2 
Imprinted  223457_at  coatomer protein complex, subunit gamma 2  COPG2 
Imprinted  236131_at  Coatomer protein complex, subunit gamma 2  COPG2 
Imprinted  205832_at  carboxypeptidase A4  CPA4 
Imprinted  1554235_at  catenin (cadherin-associated protein), alpha 3  CTNNA3 
Imprinted  1556877_at  Catenin (cadherin-associated protein), alpha 3  CTNNA3 
Imprinted  220815_at  catenin (cadherin-associated protein), alpha 3  CTNNA3 
Imprinted  201893_x_at  decorin  DCN 
Imprinted  209335_at  decorin  DCN 
Imprinted  211813_x_at  decorin  DCN 
Imprinted  211896_s_at  decorin  DCN 
Imprinted  234104_at  Decorin  DCN 
Imprinted  240556_at  Decorin  DCN 
Imprinted  242605_at  Decorin  DCN 
Imprinted  207154_at  deiodinase, iodothyronine, type III  DIO3 
Imprinted  215506_s_at  DIRAS family, GTP-binding RAS-like 3  DIRAS3 
Imprinted  209560_s_at  delta-like 1 homolog (Drosophila)  DLK1 
Imprinted  213707_s_at  distal-less homeo box 5  DLX5 
Imprinted  1561316_at  Gamma-aminobutyric acid (GABA) A receptor, beta 3  GABRB3 
Imprinted  1569689_s_at  gamma-aminobutyric acid (GABA) A receptor, beta 3  GABRB3 
Imprinted  205850_s_at  gamma-aminobutyric acid (GABA) A receptor, beta 3  GABRB3 
Imprinted  229724_at  gamma-aminobutyric acid (GABA) A receptor, beta 3  GABRB3 
Imprinted  227690_at  Gamma-aminobutyric acid (GABA) A receptor, beta 3 /// DEAD 
(Asp-Glu-Ala-Asp) box polypeptide 1 
GABRB3 /// 
DDX1 
Imprinted  227830_at  Gamma-aminobutyric acid (GABA) A receptor, beta 3 /// DEAD 
(Asp-Glu-Ala-Asp) box polypeptide 1 
GABRB3 /// 
DDX1 
Imprinted  200780_x_at  GNAS complex locus  GNAS 
Imprinted  200981_x_at  GNAS complex locus  GNAS 
Imprinted  211858_x_at  GNAS complex locus  GNAS 
Imprinted  212273_x_at  GNAS complex locus  GNAS 
Imprinted  214157_at  GNAS complex locus  GNAS 
Imprinted  214548_x_at  GNAS complex locus  GNAS 
Imprinted  217057_s_at  GNAS complex locus  GNAS 
Imprinted  217058_at  GNAS complex locus  GNAS 
Imprinted  217673_x_at  GNAS complex locus  GNAS 
Imprinted  228173_at  GNAS complex locus  GNAS 
Imprinted  229274_at  GNAS complex locus  GNAS 
Imprinted  235851_s_at  GNAS complex locus  GNAS 
Imprinted  239037_at  GNAS complex locus  GNAS 
Imprinted  242816_at  GNAS complex locus  GNAS 
Imprinted  242975_s_at  GNAS complex locus  GNAS 
Imprinted  209409_at  growth factor receptor-bound protein 10  GRB10 
Imprinted  209410_s_at  growth factor receptor-bound protein 10  GRB10 
Imprinted  210999_s_at  growth factor receptor-bound protein 10  GRB10 
Imprinted  215248_at  growth factor receptor-bound protein 10  GRB10 
Imprinted  224646_x_at  H19, imprinted maternally expressed untranslated mRNA  H19 
Imprinted  224997_x_at  H19, imprinted maternally expressed untranslated mRNA  H19 
Imprinted  214834_at  HBII-437 C/D box snoRNA /// HBII-13 snoRNA  HBII-437 ///   297 
  Probe Set ID  Gene Title  Gene Symbol 
HBII-13 
Imprinted  207135_at  5-hydroxytryptamine (serotonin) receptor 2A  HTR2A 
Imprinted  211616_s_at  5-hydroxytryptamine (serotonin) receptor 2A /// 5-
hydroxytryptamine (serotonin) receptor 2A 
HTR2A 
Imprinted  215513_at  hydatidiform mole associated and imprinted  HYMAI 
Imprinted  202410_x_at  insulin-like growth factor 2 (somatomedin A)  IGF2 
Imprinted  210881_s_at  insulin-like growth factor 2 (somatomedin A)  IGF2 
Imprinted  201392_s_at  insulin-like growth factor 2 receptor  IGF2R 
Imprinted  201393_s_at  insulin-like growth factor 2 receptor  IGF2R 
Imprinted  218637_at  hypothetical protein IMPACT  IMPACT 
Imprinted  222698_s_at  hypothetical protein IMPACT  IMPACT 
Imprinted  206598_at  insulin  INS 
Imprinted  213447_at  imprinted in Prader-Willi syndrome  IPW 
Imprinted  204486_at  potassium voltage-gated channel, KQT-like subfamily, member 1  KCNQ1 
Imprinted  204487_s_at  potassium voltage-gated channel, KQT-like subfamily, member 1  KCNQ1 
Imprinted  211217_s_at  potassium voltage-gated channel, KQT-like subfamily, member 1  KCNQ1 
Imprinted  220629_at  KCNQ1 downstream neighbor  KCNQ1DN 
Imprinted  1557457_at  Potassium voltage-gated channel, KQT-like subfamily, member 1  KCNQ1OT1 
Imprinted  1570123_at  Potassium voltage-gated channel, KQT-like subfamily, member 1  KCNQ1OT1 
Imprinted  234590_x_at  Potassium voltage-gated channel, KQT-like subfamily, member 1  KCNQ1OT1 
Imprinted  237249_at  Potassium voltage-gated channel, KQT-like subfamily, member 1  KCNQ1OT1 
Imprinted  243428_at  KCNQ1 overlapping transcript 1  KCNQ1OT1 
Imprinted  243435_at  KCNQ1 overlapping transcript 1  KCNQ1OT1 
Imprinted  244727_at  KCNQ1 overlapping transcript 1  KCNQ1OT1 
Imprinted  206822_s_at  l(3)mbt-like (Drosophila)  L3MBTL 
Imprinted  206823_at  l(3)mbt-like (Drosophila)  L3MBTL 
Imprinted  210306_at  l(3)mbt-like (Drosophila)  L3MBTL 
Imprinted  213837_at  l(3)mbt-like (Drosophila)  L3MBTL 
Imprinted  216077_s_at  l(3)mbt-like (Drosophila)  L3MBTL 
Imprinted  242637_at  L(3)mbt-like (Drosophila)  L3MBTL 
Imprinted  219894_at  MAGE-like 2  MAGEL2 
Imprinted  1558144_at  maternally expressed 3  MEG3 
Imprinted  210794_s_at  maternally expressed 3  MEG3 
Imprinted  212732_at  maternally expressed 3  MEG3 
Imprinted  222328_x_at  Maternally expressed 3  MEG3 
Imprinted  226210_s_at  maternally expressed 3  MEG3 
Imprinted  226211_at  maternally expressed 3  MEG3 
Imprinted  227390_at  maternally expressed 3  MEG3 
Imprinted  229557_at  maternally expressed 3  MEG3 
Imprinted  231529_at  Maternally expressed 3  MEG3 
Imprinted  235077_at  maternally expressed 3  MEG3 
Imprinted  242246_x_at  Maternally expressed 3  MEG3 
Imprinted  231467_at  Maternally expressed (in Callipyge) 8  MEG8 
Imprinted  240083_at  Maternally expressed (in Callipyge) 8  MEG8 
Imprinted  241260_at  Maternally expressed (in Callipyge) 8  MEG8 
Imprinted  202016_at  mesoderm specific transcript homolog (mouse)  MEST 
Imprinted  206585_at  makorin, ring finger protein, 3  MKRN3 
Imprinted  209550_at  necdin homolog (mouse)  NDN 
Imprinted  204239_s_at  neuronatin  NNAT 
Imprinted  223464_at  oxysterol binding protein-like 5  OSBPL5 
Imprinted  233734_s_at  oxysterol binding protein-like 5  OSBPL5 
Imprinted  241467_at  Oxysterol binding protein-like 5  OSBPL5 
Imprinted  212092_at  paternally expressed 10  PEG10 
Imprinted  212094_at  paternally expressed 10  PEG10 
Imprinted  209242_at  paternally expressed 3  PEG3 
Imprinted  209243_s_at  paternally expressed 3  PEG3 
Imprinted  230068_s_at  Paternally expressed 3  PEG3 
Imprinted  209802_at  pleckstrin homology-like domain, family A, member 2  PHLDA2 
Imprinted  209803_s_at  pleckstrin homology-like domain, family A, member 2  PHLDA2 
Imprinted  229494_s_at  Pleckstrin homology-like domain, family A, member 2  PHLDA2 
Imprinted  1559282_at  Pleiomorphic adenoma gene-like 1  PLAGL1   298 
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Imprinted  207002_s_at  pleiomorphic adenoma gene-like 1  PLAGL1 
Imprinted  207943_x_at  pleiomorphic adenoma gene-like 1  PLAGL1 
Imprinted  209318_x_at  pleiomorphic adenoma gene-like 1  PLAGL1 
Imprinted  244836_at  Pleiomorphic adenoma gene-like 1  PLAGL1 
Imprinted  206344_at  paraoxonase 1  PON1 
Imprinted  206345_s_at  paraoxonase 1  PON1 
Imprinted  221088_s_at  protein phosphatase 1, regulatory (inhibitor) subunit 9A  PPP1R9A 
Imprinted  228494_at  Protein phosphatase 1, regulatory (inhibitor) subunit 9A  PPP1R9A 
Imprinted  231966_at  protein phosphatase 1, regulatory (inhibitor) subunit 9A  PPP1R9A 
Imprinted  233985_x_at  protein phosphatase 1, regulatory (inhibitor) subunit 9A  PPP1R9A 
Imprinted  232629_at  prokineticin 2  PROK2 
Imprinted  232976_at  Prader-Willi syndrome chromosome region 1  PWCR1 
Imprinted  1554992_at  Ras protein-specific guanine nucleotide-releasing factor 1  RASGRF1 
Imprinted  210550_s_at  Ras protein-specific guanine nucleotide-releasing factor 1  RASGRF1 
Imprinted  215688_at  Ras protein-specific guanine nucleotide-releasing factor 1  RASGRF1 
Imprinted  202026_at  succinate dehydrogenase complex, subunit D, integral membrane 
protein 
SDHD 
Imprinted  215652_at  succinate dehydrogenase complex, subunit D, integral membrane 
protein 
SDHD 
Imprinted  204688_at  sarcoglycan, epsilon  SGCE 
Imprinted  204981_at  solute carrier family 22 (organic cation transporter), member 18  SLC22A18 
Imprinted  207429_at  solute carrier family 22 (organic cation transporter), member 2  SLC22A2 
Imprinted  1570482_at  Solute carrier family 22 (extraneuronal monoamine transporter), 
member 3 
SLC22A3 
Imprinted  205421_at  solute carrier family 22 (extraneuronal monoamine transporter), 
member 3 
SLC22A3 
Imprinted  242578_x_at  Solute carrier family 22 (extraneuronal monoamine transporter), 
member 3 
SLC22A3 
Imprinted  1555345_at  solute carrier family 38, member 4  SLC38A4 
Imprinted  220786_s_at  solute carrier family 38, member 4  SLC38A4 
Imprinted  1559342_a_at  Small nuclear ribonucleoprotein polypeptide N  SNRPN 
Imprinted  1559343_at  Small nuclear ribonucleoprotein polypeptide N  SNRPN 
Imprinted  1559545_at  Small nuclear ribonucleoprotein polypeptide N /// Clone RT-24 
SNURF-SNRPN mRNA, partial sequence; alternatively spliced 
SNRPN 
Imprinted  1559546_s_at  Small nuclear ribonucleoprotein polypeptide N /// Clone RT-24 
SNURF-SNRPN mRNA, partial sequence; alternatively spliced 
SNRPN 
Imprinted  1560741_at  Small nuclear ribonucleoprotein polypeptide N  SNRPN 
Imprinted  216850_at  small nuclear ribonucleoprotein polypeptide N  SNRPN 
Imprinted  221974_at  Small nuclear ribonucleoprotein polypeptide N  SNRPN 
Imprinted  226587_at  Small nuclear ribonucleoprotein polypeptide N /// CDNA FLJ33569 
fis, clone BRAMY2010317 
SNRPN 
Imprinted  226591_at  Small nuclear ribonucleoprotein polypeptide N  SNRPN 
Imprinted  228370_at  Small nuclear ribonucleoprotein polypeptide N  SNRPN 
Imprinted  201522_x_at  small nuclear ribonucleoprotein polypeptide N /// SNRPN upstream 
reading frame 
SNRPN /// 
SNURF 
Imprinted  206042_x_at  small nuclear ribonucleoprotein polypeptide N /// SNRPN upstream 
reading frame 
SNRPN /// 
SNURF 
Imprinted  1552860_at  transcription elongation factor B polypeptide 3C (elongin A3)  TCEB3C 
Imprinted  1554379_a_at  tumor protein p73  TP73 
Imprinted  220804_s_at  tumor protein p73  TP73 
Imprinted  232546_at  Tumor protein p73  TP73 
Imprinted  223935_at  transient receptor potential cation channel, subfamily M, member 5  TRPM5 
Imprinted  218612_s_at  tumor suppressing subtransferable candidate 4  TSSC4 
Imprinted  206512_at  U2(RNU2) small nuclear RNA auxillary factor 1-like 1  U2AF1L1 
Imprinted  211285_s_at  ubiquitin protein ligase E3A (human papilloma virus E6-associated 
protein, Angelman syndrome) 
UBE3A 
Imprinted  211575_s_at  ubiquitin protein ligase E3A (human papilloma virus E6-associated 
protein, Angelman syndrome) 
UBE3A 
Imprinted  212278_x_at  ubiquitin protein ligase E3A (human papilloma virus E6-associated 
protein, Angelman syndrome) 
UBE3A 
Imprinted  213128_s_at  ubiquitin protein ligase E3A (human papilloma virus E6-associated 
protein, Angelman syndrome) 
UBE3A 
Imprinted  213291_s_at  ubiquitin protein ligase E3A (human papilloma virus E6-associated  UBE3A   299 
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protein, Angelman syndrome) 
Imprinted  214980_at  Ubiquitin protein ligase E3A (human papilloma virus E6-associated 
protein, Angelman syndrome) 
UBE3A 
Imprinted  234163_at  Ubiquitin protein ligase E3A (human papilloma virus E6-associated 
protein, Angelman syndrome) 
UBE3A 
Imprinted  234166_at  Ubiquitin protein ligase E3A (human papilloma virus E6-associated 
protein, Angelman syndrome) 
UBE3A 
Imprinted  240204_at  Ubiquitin protein ligase E3A (human papilloma virus E6-associated 
protein, Angelman syndrome) 
UBE3A 
Imprinted  220895_at  ubiquitin specific peptidase 29  USP29 
Imprinted  206067_s_at  Wilms tumor 1  WT1 
Imprinted  216953_s_at  Wilms tumor 1  WT1 
Imprinted  214218_s_at  X (inactive)-specific transcript  XIST 
Imprinted  221728_x_at  X (inactive)-specific transcript  XIST 
Imprinted  224588_at  X (inactive)-specific transcript  XIST 
Imprinted  224589_at  X (inactive)-specific transcript  XIST 
Imprinted  224590_at  X (inactive)-specific transcript  XIST 
Imprinted  227671_at  X (inactive)-specific transcript  XIST 
Imprinted  231592_at  X (inactive)-specific transcript  XIST 
Imprinted  235446_at  X (inactive)-specific transcript  XIST 
Imprinted  243712_at  X (inactive)-specific transcript  XIST 
Imprinted  220653_at  zinc finger, imprinted 2  ZIM2 
Imprinted  1553022_at  zinc finger, imprinted 3  ZIM3 
Imprinted  1555510_at  zinc finger protein 215  ZNF215 
Imprinted  220214_at  zinc finger protein 215  ZNF215 
Imprinted  1558698_at  zinc finger protein 264  ZNF264 
Imprinted  205917_at  zinc finger protein 264  ZNF264 
Imprinted  230063_at  Zinc finger protein 264  ZNF264 
   miRNA processing genes    
miRNA  223653_x_at  bruno-like 4, RNA binding protein (Drosophila)  BRUNOL4 
miRNA  223654_s_at  bruno-like 4, RNA binding protein (Drosophila)  BRUNOL4 
miRNA  231220_at  bruno-like 4, RNA binding protein (Drosophila)  BRUNOL4 
miRNA  232719_at  bruno-like 4, RNA binding protein (Drosophila)  BRUNOL4 
miRNA  238966_at  Bruno-like 4, RNA binding protein (Drosophila)  BRUNOL4 
miRNA  243665_s_at  Bruno-like 4, RNA binding protein (Drosophila)  BRUNOL4 
miRNA  243666_at  Bruno-like 4, RNA binding protein (Drosophila)  BRUNOL4 
miRNA  1555467_a_at  CUG triplet repeat, RNA binding protein 1  CUGBP1 
miRNA  204113_at  CUG triplet repeat, RNA binding protein 1  CUGBP1 
miRNA  209489_at  CUG triplet repeat, RNA binding protein 1  CUGBP1 
miRNA  221742_at  CUG triplet repeat, RNA binding protein 1  CUGBP1 
miRNA  221743_at  CUG triplet repeat, RNA binding protein 1  CUGBP1 
miRNA  235297_at  CUG triplet repeat, RNA binding protein 1  CUGBP1 
miRNA  235865_at  CUG triplet repeat, RNA binding protein 1  CUGBP1 
miRNA  218650_at  DiGeorge syndrome critical region gene 8  DGCR8 
miRNA  219811_at  DiGeorge syndrome critical region gene 8  DGCR8 
miRNA  64474_g_at  DiGeorge syndrome critical region gene 8  DGCR8 
miRNA  91617_at  DiGeorge syndrome critical region gene 8  DGCR8 
miRNA  1557063_at  Dicer1, Dcr-1 homolog (Drosophila)  DICER1 
miRNA  206061_s_at  Dicer1, Dcr-1 homolog (Drosophila)  DICER1 
miRNA  212888_at  Dicer1, Dcr-1 homolog (Drosophila)  DICER1 
miRNA  213229_at  Dicer1, Dcr-1 homolog (Drosophila)  DICER1 
miRNA  216260_at  Dicer1, Dcr-1 homolog (Drosophila)  DICER1 
miRNA  216280_s_at  Dicer1, Dcr-1 homolog (Drosophila)  DICER1 
miRNA  216281_at  Dicer1, Dcr-1 homolog (Drosophila)  DICER1 
miRNA  218287_s_at  eukaryotic translation initiation factor 2C, 1  EIF2C1 
miRNA  222576_s_at  eukaryotic translation initiation factor 2C, 1  EIF2C1 
miRNA  219426_at  eukaryotic translation initiation factor 2C, 3  EIF2C3 
miRNA  1569408_at  Eukaryotic translation initiation factor 2C, 4  EIF2C4 
miRNA  219190_s_at  eukaryotic translation initiation factor 2C, 4  EIF2C4 
miRNA  222842_at  Eukaryotic translation initiation factor 2C, 4  EIF2C4 
miRNA  227930_at  Eukaryotic translation initiation factor 2C, 4  EIF2C4   300 
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miRNA  214868_at  piwi-like 1 (Drosophila)  PIWIL1 
miRNA  218269_at  ribonuclease III, nuclear  RNASEN 
miRNA  241269_at  Ribonuclease III, nuclear  RNASEN 
miRNA  223055_s_at  exportin 5  XPO5 
miRNA  223056_s_at  exportin 5  XPO5 
miRNA  223057_s_at  exportin 5  XPO5 
miRNA  233677_at  Exportin 5  XPO5 
   Nucleosome assembly    
Nucleosome  234960_at  ---  --- 
Nucleosome  213497_at  ankyrin repeat and BTB (POZ) domain containing 2  ABTB2 
Nucleosome  232624_at  ankyrin repeat and BTB (POZ) domain containing 2  ABTB2 
Nucleosome  233628_at  Ankyrin repeat and BTB (POZ) domain containing 2  ABTB2 
Nucleosome  233691_at  Ankyrin repeat and BTB (POZ) domain containing 2  ABTB2 
Nucleosome  203427_at  ASF1 anti-silencing function 1 homolog A (S. cerevisiae)  ASF1A 
Nucleosome  203428_s_at  ASF1 anti-silencing function 1 homolog A (S. cerevisiae)  ASF1A 
Nucleosome  213561_at  ASF1 anti-silencing function 1 homolog A (S. cerevisiae)  ASF1A 
Nucleosome  1555266_a_at  additional sex combs like 2 (Drosophila)  ASXL2 
Nucleosome  218659_at  additional sex combs like 2 (Drosophila)  ASXL2 
Nucleosome  201518_at  chromobox homolog 1 (HP1 beta homolog Drosophila )  CBX1 
Nucleosome  215989_at  chromobox homolog 2 (Pc class homolog, Drosophila)  CBX2 
Nucleosome  224138_at  chromobox homolog 2 (Pc class homolog, Drosophila)  CBX2 
Nucleosome  226473_at  chromobox homolog 2 (Pc class homolog, Drosophila)  CBX2 
Nucleosome  1555920_at  Chromobox homolog 3 (HP1 gamma homolog, Drosophila)  CBX3 
Nucleosome  200037_s_at  chromobox homolog 3 (HP1 gamma homolog, Drosophila) /// 
chromobox homolog 3 (HP1 gamma homolog, Drosophila) 
CBX3 
Nucleosome  201091_s_at  chromobox homolog 3 (HP1 gamma homolog, Drosophila)  CBX3 
Nucleosome  230998_at  Chromobox homolog 3 (HP1 gamma homolog, Drosophila)  CBX3 
Nucleosome  206724_at  chromobox homolog 4 (Pc class homolog, Drosophila)  CBX4 
Nucleosome  227558_at  chromobox homolog 4 (Pc class homolog, Drosophila)  CBX4 
Nucleosome  209715_at  chromobox homolog 5 (HP1 alpha homolog, Drosophila)  CBX5 
Nucleosome  212126_at  Chromobox homolog 5 (HP1 alpha homolog, Drosophila)  CBX5 
Nucleosome  226085_at  Chromobox homolog 5 (HP1 alpha homolog, Drosophila)  CBX5 
Nucleosome  231862_at  Chromobox homolog 5 (HP1 alpha homolog, Drosophila)  CBX5 
Nucleosome  234990_at  Chromobox homolog 5 (HP1 alpha homolog, Drosophila)  CBX5 
Nucleosome  242069_at  Chromobox homolog 5 (HP1 alpha homolog, Drosophila)  CBX5 
Nucleosome  202047_s_at  chromobox homolog 6  CBX6 
Nucleosome  202048_s_at  chromobox homolog 6  CBX6 
Nucleosome  229733_s_at  Chromobox homolog 6  CBX6 
Nucleosome  212914_at  chromobox homolog 7  CBX7 
Nucleosome  219755_at  chromobox homolog 8 (Pc class homolog, Drosophila)  CBX8 
Nucleosome  204962_s_at  centromere protein A, 17kDa  CENPA 
Nucleosome  210821_x_at  centromere protein A, 17kDa  CENPA 
Nucleosome  203975_s_at  chromatin assembly factor 1, subunit A (p150)  CHAF1A 
Nucleosome  203976_s_at  chromatin assembly factor 1, subunit A (p150)  CHAF1A 
Nucleosome  214426_x_at  chromatin assembly factor 1, subunit A (p150)  CHAF1A 
Nucleosome  229808_at  Chromatin assembly factor 1, subunit A (p150)  CHAF1A 
Nucleosome  204775_at  chromatin assembly factor 1, subunit B (p60)  CHAF1B 
Nucleosome  203274_at  coagulation factor VIII-associated (intronic transcript) 1  F8A1 
Nucleosome  1552853_at  hypothetical protein FLJ32784  FLJ32784 
Nucleosome  1552854_a_at  hypothetical protein FLJ32784  FLJ32784 
Nucleosome  232622_at  Hypothetical protein FLJ32784  FLJ32784 
Nucleosome  208886_at  H1 histone family, member 0  H1F0 
Nucleosome  1553064_at  H1 histone family, member O, oocyte-specific  H1FOO 
Nucleosome  204805_s_at  H1 histone family, member X  H1FX 
Nucleosome  231004_s_at  H1 histone family, member X  H1FX 
Nucleosome  214412_at  H2A histone family, member B3 /// H2A histone family, member 
B1 
H2AFB3 /// 
H2AFB1 
Nucleosome  220936_s_at  H2A histone family, member J  H2AFJ 
Nucleosome  224301_x_at  H2A histone family, member J  H2AFJ 
Nucleosome  225245_x_at  H2A histone family, member J  H2AFJ 
Nucleosome  228213_at  H2A histone family, member J  H2AFJ   301 
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Nucleosome  202487_s_at  H2A histone family, member V  H2AFV 
Nucleosome  212205_at  H2A histone family, member V  H2AFV 
Nucleosome  212206_s_at  H2A histone family, member V  H2AFV 
Nucleosome  227085_at  H2A histone family, member V  H2AFV 
Nucleosome  205436_s_at  H2A histone family, member X  H2AFX 
Nucleosome  212524_x_at  H2A histone family, member X  H2AFX 
Nucleosome  212525_s_at  H2A histone family, member X  H2AFX 
Nucleosome  213344_s_at  H2A histone family, member X  H2AFX 
Nucleosome  207168_s_at  H2A histone family, member Y  H2AFY 
Nucleosome  214500_at  H2A histone family, member Y  H2AFY 
Nucleosome  214501_s_at  H2A histone family, member Y  H2AFY 
Nucleosome  226840_at  H2A histone family, member Y  H2AFY 
Nucleosome  229593_at  H2A histone family, member Y  H2AFY 
Nucleosome  1563319_at  H2A histone family, member Y2  H2AFY2 
Nucleosome  218445_at  H2A histone family, member Y2  H2AFY2 
Nucleosome  200853_at  H2A histone family, member Z  H2AFZ 
Nucleosome  213911_s_at  H2A histone family, member Z  H2AFZ 
Nucleosome  208579_x_at  H2B histone family, member S  H2BFS 
Nucleosome  208755_x_at  H3 histone, family 3A  H3F3A 
Nucleosome  200080_s_at  H3 histone, family 3A /// H3 histone, family 3A /// H3 histone, 
family 3A pseudogene /// H3 histone, family 3A pseudogene 
H3F3A /// 
LOC440926 
Nucleosome  211940_x_at  H3 histone, family 3A /// H3 histone, family 3A pseudogene  H3F3A /// 
LOC440926 
Nucleosome  213828_x_at  H3 histone, family 3A /// H3 histone, family 3A pseudogene  H3F3A /// 
LOC440926 
Nucleosome  209069_s_at  H3 histone, family 3B (H3.3B)  H3F3B 
Nucleosome  211997_x_at  H3 histone, family 3B (H3.3B)  H3F3B 
Nucleosome  211998_at  H3 histone, family 3B (H3.3B)  H3F3B 
Nucleosome  211999_at  H3 histone, family 3B (H3.3B)  H3F3B 
Nucleosome  218166_s_at  hepatitis B virus x associated protein  HBXAP 
Nucleosome  222540_s_at  hepatitis B virus x associated protein  HBXAP 
Nucleosome  222541_at  hepatitis B virus x associated protein  HBXAP 
Nucleosome  223818_s_at  hepatitis B virus x associated protein  HBXAP 
Nucleosome  235381_at  Hepatitis B virus x associated protein /// Homo sapiens, clone 
IMAGE:3457110, mRNA 
HBXAP 
Nucleosome  231229_at  spermatid-specific linker histone H1-like protein  HILS1 
Nucleosome  208484_at  histone 1, H1a  HIST1H1A 
Nucleosome  214534_at  histone 1, H1b  HIST1H1B 
Nucleosome  209398_at  histone 1, H1c  HIST1H1C 
Nucleosome  214537_at  histone 1, H1d  HIST1H1D 
Nucleosome  208553_at  histone 1, H1e  HIST1H1E 
Nucleosome  1553568_a_at  histone 1, H1t  HIST1H1T 
Nucleosome  207982_at  histone 1, H1t  HIST1H1T 
Nucleosome  208569_at  histone 1, H2ab  HIST1H2AB 
Nucleosome  215071_s_at  histone 1, H2ac  HIST1H2AC 
Nucleosome  214469_at  histone 1, H2ae  HIST1H2AE 
Nucleosome  207156_at  histone 1, H2ag  HIST1H2AG 
Nucleosome  214542_x_at  histone 1, H2ai  HIST1H2AI 
Nucleosome  208583_x_at  histone 1, H2aj  HIST1H2AJ 
Nucleosome  214644_at  histone 1, H2ak  HIST1H2AK 
Nucleosome  214554_at  histone 1, H2al  HIST1H2AL 
Nucleosome  214481_at  histone 1, H2am  HIST1H2AM 
Nucleosome  241519_at  histone 1, H2ba  HIST1H2BA 
Nucleosome  208547_at  histone 1, H2bb  HIST1H2BB 
Nucleosome  214455_at  histone 1, H2bc  HIST1H2BC 
Nucleosome  236193_at  histone 1, H2bc  HIST1H2BC 
Nucleosome  209911_x_at  histone 1, H2bd  HIST1H2BD 
Nucleosome  222067_x_at  histone 1, H2bd  HIST1H2BD 
Nucleosome  235456_at  Histone 1, H2bd  HIST1H2BD 
Nucleosome  235681_at  Histone 1, H2bd  HIST1H2BD 
Nucleosome  208527_x_at  histone 1, H2be  HIST1H2BE   302 
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Nucleosome  208490_x_at  histone 1, H2bf  HIST1H2BF 
Nucleosome  210387_at  histone 1, H2bg  HIST1H2BG 
Nucleosome  215779_s_at  histone 1, H2bg  HIST1H2BG 
Nucleosome  208546_x_at  histone 1, H2bh  HIST1H2BH 
Nucleosome  208523_x_at  histone 1, H2bi  HIST1H2BI 
Nucleosome  214502_at  histone 1, H2bj  HIST1H2BJ 
Nucleosome  209806_at  histone 1, H2bk  HIST1H2BK 
Nucleosome  207611_at  histone 1, H2bl  HIST1H2BL 
Nucleosome  208515_at  histone 1, H2bm  HIST1H2BM 
Nucleosome  207226_at  histone 1, H2bn  HIST1H2BN 
Nucleosome  214540_at  histone 1, H2bo  HIST1H2BO 
Nucleosome  208575_at  histone 1, H3a  HIST1H3A 
Nucleosome  208576_s_at  histone 1, H3b  HIST1H3B 
Nucleosome  208577_at  histone 1, H3c  HIST1H3C 
Nucleosome  214472_at  histone 1, H3d  HIST1H3D 
Nucleosome  214522_x_at  histone 1, H3d  HIST1H3D 
Nucleosome  239669_at  Histone 1, H3d  HIST1H3D 
Nucleosome  214616_at  histone 1, H3e  HIST1H3E 
Nucleosome  208506_at  histone 1, H3f  HIST1H3F 
Nucleosome  208496_x_at  histone 1, H3g  HIST1H3G 
Nucleosome  206110_at  histone 1, H3h  HIST1H3H 
Nucleosome  214509_at  histone 1, H3i  HIST1H3I 
Nucleosome  214646_at  Histone 1, H3j  HIST1H3J 
Nucleosome  208046_at  histone 1, H4a  HIST1H4A 
Nucleosome  214516_at  histone 1, H4b  HIST1H4B 
Nucleosome  205967_at  histone 1, H4c  HIST1H4C 
Nucleosome  208076_at  histone 1, H4d  HIST1H4D 
Nucleosome  206951_at  histone 1, H4e  HIST1H4E 
Nucleosome  208026_at  histone 1, H4f  HIST1H4F 
Nucleosome  208551_at  histone 1, H4g  HIST1H4G 
Nucleosome  208180_s_at  histone 1, H4h  HIST1H4H 
Nucleosome  208181_at  histone 1, H4h  HIST1H4H 
Nucleosome  232035_at  histone 1, H4h  HIST1H4H 
Nucleosome  208580_x_at  histone 1, H4k /// histone 1, H4j  HIST1H4K /// 
HIST1H4J 
Nucleosome  214463_x_at  histone 1, H4k /// histone 1, H4j  HIST1H4K /// 
HIST1H4J 
Nucleosome  214562_at  histone 1, H4l  HIST1H4L 
Nucleosome  214290_s_at  histone 2, H2aa  HIST2H2AA 
Nucleosome  218279_s_at  histone 2, H2aa  HIST2H2AA 
Nucleosome  218280_x_at  histone 2, H2aa  HIST2H2AA 
Nucleosome  227943_at  Histone 2, H2aa  HIST2H2AA 
Nucleosome  202708_s_at  histone 2, H2be  HIST2H2BE 
Nucleosome  207046_at  histone 2, H4  HIST2H4 
Nucleosome  230738_at  Histone H4/o  HIST2H4 
Nucleosome  230795_at  Histone H4/o  HIST2H4 
Nucleosome  238529_at  Histone H4/o  HIST2H4 
Nucleosome  221582_at  histone 3, H2a  HIST3H2A 
Nucleosome  231681_x_at  Histone 3, H2a  HIST3H2A 
Nucleosome  208572_at  histone 3, H3  HIST3H3 
Nucleosome  208808_s_at  high-mobility group box 2  HMGB2 
Nucleosome  236091_at  high-mobility group box 2  HMGB2 
Nucleosome  243368_at  High-mobility group box 2  HMGB2 
Nucleosome  1554251_at  heterochromatin protein 1, binding protein 3  HP1BP3 
Nucleosome  220633_s_at  heterochromatin protein 1, binding protein 3  HP1BP3 
Nucleosome  224591_at  heterochromatin protein 1, binding protein 3  HP1BP3 
Nucleosome  224592_x_at  heterochromatin protein 1, binding protein 3  HP1BP3 
Nucleosome  1559142_at  MYST histone acetyltransferase (monocytic leukemia) 3  MYST3 
Nucleosome  202423_at  MYST histone acetyltransferase (monocytic leukemia) 3  MYST3 
Nucleosome  216361_s_at  MYST histone acetyltransferase (monocytic leukemia) 3  MYST3 
Nucleosome  221715_at  MYST histone acetyltransferase (monocytic leukemia) 3 /// MYST  MYST3   303 
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histone acetyltransferase (monocytic leukemia) 3 
Nucleosome  226547_at  MYST histone acetyltransferase (monocytic leukemia) 3  MYST3 
Nucleosome  242480_at  MYST histone acetyltransferase (monocytic leukemia) 3  MYST3 
Nucleosome  1562236_at  MYST histone acetyltransferase (monocytic leukemia) 4  MYST4 
Nucleosome  211874_s_at  MYST histone acetyltransferase (monocytic leukemia) 4  MYST4 
Nucleosome  212452_x_at  MYST histone acetyltransferase (monocytic leukemia) 4  MYST4 
Nucleosome  214496_x_at  MYST histone acetyltransferase (monocytic leukemia) 4  MYST4 
Nucleosome  243479_at  MYST histone acetyltransferase (monocytic leukemia) 4  MYST4 
Nucleosome  1556121_at  nucleosome assembly protein 1-like 1  NAP1L1 
Nucleosome  204528_s_at  nucleosome assembly protein 1-like 1  NAP1L1 
Nucleosome  208752_x_at  nucleosome assembly protein 1-like 1  NAP1L1 
Nucleosome  208753_s_at  nucleosome assembly protein 1-like 1  NAP1L1 
Nucleosome  208754_s_at  nucleosome assembly protein 1-like 1  NAP1L1 
Nucleosome  212967_x_at  nucleosome assembly protein 1-like 1  NAP1L1 
Nucleosome  213864_s_at  nucleosome assembly protein 1-like 1  NAP1L1 
Nucleosome  219368_at  nucleosome assembly protein 1-like 2  NAP1L2 
Nucleosome  204749_at  nucleosome assembly protein 1-like 3  NAP1L3 
Nucleosome  1556567_at  nucleosome assembly protein 1-like 4  NAP1L4 
Nucleosome  1560339_s_at  nucleosome assembly protein 1-like 4  NAP1L4 
Nucleosome  201414_s_at  nucleosome assembly protein 1-like 4  NAP1L4 
Nucleosome  220514_at  Nucleosome assembly protein 1-like 4  NAP1L4 
Nucleosome  222319_at  Nucleosome assembly protein 1-like 4  NAP1L4 
Nucleosome  229505_at  Nucleosome assembly protein 1-like 4  NAP1L4 
Nucleosome  236188_s_at  Nucleosome assembly protein 1-like 4  NAP1L4 
Nucleosome  244001_at  nucleosome assembly protein 1-like 4  NAP1L4 
Nucleosome  228062_at  nucleosome assembly protein 1-like 5  NAP1L5 
Nucleosome  228063_s_at  nucleosome assembly protein 1-like 5  NAP1L5 
Nucleosome  204412_s_at  neurofilament, heavy polypeptide 200kDa  NEFH 
Nucleosome  33767_at  neurofilament, heavy polypeptide 200kDa  NEFH 
Nucleosome  1559889_at  Similar to histone H2B histone family  RP5-998N21.6 
Nucleosome  200630_x_at  SET translocation (myeloid leukemia-associated)  SET 
Nucleosome  200631_s_at  SET translocation (myeloid leukemia-associated)  SET 
Nucleosome  210231_x_at  SET translocation (myeloid leukemia-associated)  SET 
Nucleosome  213047_x_at  SET translocation (myeloid leukemia-associated)  SET 
Nucleosome  213048_s_at  SET translocation (myeloid leukemia-associated)  SET 
Nucleosome  40189_at  SET translocation (myeloid leukemia-associated)  SET 
Nucleosome  215780_s_at  SET translocation (myeloid leukemia-associated) /// similar to SET 
protein (Phosphatase 2A inhibitor I2PP2A) (I-2PP2A) (Template 
activating factor I) (TAF-I) (HLA-DR associated protein II) 
(PHAPII) (Inhibitor of granzyme A-activated DNase) (IGAAD) 
SET /// 
LOC389168 
Nucleosome  1560171_at  SNF2 histone linker PHD RING helicase  SHPRH 
Nucleosome  226366_at  SNF2 histone linker PHD RING helicase  SHPRH 
Nucleosome  243964_at  SNF2 histone linker PHD RING helicase  SHPRH 
Nucleosome  202303_x_at  SWI/SNF related, matrix associated, actin dependent regulator of 
chromatin, subfamily a, member 5 
SMARCA5 
Nucleosome  213251_at  SWI/SNF related, matrix associated, actin dependent regulator of 
chromatin, subfamily a, member 5 
SMARCA5 
Nucleosome  213859_x_at  SWI/SNF related, matrix associated, actin dependent regulator of 
chromatin, subfamily a, member 5 
SMARCA5 
Nucleosome  217160_at  testis specific protein, Y-linked 1  TSPY1 
Nucleosome  217162_at  testis specific protein, Y-linked 1  TSPY1 
Nucleosome  207918_s_at  testis specific protein, Y-linked 1 /// testis specific protein, Y-linked 
2 
TSPY1 /// TSPY2 
Nucleosome  1560647_at  TSPY-like 1  TSPYL1 
Nucleosome  1560648_s_at  TSPY-like 1  TSPYL1 
Nucleosome  221493_at  TSPY-like 1  TSPYL1 
Nucleosome  218012_at  TSPY-like 2  TSPYL2 
Nucleosome  233617_at  TSPY-like 3 (pseudogene)  TSPYL3 
Nucleosome  212928_at  TSPY-like 4  TSPYL4 
Nucleosome  213122_at  TSPY-like 5  TSPYL5 
Nucleosome  231339_at  TSPY-like 6  TSPYL6 
   Polycomb group  Trithorax group genes      304 
  Probe Set ID  Gene Title  Gene Symbol 
PcG TxG  1565034_s_at  AF4/FMR2 family, member 3 /// myeloid/lymphoid or mixed-
lineage leukemia (trithorax homolog, Drosophila) 
AFF3 /// MLL 
PcG TxG  1556818_at  AT rich interactive domain 1B (SWI1-like)  ARID1B 
PcG TxG  1557707_at  AT rich interactive domain 1B (SWI1-like)  ARID1B 
PcG TxG  1558822_at  AT rich interactive domain 1B (SWI1-like)  ARID1B 
PcG TxG  1566989_at  AT rich interactive domain 1B (SWI1-like)  ARID1B 
PcG TxG  1566990_x_at  AT rich interactive domain 1B (SWI1-like)  ARID1B 
PcG TxG  1566991_at  AT rich interactive domain 1B (SWI1-like)  ARID1B 
PcG TxG  225181_at  AT rich interactive domain 1B (SWI1-like)  ARID1B 
PcG TxG  225184_at  AT rich interactive domain 1B (SWI1-like)  ARID1B 
PcG TxG  233339_s_at  AT rich interactive domain 1B (SWI1-like)  ARID1B 
PcG TxG  238043_at  AT rich interactive domain 1B (SWI1-like)  ARID1B 
PcG TxG  239674_at  AT rich interactive domain 1B (SWI1-like)  ARID1B 
PcG TxG  240116_at  AT rich interactive domain 1B (SWI1-like)  ARID1B 
PcG TxG  244772_at  AT rich interactive domain 1B (SWI1-like)  ARID1B 
PcG TxG  1558170_at  POU domain, class 6, transcription factor 1  ASH1L 
PcG TxG  218554_s_at  ash1 (absent, small, or homeotic)-like (Drosophila)  ASH1L 
PcG TxG  222667_s_at  ash1 (absent, small, or homeotic)-like (Drosophila)  ASH1L 
PcG TxG  226447_at  POU domain, class 6, transcription factor 1  ASH1L 
PcG TxG  215989_at  chromobox homolog 2 (Pc class homolog, Drosophila)  CBX2 
PcG TxG  224138_at  chromobox homolog 2 (Pc class homolog, Drosophila)  CBX2 
PcG TxG  226473_at  chromobox homolog 2 (Pc class homolog, Drosophila)  CBX2 
PcG TxG  206724_at  chromobox homolog 4 (Pc class homolog, Drosophila)  CBX4 
PcG TxG  227558_at  chromobox homolog 4 (Pc class homolog, Drosophila)  CBX4 
PcG TxG  219755_at  chromobox homolog 8 (Pc class homolog, Drosophila)  CBX8 
PcG TxG  209572_s_at  embryonic ectoderm development  EED 
PcG TxG  210656_at  embryonic ectoderm development  EED 
PcG TxG  203249_at  enhancer of zeste homolog 1 (Drosophila)  EZH1 
PcG TxG  211310_at  enhancer of zeste homolog 1 (Drosophila)  EZH1 
PcG TxG  239197_s_at  enhancer of zeste homolog 1 (Drosophila)  EZH1 
PcG TxG  239198_at  enhancer of zeste homolog 1 (Drosophila)  EZH1 
PcG TxG  32259_at  enhancer of zeste homolog 1 (Drosophila)  EZH1 
PcG TxG  203358_s_at  enhancer of zeste homolog 2 (Drosophila)  EZH2 
PcG TxG  1559856_s_at  myeloid/lymphoid or mixed-lineage leukemia (trithorax homolog, 
Drosophila) 
MLL 
PcG TxG  1565436_s_at  myeloid/lymphoid or mixed-lineage leukemia (trithorax homolog, 
Drosophila) 
MLL 
PcG TxG  212076_at  myeloid/lymphoid or mixed-lineage leukemia (trithorax homolog, 
Drosophila) 
MLL 
PcG TxG  212078_s_at  myeloid/lymphoid or mixed-lineage leukemia (trithorax homolog, 
Drosophila) 
MLL 
PcG TxG  212079_s_at  myeloid/lymphoid or mixed-lineage leukemia (trithorax homolog, 
Drosophila) 
MLL 
PcG TxG  216624_s_at  myeloid/lymphoid or mixed-lineage leukemia (trithorax homolog, 
Drosophila) 
MLL 
PcG TxG  229935_s_at  Myeloid/lymphoid or mixed-lineage leukemia (trithorax homolog, 
Drosophila) 
MLL 
PcG TxG  1565254_s_at  myeloid/lymphoid or mixed-lineage leukemia (trithorax homolog, 
Drosophila) /// elongation factor RNA polymerase II 
MLL /// ELL 
PcG TxG  211790_s_at  myeloid/lymphoid or mixed-lineage leukemia 2  MLL2 
PcG TxG  227527_at  myeloid/lymphoid or mixed-lineage leukemia 2  MLL2 
PcG TxG  227528_s_at  myeloid/lymphoid or mixed-lineage leukemia 2  MLL2 
PcG TxG  231974_at  myeloid/lymphoid or mixed-lineage leukemia 2  MLL2 
PcG TxG  203792_x_at  polycomb group ring finger 2  PCGF2 
PcG TxG  203793_x_at  polycomb group ring finger 2  PCGF2 
PcG TxG  213551_x_at  polycomb group ring finger 2  PCGF2 
PcG TxG  214239_x_at  polycomb group ring finger 2  PCGF2 
PcG TxG  240752_at  Polycomb group ring finger 2  PCGF2 
PcG TxG  218338_at  polyhomeotic-like 1 (Drosophila)  PHC1 
PcG TxG  225958_at  polyhomeotic-like 1 (Drosophila)  PHC1 
PcG TxG  1557852_at  Polyhomeotic-like 2 (Drosophila)  PHC2 
PcG TxG  200919_at  polyhomeotic-like 2 (Drosophila)  PHC2   305 
  Probe Set ID  Gene Title  Gene Symbol 
PcG TxG  238131_at  polyhomeotic-like 2 (Drosophila)  PHC2 
PcG TxG  1552644_a_at  polyhomeotic like 3 (Drosophila)  PHC3 
PcG TxG  1567696_at  Polyhomeotic like 3 (Drosophila)  PHC3 
PcG TxG  1567697_at  Polyhomeotic like 3 (Drosophila)  PHC3 
PcG TxG  1567698_x_at  Polyhomeotic like 3 (Drosophila)  PHC3 
PcG TxG  215521_at  polyhomeotic like 3 (Drosophila)  PHC3 
PcG TxG  220328_at  polyhomeotic like 3 (Drosophila)  PHC3 
PcG TxG  226508_at  polyhomeotic like 3 (Drosophila)  PHC3 
PcG TxG  240599_x_at  Polyhomeotic like 3 (Drosophila)  PHC3 
PcG TxG  202928_s_at  PHD finger protein 1  PHF1 
PcG TxG  40446_at  PHD finger protein 1  PHF1 
PcG TxG  208371_s_at  ring finger protein 1  RING1 
PcG TxG  35685_at  ring finger protein 1  RING1 
PcG TxG  205215_at  ring finger protein 2  RNF2 
PcG TxG  1558968_at  Sex comb on midleg-like 1 (Drosophila)  SCML1 
PcG TxG  218793_s_at  sex comb on midleg-like 1 (Drosophila)  SCML1 
PcG TxG  222747_s_at  sex comb on midleg-like 1 (Drosophila)  SCML1 
PcG TxG  206147_x_at  sex comb on midleg-like 2 (Drosophila)  SCML2 
PcG TxG  206542_s_at  SWI/SNF related, matrix associated, actin dependent regulator of 
chromatin, subfamily a, member 2 
SMARCA2 
PcG TxG  206543_at  SWI/SNF related, matrix associated, actin dependent regulator of 
chromatin, subfamily a, member 2 
SMARCA2 
PcG TxG  206544_x_at  SWI/SNF related, matrix associated, actin dependent regulator of 
chromatin, subfamily a, member 2 
SMARCA2 
PcG TxG  212257_s_at  SWI/SNF related, matrix associated, actin dependent regulator of 
chromatin, subfamily a, member 2 
SMARCA2 
PcG TxG  212258_s_at  SWI/SNF related, matrix associated, actin dependent regulator of 
chromatin, subfamily a, member 2 
SMARCA2 
PcG TxG  217707_x_at  SWI/SNF related, matrix associated, actin dependent regulator of 
chromatin, subfamily a, member 2 
SMARCA2 
PcG TxG  228926_s_at  SWI/SNF related, matrix associated, actin dependent regulator of 
chromatin, subfamily a, member 2 
SMARCA2 
PcG TxG  241756_at  SWI/SNF related, matrix associated, actin dependent regulator of 
chromatin, subfamily a, member 2 
SMARCA2 
PcG TxG  1569073_x_at  SWI/SNF related, matrix associated, actin dependent regulator of 
chromatin, subfamily a, member 4 
SMARCA4 
PcG TxG  208793_x_at  SWI/SNF related, matrix associated, actin dependent regulator of 
chromatin, subfamily a, member 4 
SMARCA4 
PcG TxG  208794_s_at  SWI/SNF related, matrix associated, actin dependent regulator of 
chromatin, subfamily a, member 4 
SMARCA4 
PcG TxG  212520_s_at  SWI/SNF related, matrix associated, actin dependent regulator of 
chromatin, subfamily a, member 4 
SMARCA4 
PcG TxG  213719_s_at  SWI/SNF related, matrix associated, actin dependent regulator of 
chromatin, subfamily a, member 4 
SMARCA4 
PcG TxG  213720_s_at  SWI/SNF related, matrix associated, actin dependent regulator of 
chromatin, subfamily a, member 4 
SMARCA4 
PcG TxG  214360_at  SWI/SNF related, matrix associated, actin dependent regulator of 
chromatin, subfamily a, member 4 
SMARCA4 
PcG TxG  214728_x_at  SWI/SNF related, matrix associated, actin dependent regulator of 
chromatin, subfamily a, member 4 
SMARCA4 
PcG TxG  215714_s_at  SWI/SNF related, matrix associated, actin dependent regulator of 
chromatin, subfamily a, member 4 
SMARCA4 
PcG TxG  217656_at  SWI/SNF related, matrix associated, actin dependent regulator of 
chromatin, subfamily a, member 4 
SMARCA4 
PcG TxG  243655_x_at  SWI/SNF related, matrix associated, actin dependent regulator of 
chromatin, subfamily a, member 4 
SMARCA4 
PcG TxG  212167_s_at  SWI/SNF related, matrix associated, actin dependent regulator of 
chromatin, subfamily b, member 1 
SMARCB1 
PcG TxG  228898_s_at  SWI/SNF related, matrix associated, actin dependent regulator of 
chromatin, subfamily b, member 1 
SMARCB1 
PcG TxG  231324_at  SWI/SNF related, matrix associated, actin dependent regulator of 
chromatin, subfamily b, member 1 
SMARCB1 
PcG TxG  201320_at  SWI/SNF related, matrix associated, actin dependent regulator of 
chromatin, subfamily c, member 2 
SMARCC2 
PcG TxG  201321_s_at  SWI/SNF related, matrix associated, actin dependent regulator of  SMARCC2   306 
  Probe Set ID  Gene Title  Gene Symbol 
chromatin, subfamily c, member 2 
PcG TxG  1566190_at  Suppressor of zeste 12 homolog (Drosophila)  SUZ12 
PcG TxG  1566191_at  Suppressor of zeste 12 homolog (Drosophila)  SUZ12 
PcG TxG  212287_at  suppressor of zeste 12 homolog (Drosophila)  SUZ12 
PcG TxG  213971_s_at  suppressor of zeste 12 homolog (Drosophila)  SUZ12 
PcG TxG  200047_s_at  YY1 transcription factor /// YY1 transcription factor  YY1 
PcG TxG  201901_s_at  YY1 transcription factor  YY1 
PcG TxG  201902_s_at  YY1 transcription factor  YY1 
PcG TxG  213494_s_at  YY1 transcription factor  YY1 
PcG TxG  206182_at  zinc finger protein 134 (clone pHZ-15)  ZNF134 
PcG TxG  227729_at  Zinc finger protein 134 (clone pHZ-15)  ZNF134 
PcG TxG  240995_at  Zinc finger protein 134 (clone pHZ-15)  ZNF134 
   Cytosine deaminases    
C deaminase  219841_at  activation-induced cytidine deaminase  AICDA 
C deaminase  224499_s_at  activation-induced cytidine deaminase /// activation-induced 
cytidine deaminase 
AICDA 
C deaminase  207158_at  apolipoprotein B mRNA editing enzyme, catalytic polypeptide 1  APOBEC1 
C deaminase  206160_at  apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 
2 
APOBEC2 
C deaminase  204205_at  apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 
3G 
APOBEC3G 
C deaminase  215579_at  apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 
3G 
APOBEC3G 
C deaminase  214995_s_at  apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 
3G /// apolipoprotein B mRNA editing enzyme, catalytic 
polypeptide-like 3F 
APOBEC3G /// 
APOBEC3F 
C deaminase  205627_at  cytidine deaminase  CDA 
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Table A3: Significant changes in gene expression between MSC 0 and MSC 5 (expression data 
not  normalized).  Log  fold  changes  in  expression  and  FDR  corrected  p-value  (q-value)  are 
indicated for each gene symbol 
 
Gene Symbol  Log Fold Change  q-value 
PEG10  3.75  0 
HIST1H2BG  2.40  0 
PEG10  1.98  0 
HDAC9  1.93  0 
ORC1L  1.59  0 
GADD45A  1.45  0 
CHAF1A  1.42  0 
CSRP2BP  1.40  0 
EZH2  1.35  1.00E-06 
SUV39H2  1.26  0 
HIST1H2BG  1.25  0 
POLE3  1.24  0 
H1F0  1.23  0 
SUV420H1  1.17  3.00E-06 
CHAF1A  1.14  0 
MLL / ELL  1.07  6.80E-05 
MLL / ELL  1.07  6.80E-05 
EED  1.04  0 
HIST1H4C  1.03  1.00E-06 
PHLDA2  1.03  1.00E-06 
CSRP2BP  1.00  1.00E-06 
SUV39H1  0.97  0 
NEFH  0.95  1.00E-06 
CHAF1B  0.94  0 
HAT1  0.93  0 
MAK3  0.90  0 
H1FX  0.89  6.00E-05 
NAP1L2  0.89  0 
Gene Symbol  Log Fold Change  q-value 
H2AFZ  0.87  0 
XPO5  0.86  1.00E-06 
CHAF1A  0.86  1.00E-06 
NAT5  0.85  0 
GRB10  0.84  0 
CBX5  0.84  3.40E-05 
CBX5  0.78  2.80E-05 
DNMT1  0.77  1.00E-06 
GTF3C4  0.77  0 
HMGB2  0.73  7.00E-06 
CENPA  0.73  6.00E-06 
HDAC2  0.72  3.00E-06 
GNPNAT1  0.71  2.00E-06 
GRB10  0.69  1.00E-06 
SMARCA5  0.67  1.00E-06 
SMARCA5  0.67  1.00E-06 
MAK3  0.67  1.00E-06 
H2AFZ  0.67  0 
AFF3 / MLL  0.65  0.000118 
 MLL / AFF3   0.65  0.000118 
BAZ1A  0.65  0.000497 
SUZ12  0.65  0 
NEFH  0.61  0.002574 
MBD1  0.61  6.20E-05 
NAP1L1  0.59  0.001352 
XPO5  0.59  5.00E-06 
SMARCA5  0.58  0.000114 
SMARCA5  0.58  0.000114   308 
Gene Symbol  Log Fold Change  q-value 
MYST4  -0.59  1.30E-05 
MYST4  -0.59  1.30E-05 
CHD3  -0.62  5.00E-06 
MLL3  -0.64  0.000497 
ZNF264  -0.68  3.60E-05 
MLL3  -0.69  6.20E-05 
SET7  -0.72  0 
HMG20B  -0.73  0 
EPAS1  -0.75  0 
ZBTB7A  -0.75  1.00E-06 
NCOA1  -0.78  4.50E-05 
MLL3  -0.78  2.00E-06 
NCOA3  -0.80  4.00E-06 
IPW  -0.81  1.00E-06 
H2AFY2  -0.83  1.00E-06 
SLC22A18  -0.91  0 
NCOA3  -0.93  0 
JMJD2B  -0.94  0 
H2AFJ  -0.94  0 
CDKN1C  -0.95  0 
SMARCA2  -0.97  0 
SMARCA2  -0.97  0 
APOBEC3G 
/ 3F  -0.99 
1.00E-06 
APOBEC3G  -0.99  3.40E-05 
CHD3  -1.01  0 
Gene Symbol  Log Fold Change  q-value 
NCOA3  -1.01  1.00E-06 
NDN  -1.01  0 
H2AFJ  -1.02  0 
JMJD2B  -1.05  0 
SUV420H1  -1.08  0 
SNRPN / 
SNURF  -1.12 
0 
SMARCA2  -1.12  0 
SMARCA2  -1.12  0 
SMARCA2  -1.13  0 
SMARCA2  -1.13  0 
DLX5  -1.17  0 
SUV420H1  -1.27  1.00E-06 
HIST2H2BE  -1.30  1.00E-06 
HDAC4  -1.31  1.00E-06 
SNRPN / 
SNURF  -1.35 
0 
SNRPN  -1.43  0 
HDAC4  -1.44  0 
SNRPN  -1.48  1.00E-06 
DCN  -2.63  0 
DCN  -2.81  0 
DCN  -3.01  0 
DCN  -3.06  0 
NAP1L3  -3.95  0 
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Table A4: Significant changes in gene expression between MSC 0 and MSC 5 (expression data 
normalized to expression of PCNA). Log fold changes in expression and FDR corrected p-value 
(q-value) are indicated for each gene symbol 
 
Gene Symbol  Log Fold Change  q-value 
NAP1L3  -4.50  0.0021 
DCN  -3.18  0.0000 
HDAC4  -1.86  0.0010 
HIST2H2BE  -1.85  0.0021 
DLX5  -1.73  0.0040 
SNRPN  -1.67  0.0002 
SUV420H1  -1.63  0.0015 
NDN  -1.57  0.0009 
KIAA0907  -1.54  0.0049 
CDKN1C  -1.50  0.0002 
H2AFJ  -1.50  0.0000 
JMJD2B  -1.49  0.0001 
SLC22A18  -1.46  0.0008 
H2AFY2  -1.38  0.0012 
PAR1  -1.36  0.0002 
NCOA3  -1.35  0.0036 
EPAS1  -1.30  0.0000 
HMG20B  -1.28  0.0023 
SET7  -1.27  0.0001 
ZNF264  -1.23  0.0002 
MLL3  -1.19  0.0072 
CHD3  -1.17  0.0038 
SMARCA2  -1.15  0.0084 
SMARCE1  -1.12  0.0005 
HDAC8  -1.08  0.0063 
Gene Symbol  Log Fold Change  q-value 
NCOA1  -1.08  0.0051 
ATP10A  -1.08  0.0030 
HDAC5  -1.05  0.0015 
SAT2  -1.05  0.0002 
MECP2  -1.04  0.0015 
ZBTB7A  -1.02  0.0022 
JMJD2C  -1.01  0.0019 
TSPYL1  -1.01  0.0011 
SIRT2  -1.01  0.0005 
H3F3A  -1.00  0.0015 
MYST4  -1.00  0.0077 
PHC3  -1.00  0.0001 
SMARCD3  -0.99  0.0006 
COPG2  -0.98  0.0008 
NCOA3  -0.97  0.0007 
NCOA1  -0.96  0.0089 
HP1-BP74  -0.95  0.0026 
SHPRH  -0.95  0.0080 
MLL  -0.94  0.0056 
MEG3  -0.93  0.0026 
CD81  -0.93  0.0009 
ABTB2  -0.92  0.0027 
HIST2H2AA  -0.92  0.0019 
H3F3A  -0.92  0.0000 
TSPYL3  -0.91  0.0054   310 
Gene Symbol  Log Fold Change  q-value 
HMG20B  -0.91  0.0022 
EIF2C3  -0.90  0.0005 
SIRT4  -0.89  0.0003 
SETMAR  -0.89  0.0014 
JMJD3  -0.89  0.0067 
PHC1  -0.88  0.0009 
EDF1  -0.88  0.0005 
JMJD2A  -0.87  0.0003 
IGF2R  -0.87  0.0034 
CREBBP  -0.86  0.0020 
EIF2C1  -0.86  0.0044 
H2AFX  -0.86  0.0043 
EPAS1  -0.85  0.0069 
ASH1L  -0.84  0.0095 
ARID1B  -0.84  0.0082 
DCN  -0.84  0.0009 
RING1  -0.84  0.0097 
KIFC1  -0.83  0.0000 
SETDB1  -0.83  0.0005 
ZNF134  -0.82  0.0019 
PAR1  -0.82  0.0068 
HIST1H3H  -0.82  0.0075 
Gene Symbol  Log Fold Change  q-value 
CPA4  -0.82  0.0033 
TAF1  -0.82  0.0022 
JMJD2B  -0.82  0.0012 
SHPRH  -0.81  0.0012 
CDKN1C  -0.81  0.0052 
GNAS  -0.81  0.0077 
SRCAP  -0.80  0.0008 
GRB10  0.29  0.0015 
NAT5  0.30  0.0002 
HAT1  0.38  0.0001 
CHAF1B  0.39  0.0046 
PHLDA2  0.47  0.0034 
EED  0.49  0.0004 
POLE3  0.69  0.0059 
SUV39H2  0.71  0.0031 
CHAF1A  0.87  0.0010 
GADD45A  0.89  0.0000 
ORC1L  1.04  0.0004 
HDAC9  1.38  0.0057 
HIST1H2BG  1.85  0.0005 
PEG10  3.20  0.0012 
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Table A5: Gene symbols of PRC2 target genes displaying SUZ12, EZH2 and H3K27me3 
occupancy in human ES cells (from Lee et al.) 
 
ABCC8 
ABTB2 
ADAMTS15 
ADAMTS18 
ADARB2 
ADCY4 
ADCY8 
ADCYAP1 
ADRA1A 
ADRA2A 
ADRB1 
ADRB3 
ALOX15 
ALX3 
ALX4 
ANKRD19 
ANKRD20A 
ANKRD20B 
ANKRD27 
AQP5 
ARHGAP20 
ARL9 
ASCL1 
ASCL2 
ASTN 
ASTN2 
ATBF1 
ATF3 
ATOH1 
ATOH8 
BAPX1 
BARHL1 
BARHL2 
BARX1 
BARX2 
BCL2 
BHLHB3 
BHLHB4 
BHLHB5 
BMP8A 
BNC1 
BTG2 
C10orf48 
C19orf4 
C1orf153 
C1orf32 
C1orf76 
C1orf92 
C20orf103 
C21orf63 
C2orf32 
C3orf15 
CA10 
CACNA1B 
CACNA1D 
CACNA1E 
CACNA1G 
CALCA 
CAMK2N1 
CASZ1 
CBLN1 
CBLN4 
CBR3 
CBX8 
CD34 
CD8A 
CDH23 
CDH7 
CDK5R2 
CDKN2C 
CDX2 
CENTA2 
CGB7 
CGB8 
CGI-38 
CH25H 
CHODL 
CHRD 
CHRDL2 
CHST8 
CHX10 
CIDEA 
CITED1 
CKLFSF2 
CLCN5 
CLEC14A 
CLSTN2 
CNNM1 
CNTFR 
COL24A1 
COL25A1 
COL27A1 
COL2A1 
COL4A5 
COL4A6 
COL9A2 
COLEC12 
COMP 
CORO6 
CRHR1 
CRLF1 
CRTAC1 
CRYBA2 
CSMD1 
CSMD3 
CTNND2 
CX36 
CXCL14 
CXCL16 
CYP24A1 
CYP26A1 
CYP26B1 
CYP26C1 
CYP27B1 
DACH1 
DACH2 
DCAMKL2 
DCC 
DCHS2 
DDAH1 
DGKG 
DGKI 
DHH 
DIO3 
DKFZP564O0823 
DKK1 
DKK2 
DLL4 
DLX1 
DLX2 
DLX3 
DLX4 
DMRT1 
DMRT2 
DMRT3 
DOK6 
DPF3 
DPY19L2 
DRD5 
DSC3 
DSCAML1 
DUOX1 
DUOX2 
DUSP4 
ECEL1 
EFNA1 
EFNA3 
EGFL6 
EGR3 
EGR4 
ELMOD1 
EN1 
EN2 
EOMES 
EPAS1 
EPB41L4A 
EPHA5 
EPHB1 
EPHB3 
ERBB4 
ESAM 
ESPN 
ESX1L 
F2R 
FAM19A4 
FAM43B 
FAM5B 
FAM5C 
FAM80A 
FAM84A 
FBN2 
FBP1 
FBXL8 
FBXO3 
FEV 
FEZ1 
FGF20 
FGF3 
FGF5 
FGF9 
FIGLA 
FLI1 
FLJ11235 
FLJ13236 
FLJ20032 
FLJ32063 
FLJ32447 
FLJ33790 
FLJ34922 
FLJ35409 
FLJ35740 
FLJ36166   312 
FLJ37440 
FLJ39553 
FLJ44815 
FLJ45455 
FLJ45983 
FLJ46347 
FLRT2 
FOXA2 
FOXB1 
FOXD2 
FOXD3 
FOXD4b 
FOXD4L1 
FOXD4L2 
FOXD4L3 
FOXE1 
FOXF1 
FOXG1B 
FOXJ1 
FOXL1 
FOXL2 
FRMD3 
FUT4 
FZD10 
FZD2 
GABRA2 
GABRA4 
GAD2 
GALGT 
GALGT2 
GALNTL4 
GALR2 
GATA2 
GATA3 
GATA4 
GATA6 
GBX2 
GDF6 
GDF7 
GDNF 
GHR 
GHSR 
GIMAP5 
GJB2 
GLT25D2 
GNA14 
GPC5 
GPM6B 
GPR10 
GPR101 
GPR12 
GPR120 
GPR88 
GRIA2 
GRID1 
GRIK1 
GRIK3 
GRIN3A 
GRM7 
GSC 
GSCL 
GSH1 
GSH2 
GUCY1A3 
GUCY2D 
HAND2 
HBA1 
HBA2 
HES2 
HES7 
HEY1 
HHAT 
HHEX 
HHIP 
HLX1 
HLXB9 
HMX2 
HMX3 
HOXB1 
HOXB13 
HOXB2 
HOXB3 
HOXB6 
HOXB7 
HOXB8 
HOXC11 
HOXC12 
HOXC4 
HOXC5 
HOXC6 
HOXC8 
HOXD1 
HOXD12 
HOXD13 
HOXD3 
HOXD4 
HOXD8 
HOXD9 
HPCAL4 
HPSE2 
HRK 
HS3ST3B1 
HS6ST1P 
HS6ST3 
HSF4 
HSPA6 
HTR1A 
HTR2C 
HTR7 
ICAM5 
IGF2AS 
IGSF21 
IL1RAPL2 
IL7 
INA 
INSM2 
INSRR 
IPF1 
IRX3 
IRX4 
IRX5 
ISL1 
ISL2 
ITGA4 
ITPKA 
JUN 
KAZALD1 
KCNA1 
KCNA3 
KCNAB1 
KCNC2 
KCNC4 
KCND3 
KCNH1 
KCNH3 
KCNK12 
KCNK13 
KCNK2 
KCNK4 
KCNMA1 
KCNQ3 
KCNV1 
KIAA1036 
KIAA1199 
KIAA1324 
KIAA1666 
KIRREL3 
KL 
KLF4 
KY 
LBX1 
LGALS3 
LGR5 
LHX2 
LHX4 
LHX5 
LHX6 
LHX8 
LMX1B 
LOC124842 
LOC127003 
LOC143903 
LOC148898 
LOC150221 
LOC153684 
LOC200030 
LOC340529 
LOC388394 
LOC388407 
LOC389289 
LOC400120 
LOC405753 
LOC440804 
LOC441413 
LOC441425 
LOC441426 
LOC441430 
LOC441459 
LOC56901 
LOC92162 
LPHN3 
LPL 
LRCH2 
LRFN5 
LRP2 
LRRTM1 
LTBP2 
LTK 
LYSMD2 
MAB21L1 
MAB21L2 
MAFB 
MAL 
MAPK4 
MAPT 
MCOLN3 
MESP1 
METRNL 
MGC11324 
MGC26690 
MGC26718 
MGC35555 
MGC39545 
MLLT3   313 
MSC 
MSX1 
MT1A 
MT1B 
MT1H 
MT1K 
MTM 
MYF6 
MYO5B 
MYOD1 
NAGS 
NAV2 
NCAM1 
NEF3 
NEFL 
NELL1 
NEUROD1 
NEUROD2 
NEUROG1 
NEUROG2 
NEUROG3 
NFIX 
NIP 
NKX2-2 
NKX2-3 
NKX2-8 
NKX3-1 
NKX6-1 
NKX6-2 
NLF1 
NOL4 
NPAS1 
NPNT 
NPR3 
NPTX1 
NPY1R 
NR2F2 
NR4A3 
NRG1 
NRG2 
NS5ATP13TP2 
NT5C1A 
NTN1 
NTNG2 
NTRK1 
NTRK2 
NXF 
OCA2 
OLFML2B 
OLIG2 
ONECUT1 
ONECUT2 
OPRD1 
OSAP 
OSR1 
OTOP1 
OTOP2 
OTOP3 
OTP 
OTX1 
OTX2 
OXCT2 
PAPPA 
PAX1 
PAX2 
PAX3 
PAX6 
PAX7 
PAX8 
PAX9 
PCDH17 
PCDH8 
PDE4DIP 
PDGFRA 
PDZK10 
PDZK3 
PENK 
PGM5 
PGR 
PHOX2A 
PHOX2B 
PIP5K1B 
PIR 
PITX1 
PITX2 
PITX3 
PKNOX2 
PKP1 
PLEC1 
PLXNA2 
PMP22 
PODN 
POLE 
POU3F1 
POU3F4 
POU4F1 
POU4F2 
POU4F3 
PPM1E 
PRAC 
PRDM12 
PRG-3 
PRKCE 
PRKG1 
PROK2 
PTF1A 
PTGDR 
PTGER2 
PTGER3 
PTGER4 
PTGFR 
PTHLH 
PTPRT 
PTPRU 
PXMP2 
PYY 
RAB6C 
RaLP 
RASGRF1 
RASSF5 
RAX 
RBP4 
REPS2 
RGC32 
RGS10 
RGS20 
RGS9BP 
RIPK3 
RNF127 
RNF128 
ROBO3 
RPS6KA6 
RRP22 
RSPONDIN 
RTN4RL2 
RYR3 
SCD5 
SCN4B 
SCNN1G 
SCTR 
SEMA6D 
SFRP1 
SFRP5 
SGPP2 
SHH 
SHOX 
SHOX2 
SIDT1 
SIM2 
SIX1 
SIX2 
SIX3 
SIX6 
SLC10A4 
SLC1A2 
SLC1A4 
SLC24A4 
SLC26A4 
SLC27A2 
SLC30A2 
SLC30A3 
SLC30A4 
SLC32A1 
SLC35F3 
SLC6A1 
SLC6A3 
SLC6A5 
SLC9A2 
SLC9A3 
SLCO2A1 
SLCO5A1 
SLIT1 
SLIT2 
SLITRK1 
SLITRK3 
SMP3 
SNFT 
SORCS1 
SORCS3 
SOX14 
SOX17 
SOX7 
SPAG6 
SPOCK3 
SPON1 
SRD5A2 
SSTR1 
SSTR2 
ST8SIA2 
STK32B 
STMN2 
STXBP6 
SUSD4 
SV2B 
SYT12 
TAL1 
TBR1 
TBX1 
TBX2 
TBX21 
TBX3 
TBX5 
TCEA3 
TCF2   314 
TFAP2E 
THBD 
TIP39 
TITF1 
TLL1 
TLX1 
TLX2 
TMEFF2 
TMEM27 
TMEM30B 
TMOD2 
TNFSF7 
TP73 
TRADD 
TRH 
TRIM36 
TRIM67 
TRIM9 
TRPC5 
TSLP 
TTYH1 
UCN 
UCP1 
UNC5C 
UNQ9433 
USH1G 
VAX1 
VAX2 
VDR 
VSX1 
WDR8 
WIT-1 
WNT1 
WNT10A 
WNT10B 
WNT11 
WNT16 
WNT2 
WNT3A 
WNT6 
WNT7A 
WT1 
ZADH2 
ZBTB16 
ZCCHC16 
ZFHX1B 
ZFYVE28 
ZIC1 
ZIC4 
ZMYND15 
ZNF312 
ZNF436 
ZNF503 
ZNFN1A3 
 
 
 
 
 
 
 
 